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ABSTRACT
(1) The effects of orotic acid, folic acid and vitamin
B treatment of rats with hypertrophying hearts were
investigated. Previous reports had demonstrated that orotic 
acid and cofactor treatment of rats, enhanced the maximum 
rate of rise of tension developed in papillary muscle pre­
parations from rats with hypertrophied hearts. The effects 
and the mechanism of action of this treatment are reported 
in this thesis.
(2) Preliminary experiments showed that the commercial 
preparations of orotic acid, used in the experiments reported 
in this thesis, were free of any contamination from other 
products due to intrinsic breakdown or to its method of 
manufacture.
(3) Cardiac hypertrophy in the rat was induced by 
aortic constriction and its progress was determined by an 
increase in heart weight. This increase in weight was first 
evident three days after surgery. Orotic acid and cofactor 
treatment, of rats with hypertrophied hearts, was found to 
increase both the cardiac RNA concentration and the cardiac 
RNA content. No significant differences in the cardiac 
protein concentration and the cardiac DNA concentration were 
found in the orotic acid treated hypertrophied hearts compared
(iv)
with the untreated, hypertrophied hearts but a 6 fold 
difference in the increased rate of protein synthesis during 
hypertrophy was found in the orotic acid treated and the 
untreated, hypertrophied hearts. These enhanced rates of 
protein synthesis and the increased RNA content in the 
orotic acid treated hearts were interpreted as a reflection 
of the increased availability of nucleic acid precursors in 
the orotic acid treated animals.
(4) The identical densitometry patterns following the 
disc gel electrophoresis of samples of contractile protein- 
membrane protein fractions and soluble protein fractions of 
both the orotic acid treated and the untreated, hypertrophied 
hearts suggested that the same populations of proteins were 
synthesised in both groups of animals. The similarity of 
the populations of proteins synthesised was also suggested
by the similar changes in the cardiac collagen content found 
in both groups of animals. These results support the idea 
that orotic acid treatment enhanced total cardiac protein 
synthesis, without favoring protein synthesis in either 
the interstitial cells or the myocytes.
(5) The results presented in this thesis also showed
2 +that the Ca stimulated ATP ase activity of cardiac myosin
was reduced in hypertrophied hearts. On the other hand,
2 +Ca -ATP ase activity was increased by 15%, over control 
values, in the orotic acid treated, hypertrophied hearts.
(V)
This was consistent with the belief that cardiac myosin 
ATP ase activity is altered during hypertrophy (due to changes 
in the isozyme pattern of myosin) and was compatible with 
the increased rate of protein synthesis observed in the 
orotic acid treated, hypertrophied hearts. These results, 
together with previous reports of increases in the maximum 
rate of rise of tension in the orotic acid treated hearts, 
suggest that orotic acid treatment of animals had a positive 
inotropic effect on cardiac contractility.
(6) It has been proposed in the literature that orotic 
acid may act as an electrolyte carrier with a special affinity 
for those tissues with an active pentose phosphate pathway.
In the experiments reported in this thesis, no correlation 
between the uptake of orotic acid and either the activity of 
the pentose phosphate pathway or altered electrolyte concen­
trations could be demonstrated.
(7) Prolonged animal toxicity trials, using cats and 
guinea pigs, revealed no toxic effects of orotic acid admin­
istration at doses up to 14 times the therapeutic dose used 
by various workers.
(8) Orotic acid treatment did not enhance the develop­
ment of renal hypertrophy, as measured by changes in renal 
RNA and DNA concentrations. It is suggested that the reason 
for the different effects of orotic acid administration on
(Vi)
cardiac and renal hypertrophy was that the rate of synthesis 
of RNA was unchanged in the hypertrophied kidney and the 
increased availability of nucleic acid precursors in the 
kidney could not be expected to effect the development of 
renal hypertrophy.
2 +(9) The free cardiac [Mg ] was found to decrease
during hypertrophy, particularly in those hearts treated
2 +with orotic acid (the free [Mg ] was 0.86 mM in the normal 
heart, 0.37 mM in the one hypertrophied heart and 0.16 mM 
in the one day hypertrophied and orotic acid treated hearts).
The percentage of ATP and ADP complexed with magnesium was 
also found to be decreased during hypertrophy. Such changes 
in the adenylate nucleotides need to be taken into considera­
tion when discussing the "kinase" type of phosphotransferase 
enzyme systems such as adenyate kinase. These changes in the 
concentration of metal bound adenine nucleotides also suggest 
that the concept of overall metabolic control by the Atkinson 
energy charge concept is untenable in the hypertrophied heart.
(10) The glycogen content of hypertrophied hearts was 
significantly increased, especially in those hearts treated 
with orotic acid, when compared with normal hearts. The 
increased glycogen content of the orotic acid treated, hyper­
trophied hearts was thought to be a mass action effect of 
the increased cardiac UTP concentration, in those animals 
treated with orotic acid, on the enzyme UDP-glucose phosphorylase
(vii)
(11) Consistent with the increased contractile tension 
developed in the hypertrophied hearts, there was a decrease 
in the adenine nucleotide ratio (ANR) and an increase in 
the mass action ratio of the substrates and products of 
the reaction catalysed by adenylate kinase. The validity 
of calculations of the cytoplasmic phosphorylation state
of the adenine nucleotides (PSAN) was discussed and the 
application of these techniques to the hypertrophied heart 
indicated that the PSAN was enhanced in the hypertrophied 
hearts treated with orotic acid, compared with untreated 
hypertrophied hearts. The cytoplasmic [NAD+][NADH]^ ratio 
was calculated and the redox state of the cytoplasm was 
found to be within the normal range of values in the orotic 
acid treated, hypertrophied hearts but became more reduced 
in the untreated, hypertrophied hearts.
(12) The levels of glycolytic intermediates and of 
adenine nucleotides were measured in the hearts of rats 
with developing cardiac hypertrophy. An examination of the
I
mass action ratio of the individual reactions of the glycolytic 
pathway revealed that the reactions catalysed by phospho- 
fructokinase and pyruvate kinase were sites of metabolic 
control in normal, hypertrophied and orotic acid treated, 
hypertrophied hearts. The results suggested a strong corre­
lation between the energy status of the cell and the contri­
bution to this energy status by the poise of the phospho- 
fructokinase and pyruvate kinase catalysed reactions in vivo.
(viii)
(13) Serum insulin levels were unchanged in the animals 
with hypertrophied hearts, although many of the events which 
have been shown to occur during hypertrophy were similar to 
the effects of insulin. Cardiac noradrenaline stores de­
clined during hypertrophy, though there were no significant 
differences in the cardiac noradrenaline stores of orotic 
acid treated and untreated hypertrophied hearts.
(14) No ultra-structural alterations could be ascribed 
to the orotic acid and cofactor treatment of hypertrophied 
hearts.
(15) The incorporation of radioactive orotic acid into 
cardiac RNA (pathway de novo of pyrimidine biosynthesis) 
was considerably lower in the rat heart than in the rat 
liver (1.46% and 10.82% of the radioactivity in the acid 
soluble fraction of the heart and liver, respectively, was 
incorporated into RNA). On the other hand, the incorporation 
of uridine ("salvage" pathway) was much greater in the rat 
heart than in the rat liver (17.63% and 2.75% of the radio­
active label of the acid soluble fraction of the heart and 
liver, respectively, was incorporated into RNA). These 
results, together with measured maximum catalytic capacities 
of the enzymes of the pathway de novo and the "salvage" 
pathway, showed that the heart relies heavily, if not 
entirely, on the "salvage" pathway of pyrimidine synthesis 
for the synthesis of pyrimidine nucleotides.
(ix)
(16) Although increases in the maximum catalytic 
capacity of the enzymes of both the "salvage" pathway and 
the pathway de novo were associated with the development of 
hypertrophy, the major source of pyrimidines in both the 
hypertrophied and the orotic acid treated, hypertrophied 
hearts was still the "salvage" pathway. Further experi­
ments showed that orotic acid administration increased the 
maximum catalytic capacity of the enzymes of the pathway
de novo in the liver. These results may be interpreted 
as showing that orotic acid administration caused an increased 
synthesis of pyrimidine nucleotides in the liver so as to 
provide preformed pyrimidine bases for the cardiac "salvage" 
pathways and hence nucleotides for the enhanced nucleic 
acid synthesis induced by compensatory cardiac hypertrophy.
(17) Results are presented which show that the vascular 
system of hypertrophied hearts treated with orotic acid was 
normal, when expressed as a function of cardiac weight. 
Compared with those animals with hypertrophied hearts
not treated with orotic acid, the coronary circulation of 
hypertrophied hearts treated with orotic acid was signifi­
cantly improved. The results suggest that the treatment of 
hypertrophied hearts with orotic acid was unlikely to preci­
pitate myocardial ischemia that might otherwise be associated 
with the enhanced energy demands of the orotic acid treated 
hypertrophied hearts.
(X)
(18) As part of the vascular studies described above,
rabbits were fed a moderate cholesterol diet supplemented 
with orotic acid. The rabbits fed this cholesterol and 
orotic acid supplemented diet were found to have increased 
serum concentrations of triglycerides and cholesterol in 
the aorta. Probable cuases of the altered lipid metabolism 
are discussed; the most probable cause being changes in 
the rates of cholesterol catabolism and excretion in the 
bile brought about by orotic acid.
(Xi)
NOMENCLATURE AND ABBREVIATIONS
1. Trivial names for sugars and sugar-P's have been used 
when there is no possibility of ambiguity. In all 
other cases systematic names have been employed, in 
accordance with the IUPAC-IUB Commission's "Tentative 
Rules for Carbohydrate Nomenclature". Biochem. J. 
(1971) 125, 673-695.
2. Abbreviations used in the text conform wherever possible 
to those used in The Biochemical Journal (Policy of the 
Journal and Instructions to Authors (1976) Biochem. J. 
153, 1-21). In addition, the following abbreviations 
have been used.
ANR Adenine nucleotide ratio
ATCase Aspartate carbamyltransferase
ATPase Adenosine triphosphatase
Butyl-PBD 2(4'-t-Butylphenyl)5-(4"-biphenylyl) 
1,3,4,-oxadiazole
CPSase Carbamyl phosphate synthetase II
DHOase Dihydro-orotase
DHOdease Dihydro-orotate dehydrogenase
DTT Dithiothreitol
E.C. Enzyme Commission
FFA Free fatty acid
GAP Glyceraldehyde 3-P
GAPDH Glyceraldehyde 3-P dehydrogenase
HDL High density lipoprotein
i.g. Intragastric
i.p. Intraperitoneal
K.l Dissociation constant of inhibitor-enzyme 
complex
(xii)
Km
LDH
Michaelis-Menten constant 
Lactate dehydrogenase
LDL Low density lipoprotein
NMKase Nucleoside monophosphate kinase
ODCase Orotidylate decarboxylase
OPRTase Orotidylate phophoribosyltransferase
3PGK Phosphoglycerate kinase
pKa
PP-ribose-P
-log (dissociation constant) 
Phosphoribosyl pyrophosphate
PSAN Phosphorylation state of the adenine 
nucleotides
Rx.yz
rxy
TCA
Multiple correlation coefficient- 
Linear correlation coefficient 
Trichloroacetic acid
TKase Thymidine kinase
TMS Trimethyl silyl derivative
UKase Uridine kinase
UPase Uridine phosphorylase
Vmax
VLDL
Maximum velocity of shortening 
Very low density lipoprotein
A Lambda (wavelength in nm)
3. Equilibrium data were reported in accordance with the 
recommendations of the Interunion Commission on 
Biothermodynamics ("Recommendations for Measurement 
and Presentation of Biochemical Equilibrium Data". 
Biochem. J. (1977) 163, 1-7).
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CHAPTER 1
GENERAL INTRODUCTION
1.1 Myocardial Hypertrophy
The response of the ventricle to a chronic increase 
in pressure load, such as is imposed by arterial hypertension, 
aortic stenosis or pulmonary hypertension, is ventricular 
hypertrophy, i.e. the ventricle increases in weight, as a re­
sult of an enlargement of individual muscle fibres. The pro­
cess of adaptation affects only those chambers upon which 
there are increased demands. Gibson (1973) wrote, "the 
ability of the heart to increase in size when subjected to 
an increased work load, compensatory hypertrophy, probably 
saves more lives annually than most cardiological drugs or 
surgery." The mechanism responsible for the development of 
cardiac hypertrophy is uncertain but is currently the subject 
of intensive research in a number of medical centres.
The myocardium consists of more than just muscle 
cells — there are three times as many non-muscle cells com­
pared with myocytes in the heart, however, the total volume 
occupied by the myocytes is far greater than that occupied 
by the interstitial cells (Gibson, 1973). it is unlikely 
that different cell populations, within an organ, use the 
same mechanism in contributing to the growth process. The 
question then arises: Does proliferation (hyperplasia) end
2at some point in organ development, with subsequent growth 
proceeding by hypertrophy? The literature regarding this 
question (see reviews by Brown, 1971, and by Rabinowitz and 
Zak, 1972) favors the view that cardiac "hypertrophy", due 
to an increased work load, takes place by hypertrophy of 
muscle cells and hyperplasia of connective tissue cells.
1.2 The Limits to Hypertrophy
Hypertrophy should be regarded as the normal com­
pensatory reaction to alterations in physiological parameters. 
It is only when the adaptive capacity of a tissue is not 
equal to the functional stress imposed upon it, that dest­
ructive changes occur, with pathological sequelae.
With respect to cardiac dimensions, the transition 
between "normality" and compensatory hypertrophy, in man, 
occurs when the average myocardial fibre diameter is about 
14 y, and that between compensatory hypertrophy and patholo­
gical enlargement, when the fibre diameter measures in the 
twenties (Roberts and Wearn, 1941 and Lowe and Bate, 1948). 
Thus, there is an upper limit, beyond which myocardial fibres 
cannot grow without undergoing irreversible, pathological 
changes. Why an upper limit of approximately 20 y should 
exist is difficult to explain, especially when one considers 
human skeletal muscle fibres may become as large as 90 y in 
diameter (Bosanquet et al., 1960). Postulated explanations 
have been that:
1) the upper limit is determined by the ability of
3the vascular bed to supply the hypertrophying fibres with 
nutrients. However, more recent evidence indicates that 
vascularization is not a limiting factor (Arai et al., 1968 
and Chapter 6).
2) While cardiac muscle fibres are mononucleate, 
skeletal muscle fibres are multinucleate, which suggests 
that the nucleo-cytoplasmic relationship may be important.
The theory of the nucleo-cytoplasmic ratio states that the 
volumes of the nucleus and cytoplasm are related in such a 
way that if one changes, so must the other. To maintain 
this balance, the cell may either reduce its cytoplasmic 
volume (by cell division) or increase its nuclear size (by 
becoming multinucleate). However, the mature cardiac muscle 
cell is incapable of division (Walker and Adrian, 1966;
Merkow and Leighton, 1967) and the nucleus of the mature 
muscle cell has only been observed to undergo mitotic div­
ision following focal injury to the myocardium, as in experi­
mentally induced infarction (Rumyantsev and Mirakjan, 1968; 
Zhinkin and Andreeva, 1963). Thus, pathological changes may 
arise when the nucleus can no longer maintain complete con­
trol over cellular metabolism. Interventions which favorably 
effect the ability of the myocardium to synthesise new com­
ponents, for cellular growth and structural renewal, should 
significantly reduce the region of infarction following 
coronary artery occlusion. While sites in the center of the 
damaged zone, with more severe ischemic injury, may only be 
partially protected, cellular metabolism at the periphery
4of the damaged zone of myocardium may be sufficiently well 
protected, by an enhancement of cellular synthesis, to 
remain viable. It has been reported that erotic acid, a 
pyrimidine precursor, accelerates the healing of damaged 
foci in experimental myocardial infarcts (Kleimenova et al., 
1973) and has a marked positive effect on the clinical course 
of myocardial infarction (section 1.4.2), though the mech­
anism of action of this compound and its site of action in 
the muscle cell have not yet been adequately explained.
1.3 Orotic Acid
Orotic acid (Fig 1.1) is the first pyrimidine 
compound formed in the pathway for pyrimidine biosynthesis, 
de novo, (Smith et al., 1972). It is converted to uridine- 
5'-monophosphate (UMP) and thence to nucleic acids, other 
pyrimidine compounds and cofactors.
Orotic acid was first discovered in milk (Biscaro and 
Belloni, 1905). In cow's milk, in which 97% of the nucleo­
tide fraction is orotic acid, the concentration of orotic 
acid is 50-100 mg/1 (Kabata et al., 1962). Commercial pow­
dered milk also has a high content, 1.0-1.3 mg/g of powder 
(Okonkova and Kinsella, 1969). By comparison, human milk 
contains only trace amounts of orotic acid, though there is 
a relatively high content of other pyrimidine compounds, 
particularly cytidine monophosphate and uridine monophosphate 
(Kabata et al., 1962).
5The therapeutic effects of orotic acid have been 
studied in a number of conditions (see Tables 1.1, 1.2 and 
1.3) and usually found to be beneficial (see Section 1.4).
The rationale behind most investigations has been that the 
administration of orotic acid would lead to a greater pro­
duction of nucleic acid precursors or to greater concentra­
tions of the various pyrimidine cofactors essential for the 
maintenance of metabolic integrity and the metabolism of 
lipids, carbohydrates, etc. The postulated overall effect 
would be promotion of growth and enhancement of the rates 
of various pathways where pyrimidine cofactors are involved. 
No adverse effects arising from orotic acid administration to 
humans have been observed, though the feeding of orotic 
acid to rats can lead to disturbances in lipid metabolism 
(see Chapter 6).
Certain reports (Seeger, 1972; and Simon, 1968) 
have emphasized the efficacy of the orotates as electrolyte 
carriers — important in view of the role of magnesium salts 
in activating the cholesterol-esterases and mobilising 
atheromatous deposits in vessel walls.
1.4.1 Aspects of Orotic Acid Metabolism in Man
Two aspects of orotic acid metabolism will be 
considered: (i) the conditions associated with excess
excretion of orotic acid, (ii) some possible therapeutic 
uses of orotic acid described in the literature.
6(i) Orotic Aciduria
At least four circumstances are known under which 
the excretion of orotic acid is significantly raised above 
normal levels in man.
(A) Hereditary orotic aciduria.
(B) Ornithine transcarbamylase deficiency.
(C) Drug therapy with 6-azauridine and allopurinol.
(D) Pregnancy.
(A) Hereditary Orotic Aciduria
The urinary excretion of orotic acid in man is 
normally less than 2 mg/24 h (Lotz et al. , 1963; Beardmore 
and Kelley, 1971). However, in hereditary orotic aciduria 
up to 1.5 g of orotic acid is excreted per 24 h ( Smith et 
al., 1972). This very rare autosomal recessive disease 
usually presents in 2-3 month old infants as growth retarda­
tion and severe megaloblastic anaemia. Effected subjects 
usually lack the enzymes orotate phosphoribosyl transferase 
(EC 2.4.2.10) and orotidine 5'-phosphate decarboxylase 
(EC 4.1.1.23) that convert orotic acid to uridine 5'-monoph­
osphate (Fig. 1.1). A satisfactory remission can be obtained 
on treatment with uridine, indicating that sufficient pyri­
midines can be utilised via salvage synthesis (Fig. 1.2).
(B) Ornithine Transcarbamylase Deficiency
Another inherited condition associated with orotic 
aciduria is ornithine transcarbamylase deficiency (Shih and 
Effron, 1972^ . It has been postulated that this is a sec­
ondary effect, resulting from the accumulation of the pyrimi­
dine precursor, carbamyl phosphate, which also serves as a
7substrate of the urea cycle enzyme,ornithine transcarbamy- 
lase (EC 2.1.3.3). Thus, impaired utilisation of carbamyl 
phosphate in the urea cycle in this disease could lead to 
an enhanced rate of pyrimidine biosynthesis, which may be 
reflected in increased production and excretion of orotic 
acid.
(C) Drug Therapy
A massive increase in the urinary excretion of 
both orotic acid and orotidine (up to 8-10 g of each/24 h ) 
is associated with the administration of the antimetabolite 
drug, 6-azauridine (Cardoso et al., 1961). A similar pattern 
of results has been reported by Fallon et al., (1962) fol­
lowing 6-azauridine administration. This drug-induced 
orotic aciduria is analogous to the genetically transmitted 
disorder (hereditary orotic aciduria) since both conditions 
are associated with a failure in the conversion of orotic 
acid to UMP (Cardoso et al. , 1961) . An elevation of urin­
ary orotidine and orotic acid excretion is also associated 
with administration of the purine analogue, allopurinol, 
used in the treatment of hyperuricaemia (Fox et al., 1970; 
Brown et al., 1972).
(D) Pregnancy
A slight degree of orotic aciduria has been 
observed in normal human pregnancy by Wood and O'Sullivan 
(1973). The amount of orotic acid excreted is about 20-40 
mg/24 h and does not vary significantly during the course 
of pregnancy.
8(ii) Possible Therapeutic Uses of Orotic Acid
Orotic acid has been investigated as a thera­
peutic agent in a number of conditions, including myocardial 
infarction (see Section 1.4.2), neonatal jaundice, pernicious 
anaemia, hyperuricaemia, and hereditary galactosaemia, with 
reportedly beneficial results. Instances or orotic acid 
administration to patients have recently been reviewed by 
O'Sullivan (1973) and Donohoe et al. (1974) and are summa­
rised in Tables 1.2 and 1.3.
Neonatal Jaundice
Another potential application of orotic acid is in 
the management of neonatal jaundice. In the foetus, bili­
rubin is partly eliminated through the placenta, whereas, 
after parturition, most of the bilirubin is conjugated to 
bilirubin glucuronide prior to urinary excretion (Brodersen, 
1965). According to this author, the enzyme uridine dipos- 
phate (UDP)-glucuronyl transferase (E.C. 2.4.1.17) is 
"induced as the need arises" and the amount of uridine co­
enzymes may be a rate limiting factor in the neonate. 
Furthermore, the initiation of both glycogen synthesis and 
galactose metabolism during the first few days after birth 
makes additional demands on the pool of uridine co-enzymes 
(Brodersen, 1965). It was demonstrated by von Euler (1963) 
that the amount of uridine nucleotide and uridine co-enzymes 
is increased in the liver of rats following the administration 
of orotic acid. It was suggested by Brodersen (1965) that 
the feeding of orotic acid, the precursor of UMP, may enhance 
the conjugation of bilirubin.
9Matsuda and Shirahata (1966) reported slightly 
lowered serum bilirubin levels following the administration 
of a daily dose of 200 mg of orotic acid to full term neo­
natal infants. More recently, Kintzel et al., (1971) have 
obtained significantly lowered values of bilirubin using a 
dose of 300 mg orotic acid per day. The trial included 102 
premature infants subjected to therapy and a further 102 in 
the control group. There were consistently lower serum bil­
irubin levels (by 25-30%) in the treated group from the 
third to the sixth day after birth. Exchange transfusion 
was felt to be necessary in only four of the treated group, 
while it was required in 30 of the control group. It is of
interest to note that orotic acid did not have a signific-
%
ant effect on the serum bilirubin levels of mature newborn 
infants studied by Schwarze et al., (1971).
Pernicious Anaemia
Rundles and Brewer (1958) administered orotic 
acid orally, in doses of 3-6 g per day, to 11 adult patients 
with pernicious anaemia. It was an unexpected finding that 
fairly complete and sustained remissions could be obtained 
in all but 2 of the patients. This effect appears to be of 
particular interest in reference to the biosynthesis of 
nucleic acids in the human and to the poorly understood fun­
ction of vitamin However, the patients maintained on
orotic acid alone for 5 to 7 months gradually relapsed, with 
increasing anaemia and lingual mucosal atrophy. It is of 
interest to note that no toxic side effects were observed
following the administration of orotic acid at this dose 
level over several months.
Hyperuricaemia
Kelley et al., (1970) have investigated the use
of orotic acid in the treatment of patients with hyperuric­
aemia (gout) using a daily oral dose of 6 g. Significant 
lowering of serum uric acid level was observed. A similar uri 
cosuric effect by orotic acid was observed by Fallon et al. 
(1962), Delbarre and Auscher (1963) and Pavesio et al., (1972)
Hereditary Galactosaemia
Tada et al., (1962) administered 1 g of orotic 
acid per day for 2 weeks to 2 galactosaemic children main­
tained on milk (a source of galactose). They reported alle­
viation of the toxicity syndrome and an improvement in gal­
actose tolerance. However, Gentil (1964) on giving orotic 
acid to 2 galactosaemic patients reported no significant 
change in galactose tolerance. Segal et al., (1966) further 
evaluated a possible relationship of orotic acid with gala­
ctose metobolism and examined three aspects of the problem.
Firstly, a study of the influence of orotic acid on the
14ability of patients with galactosaemia to oxidise (1- C)- 
galactose to was carried out. Secondly, they examined
the capacity of orotic acid to enhance the oxidation of 
radioactive galactose by blood cells of galactosaemic indi­
viduals. Thirdly, the effect of orotic acid on cataract 
formation in rats fed a high galactose diet was examined.
In all three studies, orotic acid was reported to be without
10
effect.
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1.4.2 Rationale for the Use of Orotic Acid in 
Myocardial Infarction
The administration of orotic acid was postulated 
to lead to a greater production of nucleic acid precursors 
and,by implication,thus prime the processes of protein syn­
thesis. Orotic acid administration also was believed to 
lead to a greater synthesis of pyrimidine nucleotide co­
enzymes, which are essential for energy metabolism and the 
catabolism of lipids and carbohydrates. This, together 
with the administration of folic acid (a cofactor in both 
purine and pyrimidine biosynthesis) and vitamin B^2 (which 
stimulates the synthesis of thymidine, thymine and deoxyri- 
bose, all of which are precursors for DNA synthesis), would 
form the theoretical basis to overcome any inhibition of the 
synthesis of nucleic acids and proteins, which are so essen­
tial to minimise the effects of necrotic processes following 
myocardial infarction. Clinical and experimental observations, 
made during the past decade have supported the belief that 
myocardial infarction develops in a stepwise manner (Mueller 
et al., 1974). Thus,it is proposed that myocardial tissue 
may be salvaged by supplying sufficient precursors, such as 
orotic acid, vitamin B^2 anc^  folic acid, to interupt this 
progressive necorotic process.
The administration of orotic acid to patients 
recovering from myocardial infarction has been studied in 
several Russian clinicial trails (see Table 1.3). Zimmerman 
and Rusinova (1973) reported the use of orotic acid (together
12
with vitamin and folic acid) in a study of 80 patients
(37 patients received cardiac glycosides, vasodilating agents 
and anticoagulants, while the remainder were given the same 
treatment plus orotic acid and cofactors). A summary only 
is available in English and full details of the trail, with 
a complete case breakdown, are not available outside the 
Russian literature. The abstract indicates the orotic acid 
treatment exerted a favourable effect on the clinical course 
of the disease; restoration of the ECG towards normal occur­
red earlier and there was an increase in the level of serum 
albumin and a decrease in 2~, 3-, and y-globulins.
Zharov (1972) used the orotic acid and cofactor 
therapy in patients in the acute phase of myocardial infar­
ction. Patients treated with orotic acid and cofactors 
showed a quicker restoration of myocardial contractile fun­
ction compared with those patients receiving conventional 
treatment with cardiac glycosides. The difference in the 
numbers of deaths in either group, 16 of 101 patients (16%) 
who received orotic acid and cofactors as against 31 of the 
115 patients (27%) who received conventional therapy, demon­
strated the claim for a beneficial effect of this treatment.
A similar, but smaller study, was performed by Lukomskii, et al. 
(1967) with 80 patients. The results in this case were 
similar to those reported above, only 3 of the 40 
patients (7.5%) who received orotic acid and cofactors 
(together with analgesics, anticoagulants, strophanthidin 
and noradrenaline) died, compared with 10 of 40 patients (25%) 
receiving the same treatment but without orotic acid and
cofactors.
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Maslyuk et al., (1972) observed the effect of cardiac 
glycosides and orotic acid, without folic acid and vitamin 
B.^2 cofactors, on patients with varying degrees of cardiac 
decompensation (Phase Is compensation at rest, symptoms of 
decompensation only in physical work; Phase IIA; decomposensa- 
tion at rest, comparatively mild disturbance of hemo-dynamics; 
Phase IIB: decompensation at rest, pronounced stagnation of
circulation in organs but without significant disturbance to 
their functions; Phase III: terminal decompensation). They
reported the effect of treatment in terms of "excellent", 
"satisfactory", "fair" and "absent". The results (Table 1.4) 
showed the highly favourable effect of the supplemental treat­
ment with orotic acid as compared with conventional treatment 
with glycosides and diuretics. There was a marked improvement 
of myocardial contractile function and positive hemodynamic 
indices and a reduced percentage of episodes of intoxication 
with cardiac glycosides.
1.5 Orotic Acid and Experimental Hypertrophy
Previous work in this laboratory by Kolos et al.,
(1974) confirmed that the administration of the orotic acid, 
vitamin B.^ and folic acid "cocktail" proposed by Meerson 
(1969) enhanced contractility during myocardial hypertrophy.
Length-tension relationships, derived from experiments 
on the isolated papillary muscles of rats at various times after 
the induction of hypertrophy, were studied by Kolos et al. (1974) 
(Fig. 1.3). The resting tension was found to be increased 
in those preparations from hypertrophied hearts, and this
14
possibly correlates with the increased rate of collagen 
synthesis which accompanies hypertrophy. Increases in both 
content and concentration of collagen, measured by the 
hydroxyproline method, have been found in several studies 
of cardiac hypertrophy due to pressure overload (Bing et al., 
1971 and Bartsova et al., 1969), though there was no increase 
in the collagen content in rats hearts that were enlarged as 
a result of anaemia due to iron deficiency or thyroxine 
administration (Skosey et al., 1972). The developed tension 
in papillary muscles from 1, 4 and 28 day operated rats did 
not differ significantly from normal values (Fig. 1.3) but 
was slightly elevated (p > 0.02), 7 days after the induction 
of hypertrophy. Neither the time to peak tension, nor the 
maximum rate of rise of tension varied significantly from 
normal values in any of the groups of papillary muscles from 
operated animals. All parameters (maximum tension developed, 
maximum rate of rise of tension and the time to peak tension) 
decreased in both the normal and operated animals, as the 
frequency of stimulation was increased. In particular, at 
higher rates of stimulation (0.5 Hz and 1.0 Hz) the para­
meters in the operated groups did not vary significantly 
from normal. The peak tension developed by normal rat
papillary muscle preparations, in these experiments was
22.28 ± 1.9 g/mm . Similar values for T have been pub-  ^ max ^
lished by Grimm et al., (1963).
Thus when a moderate degree of hypertrophy (with no 
heart failure) is induced, contractility appears to be normal.
These experiments were repeated, using animals whose 
hearts had been induced to hypertrophy and treated with either
15
uridine or orotic acid (10 mg/kg/day) (Fig. 1.3). Both the 
uridine and the orotic acid treated animals also received the 
cofactors vitamin B.^ (100 yg/kg/day)and folic acid (2 mg/kg/
day). The treatment was administered twice a day by stomach 
tube/starting from the time of induction of hypertrophy. The 
maximum developed tension and the maximum rate of rise of 
tension increased significantly in the orotic acid treated,
4 day hypertrophied hearts (2.88 to 3.99 g/mm2, p<0.01, and 
30.9 to 47.3 g/mm2/sec, p<0.01 respectively). With none of 
the parameters was it reasonable to conclude that there was 
any difference between the untreated hypertrophied animals 
and those treated with uridine.
The active tension developed by the contractile 
components of the muscle has been taken to be the difference 
between the total peak tension developed during contraction 
and the resting tension, in accordance with a Maxwell model 
of myocardial muscle mechanics. The length-tension relation­
ships in the 4 day operated and orotic acid and cofactor 
treated rats are shown in Fig. 1.3. The developed tension in 
the normal and 4 day operated, untreated animals was the same, 
however, the developed tension in the 4 day operated and 
orotic acid treated groups was markedly increased over control 
values. The resting tension was increased in the hypertrophied 
groups and was further increased in the hypertrophied and 
orotic acid treated groups.
16
1.6 Speculation on the Mechanism of Cardiac Hypertrophy
The initial biochemical stimulus which "switches 
on" the subcellular mechanism to increase protein synthesis 
in response to an increased work load, still remains to be 
elucidated. Methods used to induce hypertrophy fundamentally 
consist of either (1) an increase in preload, or (2) an in­
crease in afterload; however, they all result in an increase 
in ventricular wall tension which has been suggested as the 
trigger for the process of hypertrophy (Meerson, 1969). The 
problem then to be solved is how a physical stimulus, such 
as wall tension, translated to the biochemical level to 
induce increased protein synthesis.
Extra-cardiac hormones are probably not directly 
involved as Schreiber et al. (1968) have shown that increased 
protein synthesis occurred in the isolated perfused heart 
preparation when the heart was subjected to an increased 
pressure load. However, a significant degree of left ventri­
cular hypertrophy was achieved by Laks et al. (1973) over
periods of 6-63 weeks, by the administration of subhyper­
tensive doses of noradrenaline. Several studies have demon­
strated a decrease in myocardial noradrenaline content in 
both experimentally induced and naturally occurring congestive 
heart failure (Chidsey et al., 1964; De Quattro et al., 1973). 
Thus, when a chronic stress is applied to the heart, cardiac 
noradrenaline may be part of a "switch mechanism" and a 
decrease in noradrenaline content may be a factor that limits 
the degree of compensatory hypertrophy, eventually resulting 
in chronic heart failure (Section 4.3.7).
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It has been shown that an increased supply of 
amino acids can stimulate cardiac protein metabolism (Morgan, 
et al., 1971). Furthermore, when the heart is subjected to 
passive stretch there is an increase in the intracellular 
content of amino acids (Morgan et al., 1971). The formation 
of aminoacyltransfer RNA, in the first stage of cellular 
protein biosynthesis is dependent on an amino acid supply 
(Gibson, 1973). Deacylated t-RNA acts as an inhibitor of 
nucleic acid synthesis and the acylated form may act as an 
activator of protein biosynthesis (Kurland and Maaloe, 1962). 
Thus, the level of amino acids may directly effect the level 
of cardiac protein synthesis and may be one of the effectors 
of the hypertrophic response of the heart to increased wall 
tension. The activities of the 20 amino acid specific 
acyl t-RNA synthetase enzymes have been measured in the 
myocardium and some have very low activities and would be 
rate limiting for protein biosynthesis (Gibson and Harris, 1972).
Meerson and Pomoinitsky (1972) have suggested that 
cardiac hyperfunction may lead to an increased "intensity of 
function" of its structures, which in turn may activate the 
genetic apparatus of the cells and cause the activation of 
the synthesis of nucleic acids and proteins in these cells.
The increased intensity of function was thought to give rise 
to an energy deficiency which (a) may be accompanied by an 
increased disintegration of cellular structure and hence 
either a deficiency of protein or an accumulation of the pro­
ducts of the disintegration. One of these factors may then 
activate the genetic apparatus, or (b) because the adenine
19
Polyamines, which can stabilise nucleic acids, have 
also been shown to increase within 24 hours of the onset of 
an increased work load and may have a role in the control 
of the development of cardiac hypertrophy. Following con­
striction of the pulmonary artery in rabbits, Russell et al. 
(1971) observed an increase in ornithine decarboxylase activ­
ity in right verticular tissue. This increase became apparent 
4 hours after constriction and persisted throughout the 
period of observation (6 days). Caldarera et al., (1974) 
have demonstrated a close relationship between polyamine 
levels and RNA synthesis in myocardial hypertrophy; their 
perfusion experiments have shown that spermine is active in 
stimulating RNA synthesis. Thus,the role of the polyamines 
during hypertrophy, may be important in view of their effects 
on nucleic acids and cell membranes.
The early stimulation of nuclear RNA polymerase 
activity in cardiac hypertrophy (Nair et al., 1968; Schreiber 
et al., 1969) and the increased template activity of RNA 
polymerase of chromatin isolated from nuclei of hypertrophied 
myocardium (Florini and Dankberg, 1971), together with the 
inhibition of development of hypertrophy by actinomycin D 
(Meerson and Pshennikova, 1965; Zuhlke et al., 1966; Morkin et 
al., 1968) indicate that regulation at the transcriptional 
level is probably fundamental to the initiation of cardiac 
enlargement.
1.7 Outline of Areas Examined in This Thesis
Hypertrophy of the heart is a normal physiological 
process that occurs in many facets of human life, for example,
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with age, due to chronic strenuous exercise, in anaemia and 
with hypertension. The study of the ability of the heart 
to cope with such changes and of various compounds, such 
as orotic acid, to modify this capacity for change, is of 
importance and may facilitate the elucidation of the patho­
logical events found in the hypertrophied human myocardium.
The aim of this project was to investigate aspects 
of the mechanism by which orotic acid and other pyrimidines 
act as agents which exert apparently beneficial effects 
(Section 1.5) on the hypertrophying myocardium. Only aspects 
of developing hypertrophy were examined - animals with signs 
of cardiac decompensation, such as hydrothorax or hepatic 
congestion, were not included in any of the studies that 
were made.
Cardiac synthetic processes are finely controlled 
by as yet poorly understood mechanisms so as to respond to 
physiological changes that alter the work load. Orotic acid 
has been administered to patients in a number of clinical 
situations, usually with apparently beneficial results - 
the rationale being that orotic acid administration would 
lead to a greater production of nucleic acid precursors and 
pyrimidine cofactors, presumably through an enhanced formation 
of pyrimidines. However, it has not been resolved whether 
cardiac tissue can supply pyrimidine precursors de novo for 
RNA synthesis or whether these precursors must be supplied pre­
formed from extra-cardiac sources. Thus, one of the aims of this
21
project was to investigate the mode of formation of cardiac 
pyrimidines, and the effects of hypertrophy and orotic acid 
treatment on the paths of pyrimidine synthesis. The 
results suggest that cardiac tissue utilizes preformed pyri­
midine to a much greater extent than it utilizes the de novo 
pathway to supply its requirements for pyrimidines.
When cardiac hypertrophy was induced by the app­
lication of an increased work load, there was a rapid activa­
tion of the processes of nucleic acid and protein synthesis 
(Chapter 3) . Local tissue hypoxia and a depletion of energy 
stores, leading to an accumulation of metabolites, (which 
in turn derepress the synthetic processes) have been suggested 
as stimuli to hypertrophy. If hypoxia or ischemia was an 
issue, then the heart would become dependent upon the glyco­
lytic pathway for "energy" (ATP) production and, presumably, 
those animals with "enhanced" hypertrophy, due to treatment 
with orotic acid, would become even more dependent upon the 
glycolytic pathway. Thus,an aim of this project was to 
investigate the control of the glycolytic pathway during 
hypertrophy and the ability of the hypertrophied heart to 
maintain an adequate energy supply. Long term susceptibility 
to hypoxia was evaluated by an investigation as to whether or 
not hypertrophy took place at the expense of the existing 
microcirculation and thus predispose the tissue to a post 
hypertrophy episode of hypoxia.
Chemical and biological studies on orotic acid were 
also conducted. The biological studies involved prolonged
22
toxicity studies which were carried out using guinea pigs 
and cats, as well as short and long term experiments which 
investigated the ability of orotic acid to improve the cont­
rolled development of myocardial hypertrophy in rats and 
rabbits.
ASPARTATE
GLUTAMINE
co2
ATP
OROT
URIDYLATE
-> CARBAMYL-
PHOSPHATE
-4 CARBAMYL 
ASPARTATE
-* UDP ■* UTP CTP
Figure 1.1 Outline of the metabolic pathway related to 
pyrimidine biosynthesis in the heart. The 
enzymes are as follows: (1) Carbamylphosphate
synthetase (2) Aspartate carbamyl transferase 
(3) Dihydroorotase (4) Dihydroorotate 
dehydrogenase (5) OMP pyrophosphorylase 
(6) OMP decarboxylase.
URIDINE NUCLEOTIDES
URIDINE
UR IDINE~51“ PHOSPHATE
DE NOVO PATHWAY
DEGRADATION
Figure 1.2 Outline of the metabolic pathway related 
to the so-called "salvage" pathway of 
uridine nucleotide synthesis. The enzymes 
in this pathway are as follows: (1) Uridine
phosphorylase, (2) Uridine kinase, (3)
Uracil phosphoribosyl transferase.
Figure 1.3 The effect of hypertrophy and pyrimidine treatment 
on the tension of papillary muscles. (Top)shows 
average maximum tension (top), time to peak tension 
(middle), and maximum rate of rise of tension (bot­
tom) in normal 1 and 4 day operated, 1 and 4 day 
operated and uridine plus cofactor treated and 1 
and 4 day orotic acid and cofactor treated rats. 
Bars represent ±S.E.M. Numbers in parentheses = 
number of animals in each group. (Bottom)Relation 
between muscle length and tension of the papillary 
muscles from normal (circles), 4 day operated 
(triangles) and 4 day operated and orotic acid and 
cofactor treated(squares) rats. Open symbols = 
resting tension; Solid symbols = actively developed 
tension. Vertical lines with cross bars = S.E.M. 
Numbers in parentheses = number of animals in each 
group. Data from Kolos, G., Williams, J.F., and 
Hickie, J.B. (1974).
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Effect of 
treatment 
(per cent)
CONTROL 
Group I
OROTIC ACID 
Group II
Phase Phase
IIA IIB III IIA IIB III
Excellent 47 16 4 97 68 19
Satisfactory 48 51 30 0 32 56
Fair 4 24 32 0 0 25
Absent 1 9 34 3 0 0
Table 1.4 Effect of treatment(data expressed as %) on patients 
with varying degrees of failure to undergo compen­
satory cardiac adjustment during disease (de­
compensation) . Groups are: (1) Control, patients
were given therapeutic doses of digitalis prepara­
tions (orally) and in periods of acute ventricular 
failure, intravenous doses of Strophanthin.
(2) Patients were given potassium orotate (1.5 g 
daily) in addition to cardiac glycoside therapy.
Patients were classified into 4 groups, 
according to the degree of decompensation. Phase 
I: Compensation at rest. Symptoms of decompensa­
tion only in physical work. Phase IIA: Decompensa­
tion at rest, comparatively mild disturbance of 
hemodynamics. Phase IIB: Decompensation at rest,
pronounced stagnation of circulation in organs but 
without significant disturbance of their functions. 
Phase III: Terminal decompensation.
Data are tabulated from information contained 
in Fig. 1, Maslyuk et al. (1972) .
CHAPTER 2
PRELIMINARY INVESTIGATIONS
2.1 Introduction 
Chemistry of Orotic Acid
Orotic acid is uracil-6-carboxylic acid (2, 4-diox- 
otetrahydro-pyrimidine-6-carboxylic acid) and exists in two 
desmotropic forms (a and b) (synonyms for orotic acid are 
"animal galactose factor" and "whey factor"). Molecular for­
mula: CcH.N„0.. Molecular weight: 156.1.5 4 2 4
H 
O
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H O - %  AN C O O H
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B
Orotic acid is a white, finely crystalline, odour­
less powder of weakly acid taste. It is sparingly soluble in 
water; practically insoluble in ethanol, ether and chloroform; 
and partially soluble by formation of salt in aqueous alkali.
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The importance of orotic acid in pyrimidine nucle­
otide synthesis has been well established. Derivatives such 
as 5 chloro-, 5 bromo- and 5 fluoro orotic acid (Stone and 
Potter, 1956 and 1957) have been shown to exhibit orotic acid 
antimetabolite activity in various biological systems. 6-Uracil 
methyl sulfone and 6-uracil sufonamide, synthesised as orotic 
acid antagonists (Greenbaum, 1954), have exhibited antitumor 
activity against several types of tumor growth (Holmes and 
Welch, 1956).
Chemical analysis has been applied to comp-lex mole­
cules to solve analytical and structural problems, the charac­
teristic frequencies of groups being used to facilitate 
identification. It is believed that an accurate knowledge of 
the spectra of orotic acid, as well as the variation of these 
spectra with pH, will be of value in studies of the properties 
of this compound. Analysis was also undertaken to 
identify any impurities present in the preparations of orotic 
acid used in these experiments, due to the mode of manufacture. 
E. Merck Pty Ltd have stated that the product supplied by their 
company was prepared by biosynthesis, on the other hand, Lonza 
Ltd prepare orotic acid by chemical synthesis, as described 
in British patent no 1, 259, 578.
Melting point determinations were carried out using 
sealed glass capillary tubes. Samples of orotic acid, 
supplied by both Merck and Lonza, were uniformly found to 
decompose over the range 338-345°C.
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2.2.1.1 Mass Spectra of Orotic Acid
Mass spectra were recorded at 70 e.v. with an AEI 
mass spectrometer (MS-902). The source temperature was 180°C, 
and the orotic acid sample was introduced directly onto the 
ion source.
The mass spectra of free pyrimidine bases are charac­
terised by abundant molecular ions and by additional ions 
formed by the loss of small neutral molecules (Hignite, 1972). 
The mass spectrum of the sample was consistent with that of a 
monomeric form of orotic acid (see Figs 2.1 and 2.2). The 
sequence of decomposition reactions which follow ionization 
is shown in Fig 2.2 and is based on the work of Rice et al., 
(1965). The mechanistic scheme is intended to illustrate the 
origins of fragment ions and to rationalise their formation. 
Since both nitrogen and oxygen have the capacity for increased 
valency in the ionised state and since the positive charge 
is considered to be delocalized over the entire ir-bonded 
framework of an organic ion, the single valence-bond structures 
with localised charge, as used in Fig 2.2, are distortions of 
reality.
Orotic acid at 70 e.v. gives a molecular ion at m/e 
156 (Fig 2.1 and 2.2) which expels a molecular ion HNCO(43 
mass units). The initial loss of HNCO occurs via a retro 
Diels Alder fragmentation involving the and atoms since 
this produces a more conjugated ion than the ion resulting 
from loss of N-3 and C-4. (Hignite, 1972). The spectrum thus 
exhibits a metastable peak at m/e 113 (C^H^NO*) due to the
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loss of HNCO from the molecular ion. The ion at m/e 113 may 
then expel the carboxyl group (45 mass units) to give rise to 
a protonated nitile, C^f^NO* (m/e 68) , which subsequently gives 
rise to a C2H2N+ ion (m/e 40) by decarbonylation.
2.2.1.2 Gas Liquid Chromatography and Mass Spectroscopy
Silylation procedure: Orotic acid (10 mg) was reacted
with bis-(trimethylsilyl)-trifluoroacetamide (BSTFA) (1 ml) in 
a tightly closed glass tube at 80°C for 3 hours. The sample 
was cooled to room temperature and 1 yl was injected into the 
gas chromatograph.
Gas-liquid chromatography: A glass column with a
3mm i.d. was packed with 2% OV-17 (phenyl methyl silicone 
polymer) on chromosorb Q (Pierce Chemical Co., Illinois). 
Nitrogen,at 12 ml/min was used as the carrier gas. The column 
was temperature programmed from 100°C to 300°C at the rate of 
4 °/min.
Gas-liquid chromatography - mass spectroscopy: The
silylated orotic acid sample (1 yl) was chromatographed as 
described above, except that the column temperature was main­
tained at 200°C. The volatilized fractions from half-way up 
the GLC peak and at the top of the peak (Fig 2.3b) were 
analysed by mass-spectroscopy using an AEI mass spectrometer 
(MS-902) at 70 e.v. The two mass spectra were identical and 
part of the spectrum of the sample taken from the top of the 
GLC peak is reproduced in Fig 2.4.
Fig 2.3a is a typical gas chromatogram of TMS- 
orotic acid. This chromatogram represents 10 yg of orotic
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acid and is characterised by a single peak at a column temp­
erature of 168°C.
Fig 2.3b is a gas chromatogram of TMS-orotic acid 
at a constant column temperature of 200°C, again giving rise 
to a single peak. When this peak was analysed by mass spect­
roscopy, the volatilized fraction showed a molecular ion, M+, 
at m/e 372 corresponding to the TMS derivative of orotic acid. 
Other ions were observed at m/e 357 corresponding to [M-15]+, 
formed by the loss of a methyl radical from a TMS group of the 
molecular ion. Loss of a hydrogen atom at C-5, followed by 
loss of the -COO Si (CH^)^ fragment gave use to a peak at m/e 
254 (M-118). The peak at m/e 147 is due to a condensation
product of trimethylsilicanol. The (CH^^ Si=0+ -SiCCH^)^, 
molecular weight 147, is formed by the expulsion of a methyl 
group from hexamethyl disiloxane (Budzikiewicz et al., 1967). 
This may further fragment (Richter et al., 1967) to give rise 
to peaks at m/e 73 ((CH^)^Si+) and at m/e 45 (CH3Si+H2).
2.2.2 Ultraviolet Spectrum of Orotic Acid
All measurements were made with either a Beckman 
Acta MVI spectrophotometer or a Cary model 118 spectrophoto­
meter using 1 cm quartz cells. Cell corrections were estab­
lished at 20 nm intervals over the entire wavelength range 
using distilled water. The concentration of orotic acid was 
approximately 0.5 mM so that most of the important absorbance 
readings were taken in the range 0.2-0.5. The orotic acid 
was dried in an oven at 110°C for 24 hours, and kept in a 
dissicator for a further 24 hours before use. The wavelengths
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at which maximum and minimum absorbance occurred were deter­
mined by using the Beckman Acta MVI spectrophotometer in the 
differential absorbance mode. The pH values at which spectral 
measurements were made i.e. pH 1, 2, 6, 1, 8 and 12, were 
sufficiently removed from the pK values of orotic acid (2.8, 
9.45 and greater than 13,Shugar and Fox, 1952) so as to elimi­
nate the possibility of the presence of more than one species 
of the compound in solution. The solutions were made up as 
follows: pH 1 and pH 2 were solutions of hydrochloric acid -
potassium chloride, (ionic strength 0.1); pH 6.0, 7.0 were 
solutions of potassium dihydrogen phosphate-disodium hydrogen 
phosphate (ionic strength 0.1); pH 8.0 and pH 10.0 tris-HCl 
buffers, (ionic strength 0.1) ; and, finally, a 0.01 N sodium 
hydroxide solution was taken as essentially equal to pH 12.0.
The results obtained from the ultraviolet spectra 
are shown in Table 2.1. In all cases, the results are in very 
close agreement with those of Shugar and Fox (1952).
2.2.3 Infrared Spectrum of Orotic Acid
An infrared spectrum was obtained using a Perkin- 
Elmer 257 spectrophotometer and the infrared spectrum of 
orotic acid (Merck) was studied in KBr discs (see Fig 2.6).
In substituted pyrimidines, the ring stretching vibrations 
fall at 1555-1590, 1520-1565, 1400-1480 and 1375-1410 cm"1 
(in orotic acid these vibrations are seen at 1520, 1430 and 
1410 cm 1); C-H in plane deformation vibrations occur at 1220, 
1165, 1140 and 1021 cm *(in the case of orotic acid these are 
seen at 1265, 1140 and 1020 cm 1); ring skeletal vibrations
29
at 991 cm 1 (orotic acid 990 cm !); an out of plane vibration 
at 721 cm 1 (740 cm 1 orotic acid); C-H stretching vibrations 
occur at 3100-3000 cm 1 (orotic acid 3100 cm 1 ) and N-H 
stretching vibrations occur at 3450, 3400 cm 1 (orotic acid 
3500 cm 1). (Short and Thompson, 1952; Lord et al., 1957,
Wiley and Slaymaker, 1957) . The carboxyl group on has its 
own set of vibrational frequencies: the carboxylate anion
vibrates at 1330, 1610 cm 1 in orotic acid (the normal range 
of these vibrations are 1400-1300 cm *and 1610-1550 cm l ) , the 
carbonyl stretching vibration at has a strong absorption 
at 1720 cm 1 (normal range 1725-1700 cm *) and the hydroxyl 
stretching is characterised by a weak absorbance in the range 
2480-2620 cm 1 (normal range 2700-2500 cm 1) .
There is none of the strong absorbance in the range 
1410-1310 cm 1 and at about 1200 cm 1 due to 0-H bending and 
C-0 stretching vibrations that would be expected if the orotic 
acid was in an enolic form. Nor is there the sharp O-H stretch­
ing vibrations usually found between 3590 and 3650 cm 1 . 
However, there is a strong absorbance at 1650 cm 1 due to 
carbonyl stretching (the usual range HN— C =0 being 1680-1630 
cm l ) which would be characteristic of the keto form of orotic 
acid.
Thus the infrared spectrum is consistent with a pure 
sample of orotic acid in the keto form.
2.2.4 Nuclear Magnetic Resonance Spectrum
Proton NMR data were obtained at 100 MHz using a 
Varian model HA-100 spectrometer. The proton chemical shifts,
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T, were measured relative to a TMS lock signal. The NMR 
determinations were carried out at a measured temperature of
32 °C. The NMR spectrum is reproduced in Fig 2.7 and gave
following :results.
T Multiplet Intensity Designation
-0.78 Singlet 1H -N1H
-1.28 Singlet 1H -n 3h
1.66 Singlet 1H -COOH
3.95 Singlet 1H CcH 5 —
7.45 DMSO
The assignment of these signals to various protons 
was based on the work of Kokko et al. (1962) and is consis­
tent with a diketo structure rather than an enolic structure 
for orotic acid. The designation of the two amine proton 
singlets is based on the expected deshielding experienced by 
the protons as a result of both the electron withdrawing 
capacity and the anisotropic effect of the carbonyl group.
N^ is ortho to two carbonyl groups and thus the proton 
signal would be expected to be further downfield than the N^ 
proton signal.
2.2.5 Paper Chromatography of Orotic Acid
Chromatography was carried out in glass jars using 
ascending and descending techniques; Whatman, No. 1 paper 
(20 x 50 cm) was used in all cases. Orotic acid was dissolved 
in water (approximately 2 mg/ml) and the test spots were 
applied as 5-10 yg amounts.
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Solvents for Chromatography:
I Isopropanol - water - cone HC1 (56:18.4:16.6 by 
vol) . Run in ascending direction for 18 hours.
II n-Butanol-n-propanol-ethanol - 25% ammonium hydro­
xide-water (40:40:10:45:15 by vol.). Run in de­
scending direction for 12 hours.
Ill 80% (v/v) formic acid-n-butanol-n-propanol-acetone - 
30% (w/v) trichloracetic acid (25:40:20:25:15 by 
vol). Run in ascending direction in solvent satur­
ated atmosphere for 18 hours.
IV Water-n-propanol - 25% ammonium hydroxide (90:10:1 
by vol). Run in ascending direction for 3-4 hours.
V n-butanol-glacial acetic acid-water (5:1:2 by vol). 
Run in ascending direction for 21 hours.
R^ values for orotic acid are summarized in Table 
2.2. Compounds were visualised and detected on chromatograms 
using a Chromato-vue mineralight. In all cases, a single, 
discrete spot, corresponding to published Rf value for orotic 
acid,was obtained.
2.3 Summary of Data
All the chemical data presented in this chapter are 
consistent with the orotic acid used being free of any contam­
ination from other products due to intrinsic breakdown or to 
its method of manufacture. Although no tests were made to 
measure the level of sulfated ash or heavy metals in the orotic 
acid samples, Merck Pty Ltd have indicated that these levels
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are less than 0.1% and less than 0.002% respectively. Unless 
otherwise specified, orotic acid supplied by Merk Pty Ltd 
was used in all the experiments (including the prolonged 
animal toxicity studies, Chapter 3) described in this thesis.
The NMR, infrared and mass spectral patterns, to­
gether with the results of paper chromatography and gas liquid 
chromatography are consistent with the known structure of 
orotic acid (2,4-dioxotetrahydro-pyrimidine-6-carboxylic acid). 
Mass spectra of both the free acid and the TMS derivative of 
orotic acid indicate that orotic acid has a molecular weight 
of 156. Although orotic acid may be expected to exist in 
both the enolic and ketoic forms, the NMR and the infra-red 
spectra indicate that the equilibrium between these two forms 
almost exclusively favors the keto form.
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Figure 2.3 Gas chromatograph of the TMS derivative of 
orotic acid. The column was packed with 
Chromosorb Q coated with 2.0% w/w OV-17.
Nitrogen at 12 ml/min was used as the carrier 
gas.
(a) The column was temperature programmed 
from 100°C to 300°C at the rate of 4°C/ 
minute.
(b) The oven temperature was maintained at 200°C 
and the TMS-Orotic acid was analysed by mass 
spectrometry.
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Figure 2.5 Ultraviolet spectrum of orotic acid as a function 
of pH. Solid lines represent absorbance spectra 
(range 0-0.5 A, scan speed 1/16 nm/sec). Dashed 
lines represent differential absorbance spectra 
(range -0.10 - +0.10 dA, scan speed 1/2 nm/sec). 
All spectra were obtained on a Beckman Acta MVI 
spectrophotometer.
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Figure 2.7 100 mHz NMR spectrum of orotic acid in d^DMSO,
carried out a measured temperature of 32°°C. 
The proton chemical shifts, 6, were measured 
with respect to a TMS lock signal. Negative 
proton values indicate shifts downfield from 
TMS. The spectrum was obtained on a Varian 
model HA-100 nmr spectrometer. The abscissa 
gives the chemical shifts in Hertz. The 
sweep width is 1000 Hz, the sweep offset is 
200 Hz.

TABLE 2.1
SPECTRAL DATA OF OROTIC ACID
PH A (nm)max A . (nm) min
£max 
(xlO-3) 250/260 280/260 29°/260
1 204.8(205) 
278.1(280)
239.9(240)
10.93(10.9) 
7.52(7.52)
0.54 (0.55) 1.94(1.80) 1.58(1.55)
2 278.8(280)
240.5(240)
7.60(7.52) 0.55(0.55) 1.72 (1.80) 1.42 (1.55)
6 205.8(207) 
277.8 (279)
240.2(241)
11.47(11.6) 
7.60 (7.68)
0.58 (0.57) 1.70(1.71) 1.34 (1.38)
7 278.5(279)
240.7(241)
7.60(7.68) 0.55 (0.57) 1.67(1.71) 1.33 (1.38)
8 279.0
241.4
7.82 0.59 1.71 1.40
10 278.6
240.2
5.42 0.56 1.63 1.27
12 285.8(286)
242.8(244)
6.12 (5.98) 0.80 (0.79) 1.74(1.73) 1.80(1.73)
Data at pH 1, 6, 8 and 12 were obtained 
on a Beckman Acta MVI; pH 2, 7 and 10 
on a Cary model 118 spectrophotometer. 
Values in brackets are from data on 
orotic acid by Shugar and Fox (1952).
TABLE 2.2
PAPER CHROMATOGRAPHY DATA
Compound Solvents
I II III IV V
Orotic Acid 
(Merck) 0.57 0.34 0.52 0.90 0.16
Orotic Acid 
(Calbiochem) 0.57 0.35 0.49 0.90 0.20
Orotic Acid 
(Lonza) 0.57 0.35 0.49 0.90 0.20
Literature R^ Value 0.57A 0.31B 0.54 B 0.88B -
Rf values of orotic acid purchased from 
E. Merck Pty Ltd, Calbiochem Pty Ltd and 
Lonza Ltd. All values determined on 
Whatman No. 1 paper using solvents and 
running times as given in Section 2.2.5.
A - Fink, K. and Adams, W.S. (1966),
J. Chromatog., Z2, 118-129.
B - Gerlach, E., Dreisbach, R.H. and
Deuticke, B. (1965), J. Chromatog.,
, — ' 81~85* , j> f> j> j> j> j> j> f> f ?
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CHAPTER 3
METABOLIC SUPPORT OF THE ACUTELY STRESSED MYOCARDIUM
3.1 Introduction
Cardiac hypertrophy is known to occur in man under 
a variety of conditions, most of which appear to be associ­
ated with increased cardiac work. An extensive coverage of 
the methods that have been used for producing experimental 
cardiac hypertrophy is included in a review by Goss (1971). 
Stable left ventricular hypertrophy has been shown to occur 
within 6 days following banding of the thoracic aorta in 
rats (Fanburg and Posner, 1968; Nair et al., 1968), while 
the development of hypertrophy is more gradual in dogs 
(O'Kane et al., 1973) and in rabbits (Alexander et al., 1962) 
Cardiac hypertrophy in the rat has also been produced by a 
strenuous programme of treadmill exercise (Oscai et al. ,
1971) or swimming (Arcos et al., 1968), by producing an 
aorto-caval fistula (Dart and Holloszy,; 1969) ,. by, production 
of anaemia (Neffgen and Korecky, 1972) and by treatment 
with sympathomimetic drugs and thyroxine (Fanburg, 1970).
In general, operative methods such as constriction of the 
pulmonary artery, the thoracic or the abdominal aorta pro­
duce a relatively rapid increase in the heart size. A more 
gradual development of hypertrophy is produced by anaemia, 
hypoxia or exercise.
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Commensurate with myocardial hypertrophy, a 
significant increase in the rate of synthesis of protein 
(Posner and Fanburg, 1968) and nucleic acids (Fanburg and 
Posner, 1968) was reported. It is now clear that heart 
muscle possesses very active systems for the synthesis and 
breakdown of the structural components involved in muscle 
contraction and in supplying chemical energy to support 
contraction. Intracellular proteins and organelles in the 
normal heart are continually being synthesised and destroyed 
For example, cardiac mitochondial cytochromes turn over 
with a half-life of about 5 days (Huston and Krebs, 1968) 
and myosin with a half-life of 6-8 days (Busch et al., 1972) 
When cardiac hypertrophy is experimentally induced by the 
imposition of an increased work load, there is a rapid 
activation of the synthetic processes and the protein 
synthetic activity of the muscle may approach that of the 
liver or reticulocytes (Martin et al., 1974). Meerson 
(1969) proposed that during this acute phase of adjustment 
of the heart to an increased work load, there may be a 
relative deficiency of cofactors which may limit the extent 
of activation of protein and nucleic acid synthesis.
Meerson believed that the administration of an orotic acid, 
vitamin and folic acid "cocktail" would lead to a
greater production of nucleic acid precursors and thus 
prime the processes of protein synthesis. In this chapter, 
the effects of this orotic acid "cocktail" on developing 
hypertrophy of the rat heart are presented, with emphasis 
on the ability of orotic acid to enhance the processes of 
compensatory hypertrophy.
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3.2 Experimental
3.2.1 Animals
Male Wistar albino rats {Mus norvegicus albinus) 
weighing 200-240 g, were used in the experiments. The rats 
were bred in the Department of Biochemistry, Australian 
National University, and were housed in a temperature- 
controlled animal room (22°C). Illumination was provided 
for 12 hours daily. The animals were kept in groups of four 
in sawdust lined plastic cages and, unless specified, were 
fed a ration of standard rat cubes (Bunge Australia Pty Ltd, 
Murrumburrah, N.S.W.). Feed and water were available to 
the animals at all times, except for a four hour interval 
prior to the killing of the animal or the taking of blood 
samples. The food was withdrawn over this period to avoid 
post-prandial influences on tissue and plasma metabolite 
concentrations.
3.2.2 Induction of Left Ventricular Hypertrophy
Adult male rats were anaesthetized with diethyl 
ether. The main index of the depth of anaesthesia was the 
rate of respiration. Thus, if breathing became shallow or 
less frequent, the animals were allowed to breathe room air 
until the normal pattern of breathing was re-established. 
During the operation the animals were kept warm on a tempera­
ture-controlled, stainless steel table. Aseptic precautions 
were observed in the operations described here.
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Following a 2.5-3.0 cm long, midline abdominal 
incision, a 0.5 cm segment of the suprarenal abdominal aorta 
was exposed. A 3.0 black silk suture (Ethicon) was passed 
around the aorta, a 21 gauge needle (0.82 mm external 
diameter and 3 cm in length) was placed adjacent to the 
aorta, and both the aorta and the needle were encircled by 
the loop of suture material (Fig. 3.1). The suture was 
then firmly tied and the needle was withdrawn. The abdominal 
wall was closed with interrupted 3.0 black silk sutures.
The skin was then closed with a further row of sutures of 
the same material. The animal was kept warm for the follow­
ing 24 hours and allowed food and water ad libitum.
3.2.3 Induction of Renal Hypertrophy
Adult male rats were anaesthetized using diethyl 
ether, as described in Section 3.2.2. In the mature rat, 
compensatory renal hypertrophy of the contralateral kidney 
was induced by unilateral nephrectomy. The rats had their 
left kidneys removed through a midline abdominal incision.
The sham-operated rats had a small perirenal mass of fat 
(approximately 100 mg) removed. The abdominal wall and 
skin were then closed as described in Section 3.2.2.
3.2.4 Administration of Orotic Acid to Rats
Orotic acid (10 mg/kg/day) was administered by 
oral intubation twice a day, commencing immediately after
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the induction of hypertrophy. The orotic acid-treated 
animals also received the cofactors vitamin (100 mg/kg/
day) (Glaxo Allenbury, Australia) and folic acid (2 mg/kg/ 
day) (Ethnor).
3.2.5 Determination of Urinary Excretion 
Patterns of Orotic Acid
Male rats were individually maintained in wire- 
bottomed cages and were allowed free access to food and 
water. Urine was collected under toluene, centrifuged 
(10,000 g, 10 minutes) and portions of the supernatant 
fluid assayed for orotic acid by the colormetric assay of 
Stajner et al. (1968).
3.2.6 The Determination of the RNA, DNA and 
Protein Content of Cardiac and Renal Tissues
At the end of each experiment, the animals were 
killed by a blow to the head and either the heart or a kidney 
removed. The tissues were blotted on filter paper, weighed 
and stored in liquid nitrogen until assayed.
The total tissue RNA and DNA was extracted using 
a modification of the Schmidt-Thannhauser method, described 
by Munro and Fleck (1966). The total tissue RNA was estimated 
using the UV spectrophotometric procedure of Fleck and Begg 
(1965). The total DNA content was estimated using the 
indole procedure of Ceriotti (1952).
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The total tissue protein was measured by applying 
the procedure of Lowry et al. (1951) to the protein precipi­
tate of a perchloric extraction (Section 4.2.1).
3.2.7 Assay of Total Myocardial Protein Synthesis
The estimation of the rate of total myocardial
protein synthesis was carried out using the method of Posner
3and Fanburg (1968) except that the dose of [4,5 - H] leucine 
was reduced from 0.3 to 0.1 yCi/g body wt. Tritiated leucine 
(19.0 Ci/mmol) was supplied by the Radiochemical Centre, 
Amersham, Bucks, U.K..
3.2.8 Assay of the Total Collagen Content of 
the Heart
Rat hearts (about 0.7 g) were homogenised in 3 ml 
HCl (6N) and the homogenate was hydrolysed by autoclaving 
overnight at 125°C. After hydrolysis, the pH was adjusted 
to pH 8.5 ± 0.2 with KOH (2N) and the sample was diluted 
to 25 ml. The hydrolysate was centrifuged (4,000 g for 
10 minutes) and 0.5 ml aliquots were then taken for the 
estimation of hydroxyproline by the method of Kivirikko et 
al. (1967). The cardiac collagen content was calculated
by multiplying the hydroxyproline content by a factor of 
7.46 (Neuman and Logan, 1950). The collagen concentration 
was expressed in terms of the wet weight of the original 
tissue sample.
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3.2.9 Disc Gel Electrophoresis of Cardiac 
Proteins
Hearts were homogenised in 10 volumes of 0.1 M KC1 
and 5 mM histidine at pH 7.4 and 4°C. The homogenate was 
kept at 4°C for 1 hour and was centrifuged at 105,000 g 
for 1 h. The particle free supernatant fluid was removed 
and saved. The pellet was suspended in buffer (0.45 M KC1, 
0.15 M KH^PO^Jfor 12 h and centrifuged at 2000 g for 20 min. 
The first supernatant fraction was called the soluble pro­
tein fraction and the second supernatant fraction the con- 
tractile-membrane protein fraction. Both supernatant 
fractions were made 1% in sodium dodecyl sulfate and 10 mM, 
with respect to dithiothreitol and were heated at 45°C for 
2 h. The samples were exhaustively dialysed against 0.01 M 
sodium phosphate, 0.1% sodium dodecyl sulfate and 1 mM 
dithiothreitol (pH 7.0) at room temperature.
The protein extracts were subjected to polyacryl­
amide disc gel electrophoresis, as described by Weber and 
Osborn (1969). The gels were stained in a 0.25% Coomassie 
Brilliant Blue, 45.4% methanol and 9.2% glacial acetic acid 
solution for 2 h. The gels were destained in a 7.5% acetic 
acid, 5% methanol solution until clear. The destaining 
process was facilitated by the addition of about 5 g of 
Zeolite DMF mixed bed resin to the destaining solution.
Densitometer tracings of the gels were obtained 
using a Varian Techtron spectrophotometer model 635, fitted 
with a gel scanner accessory.
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3.2.10 The Purification of Cardiac Myosin and
the Assay of Cardiac Myosin ATP ase Activity
Myosin was purified using the procedure of Shiverick 
et al. (1975) and three rat hearts were pooled for each cardiac
myosin preparation. All procedures were carried out at 0°C 
and dithiothreitol (2 mM) was present in all solutions.
Prior to the assay of myosin ATP ase activity, 
dithiothreitol was removed from the myosin preparation by 
dialysis (2 h) against 0.5 M KC1, 0.05 M Tris-KCl (pH 7.5).
2 +The Ca -stimulated ATP ase activity was assayed 
in 0.05 M KC1, 10 mM CaC^/ 5 mM ATP and 0.05 M Tris-HCl 
(pH 7.5). The assay mixture for (K+)EDTA-activated ATP ase 
activity contained 0.5 M KCl, 1 mM EDTA, 5 mM ATP and
0.05 M Tris-HCl (pH 7.5). The final volume for each assay 
was 2.0 ml and, following a 5 min preincubation, reactions 
were initiated by the addition of myosin (0.2 mg) to the 
assay mixtures. All reactions were carried out at 25°C and 
were stopped by the addition of 1 ml of cold 15% (w/v)
trichloroacetic acid. Inorganic phosphate was determined 
using the method of Fiske and SubbaRow (1925).
3.2.11 Amino Acid Analysis
The heart was freeze-clamped with Wollenberger 
tongs (Wollenberger et al., 1960), which had been precooled 
in liquid nitrogen. The frozen hearts were rapidly weighed
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and, using a stainless steel mortar and pestle, were 
pulverised to a fine powder under a layer of liquid 
nitrogen. The powder was then deproteinised by homogenising 
in perchloric acid (0.6 N, 5 volumes) in a motor driven 
Potter-Elvehjem glass homogeniser. The homogenate was 
centrifuged at 10,000 g for 10 min (at 0°C). The super­
natant fluid was neutralised to pH 4-5 with 5 M K^CO^ and made 
up to 10 ml with water. Precipitated KCIO^ was subsequently 
removed by centrifugation (10,000 g for 10 min). The amino 
acids in the extract were separated from glycolytic and 
Kreb's cycle carboxylic acids by passing 4 ml through a 
Dowex-50 ion-exchange column (20 x 1.5 cm) in the H+ form 
(Bio-Rad Laboratories, California). The contaminating 
carboxylic acids were eluted with distilled water until 
the pH of the eluent was neutral. The amino acids were 
then eluted with 2.5 N NH^OH and the eluent collected.
Using a Buchi rotary evaporator, this eluate was evaporated 
and redissolved in water a number of times, until the pH 
of the distillate indicated no further release of ammonia.
The sample was then evaporated to dryness, 
dissolved in 1 ml of Technicon starting buffer (Technicon 
reference manual). Samples (0.2 ml) were injected onto 
the column of a Technicon auto analyser, packed with 
chromobeads C(2) resin and eluted with a citrate gradient, 
according to the Technicon procedure (Technicon reference 
manual).
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Intracellular amino acid levels were calculated 
assuming an intracellular volume of 56 ml/100 g of tissue 
and an extracellular volume of 22 ml/100 g of tissue, as 
determined for rat heart previously (Scharff and Wool, 1965).
3.2.12 The Estimation of Serum and Tissue
Calcium and Magnesium Concentrations
Serum calcium concentrations were studied in 
normal rats given an intraperitoneal or an intragastric 
injection of 0.5 mmol calcium/kg body wt as 0.1 M calcium 
orotate, 0.1 M calcium chloride, or 0.1 M calcium carbonate. 
Forty minutes after the injection, half the rats were killed 
and the blood collected. The remaining animals were killed 
4 h after their respective injections and the blood samples 
again collected. The serum calcium concentrations were then 
measured as described below.
Tissue calcium concentrations were studied in 
rats given an intragastric injection of calcium orotate or 
calcium chloride (0.5 mmol/kg body wt). The animals were 
killed 6 h after their injection. Tissues (liver, heart, 
kidney, lung, and gastrocnemius muscle) were freeze-clamped 
with Wollenberger tongs, weighed and pulverized under 
liquid nitrogen, as described in Section 4.2.1. The 
powdered tissue was dried overnight at 70°C, digested for 
24 h in 3 ml of a 1:2 (v/v) mixture of 60% perchloric acid 
and 30% hydrogen peroxide and the volume adjusted to 200 ml.
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The sample calcium concentrations were then determined as 
described below.
Hypertrophied rat hearts and orotic acid-treated, 
hypertrophied rat hearts (prepared as described in 
Sections 3.2.2 and 3.2.4) were freeze-clamped and digested 
as described above. The total calcium and magnesium con­
centrations in these samples were then determined.
The total sample calcium and magnesium contents 
of the above samples were then determined by atomic absorp­
tion spectroscopy (using a Varian Techtron Spectrophotometer, 
model 1200), using the procedures described in the Varian 
Techtron manual "Analytical Methods for Flame Spectroscopy".
3.2.13 Prolonged Toxicity Studies Using Orotic Acid
Prolonged toxicity studies, using orotic acid, were 
carried out in animals (cats and guinea pigs), using the 
guidelines suggested by the Australian Department of Health 
(Publication NDF4).
3.2.13.1 Animals
Guinea pigs, bred in the Animal Breeding Establish­
ment of the John Curtin School of Medical Research, Australian 
National University, were used in these experiments. The 
animals were about 3 months old at the commencement of the 
study. They were housed in a temperature-controlled animal
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room (22°C) and illumination was provided for 12 h daily.
The animals were kept in groups of four in sawdust-lined 
plastic cages. Guinea pigs were fed a ration of standard 
guinea pig cubes (Bunge Australia Pty Ltd, Murrumburrah, 
Australia), supplemented with pumpkin and green vegetables. 
Feed and water (supplemented with ascorbic acid, 0.01% w/v) 
were available to the animals at all times.
Domestic cats, about 30 weeks old, bred in the 
Animal Breeding Establishment of the John Curtin School of 
Medical Research, Australian National University were also 
used in these studies. They were housed in separate, 
sawdust-lined cages and were kept under the same conditions 
of light and temperature as the guinea pigs. The cats were 
fed a ration of commercially available feed pellets, fresh 
meat and milk, twice daily. Their diet was supplemented 
with SA37 vitamin tablets.
3.2.13.2 Administration of Orotic Acid
The animals (24 guinea pigs, 12 male and 12 female; 
8 cats, 4 male and 4 female) were maintained on the diets 
described above for a period of two weeks prior to the 
commencement of orotic acid feeding. The animals were then 
fed orotic acid (cats were fed 200 mg orotic acid/kg body wt/ 
day; guinea pigs were fed 300 mg orotic acid/kg body wt/ 
day) daily for the following 6 months. The orotic acid was 
administered to the guinea pigs in the form of a neutral
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suspension of orotic acid in water (200 mg orotic acid/ml) 
and to the cats packaged in gelatin capsules (400 mg orotic 
acid/capsule).
During the six month feeding trial, a further 
6 guinea pigs (3 male and 3 female) and 2 cats (1 male and 
1 female) were maintained, under the same conditions, as 
control animals.
3.2.13.3 Animal Studies 
(a) Appearance
The animals were examined twice weekly using an 
observational method for estimating drug actions, developed 
by Campbell and Richter (1967). Using this procedure, the 
following signs were recorded: movements (ataxia, high
gait, tremor, convulsions, writhing movements, repeated 
jumps, abducted hind legs, increased or decreased motor 
activity, the presence of a righting reflex, head drop and 
whether or not the tail was erect), eye characteristics 
(ptosis, mydriasis, miosis, whether protruding or closed, 
whether the cornea was cloudy and the occurrence of 
lacrimation) and miscellaneous signs (polyuria, haematuria, 
diarrhoea, sensitivity to noise, hyperhydrosis, salivation 
and whether the ears were flushed or pale).
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(b) Serum Components
After feeding the animals for 6 months, blood 
samples were taken and the serum fraction analysed, using 
a Technicon SMAC System (Biochemistry Department, Canberra 
Hospital). The serum was analysed for the following com­
ponents: sodium, potassium, chloride, inorganic phosphate,
calcium, iron, cholesterol, alkaline phosphatase activity, 
lactate dehydrogenase activity, alanine aminotransferase 
activity, aspartate aminotransferase activity, uric acid, 
urea, glucose, creatinine, albumin, protein, bilirubin 
and total carbon dioxide.
(c) Urine Sample
Urine samples from the guinea pigs and cats were 
obtained by cystocentosis. Samples were analysed using 
"Combur 8_ Test" test strips (Boehringer Mannheim, Australia) 
These strips tested the urine for the presence of nitrate, 
protein, glucose, ketones, urobilinogen, bilirubin and 
blood as well as determining the pH of the sample.
(d) Tissue Samples
Tissues (bone marrow, heart, kidney, liver, lung, 
skeletal muscle, spleen and thyroid) for histopathological 
examination were cut into sections (4-6 mm), fixed in phos­
phate-buffered formalin (pH 7.4) and set in paraffin blocks 
for future analysis.
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3.3 Results
3.3.1 Induction of Experimental Hypertrophy
From an initial series of experiments, it was 
established that for rats weighing 200-240 g, a 21 gauge 
needle was required for the induction of hypertrophy. In 
rats weighing less than 200 g, hypertrophy was induced in 
only a few animals. In the group of rats weighing more 
than 240 g, the mortality rate from acute cardiac failure 
became excessively high.
Twenty-five normal rats, ranging in body weight 
from 100 g to 300 g, were used to provide the data for the 
plot of body weight versus wet heart weight (whole heart, 
with great vessels trimmed away). As can be seen in Fig. 3.2, 
a linear relationship exists between body weight (above 100 g) 
and heart weight and the following regression equation was 
derived:
heart weight in mg = 235.5 + (2.008 x body weight in kg) (1)
The pre-operative body weight was used, since a variable 
loss in body weight occurred during the first fortnight 
after the operation. The expected normal heart weights 
were predicted by the use of this equation and compared with 
the experimentally determined heart weight after aortic 
constriction, in a manner similar to that of Grimm et al.
(1963). The differences were expressed as a percentage 
of the predicted values and were plotted as a function of 
post-operative time (Fig. 3.3).
In response to aortic constriction, a signifi­
cant increase in heart weight was not detected until three 
days after surgery (Fig. 3.3). The increase in heart 
weight was quite pronounced after three days (12%) and 
continued for approximately ten days after surgery, by 
which time the net rate of increase of heart weight 
gradually tapered off to an overall increase of 34% in 
heart weight at 25 days.
3.3.2 Orotic Acid and the Development of 
Myocardial Hypertrophy
Following the induction of myocardial hypertrophy, 
there were significant increases in the mass, the protein 
and RNA concentrations and the total DNA content (Figs 3.3,
3.4 and 3.5) of the heart.
The increased cardiac RNA concentration (Fig. 3.4a), 
as well as the increased cardiac RNA content, was thought 
to reflect the increased number of ribosomes (the rRNA con­
stitutes over 80% of cellular RNA, Hirsch 1967) that have 
been observed during cardiac growth (for example, Grimm et 
al., 1966; Korecky and French, 1967; Fizelova and Fizel,
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1970) .
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Although the cardiac RNA concentration increased 
with hypertrophy, the DNA concentration remained constant 
with increasing cardiac mass (Fig. 3.3), suggesting that 
increased DNA synthesis had occurred. Fanburg and Posner 
(1968) have reported that the bulk of this increased DNA 
content was associated with increased mitotic activity of 
the non-muscle tissue of the heart, such as connective 
tissue and blood vessel endothelial cells, which together 
account for 73% of cardiac nuclei (Morkin and Ashford, 1968) .
All the operated animals lost weight in the 
immediate post-operative period. This must be attributed 
to voluntary inanition following surgery. It would be 
expected that this inanition would result in a loss of 
organ weight and a decrease in the cardiac protein con­
centration. Such a decrease in cardiac protein concentra­
tion was observed in the sham-operated animals (Fig. 3.5b), 
though there were no significant decreases in the cardiac 
RNA and DNA concentrations of sham-operated animals 
(Fig. 3.4).
As Meerson (1969) had proposed, supplementing the 
diets of animals with hypertrophied hearts with nucleic 
acid precursors (such as orotic acid) enhanced the concen­
tration of cardiac nucleic acids. The results shown in 
Fig. 3.4a indicate that the hearts of those animals fed 
orotic acid contained an increased concentration of RNA, 
though there were no significant changes in either the
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protein concentration (Fig. 3.5b) or the heart weight 
(Fig. 3 . 3 ), compared with hypertrophied hearts not treated 
with orotic acid. If allowance was made for the decrease 
in the RNA concentration due to the handling of the animals 
when the orotic acid was administered, it was found that 
the orotic acid-enhanced RNA concentration (compared with 
untreated hypertrophied hearts) was maintained over the 
10 day post-operative period examined.
Since there were no significant differences in 
the weight or the DNA concentration of orotic acid-treated 
and untreated hypertrophied hearts (Fig. 3.3 and 3.4b), 
the results do not suggest any proliferation of the 
connective tissue as a result of orotic acid treatment.
The results also suggest that the size of the vascular bed 
(blood vessel nuclei account for 42% of total myocardial 
nuclei, and hence a significant proportion of the cardiac 
DNA content, Morkin and Ashford, 1968) was the same in 
orotic acid treated and untreated hypertrophied hearts.
If this was correct, it would be a cause for concern, 
because of the heightened energy demands (for nucleic acid 
and protein synthesis) and hence heightened oxygen demand 
of the orotic acid-treated hypertrophied hearts. This 
aspect of orotic acid therapy is discussed in greater 
detail in Chapter 6.
The data in Fig. 3.5 show the effect of both 
orotic acid and cofactor treatment and orotic acid treat­
ment on the rate of total myocardial protein synthesis,
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using the tritiated leucine uptake method of Posner and 
Fanburg (1968). It is apparent that, although the total 
myocardial mass and the myocardial protein concentration 
did not change as a result of orotic acid treatment during 
hypertrophy, the rate of protein synthesis was enhanced 
as a result of orotic acid treatment. In the orotic acid 
and cofactor treated group, the peak activity in protein 
synthesis occurred much earlier than in the untreated, 
operated animals. At 18 h in the operated, untreated 
group, the rate of protein synthesis was only 8% higher 
than in the normal animals. The rate was 48 ± 11% higher 
in the orotic acid and cofactor treated, hypertrophied 
group when compared with the normal group of animals.
Thus, a marked increase in the rate of protein synthesis 
was noted, 18 h after the onset of hypertrophy in the 
orotic acid and cofactor treated animals. The data of 
Fig. 3.5 also show the effect of orotic acid, without folic 
acid and vitamin B^/ on the rate of myocardial protein 
synthesis. These data indicate that irrespective of whether 
the orotic acid supplement was administered alone or in 
conjunction with folic acid and vitamin B.^/ an enhanced 
rate of protein synthesis was observed in the hypertrophied 
hearts so treated. There was no quantitative difference 
in the percentage increase in leucine uptake in the orotic 
acid and cofactor treated and the orotic acid treated 
hypertrophied hearts.
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In this section, it has been clearly shown that 
changes in macromolecular synthesis occur very soon after 
the induction of hypertrophy. A major question is: "How
is this mechanical stress translated into changes in macro- 
molecular synthesis?" Among several hypotheses which have 
received consideration (Gibson, 1973), one involves the 
proposition that an increased intracellular concentration 
of amino acids may cause an increase in the rate of macro- 
molecular syntheses. This hypothesis was of interest in 
view of studies, with mammalian cells, which have suggested 
that the amino acid supply is an important regulator of 
macromolecular synthesis (Wannemacher, 1972; Morgan et 
al., 1971).
The data of Table 3.1a show that the plasma amino 
acid concentrations were the same in sham-operated animals, 
animals with one day hypertrophied hearts and animals with 
one day hypertrophied hearts, treated with orotic acid.
The data of Table 3.1b show the intracellular amino acid 
concentrations of sham-operated, one day hypertrophied and 
one day hypertrophied and orotic acid-treated hearts.
These results indicate that, with the exception of alanine 
and serine, the amino acid concentrations were not signi­
ficantly different in the hypertrophied and the sham- 
operated hearts, one day after surgery. The results also 
show that orotic acid treatment had little effect on the 
intracellular amino acid concentration. There were no
significant differences in the intracellular amino acid 
concentrations compared with untreated animals, except 
for the increases in the intracellular concentrations of 
glycine, alanine and serine. It was, therefore, apparent 
that in the immediate post-operative period, differences 
in the amino acid concentrations could not account for 
the increased macromolecular syntheses in the hypertrophied 
hearts. Those changes that did occur (alanine and serine 
in the hypertrophied hearts and alanine, serine and glycine 
in the orotic acid treated, hypertrophied hearts) were 
small in comparison with the concentrations of these amino 
acids in normal hearts (Table 3.1) and it is unlikely that 
these minor changes would play such an outstanding regula­
tory role in protein synthesis. Moreover, these amino 
acids (alanine, serine and glycine) may all be metabolised 
to pyruvate and the increases in their concentrations may 
be due to a mass action effect of the increased pyruvate 
concentrations in the hypertrophied hearts (Table 4.3).
Reports in the literature have indicated that 
both the administration of glucocorticoids (Kaplan and 
Shimizu, 1963) and fasting (Harker et al., 1968) will 
increase the level of most amino acids in the plasma.
Kaplan and Shimizu (1963) have also shown that glucocorti­
coid administration raised the concentration of amino 
acids in skeletal muscle. Thus, the increased plasma and 
cardiac amino acid concentrations in the sham-operated
animals, compared with normal animals (Morgan et al.,
1971), was probably due to the stress of surgery (with 
accompanying adrenocortical activity) and the inanition 
of the animals following surgery.
These results do not preclude the possibility 
that changes in the cardiac intracellular concentrations 
of amino acids may play a role in the development of 
cardiac hypertrophy. Wannemacher and McCoy (1969) have 
reported an increase in the intracellular amino acid con­
centration. However, they induced hypertrophy with 
deoxycorticosterone over a four week period, before 
measuring the amino acid concentrations and it is not 
possible to correlate their results with those reported 
here. Lesch et al. (1970) have reported that the intra­
cellular amino acid concentration may be increased during 
passive stretch, resulting from an increased work load, 
however, these experiments were performed in vitro using 
rabbit hearts.
The results presented here, although only covering 
one time period, suggest that the intracellular amino acid 
concentration does not act as a switch mechanism to control 
protein synthesis during hypertrophy. They also suggest 
that the increased rate of protein synthesis in the orotic 
acid-treated, hypertrophied hearts, compared with the un­
treated, hypertrophied hearts was not due to changes in the 
intracellular leucine pool but to an enhanced rate of 
protein synthesis.
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Muscle fractions (the contractile protein-membrane 
protein fraction and the soluble protein fraction) were 
isolated and subjected to disc gel electrophoresis, as 
described in the experimental section. The banding pattern 
(as shown by the densitometry patterns shown in Fig. 3.10) 
showed no qualitative differences in either fraction when 
the hypertrophied and the hypertrophied and orotic acid- 
treated groups of hearts were compared. The data suggest 
that the same populations of cardiac proteins were synthe­
sised in the untreated and the orotic acid-treated, hyper­
trophied hearts. This does not exclude the possibility 
that the synthesis of some individual proteins was not 
normal, since a large number of components were detected 
and the complete resolution of all of them clearly was not 
possible.
Although the results of the disc gel electro­
phoresis suggested that the same populations of proteins 
were synthesised in the orotic acid-treated, hypertrophied 
hearts as in the untreated, hypertrophied hearts, the popu­
lation of proteins examined was that of the 0-80,000 
molecular weight range and did not include the collagen 
proteins of the heart. Various reports have suggested that 
there was independent growth of the fibrous tissue and the 
muscular cardiac tissue during hypertrophy (Skosey et al., 
1972; Buccino et al., 1969) and others have reported in­
creased collagen synthesis in the aorta and heart of hyper­
tensive rats (Ooshima et al., 1974). Further, Caspari et al.
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(1975) have proposed that there is independent growth of 
the muscular and collagenous components of the myocardium 
during normal development. It was, therefore, possible 
that the orotic acid treatment may have preferentially 
stimulated cardiac collagen synthesis at the expense of 
the syntheses of other cellular components. In terms of 
the capacity of the orotic acid treatment to enhance 
myocardial performance, the ability of the myocyte to cope 
with the increased work load is more important than the 
ability of the interstitial cells to synthesise collagen - 
this being all the more important in view of a report that 
the interstitial cells are amongst the first cardiac cells 
to respond to an imposed stress (Grove et al., 1969).
With a view to measuring changes in the fibrous content 
of the hypertrophied heart and the effect of orotic acid 
on the development of the cardiac fibrous component, the 
cardiac collagen concentration was measured.
The data in Fig. 3.6 show the results of experi­
ments in which the cardiac collagen concentration was deter­
mined in normal animals, treated with orotic acid, sham- 
operated animals, animals with hypertrophied hearts and 
animals with hypertrophied hearts, which had been treated 
with orotic acid. From Fig. 3.6, it is apparent that neither 
orotic acid treatment of normal hearts nor the sham-operation 
had any significant effect on the cardiac collagen content. 
However, in response to aortic constriction, there was a
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significant increase in the cardiac collagen concentration 
5-10 days after the induction of hypertrophy. The data of 
Fig. 3.6 also show that the orotic acid treatment of rats 
with hypertrophied hearts had no effect on the cardiac 
collagen concentration, compared with untreated animals.
These results show that orotic acid acts to enhance total 
cardiac protein synthesis, without favoring protein synthesis 
in either the interstitial cells or the myocytes.
3.3.3 Cardiac Hypertrophy and Cardiac ATP ase 
Activity
The results presented in Table 3.2 indicate that
2 +the Ca -stimulated ATP ase activity of cardiac myosin of
hypertrophied hearts was reduced, while the EDTA-stimulated
ATP ase activity remained unaltered during hypertrophy.
Although these results are consistent with earlier reports 
2 +of reduced Ca -stimulated ATP ase activity of myosin
(Thomas and Alpert, 1977; Katagiri and Morkin, 1974),
there is no general agreement that the activity of myosin
ATP ase from hypertrophied myocardium is reduced. Wikman-
2 +Coffelt et al. (1975) reported elevated Ca -stimulated
ATP ase and (K+) EDTA-stimulated ATP ase activities, 3 weeks 
after pulmonary banding, followed by an 11% decrease in the 
same activities 16 weeks after banding. This pattern is 
the reverse of that reported by Oganessyan et al. (1973)
for actomyosin ATP ase activity following aortic banding.
It should also be noted that, unlike the results presented
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here, others (Katagiri and Morkin, 1974; Wikman-Coffelt
et al., 1975) have reported parallel changes in both the 
2+ +Ca -stimulated and (K ) EDTA-stimulated ATP ase activities 
of myosin from hypertrophied hearts. The reason for these 
differences is unknown, but some variability may be due 
to differences in the severity and the duration of the 
imposed stress.
In those hypertrophied hearts which were treated 
2 +with orotic acid, Ca -stimulated ATP ase activity increased
(an increase in activity of 15% over control values, seven
days after the induction of hypertrophy, Table 3.2) and
the (K+) EDTA-stimulated activity, as in the untreated
hearts, remained the same. These results were compatable
with the belief that changes in the myosin ATP ase activity
during hypertrophy may be due to changes in the myosin
isozyme composition. The increased protein synthesis
following the induction of hypertrophy (Section 3.3.2) and
the increased rates of myosin turnover with pressure-
induced hypertrophy (Morkin et al., 1972) were consistent
with the appearance of an isozyme of cardiac myosin following
the induction of hypertrophy. Further, electrophoretic
analysis of rat myosin by Hoh (1975) revealed the presence
of 3 isozymes of ventricular myosin, so that shifts in the
distribution of these multiple forms of myosin may be
expected to correlate with differences in the myosin ATP ase
activities and the contractile properties of the muscle
24-fibres. The reduced Ca -stimulated ATP ase activity of
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myosin from hypertrophied hearts has been attributed to 
an alteration of the SH^ site of myosin (Shiverick et al., 
1976). However, the dependence of (K+) EDTA-activated 
ATP ase on an intact SH^ site (Reisler et al., 1974) would 
suggest that this activity would also be altered during 
hypertrophy. That this was not the case, in either the 
untreated or the orotic acid treated, hypertrophied hearts, 
would suggest a partition of the functional aspects of the 
SH^ site (as suggested by Thomas and Alpert, 1977). and/or 
possible amino acid substitutions near the SH^ site of 
the myosin isozymes.
3.3.4 Orotic Acid and Electrolyte Alterations
Nieper (1974) has proposed, from observations on 
tissue cultures, that orotates, such as calcium orotate 
and magnesium orotate, may pass through the cell membrane 
in an undissociated form and release their respective ions 
within the cell. He has emphasised the importance of the 
orotates as electrolyte carriers and has applied this 
principle of directed electrolyte transport in lithium, 
calcium and magnesium therapy (Nieper, 1969, 1970, 1973a,
1973b). Nieper has also proposed that orotates show a 
special affinity for tissues with an active pentose phos­
phate pathway (Nieper, 1974).
The present study was carried out primarily to 
investigate the pharmaco-kinetics of the calcium ion, when
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administered as calcium orotate and to determine whether 
or not orotate salts show a special affinity for tissues 
with an active pentose phosphate pathway.
Firstly, consider the activity of the pentose 
phosphate pathway. It is a convention of intermediary 
metabolism that the pentose phosphate pathway is not pre­
sent in skeletal or cardiac muscle. This convention is
14based on "old type" experiments where [1-C ] glucose and
14 14[6-C ] glucose are oxidised to CC^ •
14 14CC>2 from [1-C ] glucose
14 14CC>2 from [6-C ] glucose
greater than one is supposed to be indicative of the opera­
tion of the pentose phosphate pathway, together with glyco­
lysis and the tricarboxylic acid cycle. A C^/C^ ratio of 
one is taken to indicate that glycolysis and the reactions 
of the tricarboxylic acid cycle only operate on glucose 
(Shipp et al., 1964; Chrevasse et al., 1964). This is a
weak argument since it may be shown that the time of incuba-
14 14tion of the tissue with [1- C] glucose and [6- C] glucose, 
as well as the concentration of glucose in the incubation 
medium wholly determines the magnitude of the C^ /C^ . ratio 
(Davies, 1961) and neither the presence of the pentose 
phosphate pathway nor its contribution to glucose metabolism 
may be judged by such a ratio. For these reasons, the
A ratio of
(§r| ratio>
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pentose phosphate pathway "activity" was measured by the 
utilization of arabinose 5-P and ribose 5-P (Williams and 
Clark, 1971; Williams et al., 1977) and the production of 
triose 3-P and hexose 6-P from these substrates. The 
details of the experimental methods used to measure pentose 
phosphate pathway "activity" are shown in the legend opposite 
Table 3.3 and the experiments were performed in this labora­
tory by Dr P. Blackmore. Details of the measurement of the 
uptake of labelled orotic acid into the various tissues of 
the body are given in Chapter 6 (as well as a more complete 
discussion of this aspect of orotic acid metabolism).
Table 3.3 shows that there was no correlation 
between the uptake of labelled orotic acid and the activity 
of the pentose phosphate pathway. Splenic tissue was 
found to have a high pentose phosphate pathway activity 
and a low uptake of orotic acid; renal tissue, which showed 
the same rates of utilization of arabinose 5-P and ribose 
5-P as splenic tissue, and the greatest rate of orotic 
acid uptake of the tissues examined. These findings offer 
no support whatsoever for the finding of Nieper (1974) that 
the orotates show a special affinity for those tissues with 
an active pentose phosphate pathway.
Turning now to the concept of the orotates as 
electrolyte carriers, the pharmacokinetics of the calcium 
ion, administered as calcium orotate, were studied in rats.
It has been repeatedly recognised that alterations of the
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electrolyte metabolism do represent an important link in 
the development of myocardial lesions in animals (for 
example, Lehr, 1969; Solymoss et al., 1970). Such altera­
tions are also thought to provoke cardiac arrhythmias 
(Lee et al., 1966) and disturbances of contractility 
(Surawicz et al., 1967). Further, electrolyte alterations 
appear to occur as a result of cardiac insufficiency 
(Lossnitzer and Bajusz, 1974).
Although the stability constants of calcium orotate
and magnesium orotate complexes have not been reported in
the literature, the stability constants of cadmium (II)
orotate, cobalt (II) orotate, nickel (II) orotate and zinc
(II) orotate were measured by Tucci et al. (1967) and were
found to be 105*^ , 10^*^, 10^'^ and 10^*^ M 1 respectively.
If it were assumed that the stability constant of calcium 
5 8 —1orotate was 10 * M , the blood pH was 7.0, the pKa^ of
2 +orotic acid was 9.7 and the blood Ca concentration was 
2.5 mM, then it may be calculated that 76% of the orotic 
acid in the blood would be present as a metal complex.
Thus, although orotic acid was administered to animals as 
a sodium salt, once in the blood, it may act as a carrier 
of electrolytes to the cellular cytoplasmic structures.
In order to test this possibility, the uptake and distri­
bution of the calcium ion was observed when the calcium 
ion was administered as calcium orotate, calcium carbonate
and calcium chloride.
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The results in Table 3.4 show that there were 
no significant differences in the serum calcium concentra­
tions four hours after either an intragastric injection or 
an intraperitoneal injection of calcium salts, reflecting 
the strict control of serum calcium by the parathyroid- 
calcitonin-vitamin D interrelationships. Forty minutes 
after an injection of the calcium salts, the serum calcium 
concentrations were found to be significantly less after 
an intragastric injection than after an intraperitoneal 
injection (p < 0.005). However, irrespective of the route 
of administration, the serum calcium concentrations after 
an injection of calcium chloride or calcium carbonate were 
similar, and greater than the serum calcium concentration 
after an injection of calcium orotate. Such a finding was 
consistent with both the earlier theoretical proposition 
that most of the orotate in the serum would be present as 
an orotate salt and also account for the rapid disappearance 
of orotate from the circulatory system (Section 3.3.6).
The results presented in Table 3.5 show that the 
concentration of calcium in the tissues of rats given calcium 
orotate, although elevated when compared to normal tissue 
calcium concentrations, did not differ significantly in 
any respect from the levels obtained in animals given 
calcium chloride. Thus, although orotate salts appear to 
dissociate to a lesser extent in the blood, the results of 
Table 3.4 offer no support for the assumption that orotates 
act as electrolyte carriers.
In this chapter and succeeding chapters, it will 
be shown that orotic acid has a beneficial effect on the 
course of cardiac hypertrophy. The results presented here 
suggest that this was not the result of directed electro­
lyte transport. In this respect, these findings were 
similar to those of Smith (1976) who had reported that 
there were no differences in the pharmacokinetics of lithium 
orotate, lithium chloride and lithium carbonate, despite 
the use of lithium orotate in lithium therapy by Nieper 
(1973a). Nieper (1973a) had used lithium orotate in clinical 
trials in the hope of applying the principle of directed 
electrolyte transport in lithium therapy.
The incidental nature of the metal ion with respect 
to the apparently beneficial effects of orotate adminis­
tration during hypertrophy was further suggested by the 
results presented in Table 3.6. These results show that the 
total cardiac calcium and magnesium concentrations were the 
same in orotic acid-treated and untreated, hypertrophied 
hearts.
Thus, orotic acid does not appear to influence 
the course of cardiac hypertrophy by directed electrolyte 
transport, nor does the orotate ion show any particular 
affinity for those tissues with an active pentose phosphate 
pathway. These results, however, do not preclude the possi­
bility that orotic acid may exert an effect on the excita­
tion-contraction coupling through ionic movements within
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the cell.
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3.3.5 Orotic Acid and the Development of 
Renal Hypertrophy
The preceeding sections have indicated that the 
administration of orotic acid to animals with hypertrophying 
hearts, had an apparently beneficial effect on the develop­
ment of hypertrophy. However, there is no biochemical 
reason for the heart to be a specific target for orotic 
acid. In fact, Table 3.3 indicates that only a small per­
centage (0.06%) of a dose of labelled orotic acid was 
actually found in the heart and that much of the radio­
active label was found in the renal tissues (12.9%). It 
was, therefore, of interest to determine whether or not 
orotic acid acted as a stimulant for improving the develop­
ment of induced hypertrophy in other organs. Since the 
effects of renal hypertrophy have been well characterised 
in the literature (for example, Kurnick and Lindsay, 1968; 
Halliburton and Thomson, 1965), the effect of orotic acid 
on the development of renal hypertrophy was investigated.
The results presented in Fig. 3.7 indicated that 
during the 10 days following unilateral nephrectomy, the 
remaining kidney increased its RNA concentration and showed 
a slight decrease in DNA concentration. The increase in 
RNA concentration was fully developed at 24 h and slowly 
returned to the normal renal RNA concentration during the 
following 10 days. The DNA concentration progressively 
decreased during the 3 days immediately after nephrectomy,
but had returned to normal 5 days after nephrectomy.
These results were consistent with the view that compensa­
tory renal growth was, at least in the early stages, due 
chiefly to an increase in cell size and not to an increase 
in cell number.
As with the surgical induction of cardiac hyper­
trophy, all operated animals lost weight in the immediate 
post-operative period. This loss of weight was reflected 
in the decreased renal RNA concentrations of the sham- 
operated animals (Fig. 3.7). Those normal animals fed 
orotic acid, by oral intubation, also showed a slight de­
crease in the renal RNA concentration, though, as with the 
cardiac RNA concentration in those normal animals fed 
orotic acid, this decrease occurred more slowly (over a 
3-5 day period) than the decrease in RNA concentration 
observed in the sham-operated animals.
From the results presented here, it was apparent 
that the kidney, while developing hypertrophy, first accumu­
lated RNA and then later in the development of hypertrophy 
(after 72 h) the kidney started to accumulate DNA.
Over the 10 day period examined, the renal RNA 
and DNA concentrations of animals with a hypertrophying 
kidney which were being treated with orotic acid, were 
the same as those animals not treated with orotic acid.
Thus, the data in Fig. 3.7 show that orotic acid treatment
67.
did not influence the development of renal hypertrophy.
One difference between the experiments concerning renal and 
cardiac hypertrophy was that those animals with cardiac 
hypertrophy were treated with an orotic acid-vitamin B-^- 
folic acid mixture, whilst those animals with renal hyper­
trophy were treated with an orotic acid-vitamin B^2 mixture 
only. The reason for this difference in treatment was 
that it has been reported that folic acid itself may induce 
hypertrophy (Threlfall et al., 1966): however, this does
not effect the conclusion that orotic acid therapy did 
not enhance the development of renal hypertrophy.
It is suggested that the reason for the different 
effects of orotic acid on renal and cardiac hypertrophy is 
concerned with the following, although both processes in­
volved an increase in RNA concentration, the rate of RNA 
synthesis was unchanged in the development of renal hyper­
trophy (Hill et al., 1974). Hill et al. (1974) reported
that the specific radioactivity of renal RNA was normal 
during hypertrophy. On the other hand, Posner and Fanburg 
(1968) reported an increased specific radioactivity of 
cardiac RNA during hypertrophy, compared with normal 
animals. Thus, in the hypertrophied heart, orotic acid 
may act as a precursor for nucleic acid synthesis and an 
enhanced concentration of orotic acid may accelerate the 
rate of synthesis of nucleic acids. In the hypertrophied 
kidney, the increased RNA concentration was not due to an 
increased rate of RNA synthesis and the orotic acid therapy 
had no perceivable effect.
3.3.6 Urinary Excretion Profiles of Orotic Acid
Various techniques are available for the estimation 
of orotic acid. The method of Friedmann and Krakow (1965) 
involved the use of partially purified dihydro-orotate 
dehydrogenase (E.C. 1.3.3.1.). However, commercially 
available preparations of the enzyme were found to be con­
taminated with other dehydrogenases and unsuitable for the 
assay of orotic acid in biological samples. The enzymatic 
assay of Rosenbloom and Seegmiller (1964) was found to give 
variable results. On the other hand, the colorimetric assay 
of Stajner et al. (1968) was found to be reliable when used
in the detection and estimation of added orotic acid.
Though this method was not absolutely specific for orotic 
acid (other compounds such as barbituric acid and indole 
derivatives also reacted in this assay), it was found to be 
reliable for the determination of gross changes in the 
orotic acid concentration of tissues and in biological fluids.
Using the techniques of Stajner et al. (1968),
orotic acid could not be detected in the blood, liver, kidney, 
thymus, gastrocnemius muscle or the heart of normal Wistar 
rats. Following the administration of orotic acid (20 mg/kg 
body wt) by oral intubation in two divided doses (12 and 2 h 
before killing the animals), no orotic acid was detected in 
any of the above tissues.
The colour yield with normal rat urine samples,
after assay by the method of Stajner et al. (1968), corresponds
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to a value of 20 ± 6 yg orotic acid/ml urine. After oral 
administration of orotic acid (dose 1900 yg/rat, average 
body weight 210 g), no increase in orotic acid excretion 
was detected over the ensuing five days. Intravenous 
injection of orotic acid (dose as above) resulted 
in the urinary excretion of 30% of the dose within 2 h of 
administration and a normal urinary excretion rate of 
orotic acid within 10 h (Fig. 3.8). The administration of 
orotic acid by intraperitoneal injection resulted in the 
urinary excretion of 5-10% of the orotic acid (dose as above) 
within 2 h of administration and a normal rate of excretion 
thereafter.
Although orotic acid did not appear to be excreted 
in the urine of rats following oral administration, it was 
detectable in human urine following oral administration.
In a single experiment, following the oral administration 
of 1.5 g of orotic acid to an adult human, orotic acid 
was detected in the urine within 30 min of ingestion. The 
urinary level of orotic acid had returned to the control 
level (5 ± 2 yg/ml) within 10 h of administration and only 
5% of the administered dose was recovered in the urine 
(Fig. 3.9).
Intravenous injection of orotic acid (1900 yg/ 
rat) resulted in the rapid disappearance of orotic acid 
from the blood. Thus, one minute after the injection of 
orotic acid, the blood orotic acid content was 15 yg/ml
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and by ten minutes, orotic acid was no longer detectable 
in blood. Upon incubation of whole blood with orotic acid 
(25 yg/ml rat blood) at 37°C, no change in orotic acid 
content was noted during the thirty minute incubation.
The data from this initial survey were consistent with a 
rapid uptake and metabolism of orotic acid in rat tissues.
In the experiments reported in this thesis, unless 
otherwise indicated, orotic acid was administered by oral 
intubation. Thus, from the results reported in this 
section, it was expected that none of the administered 
orotic acid was excreted in the urine and that the orotic 
acid was rapidly taken up by the body tissues.
3.3.7 Prolonged Animal Toxicity Studies Using 
Orotic Acid
Prolonged animal toxicity studies were undertaken, 
using as guidelines those set out in the Australian Department 
of Health publication NDF4. In view of the limited facilities 
for undertaking such a project, the guinea pig and the cat 
were chosen as experimental animals. These animals were 
maintained and fed orotic acid as described in the experi­
mental section, and the following results were obtained:
(a) Mortality
One male cat died from an upper respiratory tract 
infection, 8 weeks after the commencement of orotic acid 
feeding. There were no other deaths.
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(b) Pattern of Activity
Nothing remarkable and no differences from the 
controls were observed in any of the test groups. No 
clinical changes were established using any of the observa­
tions detailed in Section 3.2.13.3(a).
(c) Urine
No differences in levels of the components measured 
could be detected between the test groups and the control 
groups, under the conditions of the experiment (Table 3.9).
(d) Serum Enzymes
No differences in the levels of the serum enzymes 
could be detected between the test groups and the control 
groups of guinea pigs. Serum alkaline
phosphatase activity, alanine aminotransferase activity and 
aspartate aminotransferase activities were slightly elevated 
in those cats fed orotic acid. Damage to liver cells en­
tailing enzyme leakage may have occurred, however, there 
was no evidence for the development of the liver steatosis 
observed in rats fed orotic acid by Creasey et al. (1961)
(Tables 3.7 and 3.8).
(e) Serum Electrolytes
No differences between the control and test groups 
of animals could be detected under the conditions of the 
experiment (Tables 3.7 and 3.8).
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(f) Miscellaneous Serum Components (glucose, protein,
bilirubin, albumin, globulin, urea, creatinine
and urate)
There were no significant differences in these com­
ponents in the test and control groups of guinea pigs 
(Table 3.7). In the cats, all test components except 
glucose, were within the normal range of values (Table 3.8).
(g) Serum Cholesterol and Triglycerides
No differences were observed between the control 
and test groups of animals, under the conditions of the 
experiment.
Thus, under the specified conditions of the trial, 
it was possible to establish that orotic acid was non-toxic 
in doses up to 14 times the therapeutic dose for humans 
used by Zimmerman and Rusinova (1973), Lukomskii et al. 
(1967), Zharov (1972) and Maslyuk et al. (1972), i.e.
1.5 g/day (21 mg/kg/day), for six months. There was no 
evidence of the liver steatosis observed by Creasey et al. 
(1961) in rats fed orotic acid and in rabbits fed orotic 
acid and cholesterol (Chapter 6). Valli et al. (1968)
have reported that the administration of orotic acid to 
the mouse, chick and monkey was not accompanied by the 
development of liver steatosis, suggesting that the 
differences noted may be related to species variation. 
Further, Kelley et al. (1970) have reported that they found
no evidence of hepatic dysfunction in any of their human 
patients following orotic acid administration.
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3.4 Discussion
Reports from various laboratories have demonstrated 
a three phase reaction of the myocardial genetic apparatus 
in response to compensatory hyperfunction (Meerson, 1969; 
Grimm et al., 1966; Zuhlke et al., 1966). The first phase 
of the activation of the genetic apparatus is manifested 
by a rise in cardiac DNA, RNA and protein synthesis; this 
phase constitutes the basis of cardiac hypertrophy and is 
the growth phase considered in the experiments presented 
in this thesis. The second stage is characterised by normal 
activity of the genetic apparatus of the cells of the hyper­
trophied heart. The final stage is characterised by dis­
turbances in the processes of cellular renewal and leads to 
cardiac failure.
The activation of macromolecular biosynthesis is 
apparently an indispensible link in the adaptation of a 
tissue to an altered physiological environment. Inhibitors 
of the syntheses of proteins and nucleic acids prevent the 
development of adaptation to increased work loads (Meerson, 
1975). On the other hand, factors favoring the activation 
of protein and nucleic acid syntheses, appear to foster an 
accelerated development of those adaptive responses (Meerson, 
1975). In this chapter, evidence (increased protein
2 +synthesis, increased RNA concentration and increased Ca 
stimulated myosin ATP ase activity) is presented that 
orotic acid, when used to supplement the diet of rats with
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compensatory cardiac hypertrophy, enhances the processes 
involved in the adaptation of the myocardium to an 
increased work load.
Although Nieper (1974) has proposed that the 
orotates act as electrolyte carriers and show a special 
affinity for tissues with an active pentose phosphate 
pathway, no evidence to support such a statement could be 
found. The experiments do not preclude the possibility 
that orotic acid may exert an effect on the cardiac 
excitation-contraction coupling, through ionic movements 
within the cell. Indeed, various papers (Krug et al.,
1977; Roberts, 1973) have indicated that pyrimidines may 
influence neuronal excitation processes (see Section 7.1).
Though physiological cardiac hypertrophy is usually 
beneficial to cardiac function, extreme degrees of hyper­
trophy sometimes lead to failure. One reason for this is 
that coronary blood flow does not always increase to the 
same extent as the muscle mass. A second reason is that 
fibrous tissue often develops in the hypertrophied muscle, 
the fibrous tissue replacing degenerating muscle fibres.
That orotic acid could cause such "extreme degrees" of 
hypertrophic response, due to the heightened energy demands 
for macromolecular syntheses, was a problem of some concern. 
Experiments were undertaken to determine the effects of 
orotic acid treatment on cardiac energy metabolism (Chapter 4) 
and cardiac vascularity (Chapter 6). In addition, in
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Section 3 .3 .2 , it was shown that the collagen content of 
the hypertrophied heart was the same in those animals 
treated with orotic acid as in those animals not so treated. 
This, together with the data shown in Fig. 3.4b, which showed 
that normal levels of DNA concentration occurred in both 
the orotic acid-treated and the untreated hypertrophied 
hearts, suggests that orotic acid treatment does not pre­
judice the heart by increasing the proportion of fibrous 
tissue or interstitial cells.
The normal concentration of cardiac collagen in 
both the orotic acid-treated and untreated hearts, during 
the first five days of hypertrophy, also suggests that the 
increased active tension developed in the orotic acid- 
treated hypertrophied hearts, compared with normal and un­
treated hypertrophied hearts, was not due to an.increased 
collagen concentration in the orotic acid treated hearts.
It does not, however, rule out the possibility that changes 
in the active tension may have been due to an altered dis­
tribution of collagen within the heart [Buccino et al.
(1969) have reported that there was a greater deposition 
of collagen in the epimyocardium, compared with the endo- 
myocardium, during hypertrophy] or the synthesis of collagen 
isomers [within the same tissue collagen molecules may 
differ in both the primary structure and the extent to 
which proline and lysine residues were modified by post- 
translational hydroxylation and glycosylation reactions 
(Miller, 1973)].
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The normal cardiac DNA concentrations and the 
not significantly different changes in the collagen concen­
tration in the orotic acid-treated and untreated hyper­
trophied hearts suggest that orotic acid treatment does 
not appear to preferentially favor protein synthesis in 
the myocytes or the interstitial cells. Rather, as suggested 
by the disc gel electrophoresis patterns (Fig. 3.10), orotic 
acid appears to enhance the synthesis of the normal protein 
populations seen during hypertrophy. It must, however, be 
pointed out that until satisfactory methods for the separa­
tion of myocytes and interstitial cells are developed, the 
interpretation of these studies must necessarily be viewed 
with some caution.
Measurements of the myosin ATP ase activity indi- 
2 +cated that the Ca -stimulated ATP ase activity was reduced 
in hypertrophied hearts and was slightly elevated in those 
hypertrophied hearts treated with orotic acid (Table 3.2). 
These changes, in the absence of any data to the contrary, 
were attributed to changes in the myosin isozyme pattern 
during hypertrophy (Section 3.3.2).
By measuring the ATP ase activities of myosins 
extracted from muscles whose speeds of shortening had pre­
viously been measured, Barany (1967) showed that, over a 
wide range of speeds, the myosin ATP ase activity was pro­
portional to the speed of shortening. This finding is 
highly significant from the thermodynamic point of view,
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for it relates the rate of ATP utilization by the contractile
elements to the rate of power output of the muscle, the
latter being proportional to the speed of contraction.
It is, therefore, mandatory that the rate of ATP production
and utilization be equal in the actively contracting heart.
Thus, the lower V of shortening or ATP ase activity in
the untreated hypertrophied hearts may be part of the
price extracted for the advantage gained by the lower rate
of ATP utilization, and hence a lower requirement for ATP
production during hypertrophy. On the basis of a kinetic
model of the cardiac contractile element, Wong (1973) has,
however, concluded that V and hence ATP ase activity,max
2 +cannot be a major energy determinant. The elevated Ca 
stimulated ATP ase activity of the orotic acid treated, 
hypertrophied hearts may, therefore, not represent a major 
energy demand upon the heart.
There is no general agreement upon the effect of
hypertrophy on the ATP ase activity of myosin. Katagiri
2 +and Morkin (1974) reported that the Ca -stimulated ATP ase
activity was reduced and Wikman-Coffelt et al. (1975) have
2 +reported that the Ca -stimulated activity was increased.
2 +In this chapter, it was shown that the Ca -stimulated 
ATP ase activity was decreased in hypertrophied hearts 
and increased in hypertrophied hearts treated with 
orotic acid. The reason for these differences is unknown, 
though some of the variability may be due to differences
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in the severity and the duration of the imposed stress.
With this in mind, it is interesting to note that Meerson
(1965) reported an increase in the myosin ATP ase activity
during the stage of stable hyperfunction and a decrease
in activity in the stage of exhaustion and cardiosclerosis.
If these results reflect a general phenomenon, the higher
2 +activity of the Ca -stimulated ATP ase from the myosin
of orotic acid-treated, hypertrophied hearts may reflect
a more stable development of the hypertrophic response
compared with untreated, hypertrophied hearts with a lower 
24-myosin Ca -stimulated ATP ase activity.
In summary, orotic administration to animals whose 
hearts had been induced to undergo compensatory hypertrophy, 
resulted in an enhanced development of hypertrophy. That 
orotic acid administration did not similarly enhance renal 
hypertrophy appears to be due to the different methods of 
increasing the RNA concentration of the two tissues - the 
heart increased its RNA concentration by RNA synthesis and 
the kidney through a decreased rate of turnover of RNA.
Thus, the studies reported here have lent considerable 
support to Meerson's claim that orotic acid and cofactor 
treatment enhanced the process of adaptation in the myocardium 
to an increased work load (Meerson, 1969). The prolonged 
toxicity studies in experimental animals indicated that 
orotic acid was non-toxic up to 14 times the therapeutic 
dose used by Meerson and others (Section 1.4.2) in human 
patients.
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Figure 3.1 Diagram to indicate the technique 
used for narrowing the abdominal 
aorta, showing the suture in 
position around the aorta and a 
21G needle.
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Figure 3.2 The relationship between the wet 
heart weight and the body weight 
of normal male Wistar rats. 
Regression equation:
Heart weight (mg) = 235.5 + 2.008 x body wt (kg)
Correlation: 0.968.
D a y s  a f t e r  c o n s t r i c t i o n
Figure 3.3 The effects of aortic constriction
and orotic acid administration on the 
heart weight.
Values shown are the percentage increase 
in heart weight and are the mean ± S.E.M. 
for 6 to 8 determinations. Graph repre­
sents hypertrophied hearts treated with 
orotic acid ( O ) and untreated hypertrophied 
hearts ( • ).
Figure 3.4a (Top) Cardiac ribonucleic acid content per g 
wet wt on indicated post-operative days.
Figure 3.4b (Bottom) Cardiac deoxyribonucleic acid 
content per g wet wt on indicated post­
operative days.
Each point represents the mean ± S.E.M. values 
for 6 animals. The treatment of animals and 
the assay of metabolites were as described in 
the experimental section. The groups of 
animals studied were: normal animals treated
with orotic acid ( O ); sham-operated animals 
( ♦ ); hypertrophied hearts ( • ); and 
hypertrophied hearts treated with orotic acid 
and cofactors ( ■ ).
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Figure 3.5a (Top) Cardiac protein synthesis. Figure
shows the time course of the % increase
3over normal of [4,5- H] leucine uptake by 
hypertrophying ( • ), hypertrophying and 
orotic acid treated ( □ ) and hypertrophing 
and orotic acid and cofactor treated ( ■ ) 
rat myocardium. Each value represents the 
mean ± S.E.M. value of 6 animals.
Figure 3.5b (Bottom) Cardiac protein content per g wet 
wt on indicated post-operative days. The 
groups of animals studied were: normal
animals treated with orotic acid ( O ); 
sham-operated animals ( ♦ ); hypertrophied 
hearts ( # ); and hypertrophied hearts 
treated with orotic acid and cofactors ( ■ ). 
Each value represents the mean ± S.E.M. value 
of 6 animals.
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Figure 3.7a (Top) Kidney ribonucleic acid content per 
g wet wt on indicated post-operative days.
Figure 3.7b (Bottom) Kidney deoxyribonucleic acid 
content per g wet wt on indicated post­
operative days.
Each point represents the mean ± S.E.M. 
values for 6 animals. The treatment of 
animals and the assay of metabolites were 
as described in the experimental section. 
The groups of animals studied were: 
normal animals treated with orotic acid 
( ♦ ); sham-operated animals ( O ); 
hypertrophied hearts ( • ); hypertrophied 
hearts treated with orotic acid ( ■ ).
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Figure 3.8 Time course of changes in
urinary orotic acid concentration 
after intravenous administration 
of orotic acid to 4 rats. Shaded 
area represents the normal range 
of orotic acid concentration in 
rat urine, as measured by the 
method of Stajner et al. (1968).
Each point represents the mean 
± S.E.M..
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Figure 3.9 Time course of changes in the urinary 
orotic acid concentration after oral 
administration of 1.5 g of orotic acid 
in man. Urinary orotic acid content 
was measured by the method of Stajner 
et al., 1968.
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Figure 3.10 Disc gel electrophoresis of the contractile-membrane
protein fractions (bottom) and the soluble protein fractions
(top) isolated from 3 day hypertrophied rat hearts (--- )
and 3 day hypertrophied rat hearts treated with orotic acid
(--- ). Protein fractions were prepared and analysed as
described in the experimental section.
TABLE 3.1a
THE EFFECT OF HYPERTROPHY AND OROTIC 
ACID TREATMENT ON THE SERUM AMINO ACID LEVELS
Sham-Operated
Animals
One Day 
Hypertrophied 
Animals
One Day 
Hypertrophied 
and Orotic Acid 
Treated Animals
Aspartate 26, 32 NJ 00 35 23, 30
Glutamate 162, 184 199, 221 184, 219
Alanine 412, 438 564 , 611 525, 539
Glycine 153, 282 299, 324 308 , 340
Serine 261, 307 299, 287 273 , 285
Threonine 232 , 251 257, 281 236, 255
Proline 205, 231 187, 204 174, 199
Valine 165, 192 178, 288 151, 169
Methionine 37, 48 47, 60 50, 63
Iso-leucine 74, 82 102, 117 91, 106
Leucine 120, 139 125, 143 142, 155
Tyrosine 62, 93 60, 85 68, 95
Phenylalanine 73, 85 99, 88 77, 89
Amino acid levels in 
hypertrophied and one
the
day
serum of sham-operated 
hypertrophied, orotic
, one 
acid
day
treated
animals. The results of two determinations are shown in the 
table and the amino acid levels are expressed as mmol/litre 
of serum.
TABLE 3.1b
THE EFFECT OF OROTIC ACID AND HYPERTROPHY ON 
THE CARDIAC AMINO ACID LEVELS
Animals with One Day
Sham-Operated One Day Hypertrophied
Animals Hypertrophied and Orotic Acid
Hearts Treated Animals
Aspartate 1381,1458 1372, 1506 1697 ,1891
Glutamate 7168,7266 8247 ,8325 8340 , 8378
Alanine 1012,1126 1597 ,1799 1952 ,2030
Glycine 558, 623 639 , 668 869 , 880
Serine 631, 684 965, 1063 1258 ,1311
Threonine 571, 588 576, 542 570 , 580
Proline 494, 399 318, 353 325 , 373
Valine 93, 110 117, 129 106 , 133
Methionine 58, 79 65, 87 69 , 96
Iso-Leucine 63, 70 45, 57 50 , 62
Leucine 112, 129 133, 162 119 , 133
Tyrosine 94, 121 82 , 109 99 , 124
Phenylalanine 75, 98 0000 99 92 , 106
The amino acid concentrations were determined using the 
methods described in the experimental section. The results 
are of two samples and are expressed as pmo1/litre of cell
water.
TABLE 3.2
Ca2+-STIMULATED AND (K+) EDTA-STIMULATED 
ATP ase ACTIVITIES
Myosin
ATP ase Activity 
(ymol P^.mg ^.min
Ca^+-Stimulated (K+ ) EDTA-Stimulated
Control 0.976 ± 0.055 0.511 ± 0.051 (4)
One Day Hypertrophied 
Untreated 0.967 ± 0.039 0.482 ± 0.013 (4)
Four Day Hypertrophied 
Untreated 0.856 ± 0.026 0.509 ± 0.006 (2)
Seven Day Hypertrophied 
Untreated 0.825 ± 0.029* 0.480 ± 0.020 (4)
One Day Hypertrophied 
Orotic Acid Treated 0.999 ± 0.028 0.574 ± 0.044 (4)
Four Day Hypertrophied 
Orotic Acid Treated 1.162 ± 0.050** 0.493 ± 0.011 (4)
Seven Day Hypertrophied 
Orotic Acid Treated 1.122 ± 0.032** 0.513 ± 0.013 (3)
The calcium stimulated and EDTA stimulated ATP ase activities 
were determined simultaneously for the same myosin prepara­
tion according to the conditions described in the experimental 
section. Values are mean ± S.E.M., the number of experiments 
being shown in brackets (each experiment using 3 pooled rat 
hearts).
* Denotes a statistically significant
difference (P < 0.05, Student's t-test), 
compared with the control values.
** Denotes a statistically significant 
difference when compared with the 
respective untreated groups of hearts.
TABLE 3.3
THE RELATIVE RATES OF ARABINOSE 5-P AND RIBOSE 5-P 
UTILIZATION IN REACTIONS CATALYZED BY ENZYME PREPARATIONS 
FROM VARIOUS RAT TISSUES AND THE UPTAKE OF LABELLED OROTIC 
ACID INTO THOSE TISSUES
Each incubation mixture contained, in a total volume of 
3.0 ml at 25°C: pentose 5-P (2.0 Hmole of either arabinose 5-P or ribose
5- P); enzyme preparation (2.5 mg of protein of an acetone dried powder, 
Horecker et al., 1954) and glycylglycine-KOH buffer, pH 7.4,-(0.5 mmole). 
For the measurement of the rate of pentose 5-P utilization, 0.5 ml 
samples were removed from the incubation mixture and deproteinized with 
0.5 ml of 0.6N HCIO^ at 0, 5 and 10 minutes, and from a control incubation, 
which did not contain pentose 5-P. The supernatant solution was analyzed 
for pentose 5-P content (Blackmore and Williams, 1974). Rates of hexose
6- P production were determined by enzymatic analysis of glucose 6-P and 
fructose 6-P (Bergmeyer, 1965) in deproteinized samples removed at 0, 30 
and 60 minutes from each incubation mixture described above. The initial 
rate of triose 3-P formation was determined in the coupled assay as 
follows. Each incubation in a total volume of 3.3 ml at 25°C contained: 
pentose 5-P (2.0 jimole of arabinose 5-P or ribose 5-P); enzyme preparation 
(2.5 mg of protein); glycylglycine-KOH buffer, pH 7.4 (0.5 mmol); NADH 
(0.5 ymol); triose phosphate isomerase (2.0 I.U.) and sn-glycerol 3-P 
dehydrogenase (2.0 I.U.). The formation of triose-P from arabinose 5-P 
and from ribose 5-P was measured by monitoring the decrease in the 
extinction at 340 nm due to the oxidation of NADH, when read against a 
control containing all components except pentose 5-P. Each result was
the mean of duplicate samples from two experiments. Units are expressed 
as nmol/min/mg of protein. The uptake of orotic acid was measured as 
described in Section 5.2.2 and the results are expressed as fmol orotic 
acid/2hours/mg protein.
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TABLE 3.4
SERUM CALCIUM CONCENTRATION IN RATS GIVEN AN 
INJECTION OF CALCIUM OROTATE, CALCIUM CHLORIDE 
AND CALCIUM CARBONATE
Serum Calcium Concentration (mM)
40 Minutes
Calcium orotate i.p. 3 .45 ± 0.16 2.43 ± 0.06
Calcium carbonate i.p. 3.92 ± 0.17 2.45 ± 0.07
Calcium chloride i.p. 4.17 ± 0.16 2.79 ± 0.34
Calcium orotate i.g. 2.56 ± 0.11 2.53 ± 0.14
Calcium carbonate i.g. 2.98 ± 0.14 2.50 ± 0.16
Calcium chloride i.g. 2.82 ± 0.15 2.46 + 0.17
4 Hours
Serum calcium concentration was measured as described in the experimental 
section. Rats were given either an intraperitoneal (i.p.) or an intra- 
gastric (i.g.) injection (0.5 mmol/kg body wt) of calcium orotate, calcium 
carbonate and calcium chlordie. Values are expressed as mmol/litre of 
serum and are the mean ± S.E.M. for 4 rats.
TABLE 3.5
CALCIUM CONCENTRATION IN TISSUES AFTER THE ADMINISTRATION 
OF CALCIUM OROTATE OR CALCIUM CHLORIDE
Normal Calcium Calcium
Tissue Orotate Chloride
Liver 1.10 + 0.09 1.46 ± 0.23 1.44 ± 0.20
Heart 1.24 ± 0.08 1.36 ± 0.12 1.31 ± 0.07
Kidney 1.39 ± 0.12 1.48 ± 0.04 1.75 ± 0.10
Muscle (gastrocnemius) 1.47 + 0.12 1.28 ± 0.06 1.52 ± 0.05
Lung 2.36 ± 0.13 2.49 ± 0.15 2.30 ± 0.11
Tissue calcium concentrations were measured as described in the experimental 
section. Rats were fed calcium orotate or calcium chloride (0.5 mmol/kg 
body wt) by oral intubation. Values are expressed as mmol/kg wet wt of 
tissue and are the mean ± S.E.M. for 4 rats.
TABLE 3.6
THE EFFECT OF CARDIAC HYPERTROPHY AND OROTIC ACID TREATMENT 
ON THE CARDIAC CALCIUM AND MAGNESIUM CONCENTRATIONS
Total Total
Calcium
(mM)
Magnesium
(mM)
Normal hearts 1.74 ± 0.23 16.45 ± 1.23
Sham-operated hearts 1.65 ± 0.15 15.37 ± 1.07
One day hypertrophied 
hearts 1.89 ± 0.17 16.07 ± 0.95
Three day hypertrophied 
hearts 1.77 ± 0.13 18.35 ± 0.69
One day hypertrophied 
and orotic acid 1.96 ± 0.20 16.07 ± 0.95
treated hearts
Three day hypertrophied 
and orotic acid 1.78 ± 0.11 16.32 ± 0.95
treated hearts
The treatment of the animals and the assay of metabolites 
were as described in the Sections 4.2 and 6.2.8. The 
results are expressed as mmol/litre and are shown as the 
mean ± S .D ..
TABLE 3.7
EFFECT OF OROTIC ACID FEEDING ON THE LEVELS OF SOME 
IMPORTANT CONSTITUENTS IN THE SERUM OF THE GUINEA PIG
Experimental: Animals age at killing: approx. 270 days
Duration of orotic acid feeding: 183 days
Dose of administered orotic acid: 300 mg/kg/day
Analyses: All analyses by SMAC autoanalyser. The
normal range of values of the serum com­
ponents is shown at the left of the table.
These have been taken from the following 
literature references:
A. Spector, W.S. (1956), "Handbook of Biological 
Data", W.B. Saunders, Philadelphia.
B. Hawkins, J.A. (1924 ), J. Biol. Chem. 6JL, 147-155.
C. Somogui, M. (1933), J. Biol. Chem. 103, 655-670.
D. Cheng-Chun Lee, Herrmann, R.G. and Froman, R.O. 
(1959), Proc. Soc. Exp. Biol. Med. 102, 542-544.
E. Snyder, F.H. and Tweedy, W.R. (1941), Proc. Soc.
Exp. Biol. Med. £7_, 234-236 .
F. Nambisan, B. and Kurup, P.A. (1975), Atheroscelrosis 
22_, 447-461.
* Denotes values for plasma sample only.
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TABLE 3.8
EFFECT OF OROTIC ACID FEEDING ON THE LEVELS OF SOME 
IMPORTANT CONSTITUTENTS IN SERUM OF THE CAT
Results are mean ± S.E.M., followed by the observed 
range of concentrations or activities in normal animals.
Experimental: Animals age at killing: 18 months
Duration of orotic acid feeding: 183 days
Dose of administered orotic acid: 200 mg/kg/day
Analyses: All analyses by SMAC autoanalyser. The normal
range of values of the serum components is shown 
at the left of the table. These have been taken 
from the following literature references:
A. Bloom, F. (1960), "The Blood Chemistry of the Dog 
and Cat", Gamma Publishing Inc., New York.
B. Altman, P.L. and Dittmers, D.S. (1961), "Blood and 
Other Body Fluids", Fed. of American Soc. for 
Experimental Biology, Washington D.C..
C. Analyses performed on plasma samples. Lewis, G.P.
(1967), J. Physiol. 191, 591-607.
D. Loeb, W.F. (1964) in "Feline Medicine and Surgery", 
(Catcott, E.J. ed.), Chapter 1, American Veterinary 
Publications, Illinois.
E. Laird, C.W. (1974) in "Handbook of Laboratory 
Animal Science" (Melby, E.C. and Altman, N.H. eds), 
Vol. 2, pp. 345-437. CRC Press Inc., Cleveland.
TABLE 3.8
Normal Range Orotic Acid Diet
Sodium (147-156 mMA) 156.4 ± 0.7 mM (154-160)
Potassium (4.0-6.0 mMA,B) 5.1 + 0.2 mM (4.3-6.3)
Chloride (115-130 mMA) 119.0 ± 0.4 mM (117-121)
Total C02 - 21.9 + 0.5 mM (20-24)
Urea (7.1-10.7 mMA) 9.9 ± 0.3 mM (9.0-11.7)
Creatinine (0.09-0.18 mM ) 0.156 + 0.003 mM (0.15-0.17)
Glucose (4.2-6.6 mM ) 12.8 ± 0.4 mM (10.9-13.8)
Cholesterol (1.9-3.9 mMA) 2.99 + 0.09 mM (2.61-3.47)
Triglyceride - 0.21 + 0.02 mM (9.17-0.30)
Urate (0.05-0.11 mMA) 0.008 ± 0.002 mM (0-0.01)
Chol/Trig - 14.6 ± 0.8 (11.57-17.94)
Inorg. Phosphate (1.68-2.23 mMB) 1.68 + 0.02 mM (1.62-1.75)
Calcium (1.6-3.1 mMA'°) 2.49 + 0.02 mM (2.38-2.59)
Albumin (17-28 g/1A) 27.9 + 0.49 g/1 (26-30)
Total Protein (52-66 g/lA) 73 + 1 g/1 (70-77)
Total Bilirubin (1.7-17 ]JMA) 4 .6 + 0.2 pM (4-5)
Alkaline Phosphatase (8.34 4.8 I.U. E/1 15.3 + 0.8 I.U./l (13-20)
Asp. Aminotransferase (22 9 I.U./1C) 43 ± 1 I.U./l (39-48)
Ala. Aminotransferase (37 7 I.U./1C) 69 + 6 I.U./l (46-100)
Lactate Dehydrogenase (152 143 I.U. E/1 128 + 6 I.U./l (108-153)
Iron (12-38 VIM) 13.6 ± 0.5 pM (11.9-15.3)
Globulin (24-48 g/lA) 45 ± 1 g/1 (42-50)
TABLE 3.9
EFFECT OF OROTIC ACID FEEDING ON THE LEVELS OF SOME 
IMPORTANT CONSTITUENTS IN THE URINE OF THE CAT
AND GUINEA PIG
(a) CAT
Urine Constituent:
Nitrate Negative
pH Varied over the range pH 5-7
Albumin
Blood
Negative
Negative
(less than 25 mg/100 ml)
Glucose Negative (less than 0.1 g/100 ml)
Ketone bodies Negative (less than 5 mg/100 ml)
Urobilinogen Negative 
with 1
(other
mg/100
than 
ml)
2 male cats
Bilirubin Negative (less than 0.2 mg/100 ml)
(b) GUINEA PIG
Urine Constituent:
Nitrate 
PH
Albumin
Blood 
Glucose 
Ketone bodies 
Urobilinogen 
Bilirubin
Negative
Varied over the range pH 5-7
Negative (other than 4 guinea pigs 
with 25-75 mg/100 ml)
Negative
Negative (less than 0.1 g/100 ml) 
Negative (less than 5 mg/100 ml) 
Negative (less than 1 mg/100 ml) 
Negative (less than 0.2 mg/100 ml)
Animals were fed doses of orotic acid daily for 183 days 
(cats were fed 200 mg orotic acid/kg/day, guinea pigs were fed 300 mg 
orotic acid/kg/day). Urine samples were then collected (as described 
in the text) and chemical urinalysis was carried out using "Combur 8^ 
Test" test strips.
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CHAPTER 4
THE EFFECTS OF DEVELOPING CARDIAC HYPERTROPHY 
ON GLYCOLYSIS AND ENERGY UTILIZATION
4.1 Introduction
Mechanical overload of the heart is associated 
with increased energy utilization (for example, see Meerson, 
1969). Increased energy requirements also result from the 
acceleration of the rates of protein and nucleic acid 
synthesis, found in hearts with developing hypertrophy 
(Chapter 3). Thus, the levels of glycolytic intermediates 
and adenine nucleotides were measured in the myocardium of 
rats with developing cardiac hypertrophy in order to gain 
further insight into the mechanisms involved in the control 
of glycolytic activity and energy provision. The glycolytic 
pathway is featured since it represents the only mechanisms 
for net ATP synthesis under conditions of hypoxia.
In the absence of ATP, all synthetic processes 
probably stop and the structural integrity of cell membranes 
cannot be maintained, for some or many of the structural 
elements have a rapid turnover. The permeability of the 
cellular organelles is modified. This has been documented 
in the case of mitochondria, which swell with aging but which 
can be made to contract again following the addition of ATP. 
Mitochondrial swelling leads to the distension of the
80.
cristae, modifying the relationship between the mito­
chondrial enzymes and their substrates (van Lancker, 1976).
Even when an enzyme is normally involved in 
anabolism, the conditions in the dying cytoplasm may shift 
the equilibrium in favor of hydrolysis. Although the first 
event in ischemic necrosis or autolysis of a tissue may be 
a decrease in the ATP concentration because of a lack of 
substrate, the critical alteration seems to be the dis­
tortion of the equilibrium between cellular anabolic and 
catabolic pathways (van Lancker, 1976). Vogt and Färber 
(1968) reported that in the ischemic rat kidney (in which 
most of the ATP made must be derived from glycolysis), most 
cells could survive 20 minutes anoxia, but few survived 
longer periods of anoxia. This, coupled with the observa­
tion that the ability to generate ATP was 80% of normal 
after 20 minutes of anoxia and 50% of normal after 30 
minutes, suggested that the ability to generate ATP may 
determine whether or not the damage is reversible. 
Surprisingly, this ability to generate ATP did not corre­
late with the capacity of the mitochondria to restore 
biochemical functions that had been altered by anoxia. In 
fact, mitochondria were able to recover normal oxygen up­
take and coupling of oxidation and phosphorylation even 
when they were obtained from kidney already doomed to 
necrosis (30 minutes of ischemia plus 30 minutes recovery). 
Thus, although the recovery of the ability to synthesise
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ATP appears to be essential for cell survival, other 
factors (such as changes in intracellular pH) appear to 
predispose the tissue to necrotic changes. The persis­
tence of low ATP levels is unlikely to cause irreversible 
cellular damage, for hepatic cells are known to survive 
up to 48 hours in the presence of ATP levels even lower 
than those found in ischemic kidneys (van Lancker, 1976). 
The ability of cardiac tissue to generate ATP may determine 
the extent and reversibility of cellular damage and the 
capacity of the heart to undergo compensatory hypertrophy.
Although the glycolytic pathway contributes 
rather a small percentage of the total energy available 
from the oxidation of foodstuffs (2/38 or 5.3% of the total 
ATP available from the complete oxidation of hexose units), 
it is of major importance in cardiac metabolism. The path­
way is a major source of ATP under anoxic and hypoxic 
conditions. Several authors have reported that the normal, 
well-oxygenated heart produces insignificant quantities of 
lactate (Muller-Ruchholtz and Lochner, 1971; Scheuer, 
1972), which suggests that glycolytic pyruvate production 
is normally precisely adjusted to its aerobic oxidation.
The glycolytic enzymes, glyceraldehyde 3-phosphate 
dehydrogenase and phosphoglycerate kinase, catalyze 
reactions which mediate between the phosphorylation state 
of the adenine nucleotides in the cytoplasm and the redox 
state of the [NAD+]/ [NADH] couple of the cytoplasm. There 
may also be an important positional correlation between
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the contractile elements within the myocardial cell and the 
enzymes which control the glycolytic pathway (see dis­
cussion in this Chapter).
Although the glycolytic enzymes are commonly 
described as "soluble" enzymes, there is increasing evidence 
which points to an appreciable interaction between glyco­
lytic enzymes and the particulate components of tissues.
The tendency of glycolytic enzymes to associate with the 
ultrastructure of skeletal muscle has been the subject of 
several reports (e.g. Ratner et al., 1974; Dagher and 
Hultin, 1975). Studies by Clarke and Masters (1975) have 
shown that the glycolytic enzymes displayed a significant 
degree of binding to F-actin-tropomyosin-troponin, though 
there was a wide divergence in the relative degree of 
adsorption of the individual enzymes; some (phosphofructo- 
kinase, pyruvate kinase, aldolase, glyceraldehyde 3- 
phosphate dehydrogenase, glucose 6-phosphate isomerase 
and lactate dehydrogenase) had a large proportion of their 
activities bound to F-actin-tropomyosin-troponin. Others 
(triose-phosphate isomerase, phosphoglycerate kinase, 
phosphoglycerate mutase, enolase and hexokinase) had only 
a small proportion of their activities bound. The nearly 
complete binding of phosphofructokinase (90%) was indica­
tive of a very high affinity for the thin filaments and 
showed that the reversible adsorption of enzymes to 
structural proteins may have to be taken into consideration
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when discussing the contribution of enzymes to the regula­
tion of cellular metabolism. Thus, there may be an important 
positional correlation between the intracellular sites of 
energy requiring processes on one hand and a major energy 
producing sequence and its potential control points on the 
other. Any alteration in the structural relationships 
within the muscle fibres, as occurs during hypertrophy 
(Chapter 6), may be expected to be reflected in changes of 
the glycolytic flux and the mass action ratios of the glyco­
lytic enzymes in the cell.
The accepted figure for the oxygen consumption 
of the normally beating heart is about 8-10 ml 0^/100 g 
myocardium/minute. It is evident from the literature 
(Astrand and Rodahl, 1970) that cardiac outputs 6 to 8 fold 
greater than normal, can be encountered in atheletes under 
conditions of strenuous exercise. It has been proposed 
that, under such conditions, the cardiac efficiency probably 
doubles (Gibbs and Chapman, 1977) but even so, oxygen con­
sumption must reach 30-40 ml/100 g myocardium/minute. This 
means that aerobic ATP production must reach 15-20 mmol/ 
ATP/100 g/minute (assuming AHATp = -46 kJ/mol). This very 
high energy demand can probably be accommodated because of the 
high concentration of mitochondria in the heart.
The mechanism of respiratory control has been 
elucidated by Chance et al. (1956, 1967). The rate of 
oxidative phosphorylation is coupled to the electron
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transport rate, which in turn is dependent upon the level 
of the phosphate acceptor ADP. ADP is probably not an 
important effector molecule in cardiac metabolism for the 
presence of creatine phosphokinase bound to the m-line of 
myosin (Turner et al., 1973) and of adenylate kinase in the 
cytoplasm, make it unlikely that ATP can reach the mito­
chondria and thus act as an effector molecule for the con­
trol of energy production. In addition,ADP may be bound 
to actin (Mommaerts, 1974) and not act as a regulatory 
molecule in cytoplasmic reactions. In order to maintain 
a high cytoplasmic energy charge, the ADP bound to the 
actin would have to be phosphorylated at the contractile 
site and this may be the function of the creatine phospho­
kinase bound to the m-line of myosin.
It has been shown that heart mitochondria contain 
a specific isoenzyme of creatine phosphokinase which 
accounts for 30% of the total creatine phosphokinase 
activity (Saks et al., 1974). Saks has suggested that this 
isoenzyme plays an important role in the energy transfer 
from ATP of the intermembrane space of the mitochondria 
to creatine phosphate in the cytoplasm. In the cytoplasm, 
creatine phosphate may be used for ATP synthesis by another 
creatine phosphokinase isoenzyme localised near the sites 
of energy utilization, mainly near the myofibrils (Jacobus 
and Lehninger, 1973). Thus, creatine phosphokinase does 
not function solely to buffer the supply of ATP to the
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contractile proteins and ion pumps but may serve as a high 
energy phosphate transport system, transmitting the redox 
energy of respiration across the mitochondrial membrane 
and thereby establishing a high energy phosphate potential 
within the cardiac cell.
With the development of hypertrophy, disturbances 
of the structure, metabolism and regulation of cardiac 
activity may lead to progressive cardiosclerosis and gradual 
exhaustion of the tissue. In the present study, the results 
of investigations into the control of cardiac glycolysis 
and the ability of the heart to maintain adequate "high- 
energy phosphate" reserves and the cytoplasmic [NAD+]
[NADH]£ redox couple are reported. These studies were 
extended to investigate the efficacy of orotic acid, 
administered to animals with experimentally induced cardiac 
hypertrophy, in maintaining the control of cardiac glyco­
lysis and enhancing the availability of phosphorylated 
adenylates and reducing equivalents in the cytoplasm. In 
the present study, the effects of hypertrophy and orotic 
acid on cardiac glycogen stores were measured, for both 
marked and minor elevations in cardiac glycogen stores are 
associated with greater glycolytic reserve and improved 
mechanical resistence to anoxia (Scheuer and Stezoski,
1970). Examination of aspects of the control of glycolysis 
in the hypertrophying heart was made possible by the con­
ceptual framework developed by Williamson (1965a) and
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Kubier and Spieckerman (1970) in their studies of the 
regulation of glycolysis in the ischemic heart.
4.2 Experimental
4.2.1 Measurement of Glycolytic Intermediates
Cardiac hypertrophy was induced in male wistar rats 
by the methods outlined in Section 3.2.2. The rats, anaesthe­
tised with "nembutal" (Abbott Laboratories, Australia) and 
artificially ventilated via a tracheostomy tube, were placed 
on a temperature-controlled table (37°C). After the experi­
mental animal had been anaesthetised for 5 minutes, the chest 
was opened and the heart freeze-clamped with Wollenberger 
tongs (Wollenberger et al., 1960), which had been pre-cooled 
in liquid nitrogen. The frozen hearts were rapidly weighed 
and, using a stainless steel mortar and pestle (pre-cooled 
with liquid nitrogen), pulverised to a fine powder under a 
layer of liquid nitrogen. The powder was then deproteinized 
by homogenising in perchloric acid (0.6N, 5 volumes) in a 
motor driven Potter-Elvehjem glass homogeniser (at 0°C). The 
homogenate was centrifuged at 10,000 g for 10 minutes 
(at 0°C). The supernatant fluid was neutralised to pH 
6.7-7.4 with KOH (0.5N) and the precipitated potassium 
perchlorate removed by a further centrifugation step (10,000 g, 
10 minutes at 0°C) (final volume approximately 7.5 ml; final 
pH approximately 7.0).
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After the above extraction, the following 
metabolites were measured on the day:
Adenosine triphosphate (ATP) by the method of 
Lamprecht and Trautschold (Bergmeyer, 1974); Adenosine 
diphosphate (ADP) and Adenosine monophosphate (AMP) by 
the method of Jaurorek et al. (Bergmeyer, 1974); Inorganic 
phosphate by the method of Martin and Doty (1949);
D-Glucose by the method of Bergmeyer et al. (Bergmeyer, 
1974); D-Glucose 1-phosphate (G-l-P) and D-Fructose 
6-phosphate (F-6-P) by the method of Bergmeyer and Michal 
(Bergmeyer, 1974); D-Fructose 1, 6-diphosphate (F-D-P), 
Dihydroxy-acetone phosphate (DHAP) and D-Glyceraldehyde 
3-phosphate (GAP) by the method of Michal and Beutler 
(Bergmeyer, 1974); D-Glycerate 3-phosphate (3PGA), 
Phosphoenolpyruvate (PEP) and D-Glycerate 2-phosphate 
(2PGA) by the method of Czok and Eckert (Bergmeyer, 1965); 
Pyruvate (pry) by the method of Bucher et al. (Bergmeyer, 
1965); L (+) Lactate by the method of Gutmann and Wahlefeld 
(Bergmeyer, 1974); L(-) Glycerol 3-phosphate by the method
of Michal and Lang (Bergmeyer, 1974).
Metabolite contents were expressed on a nanomole 
per gram wet weight of cardiac tissue basis.
4.2.2 Determination of Glycogen
A fine powder of heart tissue was prepared as 
described in Section 4.2.1. The powder was homogenised in
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2 volumes of hot 30% KOH and the glycogen isolated using 
the method of Pfeiderer (Bergmeyer, 1965). After acid 
hydrolysis, the glycogen was enzymatically determined as 
glucose (Section 4.2.1).
4.2.3 Administration of Reserpine
Reserpine (3,4,5,- Trimethoxybenzoyl methyl 
reserpate, Ciba Pty Ltd, Australia) was injected intra­
muscularly (5 mg/kg body weight) at twelve hour intervals. 
The reserpine used was a lyophilized preparation of 
reserpine phosphate, containing 20 mg of ascorbic acid 
and 12 mg of lactose for each 10 mg of base.
4.2.4 Estimation of Blood Insulin and Cardiac 
Catecholamines
Blood insulin was estimated by radioimmuno assay, 
using an Insulin RIA kit (Radiochemical Centre, Amersham, 
England).
Cardiac catecholamines were estimated by adsorption 
onto aluminium oxide (Anton and Sayre, 1962). Hearts were 
homogenised in ice-cold 0.4N perchloric acid and the homo­
genate was centrifuged at 15,000 g for 10 minutes. The 
supernatant fluid volume was adjusted to 25 ml with 0.4N 
perchloric acid, mixed with 400 mg of aluminium oxide,
200 mg EDTA and 10 mg of sodium metabisulfate, and the pH 
was adjusted to 8.6 with IN sodium hydroxide. After stirring
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for 5 minutes, the aluminium oxide was allowed to settle 
and the supernatant fluid was aspirated. The aluminium 
oxide was washed four times with 10 ml of water and the 
catecholamines were then eluted from the washed aluminium 
oxide with 3 ml of 0.05N perchloric acid. The mixture was 
centrifuged (15,000 g, 10 minutes) and the cardiac catecho­
lamines in the supernatant fraction were estimated using 
the trihydroxyindole procedure of Crout (1961).
4.2.5 Estimation of Intracellular Magnesium
Hearts were freeze-clamped with Wollenberger tongs, 
weighed and pulverised under liquid nitrogen as described 
in Section 4.2.1. The powdered cardiac tissue was dried 
overnight at 70°C, digested for 24 hours in 3 ml of a 
1:2 (v/v) mixture of 60% perchloric acid and 30% hydrogen 
peroxide and the volume adjusted to 200 ml with water.
1 ml of 0.64M potassium chloride was added to 4 ml of the 
digest and the total magnesium in this solution was esti­
mated by atomic absorption spectroscopy, using a Varian 
Techtron Spectrophotometer, model 1200.
The total magnesium bound to the intracellular 
acid-extractable metabolites plus the free intracellular 
magnesium was estimated by measuring, by atomic absorption 
spectroscopy, the total magnesium in a perchloric acid 
(0.6N) extract of cardiac tissue (Section 4.2.1).
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4.2.6 Thin Section Electron Microscopy
Rats were heparinised by an intraperitoneal 
injection of 100 I.U. of heparin dissolved in 0.5 ml 
of Krebs-Ringer solution (Sonnenblick, 1962) and were 
killed fifteen minutes later by a blow to the head.
The ascending aorta was rapidly cannulated and the 
coronary circulation perfused for 2-3 minutes with ice- 
cold, oxygenated Krebs-Ringer solution followed by a 
solution of glutaraldehyde-formaldehyde fixative in 
o .1M cacodylate buffer pH 7.4 (Karnovsky, 1965) for a 
further 2-3 minutes. The left ventricle was then cut
3into small (0.5 mm ) pieces and fixed in the above fixa­
tive for three hours. An overnight wash in 0.1M caco­
dylate buffer pH 7.4 was followed by further fixation 
in 2% OsO^ in 0.1M cacodylate buffer pH 7.4. The blocks 
were stained with 2% uranyl acetate in distilled water 
for one hour and then with 1% paraphenylenediamine in 
50% alcohol for 5 minutes, dehydrated in an alcohol 
series and embedded in araldite (Fluka). Sections were 
cut using a Du Pont diamond knife on a Reichert OmU2 
ultramicrotome and mounted on 200 mesh carbon and 
collodion coated grids and stained with lead citrate 
(Reynolds, 1963). The sections were examined using a 
Phillips EM 300 electron microscope.
4.3 Results
4.3.1 The Effect of Magnesium on the Adenylate 
Kinase Equilibrium
Magnesium is a major intracellular cation of para­
mount metabolic importance. It exists in two forms, free 
2 +Mg and bound magnesium, of which the latter form pre­
dominates due to the high capacity of many intracellular 
components to form co-ordination complexes with magnesium 
ions. A precise knowledge of the concentrations of the 
free and bound forms of magnesium is both important and 
relevant, for each form may effect metabolic processes in 
the cell (for example Purich and Fromm, 1971; Veloso et al., 
1973). Free magnesium may act to change the concentra­
tions of substrates available in enzyme catalysed reactions 
[enzyme catalysed reactions which are sensitive to the 
concentrations of magnesium bound substrates include those 
catalysed by phosphotransferases (Morrison and O'Sullivan, 
1965), phosphohydrolases (Selwyn, 1967), and hydro-lyases 
(Penner and Cohen, 1969)]. Cations, such as magnesium, 
may also modify enzymes themselves, for instance,pyruvate 
kinase (Mildvan and Cohn, 1965). Further, the concentra­
tion of non-magnesium complexed metabolites is of importance. 
For example, a number of investigators (including Purich 
and Fromm, 1971; Irving and Williams, 1973; Lowry and
Passonneau, 1966) have found that the uncomplexed forms of
4 - 3-ATP and ADP (ATP and ADP ) may cause appreciable inhibition
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of the "kinase" type of phosphotransferase enzyme system.
The energy charge concept in its present form ignores these 
demonstrable effects and suggests that a rise in the energy 
charge will only result in an acceleration of the ATP 
utilizing reactions and an inhibition of those reactions 
which generate ATP. An increase in the energy charge would, 
however, result in an inhibition of the ATP utilizing 
reactions if the total ATP concentration exceeded the total, 
non-particulate magnesium ion concentration. Stadtman 
(1970), however, has proposed (though not very convincingly) 
that these metal ion effects are only an extension of 
Atkinson's energy charge hypothesis.
Although there is an excess of total magnesium
over ATP plus ADP concentrations in animal cells, not all
the magnesium is available to adenine nucleotides (Tables
4.12 and 4.11 show that 65% of the total magnesium in the
rat heart was bound to cellular metabolites and of this
65%, 82% was bound to the adenylates). The concentration
of magnesium adenylate complexes is determined by the hydro-
2 +gen ion concentration and the availability of free Mg
(which in turn is dependent upon the competitive binding
between metabolites and membranes). For example, lowering
the pH increases the protonation of the gamma phosphate
of ATP (pK 6.5) and thereby decreases the binding energy 
2+of ATP for Mg (Sanui, 1970) but such extra protonation 
has no effect on the binding of divalent cations to the 
phospholipid layers (Dawson and Hauser, 1970). Thus,
lowered pH may be expected to coordinately inhibit an 
24-array of Mg dependent pathways in the cell.
2 +One approach to the estimation of free [Mg ]
has involved measuring all of the major cellular magnesium
sites experimentally. These values, together with the
corresponding stability constants, have been used for calcu-
2 +lations of free [Mg ] (Table 4.12) . The total magnesium 
concentrations were determined by atomic absorption spectro­
scopy (probably the most sensitive method for the deter­
mination of total magnesium available); the values reported 
in Table 4.11 for the total magnesium concentration in 
normal rat hearts concur with previously published data 
(16.45 ± 1.23 mM in normal rat heart, Table 4.11; and
14.7 mM, Watchorn and McCance, 1937). ATP^ , with a
4 -1stability constant of 5.9 x 10 M , is the metabolite
that presents the highest affinity for magnesium; it is
followed by ADP (3370 M )^ and citrate (1580 M ^). The
magnesium stability constants of other cellular metabolites
are lower than 300 M  ^and only those metabolites with a
tissue concentration of 100 yM and above and having a
relatively high stability constant were chosen for further
consideration. Even if it was possible to list all
possible tissue metabolites capable of binding magnesium,
2 +it would be unlikely to change the estimate of free [Mg ],
for even amongst those metabolites listed, malate binds
less than 0.01% of the total magnesium. The free magnesium, 
2 +Mg , was calculated according to the formula:
Total [Mg] = [MgATP] + [MgATP]([ATP ]-[MgATP])KTOTAL MgATP
+ i£1 ( [ATPi
n [MgATP] [Bi] [K±]
TOTAL + [MgATP]
where free [Mg ] = [MgATP] (1 )([ATP ]-[MgATP])KTOTAL ‘MgATP
and [MgBi] = TIä t p
[MgATP][B±][K±]
TOTAL + [MgATP]
i.e. the concentration of the magnesium complex of each
binding agent is given by the value of the term in which
and the stability constant appear (Veloso et al.,
1973). The total magnesium concentration used to solve
equation (1) was the total magnesium concentration bound to
metabolites (see Table 4.11). Solving equation (1), gave
the estimates for [MgB^] tabulated in Table 4.12, and 
2 +[Mg ] of 0.86, 0.37 and 0.16 mM in normal, one day hyper­
trophied and one day hypertrophied and orotic acid treated 
rats respectively. Table 4.12 also shows that as the con­
centration of total adenylates increased from 6.3 to 7.6 
and 12.9 ymol/g wet wt in normal, one day hypertrophied 
and one day hypertrophied and orotic acid treated hearts, 
respectively, the percentage of ATP complexed to magnesium 
decreased from 98% to 96% and 90% respectively and the per­
centage of total ADP complexed to magnesium fell from 74% 
to 56% and 35% respectively. Thus, due to the published
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2-differences in the stability constants of MgATP ,
MgHATP^ , MgADP^ , MgHADP and MgAMP complexes, studies 
of the "energy charge", the "phosphorylation state" or the 
apparent equilibrium constants of the "kinase" type of 
phosphotransferase enzyme systems, require that the free 
magnesium concentration be taken into consideration.
2 +The value of 0.86 mM for the free IMg ] in the
normal heart, and reported values of 0.58 and 0.93 mM 
2 +iMg J in the brain and liver, respectively, (Veloso et
2 +al., 1973) are comparable to the free [Mg ] of 0.47 to 
0.90 mM reported in a number of different extracellular 
fluids (Walser, 1961; Heaton, 1967; Nielson, 1969), in 
spite of the relatively large differences in the total 
magnesium concentrations between intracellular and extra­
cellular fluids. The similarity in the concentration of
2 +free intracellular and extracellular [Mg ] suggests that
there is very little or no chemical gradient for free 
2 +[Mg ] across most cell membranes.
The enzyme adenylate kinase (E.C. 2.7.4.3.) 
catalyses the following reaction:
ATP + AMP t 2 ADP (2 )
This allows the calculation of a mass action ratio, T, 
such that:
[ADP]2 
[ATP] [AMP] (2a)
Substituting the concentrations of ATP, ADP, and AMP 
into equation (2a) gives T (Table 4.11). However, the 
actual species involved in the reaction are:
2- 2- - 3-MgATP + AMP t MgADP + ADP
i.e. f  = 1!ADP. ). (Noda, 1962) (3)
[MgATP ][AMP ]
Thus, the value of the mass action ratio of adenylate kinase 
is strongly dependent upon the value of the free magnesium 
concentration in the cell. The decrease in the percentage 
of magnesium complexed adenylates found during hypertrophy 
and orotic acid treatment would, therefore, have important
effects on the adenylate kinase equilibria. Substituting
2- - 3- 2-the concentrations of MgATP , MgADP , ADP and AMP
(Table 4.12) into equation (3) gives T' (Table 4.11).
Although it is necessary to consider these interactions with
protons and magnesium ions, the value of the mass action
ratio as a reflection of the situation, in vivo, will depend
upon the following assumption - that adenylate kinase was
present and available to the whole nucleotide pool. An
appreciable proportion of the nucelotides appears to be
bound to protein and consequently may be unable to react
with adenylate kinase. Seraydarian et al. (1962) found
that 0.4 ymol ADP bind per gram of actin; Barany and
Barany (1972) found 0.42 and 0.48 ymol of nucleotide
binding sites per gram of myosin and actin respectively;
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and Marston and Tregear (1972) found a further 0.2 jjM 
ADP in myosin of relaxed muscle fibres of the rabbit psoas 
muscle. Thus/appreciable amounts of ADP are bound to 
muscle protein and may be inaccessible to adenylate kinase.
The thermodynamic equilibrium constant was calcu­
lated for equation (3) by Khoo and Russell (1970) [from 
the observed equilibrium constants of Su and Russell (1968), 
at pH 7.0 and assuming that the amount of MgAMP is negligible] 
to give a value of 0.32. The mass action ratio, T', and 
the thermodynamic equilibrium constant were of the same 
order of magnitude in the normal and untreated, hypertrophied 
rat heart (T' was 0.19 and 0.12 in the normal and one day 
hypertrophied rat heart respectively, Table 4.11), suggest­
ing the enzyme is at equilibrium and in contact with the 
whole nucleotide pool. The high value of the mass action 
ratio of adenylate kinase in the one day hypertrophied 
hearts treated with orotic acid (1.43, Table 4.11) would 
suggest that the adenine nucleotides are not in equilibrium 
throughout these cells. This is a distinct possibility, for 
even though adenylate kinase is present in the cytosol and 
the mitochondrial fractions (Adelman et al., 1968), it has 
also been reported that the enzyme is absent from the mito­
chondrial matrix (Heldt and Schwalback, 1967). Any in­
crease in the AMP concentration in this compartment, such 
as that which is caused by the activation of fatty acids, 
is sufficient to alter the mass action ratio of adenylate
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kinase in the mitochondria and the tissue as a whole 
(Williamson et al., 1968).
The presence of significant concentrations of 
uncomplexed adenylates will also affect the equilibrium 
position of phosphocreatine kinase (E.C. 2.7.3.2.).
Creatine kinase catalyzes the reaction:
2-MgATP 4- creatine Z MgADP + phosphocreatine (4)
3-ADP is a competitive inhibitor with respect to MgADP 
and a non-competitive inhibitor with respect to phospho­
creatine (Morrison and O'Sullivan, 1965). In the one day 
hypertrophied and orotic acid treated hearts, with a low
- 3_[MgADP ] relative to [ADP ], the creatine kinase reaction 
may be in favor of creatine phosphate synthesis and may 
contribute to the observed decrease in the "energy charge" 
and the disequilibrium of the mass action ratio of adenylate 
kinase seen in these animals.
4.3.2 The Effect of Hypertrophy on Myocardial 
Adenylates
An increase in ATP and 0  ^consumption in heart 
muscle accompanies increased ventricular pressure develop­
ment or increased heart rate. An increase in pressure 
development may arise from either an increased end-diastolic 
volume, due to higher atrial filling pressure or, as in
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these experiments, to higher resistance in the aortic 
outflow tract (Morgan et al., 1965; Neeley et al.,
1967a,b; Opie, 1965). During mechanical overload of the 
heart, increased energy requirements are also involved in 
the acceleration and extent of protein and nucleic acid 
synthesis (Chapter 3).
The changes in the myocardial energy stores
during the first three days of morphologic and metabolic
adaptation of the heart to mechanical overload, are shown
in Tables 4.1 and 4.2. Table 4.1 indicates that ATP
levels were normal during the first two days of hypertrophy
(compared with sham operated animals, p > 0.1) but had
significantly increased by the third day after the onset
of hypertrophy (ATP had increased from 5.3 ymol/g wet wt
in the sham operated animals to 6.4 pmol/g wet wt in
hypertrophied animals 3 days after constriction of the
abdominal aorta). Although the ATP concentration did not
change significantly during the first 2 days of hypertrophy,
the concentration of total adenylates (ATP + ADP + AMP)
increased by 17%, 2 days after the induction of hypertrophy.
This was due to increased ADP and AMP concentrations and
was reflected in a decrease in the total energy charge,
*the ANR and an increase in the adenylate kinase mass
* In this Section, the abbreviation ANR (the adenine 
nucleotide ratio) is used exclusively for the experi­
mentally determined ratio
[ATP]T0T/[ADP]T0T.[HP04 ]T0T.
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action ratio. The relative increases in the concentra­
tions of ADP and AMP were due to the greater metabolic 
activity (Chapter 3) and the greater contractile tension 
developed (Chapter 1) in hypertrophied hearts.
In those animals, with hypertrophied hearts, 
which were treated with orotic acid, ATP concentrations 
remained the same as in sham operated animals during the 
first 2 days and, as with the untreated animals, increased 
during the third day of hypertrophy. A significant effect 
of orotic acid was a six fold increase in the concentration 
of ADP, one day after the onset of hypertrophy. A possible 
explanation of this increase was a lack of specificity in 
the measurement of ADP; Adam (1965) had indicated that 
the assay method, using pyruvate kinase and lactate dehydro­
genase, also reacted with IDP, GDP and UDP. Although orotic 
acid stimulated uridine nucleotide synthesis (Chapter 5), 
the concentration of UDP in the one day hypertrophied heart 
treated with orotic acid, was only 54 nmol/g wet wt 
(Table 4.9). The concentration of GTP in cardiac ventricu­
lar tissue was reported to be 0.18 ymol/g wet wt (Fox, 1971) 
and Potthast and Hamm (1969) have reported that IDP was not 
present in measurable amounts in muscle tissue. These low 
concentrations of UDP, IDP and GDP, compared to the con­
centration of ADP, make it unlikely that the assay of these 
nucleotides was responsible for a 6 fold increase in the
cardiac "ADP" concentration.
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The administration of other pyrimidines (uracil, 
uridine, and dihydroorotic acid) to animals one day after 
the induction of hypertrophy, did not cause the same 
increases in ADP concentration and total adenylate con­
centration, though the administration of dihydroorotic 
acid (the immediate metabolic precursor of orotic acid) 
did cause the ADP concentration of the heart to be doubled.
The reasons for these observed changes in the 
adenine nucleotide concentrations and the regulation of 
adenine nucleotide metabolism in cardiac tissue is dis­
cussed in Section 4.4.1.
It is generally assumed that adenylate kinase 
regulates the equilibrium of the adenine nucleotides in 
animal tissues. The low activity of adenylate kinase in 
cardiac tissue (in the heart, the total adenylate concen­
tration was 6.3 ymol/g wet wt, Table 4.1, and the adenylate 
kinase activity was 0.1 units/g wet wt; in the liver, 
the total adenylate concentration was 3.5 ymol/g wet wt 
and the adenylate kinase activity was 135 units per g wet 
wt (Adelman et al., 1968)) suggests that this may not be 
the case in cardiac tissue. In order to show that adenylate 
kinase regulates the equilibrium of the adenine nucleotides 
in the heart, two requirements must be satisfied: firstly,
the tissue must contain the enzyme and, secondly, the 
experimentally determined concentrations of the adenine 
nucleotides must be in accordance with the hypothesis of
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adenylate kinase intervention. As mentioned above,
Adelman has shown that the enzyme occurs in cardiac tissue.
In a system where the equilibrium between the 
adenine nucleotides is controlled by the adenylate kinase 
reaction, the level of each nucleotide may be determined if 
one knows the values of three parameters: the sum of the
adenosine 5'-mono-, di' and triphosphates; the apparent 
equilibrium constant of adenylate kinase; and the sum of 
the energy rich bonds of the adenylate system. From these 
parameters, the amounts of the different adenine nucleo­
tides may be calculated (see equations (5), (6) and (7)
in Table 4.14). If it is assumed that the total adenine 
nucleotide content of the heart was constant, then the 
shape of a theoretical plot of the proportions of the 
different adenine nucleotides against energy charge (as 
in Fig. 4.4) will be determined solely by the mass action 
ratio of adenylate kinase. Fig. 4.4 shows a graphic com­
parison of the experimental and theoretical values of the 
adenine nucleotides as a function of energy charge. The 
theoretical curves and experimental curves showed the 
closest correlation when a value of 0.83 was used for the 
apparent equilibrium constant of adenylate kinase. The 
results in Fig. 4.4 suggest that adenylate kinase regulates 
the levels of the adenine nucleotides in the heart, even 
when the energy charge varies over a wide range of values. 
In two groups of animals (the orotic acid treated, one
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day hypertrophied animals and the reserpine pretreated, 
one day hypertrophied hearts, labelled A and B, 
respectively, in Fig. 4.4) it was apparent that the 
enzyme was unable to maintain an equilibrium among the 
adenylate nucleotides. Presumably the high total 
adenylate concentration in these groups of animals was 
in excess of the capacity of the enzyme adenylate kinase 
to catalyse a thermodynamic equilibrium among the 
adenylates. Two days after the induction of hypertrophy, 
the total adenylate concentration in the orotic acid treated 
hearts, though still above normal values (6.5 ymol/g wet 
wt), had decreased from 12.9 ymol/g wet wt in the one day 
hypertrophied heart to 7.3 ymol/g wet wt (Table 4.1).
With this decrease in the total adenylate concentration, 
a thermodynamic equilibrium among the adenylates was re­
established, as judged by either the mass action ratios 
of adenylate kinase (Table 4.6) or the predicted distri­
bution of the adenine nucleotides (Fig. 4.4).
These experiments demonstrate that an equilibrium 
between the adenine nucleotides, similar to that observed 
in vitro by adenylate kinase, also occured in vivo, pro­
vided that the total adenylate concentration was not 
excessive. This leads to the conclusion that, provided 
the capacity of the enzyme was not exceeded, the enzyme 
was efficient in regulating the level of the adenine 
nucleotides in the entire cell and implies that the
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different cellular pools of adenine nucleotides were at 
the same energy level. The results also imply that the 
exchange of nucleotides, between different pools, must be 
extremely rapid.
The predicted response of enzymes to the 
Atkinson energy charge assumes that the adenylate kinase 
catalyses an equilibrium reaction and that the mass 
action ratio was 0.8. That the mass action ratio of 
adenylate kinase is markedly dependent upon the concen­
tration of magnesium ions is well established (Section 
4.3.1; Purich and Fromm, 1972), yet the energy charge 
model of control ignores this fact in assuming a value of 
0.8 for the mass action ratio. In assessing the concept 
of cellular control by the Atkinson energy charge, two
central questions must be considered: (1) "Does the
2 +[Mg ] concentration fluctuate under the conditions being 
considered?"; and (2) "Is the adenylate kinase catalysed 
system at equilibrium under the conditions under considera­
tion?". The results presented in Section 4.3.1 suggest 
that the answer to the first question was affirmative.
The results presented above indicate that the adenylate 
kinase system was at equilibrium in most of the groups of 
animals examined but that it was not at equilibrium under 
the conditions of high total adenylate concentrations, as 
in the one day, hypertrophied, orotic acid treated hearts. 
The answers to these questions suggest that the concept of
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overall cellular energy control by the energy charge 
concept is untenable.
The importance of the adenine nucleotides and 
inorganic phosphate to the regulation of cellular 
metabolism is drawn largely from observations of the 
effects of these modifiers on enzyme catalysed reactions 
in vitro. Since the validity of any regulatory mechanism, 
however precisely it may be defined at the molecular level, 
ultimately depends upon its relevance to events in the 
living cell, many attempts have been made to measure the 
levels of the adenine nucleotides in vivo. The wide 
variation between results in the literature, clearly demon­
strates that the physiological range of ATP levels in the 
normal rat heart remains to be defined (for example, the 
reported range of ATP levels in the normal rat myocardium 
varies from 3.4 ymol/g (Gruber et al., 1966) to 5.5 ymol/g 
(Paterson, 1971)).
The energy status of the cell may be expressed 
as either the ANR (Section 4.3.4) or the Atkinson energy 
charge (Atkinson, 1968). The phosphorylation state is the 
more satisfactory parameter thermodynamically for the 
energy charge does not take into account the concentration 
of inorganic phosphate, an essential reactant in oxidative 
and glycolytic phosphorylations. The energy charge is a 
measure of the extent to which the ATP-ADP-AMP system is 
"filled" with high energy phosphate groups and the "poise"
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of the allosteric modulators ATP, ADP, and AMP. Although 
studies of enzyme kinetics indicate that the energy charge 
may be a fundamental regulator of cellular metabolism, 
exerting maximal regulatory activity (both as a positive 
and a negative effector) in the region of energy charge 
0.85-0.95 (Atkinson, 1968), it must be remembered that 
the energy charge concept is wholly empirical in nature.
The energy charge concept is based on experience and was 
not derived in a rigorous, mathematical manner. The two 
parameters, energy charge and the ANR,are, however, closely 
related for the ratio [ATP]/[ADP] is a major determinant 
of both parameters and their regulatory properties are 
similar.
The relationship of the energy charge to the ANR 
is shown in Fig. 4.3 and the two parameters were found to 
be highly correlated (correlation i■ x = 0.96). From 
Fig. 4.3, the values of the log of the ANR, corresponding 
to the presumed physiological range of the energy charge 
(0.85-0.95), were estimated to be in the range 1,000 M  ^- 
3,000 M ■*". This range may be an underestimate of the true 
range,for Dawson et al. (1976) have reported that the true
inorganic phosphate concentration may be only 0.9ymol/g, 
less than 1/3 the value determined by conventional methods. 
Hence,the true physiological range of the cardiac ANR may 
be 3,000 M  ^ - 10,000 M an estimate in close agreement 
with a value of 2,000 M  ^ - 10,000 M  ^in the normal liver, 
determined by Reed (1976).
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This relationship between the energy charge and 
the ANR was developed using only those groups of hearts for 
which the energy charge concept was valid (that is, where 
the enzyme adenylate kinase catalysed an equilibrium 
reaction and the free magnesium concentration did not 
appreciably alter the value of the mass action ratio of 
this reaction). The use of the energy charge parameter 
should not be taken to imply agreement with the concept 
for as shown in this chapter and in Section 7.2, it is an 
inappropriate parameter to use as a measure of the energy 
status of cardiac tissue. The relationship between the 
presumed physiological range of values of the energy charge 
(as determined from experiments using purified enzymes) 
and a more rigorously determined parameter, the ANR, was 
developed in an attempt to relate the results of experi­
ments in vitro and a thermodynamic property of the cell.
In summary, the administration of pyrimidine 
compounds was not found to alter the concentration of 
cardiac purine compounds after the first day of hypertrophy. 
Although greater demands were placed upon those hyper­
trophied hearts which were treated with orotic acid, with 
regard to protein synthesis and nucleic acid synthesis 
(Chapter 3), the concentration of ATP remained the same in 
normal and one and two day hypertrophied hearts,treated 
with orotic acid.
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The constancy of the separate values of the 
Atkinson energy charge, the ANR and the mass action ratio 
of the reaction catalysed by adenylate kinase, clearly 
indicates that equilibrium (and thus the status of regula­
tory control) among the various chemical forms of the adeny­
lates was maintained in the normal, hypertrophying and 
hypertrophying and orotic acid treated hearts (except in 
the one day hypertrophied and orotic acid treated hearts 
and the reserpine pretreated, one day hypertrophied hearts).
4.3.3 The Effect of Hypertrophy on Cardiac 
Glycogen
There was no significant difference in the cardiac 
glycogen content of sham operated animals compared with 
normal animals. However, the glycogen content was signifi­
cantly increased in those animals with hypertrophied hearts 
(36.4 ± 6.1, 49.8 ± 7.6 and 98.2 ± 10.5 ymol/g wet wt in 
normal, one day hypertrophied and one day hypertrophied 
and orotic acid treated hearts, respectively (Table 4.3)).
In the well oxygenated heart, glycogen breakdown 
is restricted since glycogen phosphorylase (E.C. 2.4.1.1.) 
is almost entirely in the b (inactive) form due to the 
low activity of the phosphorylase b kinase enzyme (Posner 
et al., 1965). In the various categories of hearts studied, 
the activity of the b form of glycogen phosphorylase was 
further restrained by the high tissue concentrations of
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ATP and glucose 6-phosphate. Although the AMP concentra­
tions were well above the K value for the activation ofm
phosphorylase b by AMP (K 0.09 mM, Morgan and Parmeggiani 
(1964) and the measured AMP values were 0.218, 0.566 and 
1.12 mmol/kg in the normal, one day hypertrophied and one 
day hypertrophied and orotic acid treated hearts, 
respectively), the ATP level in all of the groups of hearts 
studied was at least 6.9 mM (Tables 4.1, 4.2 and 4.12), 
ensuring a strong and severe inhibition of phosphorylase b 
(Morgan and Parmeggiani, 1964). The higher levels of 
glucose 6-phosphate (Table 4.3) found in both the treated 
and untreated hypertrophied hearts could also be expected 
to inhibit net glycogenolysis by inhibiting the activation 
of phosphorylase b by AMP and by providing substrate for 
the synthesis of glycogen through glucose 6-phosphate.
(Glucose 1-phosphate concentrations increased from 18 ± 6 
nmol/g wet wt to 76 ± 19 and 59 ± 13 nmol/g wet wt in the 
normal, one day hypertrophied and one day hypertrophied 
and orotic acid treated hearts, respectively (Table 4.3).)
The high concentrations of glucose 6-phosphate may also be 
responsible for activating the glycogen synthetase system 
(Leloir et al., 1959). Since the of glycogen phosphoryl­
ase for inorganic phosphate, in the presence of aerobic 
concentrations of ATP and AMP, is approximately 18 mM 
(Morgan and Parmeggiani, 1964), the level of inorganic 
phosphate measured in all groups of animals (3.6 - 4.1 mM) 
may also contribute to the low rate of glycogen phosphorylase
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activity. UDP-glucose is reported to inhibit both glycogen 
phosphorylase a and b activity (Morgan and Parmeggiani,
1964) (at a concentration of 1 mM UDP-glucose, the activi­
ties of phosphorylase a and b were inhibited 29% and 34% 
respectively). However, the concentration of UDP-glucose, 
even in the orotic acid treated hypertrophied hearts 167.4 ±
6.6 nmol/g wet wt or 0.22 mM (Table 4.9)), was too low for 
this to be an important factor.
Wollenberger and Krause (1968) have reported that 
the activation of phosphorylase b is inhibited by the 
addition of ß adrenergic blocking agents or the depletion 
of endogenous stores of catecholamines. However, as shown 
in Fig. 4.1, catecholamine depletion in the hypertrophied 
heart was not significant until the third day of hyper­
trophy and,therefore,cannot be considered to contribute to 
the inhibition of glycogen breakdown.
Glycogen synthesis during hypertrophy and orotic 
acid stimulated hypertrophy may also change in a number of 
ways. For example, it was noted (Table 4.4) that the cardiac 
glycogen content was elevated in catecholamine depleted 
(reserpine pretreated) hearts (glycogen concentrations were
34.6 ± 6.1 and 45.6 ± 2.1 ymol glucose equivalents/g wet wt 
in normal and reserpine pretreated hearts respectively).
As glycogenolysis was almost completely restricted in 
normal aerobic hearts, most of the increase in glycogen 
concentration was probably due to increased glycogen synthesis.
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This suggests that glycogen synthesis, as well as 
glycogenolysis, was stimulated by catecholamine depletion. 
Although glucose uptake by the heart is normally 
restricted, increased ventricular pressure (as well as 
insulin, growth hormone, adrenaline and anoxia) is known 
to accelerate glucose transport into cardiac tissue 
(Neely et al., 1967a,b). One day after the induction of 
hypertrophy, in both untreated and orotic acid treated 
animals, the maximum tension developed was increased 
(Fig. 1.3) and glucose transport into the heart could be 
expected to increase. Any enhanced intracellular trans­
port can logically be expected to be directed towards 
glycogen synthesis rather than glycolysis, since there 
is a severe restriction of flux at the phosphofructokinase 
catalysed reaction (Fig. 4.5).
Although accounting for the increased glycogen 
synthesis, the above arguments do not readily explain why 
orotic acid treated hearts contain twice as much glycogen 
as the untreated hearts, one day after the induction of 
hypertrophy. A good reason for this difference is the 
fact that orotic acid caused an increase in the concen­
tration of uridine nucleotides in the heart (Table 4.9): 
in the one day hypertrophied hearts, the total uridine 
nucleotide concentration (UDP-glucose, UTP, UDP and UMP) 
increased from 140.4 ± 18.2 nmol/g wet wt in the untreated 
hearts to 377.0 ± 13.2 nmol/g wet wt in the orotic acid
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treated hearts, and UDP-glucose increased from 45.6 ± 
5.0 nmol/g wet wt in the untreated hearts to 167.4± 6.6 
nmol/g wet wt in the orotic acid treated hearts. Thus, 
the effect of orotic acid on cardiac glycogen was 
probably the result of increased cardiac UTP concentra­
tions and a simple mass action effect, since the enzyme 
UDP-glucose pyrophosphorylase (E.C. 2.7.7.9.) has been 
claimed to catalyse a near equilibrium reaction (Guynn 
et al., 1974).
4.3.4 Estimation of the Cytoplasmic Phosphory­
lation State of the Adenine Nucleotides 
(PSAN)*.
All living cells are capable of coupling exergonic 
catabolic reactions with the endergonic synthesis of ATP 
from ADP and Pi. The amount of energy required for this 
synthesis involves the value of the phosphorylation state 
of the adenine nucleotides and is expressed by the relation:
AG = AG° + RT In [ATP]/ [ADP][HPO^~] (10)
* In this section, PSAN (the phosphorylation state of the
adenine nucleotides) is used exclusively for the phosphoryl­
ation state determined using the method of Veech et al. 
(1970). The abbreviation ANR (adenine nucleotide ratio) 
is used exclusively for the experimentally determined ratio
[a t p]tot/[a d p]t o t [hpo4_]t o t* In cases which app!y to both 
the PSAN and the ANR, the term "phosphorylation state" 
is used.
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i.e. it is a function of the standard Gibbs Free Energy 
change (AG°) of the reaction:
ADP + HPO^“ t ATP + H20 (11)
under the prescribed conditions of pH independence, and of 
the concentrations of ADP, Pi and ATP. The change in Gibbs 
energy is related to the equilibrium constant for the hydro­
lysis of ATP:
AG° = - R T ln K (12)
and depends on the reaction that is being studied. In 
practice, it is convenient to express the experimental 
results in terms of an observed equilibrium constant:
K- = [ADP]T0T[Pi]T0T/[ATP]T0T (13)
where the symbols [ADP]TQT, etc., refer to the total concen­
trations of these compounds, including all ionic species,
both metal-free and metal (e.g. potassium and magnesium)
o 1complexes. The AG value is then equal to - R T ln K', 
and is only valid for the pH and cation concentrations 
specified.
In summary, the phosphorylation state is the 
principal determinant of the free energy of hydrolysis of 
ATP, an approximation of which is given by the equation:
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[ADP] [HPO? ]
AGATP(kJ> = AGATP + RT ln --- [ATP]----- (14)
Assuming that AG° , the standard free energy of hydrolysis
x~r X Jl
of ATP, is -31.8 kJ (at [Mg2+] of 1 mM, 25°C, pH 7.0 and 
all other reactant concentrations being 1M (Guynn and Veech, 
1973)), equation (10) then becomes:
AG (kJ) = -31.80 + 5.70 (-log phosphorylation state)X ir
Since AG is directly proportional to the negative log
ri X Jl
of the phosphorylation state, both AGATp and the ANR (from
the various groups of hearts studied) were plotted against
the Atkinson energy charge (Fig. 4.3). The data were
analysed by regression analysis (r 0.96) and a rangexy
covering the presumed physiological values of the Atkinson 
energy charge (0.85 - 0.90, Reed, 1976) was found to be
associated with an apparent AGATp ranging from 48.9 - 51.4 
kJ/mole (11.7 - 12.3 kcal/mole). Wilson et al. (1974)
have reported that the average free energy change of the 
first two phosphorylation sites of the mitochondrial 
electron transport chain ranged from 49.7 - 53.9 kJ/mole 
of ATP formed and this coincidence tends to support the 
theory that a state of equilibrium exists between the ANR 
of the cell and the redox potential across at least the 
first two mitochondrial phosphorylation sites, under 
physiological conditions.
The ANR of normal, hypertrophied, and hyper­
trophied and orotic acid treated hearts were calculated
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and the values tabulated in Table 4.10. The values of
[ATP] and [ADP] used in the calculations were the total
concentrations of these compounds, including all ionic
species, determined experimentally (Table 4.1). The 
2-values of [HPO^ ] were calculated from the experimentally 
determined total inorganic phosphate concentration as 
follows:
O  "IPi = [HP04-] + [MgHPO°] + [CaHP0°] + [I^PO^] (15)
That is:
Pi = [hpo4_] [l + —  + h— j (16)
** JA, . _  JA ~  J A ^ t^MgP CaP 2P
where KMgP/ Kcap anc^  K2P are t*ie comPlex dissociation 
constants and acid dissociation constants (at 25°C and 
0.2 ionic strength) of MgHPO°, CaHPO° and H^ PO^ "^ , 
respectively. The values of these constants were taken 
to be pK = 1.88, 1.70 and 6.78 respectively, (Smith and 
Alberty, 1956). Using the values of [Mg^+] tabulated in 
Table 4.11, assuming the intracellular pH to remain con­
stant during hypertrophy and to be 7.04 (Walker et al.,
2 +1969) and assuming [Ca ] to be 1 yM, the concentration 
2-of HPO^ was found to be 0.64 [Pi] in normal, hypertrophied,
and hypertrophied and orotic acid treated hearts. Although 
2 +[Mg ] varied over the range 0.16 - 0.86 mM (Table 4.11),
2 +the effect of this variation in [Mg ] only caused a
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2-change of less than 1% in the [HPO^ ]/[Pi] ratio.
2 +Estimating the [Ca ] in cardiac tissue was difficult
2+ -5 -7for [Ca ] varied over the range 10 - 10 M (Nayler
and Dunnet, 1974) due to the contraction-relaxation
cycle of the myofibrils. However, like variations in 
2 +[Mg ], the effect of these alterations was not signi­
ficant for it caused a change of less than 0.5% in the 
[HPO^~]/ [Pi] ratio.
The phosphorylation state of the adenylates is 
a measure of the energy status of cells which, in the 
absence of an energy input, has a value of about 5M  ^ at 
25°C (Lehninger, 1975). The extent to which this value 
is exceeded by the observed phosphorylation state ratio, 
in the cell, is a measure of the potential of the cell for 
carrying out ATP-dependent processes. The phosphorylation 
state is a more satisfactory thermodynamic measure of the 
energy status than the Atkinson energy charge, for the 
energy charge (Atkinson, 1968) does not take into considera­
tion the concentration of inroganic phosphate, an essential 
reactant in oxidative and glycolytic phosphorylations.
As shown in Table 4.10, the phosphorylation
state of the adenine nucleotides was very sensitive to
changes in the metabolic status of the heart. The ANR of
normal hearts was experimentally determined to be 1.35 x 
3 -110 M . The experimentally determined cardiac ANR was 
depressed during hypertrophy and appeared to remain constant
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3 -1during the first three days of hypertrophy (L.05 x 10 M ).
In the orotic acid treated, hypertrophied hearts, the ANR
was further depressed one day after the induction of
3 -1hypertrophy (0.2 x 10 M ) but had returned towards normal
3 -1by the third day of hypertrophy (0.91 x 10 M ). This
decrease in the value of the ANR was not an effect of
orotic acid itself, for in normal animals treated with
3 -1orotic acid, the ANR was 1.8 x 10 M (compared with 
3 -11.4 x 10 M in untreated normal animals). The observed 
decreased ANR, during hypertrophy, was consistent with an 
enhanced rate of energy utilization as a result of an 
acceleration of the rates of protein and nucleic acid 
synthesis in developing hypertrophy (Chapter 3).
The investigation of cellular metabolism requires 
insight into the metabolite concentrations in the two major 
compartments of the cell, i.e., the mitochondria and the 
cytoplasm. The methods of tissue analysis used here to 
calculate the phosphorylation state of the adenylates only 
provide data for the cell as a whole. An estimate of the 
cytoplasmic phosphorylation state (PSAN) may be derived 
from the data in Tables 4.3 and 4.4, using the methods of 
Veech et al. (1970).
Veech et al. (1970) have shown that changes in 
the cytoplasmic [NAD+]/ [NADH] redox couple in the liver must 
be reflected in parallel and directly related changes in 
the cytoplasmic phosphorylation state of the adenylate
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system (PSAN). At equilibrium,the cytoplasmic [NAD+]/ [NADH] 
couple and the cytoplasmic phosphorylation state of the 
liver are related because of the role of the enzymes 
3-phosphoglycerate kinase (E.C. 2.7.2.3.) and glyceraldehyde 
3-phosphate dehydrogenase (E.C.1.2.1.12.) in the reactions:
Glyceraldehyde 3-P + P^ + NAD+ Z 1,3-diphosphoglycerate 
+ NADH catalysed by glyceraldehyde 3-phosphate 
dehydrogenase
and
1,3-diphosphoglycerate + ADP + H+ ■* 3-phosphoglycerate 
+ ATP catalysed by 3-phosphoglycerate kinase
These equations may then be combined to give the 
following equation:
[ATP]____  _ [NAD+] [Glyceraldehyde 3-phosphate]
[ADP][HPO^-] ~~ [NADH] * [3-phosphoglycerate]
*KGAPDH‘K3PGK (17
The cytoplasmic [NAD+]/ [NADH] ratio may be obtained from 
any of the cytoplasmic NAD+ dependent pyridine nucleotide 
dehydrogenase systems that are at or close to equilibrium. 
Among these,lactate dehydrogenase was the most satisfactory 
because of its high activity in hepatic tissue (294 mol/ 
min/g wet wt, Knox, 1972) and the ease of the determination 
of the concentrations of lactate and pyruvate. Thus, 
equation (17) may now be expressed as:
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[ATP]/ [ADP][HPO^ ] = [Pyruvate]/ [Lactate].KGApDH.K3pGK/KLDH
.[Glyceraldehyde 3P]/ [3-Phosphoglycerate]
(18)
where KP7.nnu, K and K are the equilibrium constants
vaAPDri JP L jK .LDri
of the glyceraldehyde 3-phosphate dehydrogenase, 3-phospho- 
glycerate kinase and lactate dehydrogenase reactions. It 
is thus clear that there is a close parallel relationship 
between the nicotinamide and adenine nucleotide systems in 
the cytoplasm of hepatic cells.
The justification for this approach to the esti­
mation of the cytoplasmic phosphorylation state of the 
adenine nucleotides (PSAN) depends upon the validity of 
the following postulates: (a) that the concentrations of
the substrates and products of the enzymes glyceraldehyde 
3-P dehydrogenase, 3-phosphoglycerate kinase and lactate 
dehydrogenase are all in thermodynamic equilibrium in the 
intact cell and the maximum catalytic capacities of these 
enzymes are sufficient to maintain the thermodynamic 
equilibrium; (b) an equilibrium is established with a 
common pool of pyridine nucleotides; (c) the concentra­
tions of pyruvate and lactate in the cytoplasm are repre­
sentative of the levels determined in a whole tissue 
extract; (d) the pH of the cytoplasm and the mitochondria 
is pH 7; (e) the ionic strength of the cytoplasm and the
mitochondria is 0.25.
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The appropriateness of this method for the 
estimation of the cytoplasmic phosphorylation state of the 
adenine nucleotides in cardiac tissue will depend upon the 
experimental realization of all of the above postulates.
In the absence of quite accurate information on some of 
these points, some assumptions were necessary. It is, in 
fact, likely that there are pH differences between the cyto­
plasm and the mitochondria, and even within the cytoplasm. 
The average intracellular pH may not be 7.0 but may be as 
low as pH 6.5 (Henderson et al., 1969). However,other 
estimates of the cardiac intracellular pH give values of 
7.04 (Walker et al., 1969) and 6.91 (Albers, 1977).
Recently, Albers (1977) reported that the hypertrophied 
heart had a stronger buffering capacity than the normal 
heart and an intracellular pH of 6.99. Thus, the assumption 
that the intracellular pH of both normal and hypertrophied 
hearts was 7.0 appears to be a reasonable postulate.
There is no precise information on the intra­
cellular ionic strength and it is most probable that there 
are concentration gradients within the cell which may change 
the ionic strength. There is considerable evidence that 
the ions and water within the cell do not constitute a 
dilute, aqueous solution comparable with that on the out­
side of the cell (Hazlewood et al., 1971; Cope, 1969). 
Indeed, not only is a significant portion of the tissue 
water ordered,giving it different solvent properties, but
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in several tissues, such as muscle, most of the intra­
cellular sodium and potassium may be bound to intra­
cellular components (Cope, 1970). Also, the concentration 
of ions may vary from one part of the heart to another 
(for example, the canine ventricular tissue sodium concen­
tration was 30.9 mmole/kg while the sodium concentration 
in the cardiac purkinje fibres was 100 mmole/kg tissue, 
Vick et al., 1970). Although these findings will cast 
doubt on any estimate of the intracellular cardiac ionic 
strength, it would seem reasonable to assume a similar 
intracellular ionic strength in both the liver and heart 
in view of the similar ionic composition of plasma, inter­
stitial and intracellular fluids. For this reason, an 
intracellular ionic strength of 0.25 was assumed 
(Williamson et al., 1967) and the equilibrium constants 
used in these calculations were those determined at an 
ionic strength of 0.25.
Calculation of the redox state using the lactate 
dehydrogenase reaction depends upon lactate and pyruvate 
being at equilibrium throughout the cell. Various reports 
suggest that this condition may not be satisfied.
Henderson et al. (1969) have reported that there may be
different compartments within the cell with different 
permeabilities to lactate and pyruvate; Halestrap and 
Denton (1975) have reported that pyruvate is actively 
transported into the mitochondria; and Spencer and
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Lehninger (1976) have reported that lactate transport 
into cells was competitively inhibited by other sub­
stituted monocarboxylic acids such as pyruvate. On the 
other hand,there is also evidence that lactate and 
pyruvate are at equilibrium concentrations for the 
[lactate]/ [pyruvate] ratio in the heart (Table 4.3) was 
the same as the ratios found in fluids that readily 
exchange with the tissues [the [lactate]/ [pyruvate] ratio 
was 14.2 in the heart (Table 4.3), 12.4 in the liver and 
11.2 in whole blood (Bergmeyer, 1974)].
Lastly, the values of the combined mass action 
ratios of glyceraldehyde 3-phosphate dehydrogenase and 
phosphoglycerate kinase are near the apparent thermodynamic 
equilibrium constants of the enzymes (Section 4.3.5) 
suggesting the enzymes catalyze equilibrium reactions in 
the heart and that the substrates and products of these 
reactions are in thermodynamic equilibrium in the intact 
cell.
Thus,the assumptions used in the derivation and 
application of equation (18) are satisfied by the rat heart 
and allow the use of this equation to calculate the cyto­
plasmic cardiac phosphorylation state of the adenylates.
-1These ratios were calculated using .K_ _ = 59 M
(Veech et al. , 1970) and KTT^ U = 1.11 x 10  ^ (Williamson etLDri
al. , 1967) and are tabulated in Table 4.10.
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In general, the experimentally determined ANR 
and the calculated PSAN were not in close agreement; the 
PSAN values being greater than the ANR values (Table 4.10) .
It should be noted that the experimentally derived value 
of the phosphorylation state was that of the ratio involving 
the magnesium complexes of the adenylates:
--- tM9ATp2~l 2 (19)
[MgADP ][HPO4 ]
(the calculation of the concentration of magnesium 
adenylates was described in Section 4.3.1). The theoretical 
derivation of the cytoplasmic phosphorylation state followed 
as a consequence of the reactions catalysed by glyceraldehyde 
3-phosphate dehydrogenase and phosphoglycerate kinase, in 
the sum reaction described in equation (20).
2- + 2- - 3- 2- +GAP + NAD + HP04 + MgADP = 3PGA + NADH + MgATP + H
(20)
Thus equation (18) should be rewritten as:
[MgATP2-]/ [MgADP-][HPO2-] = [Pyruvate]/ [Lactate].K pDH.
•K3PGK/KLDH' [GAPl/[3PGA1 (18a)
A valid comparison of the experimental and the estimated 
phosphorylation states may now be made.
Though both the ANR and the PSAN purport to give 
a value of the phosphorylation state, neither reflect the
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situation in v i v o. Consider first the experimentally deter­
mined value of the phosphorylation state. Experimentally,
2-the concentration of HPO^ in the heart is difficult to 
measure. The currently accepted values of the cardiac 
inorganic phosphate concentration (and those determined in
these experiments) appear to be 2-3 fold greater than the
2-"true" intracellular concentration of HPO^ determined by 
31P nuclear magnetic resonance spectroscopy (Dawson et al.,
1976). If Dawson's estimate of the inorganic phosphate
concentration (1.2 mM) is correct, the phosphorylation
3 -1state of the normal heart would become 4.07 x 10 M 
rather than 1.39 x 10~* M  ^ (Table 4.10).
Further, Faupel et al. (1972), in their studies 
of the effects of delayed freezing on the concentrations 
of tissue metabolites, have shown that the [ATP]/[ADP] 
ratio is very sensitive to anoxia. Assuming that the same 
percentage changes in metabolite concentrations occur in 
the heart as Faupel et al. (1972) have reported in the liver, 
then during the 8 seconds taken to remove and freeze the 
heart, the ratio [ATP]tot/[ADP] fell to 64% of its value
at zero time. Thus an estimate of the zero time phosphoryla-
3 - 1  3 - 1tion state would be 6.36 x 10 M , rather than 4.07 x 10 M
The experimentally determined value of [ADP] 
overlooks the reported binding of ADP to actin. Seraydarian 
et al. (1962) have reported that 0.4 pmol ADP/gram wet wt
of muscle was bound to actin and Marston and Tregear (1972)
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have reported that a further 0.2 ymol ADP/gram wet wt 
of muscle was bound in the resting muscle. Thus,0.6 ymol 
ADP/gram of tissue is not part of the soluble ADP pool 
and, consequently, was not in equilibrium with other enzyme 
catalysed systems. Since the phosphorylation state is a 
measure of the energy status of the cell in relation to 
metabolic control, 0.6 ymol ADP/gram should be deducted 
from the total ADP concentration. Thus, the ADP concentra­
tion in normal hearts now becomes 0.44 ymol/g rather than 
1.04 ymol/g (Table 4.1), and the ANR is further increased 
from 6.36 x 1C3 M_1 to 15.03 x 103 M_1.
Just as the value of the ANR was underestimated 
because of the time taken to remove and freeze the heart, 
so too was the value of the PSAN. Using Faupel's estimates 
of the change of concentration of glycolytic intermediates, 
then during the 8 seconds taken to remove and freeze the 
heart, the value of the ratio [pyruvate]/[lactate].[GAP]/
[3PGA] fell to 26.5% of its value at zero time, that is, 
the value of the PSAN was 26.5% of its value at zero time. 
Therefore, a more accurate estimate of the PSAN may be 
13.02 x 103 M  ^ rather than 3.45 x 103 M  ^ (Table 4.10).
Thus, the experimentally determined value of the 
3 -1ANR (15 x 10 M ) appears to be greater than the calculated 
value of the PSAN (13 x 103 M ^), a situation which is 
incorrect for two reasons. Firstly, if the ADP is initially 
phosphorylated within the mitochondria and is then
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transported outside, as is generally believed, it is 
thermodynamically impossible for the phosphorylation 
state of the reacting species within the mitochondrion, 
and hence the total cell, to be greater than that in 
the cytoplasm. Secondly, Klingenberg et al. (1969) point
out that differences in the [ATP]/[ADP] ratio occur in­
side and outside the mitochondrion as a consequence of 
the preference of the adenine nucleotide translocator 
for ADP rather than ATP for transfer into the mitochondrion, 
with no preference for the transfer in the opposite 
direction. This suggests that the value of the cyto­
plasmic phosphorylation state is still too low. Several 
explanations of this discrepancy may be considered, 
however, they are difficult to quantitate. Firstly, there 
is an error involved in the measurement of the extremely 
small amounts of glyceraldehyde 3-phosphate in the heart. 
Secondly, it was assumed that the intracellular ionic 
strength was 0.25, as Veech et al. (1970) have assumed 
was the case in hepatic tissue, and so the equilibrium 
constants used in the calculation of the cytoplasmic 
phosphorylation state were those determined at an ionic 
strength of 0.25. As mentioned earlier in this section, 
it was very difficult to estimate the true intracellular 
ionic strength and the values of the various equilibrium 
constants may be in error (Bücher et al., 1972, have 
reported that the equilibrium constant of lactate dehydro­
genase had values of 0.81 x 10 \  0.88 x 10 and
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0.96 x 10  ^ at ionic strengths of 0.20, 0.10 and 0.05, 
respectively). Thus,estimates of the phosphorylation 
state will vary according to the ionic strength and/ 
without an accurate knowledge of the intracellular con­
ditions, estimates of the cytoplasmic phosphorylation state 
will only approximate the situation in vivo.
With the above reservations in mind, the values 
of the PSAN indicate a higher value for this parameter in 
those hearts treated with orotic acid (Table 4.10) compared 
with those hypertrophied hearts not so treated. These 
results are the opposite of those determined experimentally 
for the whole cell and suggest that orotic acid was having 
its effect primarily in the cytoplasmic compartment.
Guynn et al. (1974) attempted to determine the 
concentration of free PP^ in the cytoplasm using an approach 
similar to that previously adopted to determine the ratio 
of free [ATP]/[ADP][HPO^ ] (Veech et al., 1970) in the 
liver cytoplasm. The enzyme UDP-glucose pyrophosphorylase 
is found only in the cytoplasm and catalyzes the following 
reversible reaction:
4- 2- 2- 4-UTP + glucose + phosphate Z UDP-glucose + PP^
It is therefore possible to calculate the cytoplasmic free 
[PP^ ] by measuring the concentrations of UTP, glucose 1-P 
and UDP-glucose in the freeze-clamped heart.
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Free [PP^] = [glucose 1-phosphate][UTP][UDP-glucose] K.UDP-glucose pyrophosphorylase
This approach has been used to measure free [PP^] in cardiac 
tissue (3.4 nmol/g wet wt in normal hearts, 12.96 nmol/g 
wet wt in one day hypertrophied hearts and 10.53 nmol/g 
wet wt in one day hypertrophied and orotic acid treated 
hearts, Table 4.10), assuming a value of the thermodynamic 
equilibrium constant of UDP-glucose pyrophosphorylase 
equal to 4.55 (Guynn et al., 1974). Although pyrophosphate 
may be formed in many reactions (for example, the activa­
tion of fatty acids, amino acids, DNA synthesis as well as 
the reaction catalysed by alkaline phosphatase), the four 
fold increase in the pyrophosphate concentration of the 
cytoplasm was suggestive of enhanced fatty acid activation.
Glucose enters the glycolytic pathway as glucose 
6-P, the reaction being catalysed by hexokinase (E.C. 2.7.1.1.):
Under physiological conditions, the reaction is essentially 
irreversible and is regulated (in cardiac muscle) by a 
number of metabolites including ATP (Km 0.5 mM), ADP (K^ 
0.68 mM) and AMP (K-^  0.37 mM) (England and Randle, 1967). 
Although the concentrations of ATP, in all of the groups of
4.3.5 The Effect of Hypertrophy on the 
Control of Cardiac Glycolysis
Glucose + ATP —^2-- > glucose 6-P + ADP (21)
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hearts studied, were at least ten times the Km (0.5 mM) 
for ATP (Tables 4.1 and 4.2), the activity of hexokinase 
can be expected to be restricted because of inhibition of 
the enzyme by glucose 6-phosphate, ADP arid AMP. The Ki 
for glucose 6-phosphate was 0.16 mM (Glucose 6-P concentra­
tion was at least 0.37 mM in hypertrophied and hypertrophied 
and orotic acid treated hearts). The K^ for ADP with 
respect to ATP was 0.68 mM for the soluble enzyme (ADP 
concentration was at least 1.6 mM in the various groups 
of hearts studied) and the for AMP with respect to ATP 
was 0.37 mM for the soluble enzyme (the AMP concentration 
was at least 0.7 mM in the hypertrophied hearts). Although 
ATP and Pi may modify the degree of inhibition of hexo­
kinase by glucose 6-phosphate (Fromm and Zewe, 1962 and 
Rose et al., 1964), the data in these reports suggest 
that the effect of ATP and Pi in the concentrations found 
in the heart would be marginal. Thus, in the normal, 
hypertrophied and hypertrophied and orotic acid treated 
hearts, the activity of hexokinase will be considerably 
restricted, owing to the high tissue concentrations, 
relative to their respective K^'s, of glucose 6-phosphate, 
ADP and AMP. However, the intracellular level of glucose 
6-phosphate is dependent upon the activity of phospho- 
fructokinase rather than that of hexokinase.
The mass action ratio and the apparent equilibrium 
constant of phosphoglucoisomerase (E.C. 5.3.1.9.) were
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equal in hypertrophied hearts, hypertrophied hearts 
treated with orotic acid and in normal hearts treated with 
either orotic acid or reserpine (Fig. 4.5), which suggests 
that the enzyme catalysed reaction is at equilibrium in 
all of these conditions and the phosphoglucoisomerase 
catalysed reaction is not an important rate controlling 
step in glycolysis.
The next site of regulation in the glycolytic 
sequence is the reaction catalyzed by phosphofructokinase 
(E.C. 2.7.1.11. ) :
Fructose 6-phosphate + MgATP -*■ Fructose 1,6-diphosphate +
MgADP  ^2.
Allosteric control of phosphofructokinase through homo­
tropic and heterotropic modifiers, phosphorylation and 
dephosphorylation and sensitivity to pH is extensive (Bock 
and Frieden, 1976; Brand and Soling, 1975). Intracellular 
pH appears to have a large effect on phosphofructokinase 
activity. The purified enzyme is particularly sensitive 
to allosteric control over the range pH 6.8 - 7.3 (Mansour, 
1972), though the effect of this pH dependence in the 
heart in vivo is not clear, as the intracellular pH has 
been variously reported as pH 6.5 (Henderson et al., 1969)
and pH 7.04 (Walker et al., 1969). Phosphofructokinase
-4 -2is inhibited by both ATP and MgATP , though by different 
mechanisms (Kemp and Krebs, 1967) and by citrate (Mansour,
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1972), while ADP, AMP (Trivedi and Danforth, 1966) and 
cAMP (Mansour, 1972) activate the enzyme. Shen et al.
(1968) have also demonstrated experimentally that the 
phosphofructokinase activity is inversely proportional 
to the energy charge. Factors accounting for the activa­
tion of phosphofructokinase in hearts exposed to increas­
ing ventricular end-diastolic pressures are subject to 
some controversy: Opie et al. (1971) reported a reduction
in ATP and an increase in ADP, AMP and Pi, leading to the 
activation of phosphofructokinase, whereas Neely et al. 
(1972a) did not observe these changes. The results 
reported here suggest that it is the overall energy charge 
or phosphorylation state of the adenylates which deter­
mines the activity of phosphofructokinase, as reflected 
in the mass action ratio of the enzyme (Fig. 4.5), the 
correlation between the log of the mass action ratio and 
the energy charge, r^ ^, being 0.81. (The correlation 
coefficient being a measure of the "strength" of the linear 
relationship between two variables.)
In all the groups of hearts studied, the log 
(mass action ratio/K^^) of phosphof ructokinase was less 
than -2, indicating that the enzyme catalyzes a major 
control point in the glycolytic sequence. This tightening 
of control at phosphofructokinase was mainly achieved by 
the high intracellular ATP concentration (at least 7 mM 
in the groups of hearts studied), which was many fold
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greater than the for ATP (0.08 - 0.3 mM over the 
physiological range of fructose-6P, Neely and Morgan,
1974). In the one day hypertrophied, orotic acid treated 
hearts or reserpine pretreated, hypertrophied hearts, 
there was a relaxation of control due to high concentra­
tions of activators of phosphofructokinase present.
These activators are ADP (8.9 mM and 7.8 mM in the orotic 
acid and reserpine pretreated hearts respectively, Km 
0.5 yM, Kemp and Krebs, 1967), AMP (1.51 mM in the orotic 
acid treated hypertrophied hearts and Km 1.8 yM, Kemp and 
Krebs, 1967) and Fructose 1,6-diphosphate [183 yM and 
160 yM in the orotic acid treated and reserpine pretreated 
hearts respectively, Km 1 yM (Mansour, 1972)]. Thus, the 
reaction catalysed by phosphofruetokinase is a major con­
trol point in glycolysis. Control was not decreased 
during hypertrophy, although one day after the induction 
of hypertrophy, there was a temporary relaxation of control 
in those animals treated with orotic acid; this was not 
the case when other pyrimidines were used.
The next reaction of the pathway is catalysed 
by aldolase (E.C. 4.1.2.13.) and involves the conversion 
of fructose 1,6-diphosphate to dihydroxyacetone phosphate 
and glyceraldehyde 3-phosphate. The mass action ratios 
of the products and substrates of aldolase catalysis, in 
all the groups of hearts studied, were displaced from 
equilibrium (Fig. 4.4). This deviation from equilibrium
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may be due to the binding of dihydroxyacetone phosphate 
to the enzyme rather than restraint on flux at this point 
(Williamson, 1965b). Similarly, the isomerization of the 
triose phosphates by triose phosphate isomerase 
(E.C. 5.3.1.1.) is not thought to represent an important 
regulatory reaction in glycolysis. On the other hand, the 
ratio of dihydroxyacetone phosphate concentration to 
glyceraldehyde 3-phosphate concentration in the heart does 
not reach the thermodynamic equilibrium ratio of 22 (17 in 
normal hearts, 5 in hypertrophied hearts and 5 in orotic 
acid treated, hypertrophied hearts).
Experimentally, the determination of the content 
of 1,3-diphosphoglycerate was difficult because it was 
present only in very low concentrations. It is,thereforef 
convenient to combine the thermodynamic properties of the 
enzymes that catalyse reactions which utilise and form this 
compound. These enzymes are glyceraldehyde-3P dehydrogenase 
(E.C. 1.2.1.12.) and phosphoglycerate kinase (E.C. 2.7.2.3.) 
The calculation of the mass action ratio may still involve 
large errors because of the low concentrations of glyceral­
dehyde 3-phosphate and 3-phosphoglycerate. Although the 
glyceraldehyde-3P dehydrogenase reaction has been proposed 
to control the glycolytic rate in perfused hearts under 
anoxic or ischaemic conditions (Kiibler and Spieckermann, 
1972), there is little evidence from the experiments pre­
sented here that the dehydrogenase may be rate limiting.
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The activity of the glyceraldehyde 3-phosphate dehydro­
genase enzyme in cardiac tissue is high, relative to the 
concentrations of its substrates or products (Knox, 1972). 
The results tend to indicate that one could consider that 
the enzyme may catalyse an equilibrium reaction. However, 
this proposition may be disqualified because the pH 
optimum of the enzyme is approximately 2 pH units above 
the intracellular pH. Further, the enzyme is inhibited by 
increasing concentrations of ATP (Constantinides and Deal, 
1969; Francis et al., 1971). Phosphoglycerate kinase is
3-sensitive to changes in the concentration of ADP , which 
appears to act by binding to the MgADP site (Melchior,
1965). In the one day orotic acid treated hypertrophied
3-hearts, in which there was a high free ADP concentration, 
there was a decrease in the mass action ratio of phospho­
glycerate kinase (Fig. 4.5), compared with either untreated 
hypertrophied hearts or the 2 and 3 day orotic acid treated 
hypertrophied hearts.
Although the combined mass action ratio of 
glyceraldehyde-3P dehydrogenase and phosphoglycerate kinase 
was displaced one order of magnitude from the apparent 
thermodynamic equilibrium of the enzymes in the one day, 
orotic acid treated, hypertrophied hearts (due to the high 
pH optimum of glyceraldehyde-3P dehydrogenase and the high 
ATP concentration in the heart), the mass action ratio was 
displaced towards normal in the 2 and 3 day orotic acid 
treated hypertrophied hearts and uridine, uracil and
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dihydroorotic acid treated hypertrophied hearts. The 
reaction was maintained at equilibrium in the sham 
operated and untreated hypertrophied hearts, suggesting 
a possible relaxation of control in glycolysis in the 
reactions catalysed by these enzymes.
The next reaction of the glycolytic sequence is 
catalysed by phosphoglyceromutase (E.C. 2.7.5.3.):
M q 2 +D-3-Phosphoglycerate — ---> D-2-Phosphoglycerate (23)
The mass action ratio and the apparent equilibrium constant 
were the same in all the groups of hearts studied (Tables 
4.8, 4.6 and 4.7), suggesting the enzyme does not catalyse 
an important rate controlling step in glycolysis.
Enolase (E.C. 4.2.1.11.) catalyses the reaction:
M or Mn^ "*"2-Phosphoglycerate — ---— ---- *■ Phosphoenolpyruvate (24)
The mass action ratio and the apparent equilibrium constant 
were the same in normal hearts, orotic acid treated normal 
hearts and pyrimidine treated, hypertrophied hearts, data 
which are consistent with the proposal that the enzyme does 
not catalyse an important rate controlling step in glycolysis. 
Wood (1964) showed that the maximum catalytic activity of 
enolase occurred with a free magnesium concentration of 
1 mM; however, the high cardiac activity of the enzyme 
(11.6 nmol/min/g, Knox 1972) compared to the concentrations
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of its substrates and products make it unlikely that the
2 +enzyme is rate limiting at the lower free Mg concentra­
tions occurring in the hypertrophied hearts (0.37 mM and 
2 +0.16 mM Mg in the one day hypertrophied and one day 
hypertrophied, orotic acid treated hearts, respectively, 
Section 4.3.1). (The data of Wood (1964) suggests that
the catalytic activity of enolase is 88% of maximum at
2+ 2 +0.37 mM Mg and 65% of maximum at 0.16 mM Mg .)
The reaction catalysed by pyruvate kinase 
(E.C. 2.7.1.40.) is given in equation (25):
+ K+Phosphoenolpyruvate + MgADP + H ---»- Pyruvate + MgATP (25)
has been proposed as a regulatory site in glycolysis in 
the isolated, perfused rat heart (Williamson, 1965b).
Pyruvate kinase may act as a determinant of glycolytic 
activity by competing with the enzymes involved in 
oxidative phosphorylation for available ADP (Gosalvez et 
al., 1974). The finding that the mass action ratio of 
the products and substrates of pyruvate kinase (Tables 
4.6 and 4.7) in the groups of hearts studied, was displaced 
from equilibrium values by three orders of magnitude 
(Fig. 4.5) strongly indicates that pyruvate kinase may 
act to restrict the glycolytic flux in vivo.
3-Muscle pyruvate kinase is inhibited by ADP
2 -and MgATP , both of which compete at the MgADP binding
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site (Melchior, 1965). The for ATP is 0.14 mM 
(Boyer, 1969); the cardiac ATP concentration was at 
least 6.7 mM in the groups of hearts studied suggesting 
that the enzyme was considerably displaced from equilibrium.
In the hypertrophied hearts, the activity of 
pyruvate kinase may be further restricted, i.e. the mass 
action ratio of the enzyme was reduced, because of the
3_increasing concentrations of ADP (Table 4.12). Inhibition 
of pyruvate kinase resulted in the accumulation of metabo­
lites preceeding the reaction catalysed by pyruvate kinase. 
The accumulated metabolites would be expected to include
1.3- diphosphoglycerate (the cardiac concentration of
1.3- diphosphoglycerate was too small to be accurately 
determined), a powerful inhibitor of glyceraldehyde-3P 
dehydrogenase. The effects of cardiac adenylates on the 
mass action ratio of pyruvate kinase are shown in Fig. 4.6; 
statistical analysis of the results gave a correlation of 
0.89 between the Atkinson energy charge (and the phosphoryl­
ation ratio of the adenine nucleotides) and the mass action 
ratio of the reaction catalysed by pyruvate kinase. These 
results suggest a strong correlation between the energy 
status of the cell and the contribution to this energy 
status by the poise of the pyruvate kinase reaction in vivo.
In summary, the greater the concentration of ATP 
relative to the concentrations of other adenylates, the 
less restricted was the carbon flux through the reaction
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catalysed by pyruvate kinase (Fig. 4.6). The inverse of 
this generalisation (that is, the greater the concentra­
tion of ATP relative to the concentrations of other 
adenylate nucleotides, the more restricted was the carbon 
flux) was found to occur with the reaction catalysed by 
phosphofructokinase.
4.3.6 The Effect of Orotic Acid and Hypertrophy 
on the Cytoplasmic [NAD+] [ N A D H ]  ^ Ratio
Redox and adenylate ratios are characteristic and 
regulatory parameters of every living cell. The ratio of 
the concentration of free NAD+ to NADH is of importance, 
since it determines the metabolic behaviour of oxidizable 
and reducible substrates and has the potential to drive 
either anabolic or catabolic processes. The redox state 
may be calculated from the following equation:
[oxidized substrate] . [NAD(P)H] _ ,26
[reduced substrate] [NAD(P)] [H]
where K represents the equilibrium constant for the 
particular enzyme system. In the cytoplasmic compartment, 
there are at least two enzyme systems which may be used in 
the calculation of the cytoplasmic [NAD+] / [NADH]  ^ ratio: 
lactate dehydrogenase and a-glycerophosphate dehydrogenase. 
The validity of equation (26) and the applicability of this 
equation to the calculation of the cardiac cytoplasmic redox 
ratio, depend upon assumptions discussed and justified in
Section 4.3.4.
139 .
The a-glycerophosphate dehydrogenase system 
used in these calculations suffers from the disadvantage 
that the activity of the enzyme is low in cardiac tissue 
and the possible disadvantage that the operation of a 
glycerophosphate cycle may displace the system from 
equilibrium (Bücher and Russman, 1964). The glycerophos­
phate cycle, however, appears not to be of major importance 
in cardiac tissue (Opie and Mansford, 1971) and, in fact, has 
only ever been shown to act physiologically in insect 
tissues.
Thus, the lactate dehydrogenase method may be the 
more reliable,for lactate dehydrogenase has a higher 
activity and is confined entirely to the cytoplasm 
(Crabtree and Newsholme, 1972).
Cytoplasmic [NAD+][N A D H ]  ratios, calculated 
using both the lactate and a-glycerophosphate dehydrogenase 
equilibrium constants, are given in Table 4.5. Though the 
two methods of calculation yield quantitatively different 
values for the cytoplasmic [NAD+] [ N A D H ]  ratio, both 
indicate that it was maintained in hypertrophied hearts, 
treated with pyrimidine compounds, but that it became more 
reduced in the untreated hypertrophied hearts.
The intracellular NADH levels tend to reflect 
the availability of hydrogen acceptors such as dihydroxy- 
acetone phosphate and pyruvate, and the rapidity with which
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the cell can release a build up of reduced products 
(electrons). Interventions into cardiac metabolism 
which aim at improving glycolytic flux should perhaps 
be directed towards accelerating the release of lactate 
or the provision of other hydrogen acceptors for the 
reoxidation of NADH. For example, if glucose is supplied 
to the tissue when the reoxidation of NADH does not occur, 
the glucose may be toxic since ATP may be consumed for 
the production of glucose 6-phosphate and fructose 1,6- 
diphosphate without ever achieving glycolytically 
generated ATP synthesis. The ability of orotic acid 
and other pyrimidines to maintain the redox state of the 
cytoplasm at a more positive potential should, therefore, 
exert a most favorable effect on the course of hyper­
trophy and the survival of the subject.
The results in Table 4.5 indicate that the 
[NAD+][NADH] ratio became more reduced in the untreated 
hypertrophied hearts, thereby placing the heart at risk, 
for excessive reduction may inhibit such enzymes as 
glyceraldehyde-3P dehydrogenase or divert too much 
material to a-glycerophosphate and lactate. The increase 
in cardiac pH during hypertrophy [Albers (1977) has esti­
mated that the intracellular cardiac pH increased from 
pH 6.9 in the normal heart to pH 6.99 in the hypertrophied 
heart] may be partly responsible for the more reduced 
state of the hypertrophied heart by driving the [NADH][H+]/ 
[NAD+] equilibria toward NADH. In contrast to the untreated
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animals with hypertrophied hearts, those animals treated 
with pyrimidines appeared to have a normal [NAD+][NADH]^ 
ratio which should exert a favorable effect on the course of 
hypertrophy.
Any breakdown of creatine phosphate, in muscle 
fibres that contain mitochondria, will make the oxidation 
of cytoplasmic NADH more difficult because of the reduction 
of the perimitochondrial ANR (Ottway and Mowbray, 1977).
The results in Table 4.5 would therefore be consistent with 
less large scale breakdown of creatine phosphate in the 
orotic acid treated hypertrophied animals than in the un­
treated hypertrophied animals.
4.3.7 The Effect of Hypertrophy on Serum 
Insulin Concentrations and Cardiac 
Noradrenaline Stores
As shown in Table 4.3, the administration of 
orotic acid to animals with hypertrophied hearts caused the 
glycogen content of those hearts to double. The observations 
that insulin also enhanced glycogen synthesis (Seglen, 1973) 
and glycolytic flux through the activation of phosphofructo- 
kinase raised the possibility that orotic acid may stimulate 
hypertrophy and glycogen synthesis through an indirect 
effect on insulin secretion. Moreover insulin has been 
reported to increase protein and nucleic acid synthesis and 
enhance amino acid transport into the cell (Randle et al.,
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1966); these changes have also been observed during 
cardiac hypertrophy (Chapter 3). This parity between the 
effects of insulin and changes observed during developing 
cardiac hypertrophy together with the finding that alloxan- 
induced diabetes may be normalised by the administration of 
orotic acid, provided a prima facie case for the involve­
ment of insulin in developing cardiac hypertrophy.
Plasma insulin concentrations were determined by 
radioimmunoassay. This method underestimates the true con­
centration of rat serum insulin since the immuno-precipita- 
tion reaction was carried out using antibodies to human 
insulin, not rat insulin. The results are shown in Table 
4.13. They demonstrated that neither orotic acid nor hyper­
trophy increased the serum insulin concentration. Thus, 
changes in the hypertrophied heart, such as the enhance­
ment of protein and nucleic acid synthesis, an increase 
in cardiac glycogen stores and an increase in the intra­
cellular levels of amino acids, should not, in the long 
term (greater than 24 hours), be attributed to increased 
serum insulin concentrations. Rather, there was a drop in 
serum insulin levels in both untreated and orotic acid 
treated hypertrophied hearts, probably reflecting a 
decreased post-operative dietary intake of food.
Laks and Morady (1976) have suggested that, when 
a chronic stress was applied to the heart, a decrease in 
noradrenaline stores may be the factor that limits the
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degree of compensatory hypertrophy, eventually resulting 
in chronic heart failure. Laks et al. (1973) , using sub­
hypertensive doses of noradrenaline in conscious dogs, 
reported that the administration of the hormone caused a 
significant degree of left ventricular hypertrophy.
Mallov (1976) demonstrated an enhancement of cardiac pro­
tein synthesis following the administration of noradrenaline, 
both in the isolated perfused rat heart (5.5 ymol nor­
adrenaline/kg) and the rat heart in vivo (5.75 ymo.l nor­
adrenaline/kg) . It is possible that the latter effect may 
be an adaptive response to cardiac injury produced by the 
drug. There is also strong evidence that noradrenaline 
augments cardiac contractility by enhancing adenyl cyclase 
activity (Epstein et al., 1971).
As shown in Fig. 4.1, myocardial noradrenaline 
stores declined during hypertrophy. One day after the in­
duction of hypertrophy, there were no changes in the levels 
of cardiac noradrenaline but there was a significant 
depletion of noradrenaline stores three days after the 
induction of hypertrophy (decreases of 11 and 16%, 3 and 5 
days after the induction of hypertrophy, respectively). 
Although myocardial contractility in particular, and hyper­
trophy in general, were enhanced by the administration of 
orotic acid, there were no significant differences in the 
noradrenaline stores of treated and untreated animals.
The possibility that noradrenaline depletion was the result
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of the operative procedure and the acute hemodynamic 
burden imposed on the heart, must also be considered, 
although this is unlikely in view of the small decrease 
noted in the sham operated animals (4%). The depletion 
of noradrenaline stores may also be attributed to 
increased cardiac sympathetic nervous activity, the 
positive inotropic influence of which is though to assist 
the heart in meeting increased mechanical demands.
However, Spilker and Hayden (1970) found no differences in 
the spontaneous post-gangleonic sympathetic nerve discharge 
rate between normal cats and those with congestive heart 
failure. These authors also noted that catecholamine deple­
tion occurred independently of a change in the spontaneous 
activity of the sympathetic nervous system.
The augmentation of contractile force by catecho­
lamines may be caused by a direct or indirect effect of the 
catecholamines, either on the electromechanical coupling 
(Antoni et al., 1960) or the performance of the contractile 
elements (Honig, 1968) and, as a consequence, may cause 
changes in the adenine nucleotide concentrations and the 
regulation of glycolysis and glycogenolysis. The changes 
in the levels of glycolytic metabolites in reserpine pre­
treated (i.e. catecholamine depleted) hypertrophied hearts 
were measured in order to investigate the effects of cate­
cholamine reserves on hypertrophy. Reserpine was adminis­
tered intramuscularly at a concentration of 5 mg/kg,
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sufficient to cause the disappearance of 90% of cardiac 
noradrenaline within 2 hours (Paasonen and Krayer, 1958). 
Although reserpine pretreatment effected the general con­
dition of the animals (they were very docile and quiescent), 
there was apparently normal control of the glycolytic 
sequence and only a slight change in the Atkinson energy 
charge (Tables 4.2 and 4.4). The tissue levels of ATP were 
maintained, but ADP and AMP concentrations were slightly 
increased (Table 4.2). These changes in the adenylates did 
not appear to effect the regulation of cardiac glycolytic 
metabolism - the mass action ratios of phosphoglucomutase, 
phosphoglucoisomerase, phosphoglyceromutase and adenylate 
kinase were at equilibrium (Figs. 4.5 and 4.4 and Table 4.7). 
The values of the mass action ratios of phosphofructokinase 
and pyruvate kinase, the two glycolytic enzymes that appear 
to dominate the regulatory status of glycolysis in vivo, 
were considerably displaced from equilibrium and were the 
same as in normal untreated animals. Thus, the levels of 
endogenous noradrenaline stores per se, cannot be considered 
to effect the control of glycolysis in normal animals.
When the hearts of the reserpine pretreated animals 
were induced to hypertrophy, the changes in the control of 
glycolysis that were observed were similar to the changes 
observed in the one day, orotic acid treated hypertrophied 
hearts, i.e. an apparent relaxation of control at the 
phosphofructokinase reaction, maintenance of control at the
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glyceraldehyde 3-phosphate dehydrogenase - phosphoglycerate 
kinase step and a tightening of control at the pyruvate 
kinase step (Fig. 4.5). These data suggest that either 
noradrenaline is not essential to the process of hypertrophy 
or that hypertrophy reported to be induced by noradrenaline 
occurred through a different mechanism to that induced by 
aortic stenosis. The latter would appear to be the case 
because (1) a high mortality rate was observed when hyper­
trophy was induced by aortic stenosis in reserpine pre­
treated animals (50% mortality in reserpine pretreated 
animals compared with 10% mortality when hypertrophy was 
induced in normal animals); (2) when hypertrophy was in­
duced by aortic stenosis, hypertrophy occurred very rapidly 
over a seven day period (Chapter 3) whereas hypertrophy 
induced by noradrenaline occurred over a much longer 
period (up to 63 weeks, Laks et al., 1973).
Thus, the enhancement of hypertrophy by the admin­
istration of orotic acid does not appear to directly involve 
changes in the myocardial noradrenaline stores or serum 
insulin, even though the reported effects of insulin 
appear to be similar to many of the effects of orotic acid.
4.3.8 The Effect of Hypertrophy and Orotic Acid
on the Ultrasturcture of the Rat Myocardium
The ultrastructural features of normal, four day 
hypertrophied and four day hypertrophied and orotic acid
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treated hearts are shown in Figs 4.7 to 4.9. Lipid 
droplets are normally seen in the myocardium of the rat 
(Travis and Travis, 1972) as shown in Fig. 4.7.
A striking feature of both the orotic acid treated 
(Fig. 4.8) and untreated (Fig. 4.9) hypertrophied hearts 
was the disappearance of lipid droplets. This would 
correlate with the increase in energy utilisation during 
the development of hypertrophy. Endogenous triglycerides 
can serve as a source of fatty acids for energy metabolism, 
whereas phospholipids appear to function primarily as 
structural lipids contributing little, if any, fatty acid 
for energy metabolism. When an exogenous supply of fatty 
substances was not provided, endogenous stores of tri­
glycerides were metabolised (Olson and Hoeschen, 1967) in 
preference to exogenous glucose or tissue glycogen. The 
absence of tissue lipids, only four days after the induction 
of hypertrophy/ emphasises the importance of cardiac glycogen 
in providing and maintaining an endogenous source of sub­
strates for energy metabolism. It is suggested that the 
increased cardiac glycogen stores, subsequent to the 
administration of orotic acid, may be associated with 
greater glycolytic reserve and improved mechanical resist­
ance to anoxia.
The myofilaments from both treated and untreated 
hypertrophied hearts were essentially unchanged in size and 
morphology. However, in both of these groups, distortion 
of the I band and thickening of the Z band of the sacromeres
were noted.
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The mitochondrial morphology of the myocardium 
was found to be essentially normal in both operated and 
operated and treated rats. Swelling of mitochondria has 
been noted early in the development of hypertrophy (Novi, 
1968). In acute and chonic heart failure, secondary to 
aortic constriction, mitochondrial swelling, splitting of 
myofibrils and disintegration of the Z band have been 
observed (Novi, 1968; Hatt et al., 1965). In this study, 
there was no evidence of the cardiac villus formation 
found in hypertrophied human left ventricles described 
by Dowlatshahi and Hunt (1969).
Thus, no ultrastructural differences between the 
sections of myocardium from hypertrophied and hypertrophied 
and orotic acid treated hearts could be discerned.
4.4 Discussion
4.4.1 Myocardial Adenine Nucleotide Metabolism 
During Hypertrophy
In cardiac tissue, the degradation of adenine 
nucleotides may proceed only until the stage of hypoxanthine 
formation. Salvage pathways to conserve the concentration 
of purine bases in the heart do exist and several degrada­
tion products, including hypoxanthine, may be reconverted 
into adenine nucleotides (Maguire et al., 1972) (Fig. 4.10).
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Various mechanisms have been proposed to explain 
changes in the adenine nucleotide concentration in cardiac 
tissue. Such mechanisms must explain why the adenine nucleo­
tide concentration in a working, aerobic rat heart is constant 
with time (Opie et al., 1971); explain the progressive loss 
of adenine nucleotides under such pathological conditions 
as anoxia (Rovetto et al., 1973) and ischemia (Neely et al., 
1973); and explain the changes in the adenine nucleotide 
concentrations observed in these experiments.
One possible pathway suggests that adenine nucleo­
tides may be degraded by the conversion of AMP to IMP and 
adenosine (Fig. 4.10) in reactions catalysed by AMP 
deaminase (E.C. 3.5.4.6.) and 5' nucleotidase (E.C. 3.1.3.5.) 
Richman and Wyborny (1964) were unable to show any IMP in 
the perfusate of normal or hypoxic hearts, though it is 
possible that IMP was being reconverted to AMP via adenyl- 
succinate and the pathway of the purine nucleotide cycle 
(Tornhein and Lowenstein, 1972) rather than being dephos- 
phorylated by the action of 5' nucleotidase. Further, the
K of AMP deaminase for AMP is about 1 mM (Zielke and m
Suelter, 1971). Since most of the total cellular AMP is 
in the mitochondria (LaNoue et al., 1972), it is unlikely 
that cytoplasmic AMP will reach a concentration of 1 mM in 
the normal heart and any tendency to do so would be resisted 
by the reaction catalysed by adenylate kinase. Thus, it 
is unlikely that this pathway is operative in the normal
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heart and may function only when there is a considerable 
increase in AMP concentration.
The activity of the proposed physiological 
pathway of adenine nucleotide catabolism, through IMP and 
adenosine, also fails to explain the formation of adenosine 
in ischemic cardiac tissue (Olsson, 1970) and so other path­
ways of adenylate breakdown must be active in cardiac tissue. 
Adenosine may be formed from AMP by reactions catalysed by 
AMP pyrophosphorylase (E.C. 2.4.2.7.) and purine nucleoside
phosphorylase (E.C. 2.4.2.1.) (Fig. 4.10). However, Liu
14and Feinberg (1971) found that no [ C] adenine was formed
14when ischemic rabbit hearts were perfused with [U C] adeno­
sine, indicating that the pathway was not active under con­
ditions of adenylate nucleotide degradation. Also the AMP 
pyrophosphorylase catalysed reaction has been reported to 
be strongly inhibited by pyrophosphate (Imsande and Handler, 
1961) and any increase in the pyrophosphate concentration 
would tend to inhibit this reaction (Table 4.10).
A third possible mechanism for the breakdown of 
adenine nucleotides involves the formation of adenosine 
from AMP by the reaction catalysed by 5' nucleotidase.
5' Nucleotidase was found to be localised in the sarcolemna, 
T tubules and the sarcoplasmic reticulum (Rubio et al.,
1973) and in the "microsomal cell fraction" (Olsson et al, 
1973). Thus the 5' nucleotidase could bind intracellular 
AMP and release the products extracellularly, maximising
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the effectiveness of adenosine as a vasodilator. However, 
the for uncomplexed ADP is 3 yM and for uncomplexed ATP 
is 11 yM (Olsson et al., 1973) and the concentrations of 
uncomplexed ADP and ATP in the normal heart were 138 yM and 
44 yM, respectively (Table 4.12). This suggests that the 
enzyme would normally be severely inhibited if the whole of 
the cellular adenylate pool acted as an effector. Olsson 
et al. (1973) proposed that the substrate for the 5' nucleo­
tidase was a "membranous" pool of AMP. Das (1973) reported 
a membrane bound cAMP phosphodiesterase (E.C. 3.1.4.17.) 
and a close association of adenylate kinase, cAMP phospho­
diesterase and 5' nucleotidase could provide a mechanism 
for the degradation of adenine nucleotides. Under such 
circumstances, the 5' nucleotidase would be exposed to only 
a small fraction of the cytoplasmic ADP and ATP pool (Kohn 
and Garfinkel, 1977, have estimated this fraction to be less 
than 5% of the cytoplasmic ADP and ATP pools and hence to 
be of concentrations lower than the respective values). 
Turning now to pathways of adenine nucleotide synthesis, 
possible pathways are the pathway de novo and the various 
salvage pathways. Possible substrates for the salvage 
pathways are inosine, adenosine and hypoxanthine. Adenosine 
uptake follows simple Michaelis-Menton kinetics in the rat 
heart (Hopkins and Goldie, 1971) and shares a common carrier 
with inosine (Olsson et al., 1973). Kolassa et al. (1970) 
reported that adenosine was preferentially taken up from
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the blood, with inosine being incorporated only 60% as rapidly 
as adenosine. Hypoxanthine, using a separate permease, was 
incorporated only 15% as rapidly as adenosine. Thus, the 
main sources of adenine nucleotides in the heart would 
appear to involve the pathway de novo and the substrates 
adenosine and inosine. Adenine nucleotides may be synthe­
sised from inosine by the reaction catalysed by purine 
nucleoside phosphorylase (Fig. 4.10). However, the enzyme 
is apparently found exclusively in the pericytes and endo­
thelial cells of the vascular tissue (Rubio et al., 1973) 
and the plasma membrane in muscle is generally considered 
impermeable to phosphorylated compounds. Such a compart- 
mentation of this enzyme makes it unlikely that the adenine 
nucleotides in cardiac tissue are formed from inosine to 
any great extent. Further, the adenine nucleotide pool was 
labelled to a greater extent when ischemic rabbit hearts
were perfused with [^C] adenosine (17.7% of administered
14label) than when perfused with [ C] inosine (1.2% of 
administered label) (Liu and Feinberg, 1971).
Adenosine may be used as a substrate for adenine 
nucleotide synthesis, the reaction being catalysed by 
adenosine kinase. Maguire et al. (1972) have suggested 
that the tissue capacity of adenosine kinase was too low 
for this possibility to occur, but they may have lost enough 
of the activity of this unstable enzyme in the course of 
removing interfering ATP ase activity from their preparations
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of adenosine kinase to explain the discrepancies between 
their work and the labelling experiments of Liu and 
Feinberg (1971).
In summary, the potential metabolic fluxes which 
may alter the concentrations of cardiac adenine nucleo­
tides are: the pathway of synthesis de novo; the conver­
sion of adenosine to AMP by adenosine kinase; the break­
down of AMP by AMP deaminase; and the breakdown of 
"membraneous AMP" by 5' nucleotidase. The changes in the 
concentrations of the adenine nucleotides observed during 
hypertrophy may,therefore, be analysed in terms of these 
four reactions or pathways. Firstly, consider the break­
down of adenine nucleotides. The activity of the enzyme 
adenyl cyclase is mainly regulated by a protein phosphoryl­
ation/dephosphorylation mechanism (Najjar and Constantopoulos,
1973) . Hormones, such as noradrenaline, activate the enzyme 
by stimulating a phosphoprotein phosphorylase. Besides
hormonal regulation, the activity of adenyl cyclase is
4- 3-inhibited by ATP (K^  68 yM) and HATP (665 yM) (DeHaen,
1974) and by MgPPi (K^  450 yM, Severson et al., 1972). In
4- 3-the normal heart, the concentrations of ATP plus HATP 
was 42 yM (Table 4.12) and MgPPi was 4.5 yM (3.4 ymol/kg 
wet wt, Table 4.10) and these effectors would,therefore, 
not be expected to inhibit adenyl cyclase activity. Kohn 
and Garfinkel (1977) have estimated the concentration of 
noradrenaline in the interstitial fluid of aerobic hearts
154 .
to be about 0.04 yM, which results in the adenylate cyclase 
being activated to 10% of its maximal activity. This com­
pares favorably with observations by Drummond and Duncan 
(1970) that the basal activity of adenylate cyclase in 
guinea pig hearts was about 1/8 of the maximal activity 
reported to date. Although the phosphodiesterase would 
be expected to be partially inhibited by magnesium (K^
123 yM, Nair, 1966),the phosphodiesterase reaction is a 
first order reaction (Newsholme and Start, 1974) so that 
as the cAMP concentration was increased, so would the phos­
phodiesterase activity. That this pathway does operate 
in normal cardiac tissue is suggested by several lines of 
evidence. Firstly, the administration of reserpine (which 
caused the removal of 90% of cardiac noradrenaline in 
2 hours, Paasonen and Krayer, 1958) would be expected to 
inhibit the flux through this pathway, that is, the total 
cardiac adenylate concentration would increase. This was 
shown to be the case since reserpine pretreatment caused 
an increase in the total adenylate concentration from 
6.3 ymol/g to 7.1 ymol/g in normal hearts (Table 4.1) and 
from 7.1 ymol/g to 11.4 ymol/g in hearts, one day after 
the induction of hypertrophy (Table 4.2). Secondly, under 
conditions of increased noradrenaline release, such as 
ischemia, an increase in adenyl cyclase activity and hence 
a decrease in cardiac adenylate concentrations would be 
expected. Again, this was shown to be the case: in the
ischemic, isolated perfused rat heart, the total adenylate
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concentration decreased from 29.3 ymol/g dry wt to 18.8 
ymol/g dry wt during a 10 minute perfusion period 
(unpublished results). Conversely, the pathway suggests 
that beta blockade in the ischemic heart may benefit the 
tissue. Recently, several reports (Thomas, 1976;
Waagstein and Hjalmarson, 1976) have shown that beta 
blockade does limit the area of necrosis following coronary 
occlusion.
The flux through the reaction catalysed by adeno­
sine deaminase would be expected to be limited because of 
the high Km of the enzyme for AMP (1 mM, Zielke and Suelter, 
1971) compared with the AMP concentration of the normal rat 
heart (218 yM, Table 4.12). Synthesis of adenine nucleo­
tides through the reactions catalysed by adenosine kinase 
would occur when the adenosine concentration in normal rat 
hearts was 13-27 yM compared with the Km of 0.9 yM (Alma
and Feinberg, 1971). Though the reaction has been reported
4- 3-to be inhibited by ATP and ATPH , the K.. for these in­
hibitors was 326 yM (Olsson et al., 1972) compared with 
their concentration in the normal heart of 42 yM (Table 
4.12). The flux through the pathway of purine synthesis 
de novo appears to be limited by the availability of 
PP-ribose-P in the normal heart (Zimmer and Gerlach, 1977). 
Thus, the steady state concentrations of adenine nucleotides 
in the normal heart appears to be the resultant of 
reactions catalysed by adenosine kinase, the pathway of 
synthesis de novo and the flux through adenyl cyclase.
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Since adenine nucleotide metabolism plays an 
essential role in cardiac energy metabolism as well as in 
maintenance of the structure and function of the heart, 
it would seem reasonable to suggest that there may be a 
correlation between the rate of hypertrophic growth and 
the rate of adenine nucleotide synthesis. When cardiac 
hypertrophy was induced by aortic constriction, there was 
an 8% increase in the cardiac mass after 48 hours (Chapter 3) 
and a 132% increase in the rate of cardiac adenine nucleo­
tide synthesis (Zimmer et al., 1972); on the other hand, 
when cardiac hypertrophy was induced by the administra­
tion of isoproterenol, there was a 24% increase in cardiac 
mass after 24 hours (Schwartz, 1971) and a 400% increase in 
cardiac adenine nucleotide synthesis (Zimmer and Gerlach, 
1974). Further, Zimmer and Gerlach (1974) reported a close 
correlation between the heart rate and the synthesis of 
adenine nucleotides de novo. Thus,adenine nucleotide 
synthesis appears to be related to changes in the rate of 
hypertrophy and the inotropic state of the heart and an 
enhanced rate of adenine nucleotide synthesis may be 
expected in the one day hypertrophied, orotic acid treated 
hearts, compared with the rate of synthesis in one day 
hypertrophied, untreated hearts. The flux through the 
pathway of adenine nucleotide synthesis de novo appears 
to be limited by the availability of PP-ribose-P in the 
normal heart (Zimmer and Gerlach, 1977). However, orotic 
acid treatment during hypertrophy resulted in an increased
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concentration of cardiac glucose 6-P (276 ± 46 and 
374 ± 36 nmol/g wet wt in the one day hypertrophied 
untreated and orotic acid treated hearts, respectively,
Table 4.3) and glucose 6-P is one of the substrates of the 
pentose phosphate pathway. Thus, it seems conceivable that 
orotic acid administration may lead to an increase in the 
cardiac PP-ribose-P concentration and perhaps an associated 
increase in pentose phosphate pathway activity. A con­
vincing case for the operation of the new pentose phosphate 
pathway in cardiac tissue has been developed by Williams et al., 
(1977). Unfortunately, this assumed series of events cannot 
be proven directly since it is not possible, as yet, to 
determine the concentration of PP-ribose-P in cardiac 
tissue because of its high instability during the extrac­
tion process. Whether or not adenine nucleotide synthesis 
was elevated because of the greater availability of PP- 
ribose-P or another mechanism associated with an enhanced 
rate of hypertrophy, an increased rate of adenine nucleo­
tide synthesis resulted in an increased concentration of 
total adenylates in the one day hypertrophied hearts 
treated with orotic acid (Table 4.1).
Between 24 and 120 hours after the induction of 
hypertrophy, there was a decrease in the cardiac noradrena­
line stores (Fig. 4.1). This should lead to a greater flux 
through the 'hdenyl cyclase-nucleotidase" pathway (Fig. 4.10) 
and cause the observed decrease in the concentration of
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total adenylates, 48 hours after the induction of hyper­
trophy (total adenylates decreased from 7.6 ymol/g wet wt 
in the one day hypertrophied heart to 7.4 ymol/g wet wt in 
two day hypertrophied heart). In the orotic acid treated, 
hypertrophied hearts, 24-48 hours after the induction of 
hypertrophy, the adenine nucleotide concentration was 
depleted by 5,622 nmol/g wet wt (Table 4.1). 193 nmol/g
wet wt of this change was due to the "adenyl cyclase- 
nucleotidase" pathway for cardiac noradrenaline stores were 
decreasing at the same rate in both orotic acid treated 
and untreated hypertrophied hearts. The remaining 5,429 
nmol/g wet wt was lost through the reactions catalysed by 
AMP deaminase. The allosteric properties of AMP deaminase 
allow for negligible activity at physiological concentra­
tions of AMP, until ADP has accumulated. The high concen­
trations of AMP (1.1 ymol/g wet wt) and ADP (6.6 ymol/g 
wet wt, Table 4.1) in the one day hypertrophied, orotic 
acid treated hearts would result in the activation of AMP 
deaminase and a readjustment of the adenylate kinase 
equilibrium with a net conversion of ADP to AMP and ATP at 
the expense of the overall pool of adenine nucleotides. 
Thus,48 hours after the induction of hypertrophy, the total 
adenine nucleotide concentrations were 7.4 ymol/g in the 
untreated hearts and 7.3 ymol/g in the orotic acid treated
hearts.
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Three days after the induction of hypertrophy, 
the total adenine nucleotide concentrations were again 
elevated and were about the same in both orotic acid 
treated and untreated hypertrophied hearts (presumably 
due to adenosine uptake and the reactions catalysed by 
adenosine kinase). With increasing concentrations of ATP, 
PP-ribose-P synthetase activity was inhibited (Bagnara 
et al. , 1974) leaving the adenine nucleotide salvage path­
ways as the only source of adenine nucleotides. This 
suggests that the salvage pathways of adenine nucleotide 
synthesis were responsible for the elevated adenine nucleo­
tide concentrations,three days after the induction of 
hypertrophy. Also, as PP-ribose-P synthetase activity 
would be expected to be inhibited by the elevated ATP con­
centrations, the heart will also be dependent on preformed 
bases for pyrimidine synthesis. Thus, any agent, such as 
orotic acid which enhances the availability of preformed 
bases (as reported in Chapter 5) would be expected to 
facilitate the hypertrophic response.
Zimmer and Gerlach (1977) have suggested that 
adenine nucleotide synthesis may be regarded as a metabolic 
process preceding or accompanying the increased protein 
and nucleic acid synthesis observed during hypertrophy 
(Chapter 3). If this was the case, then changes in the 
concentration of total adenylates would be expected to 
mimic changes in the rates of protein synthesis. As shown
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in Fig. 4.2,there was a close correlation between changes 
in the rates of protein synthesis and total adenylate con­
centrations in both hypertrophied hearts and hypertrophied 
hearts treated with orotic acid.
Meerson and Breger (1977) have proposed that it 
was the phosphorylation state of the adenine nucleotides 
that controlled the hypertrophic response of the heart.
They further suggested that any functional increase in 
cardiac work load failing to decrease the ATP concentration 
would also fail to increase protein and nucleic acid 
syntheses. The results presented here suggest that it is 
important to distinguish between the energy status of the 
cell (as measured by the phosphorylation state of the 
adenylates or the more empirical energy charge) and the 
total ATP concentration. The results shown in Table 4.1 
and Chapter 3 indicate that enhanced protein and nucleic 
acid syntheses were compatable with increased ATP concen­
trations, provided the total adenylate pool also increased 
in size, i.e. the energy status of the cell was a more 
important parameter than the ATP concentration with respect 
to inducing a hypertrophic response.
We must now consider why orotic acid caused an 
increase in protein and nucleic acid synthesis (Chapter 3), 
increased total adenylate concentrations (Tables 4.1 and 
4.2) and enhanced contractility (Chapter 1). Zimmer and 
Gerlach (1977) reported that it seemed likely "that the
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accelerated synthesis of adenine nucleotides is an 
important factor among those metabolic processes involved 
in the stimulation of protein synthesis in the hyper- 
trophing heart" and that "the increased availability of 
PP-ribose-P which seems to be mainly responsible for the 
observed acceleration of adenine nucleotide synthesis 
de novo". In the following chapter it will be shown that 
orotic acid feeding provides a mechanism whereby cardiac 
pyrimidines may be synthesised from preformed bases, 
resulting in a lessening of the demand for PP-ribose-P 
synthesis (Bagnara et al. , 1974, reported that PP-ribose-P 
synthesis may be accelerated if cells were provided with 
base substrates for nucleotide synthesis).
4.4.2 The Effect of Orotic Acid and Hypertrophy 
on Cardiac Metabolism
Although the glycolytic flux in cardiac tissue may 
be accelerated under various conditions, the rate of glyco­
lytic ATP generation, even under anoxic conditions, has been 
variously estimated to account for only 10-15% (Gudbjarnason, 
1971) and 65-70% (Kiibler and Spieckerman, 1970) of the ATP 
formed in the well oxygenated heart. Both in vivo and in 
the isolated,perfused heart, fatty substances are used in 
preference to glucose and glycogen as metabolic substrates 
(Neely et al., 1972b). If an exogenous supply of fatty 
substances is not provided, endogenous triglycerides (but
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not phospholipids) are metabolised (Olson and Hoeschen,
1967) in preference to exogenous glucose or tissue glycogen. 
The preferential use of fatty acids by the heart involves 
an inhibition of the glycolytic flux at the phosphofructo- 
kinase reaction, the glycogen phosphorylase reaction (due 
to the high glucose 6-phosphate levels) and possibly at 
the glyceraldehyde 3-phosphate dehydrogenase reaction.
It is apparent from the results presented here that a 
"fatty acid" type of control over the glycolytic flux was 
maintained in the hypertrophied heart. In addition, there 
appears to be a restriction of flux at the pyruvate kinase 
reaction, a result which has previously been reported to 
occur only in the isolated, perfused heart.
That the hypertrophied hearts (both treated with 
orotic acid and untreated) were utilising a fatty acid type 
of metabolism was further suggested by the high tissue 
glycogen concentrations (Table 4.3), compared with normal 
hearts.
In the heart of man or the unanaesthetised dog, 
35-75% of the oxygen consumption may be accounted for by 
the oxidation of plasma free fatty acids (Lassers et al., 
1972; Little et al., 1970). In rabbits with hypertrophied 
hearts (Chapter 6) (both untreated and treated with orotic 
acid), there were no changes in the serum free fatty acid 
levels, though serum triglyceride levels were decreased
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in untreated animals with hypertrophied hearts (0.89 ± 0.07 
mM and 0.56 ± 0.06 mM in the normal and hypertrophied 
hearts, respectively, Table 6.2) suggesting an increased 
utilization of triglycerides in those animals with hyper­
trophied hearts.
Activation of lipolysis also seemed to occur in 
both the untreated and orotic acid treated hypertrophied 
hearts, for electronmicrographs of hypertrophied rat hearts 
were characterised by the absence of lipid droplets (Figs 
4.7-4.9). An enhanced rate of fatty acid activation was 
further implied by the elevated pyrophosphate concentra­
tions of both orotic acid treated and untreated hyper­
trophied hearts (Table 4.10).
The restriction of glycolytic flux at the phospho- 
fructokinase, glyceraldehyde 3-phosphate dehydrogenase and 
pyruvate kinase catalysed reactions in the hypertrophied 
rat heart occurred irrespective of the pyrimidine nucleo­
tide precursor used (orotic acid, dihydroorotic acid, 
uridine and uracil), though there was an apparent relaxation 
of control at the phosphofructokinase catalysed reaction in 
the one day hypertrophied, orotic acid treated hearts.
Thus,during the period immediately after the 
induction of hypertrophy (days one to three), the heart 
appears to rely on the metabolism of fatty substances. 
Further, associated with enhanced myocardial contractility
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(Chapter 1) and the greater cardiac uridine nucleotide 
concentrations (Table 4.9) of the orotic acid treated, 
hypertrophied hearts, a three fold increase in the 
stores of cardiac glycogen was also observed (Table 4.3).
The studies of Scheuer and Stezoski (1970) demonstrated 
that both major and minor elevations of cardiac glycogen 
stores were associated with greater glycolytic reserve 
and improved mechanical resistance to anoxia, due mainly 
to enhanced glycogenolysis and anaerobic ATP production.
Peterson and Lesch (1975) have shown that glucose prevented 
anoxic injury to myocardial tissue and may prolong cellular 
viability. Thus, the markedly increased glycogen content 
of the orotic acid treated, hypertrophied hearts should 
provide sufficient short-term substrates to overcome any 
local tissue hypoxia, maintain cellular viability and 
enhance myocardial hypertrophy.
In summary:
(1) Normal control of glycolysis by pyruvate
kinase and phosphofructokinase is maintained during hypertrophy.
(2) The presence of significant concentrations of 
uncomplexed adenylates in the hypertrophied heart and 
especially in the orotic acid treated hypertrophied hearts 
did not appear to effect the status of glycolytic control 
but did alter the adenylate kinase equilibrium.
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(3) During hypertrophy, myocardial adenylates 
increased in concentration during the first three days of 
hypertrophy and, except in the one day hypertrophied orotic 
acid treated hearts, an equilibrium among the adenylates 
was maintained.
(4) Cardiac glycogen stores increased during 
hypertrophy and should act to provide sufficient "short­
term" substrates to maintain cellular viability. This is 
especially so in the orotic acid treated animals.
(5) The cytoplasmic [NAD+] / [NADH]^ became 
more reduced during hypertrophy but was maintained near 
normal values in those hypertrophied hearts treated with 
orotic acid.
(6) Although many of the changes which occurred 
during hypertrophy were similar to the known effects of 
insulin, insulin was found not to be involved in the pro­
cesses of hypertrophy or the "enhanced" hypertrophy observed 
in those animals treated with orotic acid.
Figure 4.1 Changes in cardiac noradrenaline concentra­
tions as a function of hypertrophy
The treatment of animals and the assay of 
metabolites were as described in the experi­
mental section. Results are expressed as 
nanomoles of noradrenaline/g wet wt of heart. 
Groups of animals studied were: sham-operated
animals ( A ); untreated hypertrophied 
hearts ( □ ); and orotic acid treated hyper­
trophied hearts ( ■ ). Each point represents 
the mean ± S.E.M. and in all cases 6 animals 
were used.
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Figure 4.2 Cardiac protein synthesis and total adenine
nucleotide concentration. Figure shows the
time course of the % increase over normal of 
3[4,5— H] leucine uptake ( 9 , O ) and the 
total adenine nucleotide concentration
( ■ , □ ) in hypertrophied hearts (--- ) and
hypertrophied hearts treated with orotic
acid (--- ). Each value represents the mean
± S.E.M. value for 5 to 6 animals.
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Figure 4.3 Relationship between the energy charge and 
the free energy of hydrolysis of ATP
Each symbol represents one of the various 
groups of treated and untreated, normal and 
hypertrophied hearts studied, using data from 
Tables 4.1 and 4.2. The solid line represents 
a regression analysis of these data. The free 
energy of hydrolysis of ATP, AGATp, was cal­
culated from the equation:
&GATP(kCal) AG. __ - RT ln ANR ATP
aga t p " RT ln
[ATP]
[ADP][HPO| ]
This figure is discussed in Section 4.3.2.
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Figure 4.4 Relationship between the energy charge and 
the concentration of adenine nucleotides
The assay of metabolites and treatment of 
animals were as described in the experimental 
section. Results are expressed as percentage 
of total adenylate nucleotides: ATP ( a , a ),
ADP ( ■ , □ ) ,  AMP ( • , O ). Solid symbols 
represent the experimentally derived nucleotide 
proportions for the various groups of treated 
and untreated, normal and hypertrophied hearts 
(data from Tables 4.1 and 4.2) (A and B repre­
sent data from the one day orotic acid treated 
and the reserpine pretreated hypertrophied 
hearts, respectively). Open symbols represent 
the theoretically derived adenylate content, 
assuming an equilibrium constant of 0.83 for 
adenylate kinase (see Section 4.3.2 for details 
of calculations).
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Figure 4.5 The mass action relationships of the 
individual glycolytic enzymes
Glycolytic enzymes are plotted along the 
abscissa (phosphoglucomutase PG; glucose 
phosphate isomerase PGI; phosphofructokinase 
PFK; aldolase ALD; glyceraldehyde 3-phosphate 
dehydrogenase x phosphoglycerate kinase PGK x 
GAPDH; phosphoglycerate mutase PGM; enolase 
ENOL; pyruvate kinase PK), the log (mass 
action ratio/apparent equilibrium constant) 
is plotted along the ordinate. Data have been 
taken from Tables 4.6, 4.7 and 4.8. The treat­
ment of animals and the assay of metabolites 
were as described in the experimental section.
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Figure 4.6 Relationship between energy charge and the 
mass action ratio of pyruvate kinase and 
phosphofructokinase
Each point represents one of the various 
groups of treated and untreated, hypertrophied 
and normal hearts studied, using the data from 
Tables 4.1, 4.2, 4.6, 4.7 and 4.8. The log 
(mass action ratio/apparent equilibrium constant) 
for pyruvate kinase ( A ) and phosphofructo­
kinase ( • ) was plotted against the energy 
charge of the hearts of the particular group 
of animals studied. The lines represent the 
results of regression analysis of the data 
(solid line for phosphofructokinase, correlation 
coefficient 0.81; dashed line for pyruvate 
kinase, correlation coefficient 0.89).
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Figure 4.7 View of normal rat myocardium. Abbreviations 
used in the electron-micrograph are:
L lipid droplets; N nucleus;
M mitochondria; C lumen of capillary;
F myofilaments; and S sarcoplasmic reticulum, 
x 12,500.
Figure 4.8 View of the myocardium of an untreated rat,
4 days after aortic constriction. Note the 
regular array of myofibrils and mitochondria 
in this field. Abbreviations used in this 
electron-micrograph are: M mitochondria;
C lumen of capillary; F myofilaments; and 
Z Z band. x 13,000.
Figure 4.9 View of the myocardium of an orotic
acid treated rat, 4 days after aortic 
constriction. Abbreviations used in 
this electron-micrograph are:
M mitochondria; F myofilaments;
Z Z band; and S sarcoplasmic reticulum, 
x 39,000.
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Fig. 4 -10  O utline of the m etabolic pathways related to purine biosynthesis in mammalian tissue.
TABLE 4.1
CHANGES IN THE MEASURED PHOSPHORYLATION STATE OF THE ADENINE NUCLEOTIDES 
AND THE ATKINSON ENERGY CHARGE IN HYPERTROPHIED RAT HEARTS
Metabolite or 
Metabolite Ratio Normal
Sham
Operated
Period of Hypertrophy Period of Hypertrophy and Orotic Acid Treatment
One Day Two Day Three Day One Day Two Day Three Day
ATP 5,0871409 5,2601712 5,6871181 4,8681115 6,4491152 5,1421163 5,369+128 6,154+181
ADP 1,0411209 8361169 1,3661 78 1,5461497 1,5631 82 6,6371616 1,2161122 1,755+263
AMP 2181 88 1991 27 5661 46 1,0121 80 6481 30 1,1231103 6951 88 8261 99
HPCL"4 2,5731 65 2,5931139 2,9031120 2,885+118 2,8451 92 2,9481 73 2,692+164 2,8671 43
ATP (xlO-3)
ADP.HPO^- 1,899 2,426 1,434 1,091 1,450 263 1,640 1,223
ATP + 0.5 ADP
ATP + ADP + AMP 0.884 0.902 0.836 0.759 0.837 0.656 0.820 0.805
TOTAL ADENYLATES 6,346 6,295 7,619 7,426 8,660 12,902 7,280 8,735
Treatment of animals and the assay of metabolites were as described in the experimental section.
Results are expressed as nanomoles per gram wet weight, and the concentrations of metabolites are given
2-as mean ± S.E.M. The concentration of HPO was taken to be 64% of the inorganic phosphate concentration.
4 2-The phosphorylation state, i.e. [ATP]/[ADP][HPO^ ], is expressed as gram wet weight per mole.
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TABLE 4.13
THE EFFECT OF OROTIC ACID AND MYOCARDIAL 
HYPERTROPHY ON THE PLASMA INSULIN CONCENTRATION
Animals
Plasma Insulin 
Concentration 
(yunits/ml)
Normal 39 ± 13
Normal plus 
Orotic Acid 40 + 16
One Day Hypertrophied 
Hearts 25 ± 8
One Day Hypertrophied 
Hearts Plus Orotic Acid 31 ± 9
Plasma insulin concentrations were determined as 
described in Section 4.2.4. Results are expressed 
as yunits of insulin per ml plasma and are given 
as the mean ± S.D..
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CHAPTER 5
PYRIMIDINE NUCLEOTIDE SUPPLY OF THE HYPERTROPHIED HEART 
5.1 Introduction
All cells need a balanced supply of nucleotides 
as precursors of DNA, RNA and coenzymes. It is not as yet 
known whether a restriction in nucleotide supply plays any 
role in the differentiation of multicellular organisms, but 
the rapid response of microorganisms to changes in the con­
centrations of purine and pyrimidine bases and nucleosides, 
indicates this possibility.
In virtually all cells and organisms, two funda­
mentally different pathways are used for the synthesis of 
nucleotides. One is the pathway de novo, in which aspartate, 
glycine, glutamine, formate, carbon dioxide and phosphoribo- 
sylpyrophosphate (PP-ribose-P) are combined to form 
nucleotides. By contrast, cells can use the preformed 
purines, pyrimidines and nucleosides provided by the break­
down of nucleic acids. To this second pathway, the term 
"salvage" pathway has been applied.
The concept that the biogenesis of pyrimidines for 
RNA biosynthesis in the whole animal occurs primarily through 
the pathway for synthesis de novo, is firmly established in 
the literature. The evidence for this view stems from the 
original experiments of Barnes and Schoenheimer (1943) in
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15which [ N] ammonium salts were incorporated into both
15pyrimidines and purines of rat tissue, but when [ N]
15Uracil was given, no N was found in the bases of tissue 
nucleic acids. Most investigators have concluded that 
preformed pyrimidines are not effectively utilized as 
nucleic acid precursors by the rat and that the pathway 
de novo contributes the major portion of tissue pyrimidines 
(Hogans et al., 1971).
The sequence of reactions which culminate in the 
formation of UMP, i.e. the "orotate pathway" or the " de  
novo pathway" of pyrimidine biosynthesis, is widely distri­
buted in nature and is shown in Fig. 5.1. Glutamine- 
dependent carbamyl phosphate synthetase II (ATP: Carbamate
phosphotransferase, E.C. 2.7.2.5.) (CPS ase II) catalyses 
the first step of pyrimidine biosynthesis de n o v o . The 
presence of increased amounts of CPS ase II may be a 
necessary prerequisite for accelerated rates of growth in 
a variety of tissue and tumors. Observations by Yip and Know 
(1970) and Hager and Jones (1967) on the presence of the 
enzyme in fetal rat liver and reports of CPS ase II activity 
in regenerating rat liver (Nakanishi et al., 1968) 
hematopoietic mouse spleen (Tatibana and Ito, 1967) and 
phytohemagglutinin stimulated human lymphocytes (Ito and 
Uchino, 1973) support a qualitative association between 
significant CPS ase II activity and cellular proliferation 
in tissues.
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Aspartate transcarbamylase (Carbamyl phosphate: 
L-aspartate carbamyltransferase, E.C. 2.1.3.2.) (ATC ase) 
activity has been demonstrated in a number of animal tissues 
(Lowenstein and Cohen, 1956) and its activity is 2 to 3 
orders of magnitude greater than that of CPS ase II (Tatibana 
and Ito, 1969). Increases in the activity of ATC ase have 
been observed in developing (Kim and Cohen, 1965) and re­
generating (Calva and Cohen, 1959) rat liver, during com­
pensatory renal growth (Waymire, quoted by Manson et al.,
1976) and in neoplastic rat tissues (Herzfeld and Knox, 1972).
Dihydro-orotase (L-4, 5-Dihydro-orotate amido- 
hydolase, E.C. 3.5.2.3.) (DHO ase) catalyses the reversible 
cyclization of carbamyl aspartate to form dihydro-orotate.
The enzyme has been demonstrated to occur in a number of 
animal tissues (Mori et al., 1975; Shoaf and Jones, 1973).
The copurification of mammalian CPS ase II, ATC ase and DHO 
ase has recently been demonstrated in Ehrlich ascites cells 
(Shoaf and Jones, 1973) and liver cells (Mori et al., 1975). 
CPS ase II and ATC ase activities in the cell increase and 
decrease pari passu with the rate of cell or tissue growth 
(Yip and Knox, 1970), suggesting that the CPS ase II-ATC 
ase -DHO ase complex may be an important entity in most 
mammalian cells. However, changes in the levels of these 
enzymes may not be tightly coupled since Bresnich et al.
(1968) found (in rats given a diet containing orotic acid) 
that the activities of the two enzymes increased more or 
less simultaneously, but following the removal of orotate
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from the diet, DHO ase activity returned to normal in 2 
days, yet ATC ase activity did not return to normal till 
4 days after the cessation of orotic acid administration.
Dihydro-orotate dehydrogenase (L-4, 5-Dihydro- 
orotate oxygen oxidoreductase, E.C. 1.3.3.1.) (DHO dehase) 
is found in 3 membrane fractions of liver cells (the nuclear 
pellet, the microsomal pellet and the mitochondrial pellet 
(Miller et al., 1968) but is found only in the nuclear 
pellet of leukocytes (Smith and Baker, 1959) and Ehrlich 
ascites cells (Shoaf and Jones, 1973). It is of interest 
that the erythrocyte, lacking intracellular membrane 
structures, contains all of the enzymes for pyrimidine 
biosynthesis, except that for the conversion of dihydroorotic 
acid to orotic acid. Bresnich et al. (1968) refer to un­
published observations in which neither DHO ase nor DHO 
dehase activity changed after partial hepatectomy.
A coordinate relationship between the activities 
of orotidylate phosphoribosyl transferase (E.C. 2.4.2.10) 
(OPRT ase) and orotidylate decarboxylase (E.C. 4.1.1.23)
(ODC ase) has been demonstrated in Ehrlich ascites cells 
(Shoaf and Jones, 1973); Appel, 1968), and a number of 
papers indicate that the two enzyme activities parallel one 
another under a number of conditions (Pinsky and Krooth, 
1967a,b; Pausch et al., 1972; Brown et al., 1975). The 
measurement of the enzymes required for pyrimidine 
biosynthesis de novo in cloned hepatoma tissue culture
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cells (Hoogenraad and Lee, 1974) and Ehrlich ascites cells 
(Shoaf and Jones, 1973) suggests that a major site of 
control of pyrimidine biosynthesis is at the step of con­
version of orotate to orotidylate, though this may also 
be the result of changes in the levels of PP-ribose-P. 
Recently,the specificity of OPRTase has been questioned 
(Lindsay et al., 1968; Reyes and Guganig, 1975; Hatfield 
and Wyngaarden, 1964). Currently available evidence indi­
cates that the yeast and bacterial enzymes are specific for 
orotate, yet a pyrimidine phosphoribosyl transferase which 
utilizes 5-fluorouracil, uracil and orotate has been puri­
fied from the ascites cells of murine leukemia P1534 J 
(Reyes and Guganig, 1975). Their results also suggest that 
the pyrimidine phosphoribosyltransferase exists as a complex 
with ODC ase and functions as an OPRT ase in vivo .
Whereas the de novo routes of purine and pyrimidine 
nucleotide synthesis are virtually the same in all normal 
cells, the "salvage" routes are far more diverse in their 
nature and distribution. The principal enzymes involved in 
the "salvage" reactions are classified as follows:
(1) Nucleotide pyrophosphorylases. These enzymes 
catalyse the reactions: [purine or pyrimidine] + PP-ribose-P
-* ribonucleotide + PP^. There are conflicting reports con­
cerning the existence of a uracil phosphoribosyl transferase 
in animal tissues, but there is evidence that some tumor 
cells and erythrocytes contain enzymes which may form
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nucleotides from PP-ribose-P and pyrimidines (Hatfield 
and Wyngaarden, 1964; Kasbekar et al., 1964).
(2) Nucleoside phosphorylases, which catalyse 
the inter-conversion of bases and nucleosides (Base + 
ribose-l-P J nucleoside + P^). There are two distinct 
pyrimidine nucleotide phosphorylases in mammalian tissues, 
uridine phosphorylase (EC 2.4.2.3) and thymidine phosphory- 
lase (E.C. 2.4.2.4), and both have been shown to catalyse 
phosphorolysis and pentosyltransfer. Uridine phosphorylase 
is widely distributed in animal tissues, and the equilibrium 
of the reaction lies in favor of nucleoside synthesis , even 
if ribose-l-P is present in a smaller concentration than 
phosphate (Reichard and Skold, 1958). Nevertheless, the 
utilization of uracil in vivo appears to be much lower than 
that of orotic acid or uridine in rat or mouse tissues, 
with the exceptions of rat hepatoma (Rutman et al., 1954) 
and intestinal mucosa (Canellakis, 1957).
(3) Nucleoside kinases. These enzymes catalyse
the direct conversion of nucleosides to nucleotides. Uridine
kinase (E.C. 2.7.1.48) is present in the soluble fraction of
liver extracts and, phosphorylates uridine to form uridine
5'-phosphate. The enzyme also has an absolute requirement 
2 +  /for ATP and Mg . Galofre and Kretchmer (1970) have reported 
an inverse relationship between the activity of the pathway 
de novo and that of the salvage pathway throughout develop­
ment of the chick embryo - the activity of the pathway
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de novo decreased and the activity of uridine kinase 
increased throughout the time course of the development of 
the embryo, this phenomenon was most evident in the brain 
and the heart. In I960, Sköld showed that uridine kinase 
activity represented a rate limiting step for UMP synthesis 
and that the enzyme was present in various tissues from 
mouse, rat and man. A correlation was found between the 
enzyme activity and the growth rate in regenerating liver, 
very high levels were found in Ehrlich ascites tumor cells 
and the range of activity decreased from intestine to 
spleen, kidney, brain and liver in the mouse.
Increased thymidine kinase (E.C. 2.7.1.21) activity 
is found in many proliferating animal tissues such as re­
generating liver, mammalian tumors and fetal tissue. The 
rise in activity is highly correlated with the stimulation 
of DNA synthesis after hepatectomy, and in other tissues 
such as salivary glands when stimulated with isoproterenol 
(Barka, 1967; Baugnet-Mahieu et al., 1968; Eker, 1968; 
Adelstein et al., 1971).
Thus, both the pathway de novo and the "salvage" 
pathway may contribute to nucleotide synthesis. Which is 
the predominant pathway is difficult to establish as the 
results are fragmentary; for example, the specific activity 
of carbamyl phosphate synthetase, the limiting step of the 
pathway de novo of pyrimidines, is 10 fold lower than that of 
uridine kinase in the rate fetal liver (Roux, 1973). Some
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tissues, such as bone marrow, depend on a supply of purine 
formed in other tissues, notably liver (Lajtha and Vane, 
1958), and lack the enzymes of the "salvage" route for 
pyrimidine nucleotide synthesis (Skold, 1960a).
The activities of the enzymes of the two path­
ways of pyrimidine biosynthesis seem to change in such a 
way as to maintain a balanced supply of nucleotides for 
nucelic acid synthesis. Although the salvage enzymes seem 
more related to the adaptive responses of the cells - 
growth hormone increases the uridine kinase activity in 
rat adipose tissue whereas cortisone prevents the stimula­
tion (Epstein et al., 1969); Masui and Garren (1971) have 
shown a stimulation by ACTH of the cytosol thymidine kinase 
in the guinea pig adrenal - both salvage and de novo path­
way enzymes increase in activity in regenerating rat liver 
(Sköld, 1960a; Calva and Cohen, 1959) and during tumor 
growth (Herzfeld and Knox, 1972; Klemperer and Haynes,
1968; Vesely et al., 1971).
Many of the reported studies on pyrimidine 
biosynthesis have been limited to investigations on hepatic 
tissue and tumor bearing tissue. The requirements of other 
organs have not been at all thoroughly examined and it was 
considered most appropriate to investigate both the possible 
special needs of cardiac tissue for pyrimidines and the 
modes of pathway contributions. Important questions con­
cerning the metabolism of nucleic acids in cardiac tissue
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that have not been resolved, are whether cardiac tissue 
can itself supply pyrimidine precursors de novo for RNA 
biosynthesis, whether these precursors must be supplied 
via so-called "salvage" pathways and whether these precur­
sors must be supplied preformed from extra-cardiac sources. 
(The importance of hepatic tissue in the maintenance of 
muscle carbohydrate metabolism through the Cori cycle is 
well established.) Indeed, the activity of the entire 
pathway for the biosynthesis de novo of pyrimidine has yet 
to be directly demonstrated in cardiac tissue. These studies 
of the activities of the two pathways of pyrimidine 
synthesis, both during the adaptive response of the hyper- 
trophying heart and in the normal heart, were undertaken 
to gain some insight into the above problems. Secondly, 
orotic acid has been administered to patients in a number 
°f clinical situations (Section 1.4), based on the rationale 
that the administration of orotic acid would lead to a 
greater production of nucleic acid precursors, presumably 
through increased pyrimidine biosynthesis. Studies 
were also undertaken to test the validity of these 
assumptions. Thirdly, in Section 1.5 it was shown that 
orotic acid, but not uridine, has a positive inotropic 
effect on the myocardium and these experiments were also 
designed to determine whether or not this was a reflection 
of the different activities of the de novo and "salvage" 
pyrimidine pathways in cardiac tissue.
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5.2 Experimental
5.2.1 Materials
Myocardial hypertrophy was induced in male Wistar 
rats by the methods described in Sections 3.2.1 and 3.2.2. 
The animals included in this study had compensatory cardiac
3hypertrophy but no evidence of cardiac failure. [5- H]
uridine (6.3 Ci/m mol); [5-^ H] orotic acid (21 Ci/m mol);
3 14[5- H] uracil (26 Ci/m mol); [2- C] uracil (55 mCi/m mol);
[2-^C] uridine (60 mCi/m mol); [2-^C] thymidine (57 mCi/m
3mol); [5- H] uridine-5-phosphate (14 Ci/m mol); and
14Sodium [ C] bicarbonate (60.2 mCi/m mol) were purchased
14from the Radiochemical Centre, Amersham. [Carboxyl- C]
14orotidine-5'-monophosphate (36.9 mCi/m mol); [Carboxyl- C]
14orotic acid (42.4 mCi/m mol); [ C]-carbamyl phosphate 
(7.69 mCi/m mol) and hyamine hydroxide were purchased from 
New England Nuclear, Massachusetts. Minimum Essential 
Medium (Eagles) Modified for suspension cultures was pur­
chased from Flow Laboratories.
5.2.2 Assay of the Incorporation of Pyrimidines 
into Tissue Fractions
Radioactive compounds were administered to rats by 
intraperitoneal injections at a dose level of 2uCi/g body 
weight. After 2 hours the animals were killed by a blow to 
the head and tissues (heart, lung, liver, kidney, brain, 
spleen, gastrocnemius muscle and samples of blood) were
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removed and weighed. Blood samples were taken from the 
brachial vessels to prevent intraperitoneally administered 
isotope from contaminating the blood sample. Samples of 
tissues (approx. 0.1 g) were digested in Soluene 100 (1 ml), 
and the radioactivity determined. Further samples 
(0.2-0.3 g) were washed with ice-cold saline and homogenised 
in 10 volumes of 0.6N perchloric acid. After centrifuga­
tion at 10,000 g for 10 minutes, a 100 yl aliquot of the 
supernatant fluid was used for the determination of the 
radioactivity in the acid soluble fraction. A third sample 
of each tissue was used for the determination of radio­
activity in the ribonucleic acid fraction. Samples were 
minced and washed twice with ice cold 0.15 M KC1. Samples 
of tissue (approximately 0.4 g) were added to 2 ml of a 
solution which was made 1% with respect to sarkosyl and 
was 0.1 M NaCl, 0.1 M tris-HCl, 20 mM EDTA, pH 9.0. An 
equal volume of saturated, cold phenol was added to the 
above solution, mixed, and a further volume of a solution, 
which was a mixture of chloroform made 4% with isoamyl 
alcohol, added. The above mixture was homogenised in a 
Potter Elvehjem glass homogeniser, the suspension centri­
fuged at 10,000 g for 10 minutes at 0°C, and the bottom 
layer was removed, taking care not to disturb the interface. 
An equal volume of the chloroform 4%-isoamyl alcohol 
solution was added, the solution mixed, centrifuged as 
above, and the bottom layer was removed as before. This 
procedure was repeated two more times before the aqueous
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layer was removed for further processing. The aqueous 
layer was then re-extracted with the phenol and chloroform 
-4% isoamyl alcohol solutions, followed by a final extraction 
with chloroform -4% isoamyl alcohol alone. At this stage, 
no protein interface remained. The aqueous layer was then 
treated with 2.5 volumes of cold ethanol and 0.1 volume of 
1M NaCl and left overnight at -20°C to precipitate the 
nucleic acids. The precipitated nucleic acids were centri­
fuged at 10,000 g for 10 minutes and then dried in a vacuum 
desiccator over silica gel for an interval sufficient to 
remove any excess water and alcohol.
DNA was removed from the total nucleic acid 
extract by treatment with deoxyribonuclease. The method 
used followed that of Fiers and Sinsheimer (1962). The 
nucleic acid was incubated in 1 ml of reaction buffer for 
10 minutes at 30°C before adding DNAase (5 yg/ml). After 
15 minutes incubation with DNA ase at 30°C, the reaction 
was stopped by adding 0.6 ml of glycine buffer. The mixture 
was then re-extracted with phenol and chloroform.
RNA was estimated as described in Section 3.2 
and the radioactivity determined.
Radioactivity determinations were made using an 
automatic Beckman LS-350 liquid scintillation counter. 
Solutions were counted in a scintillant solution of com­
position 667 ml toluene, 333 ml methoxyethanol and 6 g 
Butyl PBD. The system had a counting efficiency of 47.5%
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3 14for H and 76% for C, determined using external standards.
The counting efficiency was corrected for quenching by the 
external standard ratio procedure.
The relative amounts of radioactive label in 
uridine and uracil of blood plasma were determined. Samples 
of plasma were deproteinised by the addition of 0.5 volumes 
of 1.8M perchloric acid. 100 pi of the extract were then 
chromatographed on Whatman No. 1 paper for 15 hours using 
an ammonium hydroxide-butanol solvent (86% butan-l-ol:
3N NH^OH, 94.5:5.5 v/v) and the spots (visualized under UV 
light) corresponding to uridine and uracil standard samples 
were cut out and the radioactivity determined.
The relative amounts of uridine and uracil
degraded to carbon dioxide, ammonia and ß-alanine were
14 14determined. Either [2- C] uridine or [2- C] uracil was
administered to rats at a dose level of 75 nCi/g body wt,
14and the CO  ^expired over the following 2 hour period was 
trapped in 15 ml of hyamine hydroxide. The radioactivity 
was then determined as described above.
5.2.3 Estimation of Tissue Nucleotides,
Purines and Pyrimidines
Tissue was homogenised in 5 volumes of perchloric 
acid (0.6N, 4°C), centrifuged (10,000 g, 10 minutes) and the 
supernatant fluid removed. The pellet was resuspended in 
perchloric acid (0.3N, 4°C), centrifuged (10,000 g, 10 minutes)
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and the supernatant solutions were boiled for 1 h to 
convert the purine nucleotides to purines and the 
pyrimidine nucleoside di- and triphosphates to mono­
phosphates. The hydrolysed supernatant fraction was then 
neutralised with KOH (1M) and the precipitated KCIO^ removed 
by centrifugation (10,000 g, 10 minutes) and the extinction 
of a 3 ml sample of this extract determined at 260 nm and 
280 nm. 2 ml of the neutralised extract was passed through 
a Dowex 50, H+ form, X8, 200-400 mesh column (0.6 x 10 cm) 
and the column was washed with a total of 5 mis of b^O.
The combined eluate represented the total acid-soluble 
pyrimidine nucleotide fraction and its absorbance at 260 nm 
and 280 nm was determined.
Tissue uridine-5'-triphosphate, uridine-5'- 
diphosphate and uridine-5'-monophosphate were estimated as 
described by Keppler et al. (Bergmeyer, 1974); uridine-5'- 
diphosphogalactose and uridine-5'-diphosphoglucose were 
estimated by the methods of Keppler and Decker (Bergmeyer, 
1974) .
5.2.4 Estimation of the Activities of the
Enzymes of Pyrimidine Nucleotide Synthesis
Hearts were washed with ice cold 0.25M sucrose and 
weighed. For the assay of uridine kinase (2.7.1.48.), 
thymidine kinase (2.7.1.21.), uridine phosphorylase (2.4.2.3.) 
and nucleosidemonophosphate kinase (2.7.4.10.) (uridylate
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kinase) activities, the tissue was homogenised in 5 volumes 
of 10 mM Tris-HCl, pH 7.5, 0.25 M Sucrose and 0.5 mM DTT 
and centrifuged at 105,000 g for 1 hour at 0°C. The super­
natant fraction (hereafter referred to as the tissue extract) 
was then used for the determination of enzyme activities. 
Orotidylate phosphoribosyltransferase and OMP decarboxylase 
activities were measured in a supernatant fraction, prepared 
as above, except that the hearts were homogenised in 2 
volumes of the above buffer. For the determination of the 
activities of carbamyl phosphate synthetase, aspartate 
transcarbamylase and dihydroorotase, the hearts were homo­
genised in 5 volumes of 50 mM potassium phosphate, pH 7.0,
10 mM MgCl^/ 3 mM glutamine, 1 mM DTT and 20% (v/v) glycerol 
and the 105,000 g supernatant fluid prepared as above.
Specific enzyme activities are expressed as 
nanomoles of product formed per minute per gram wet weight 
of tissue at 37°C. In all the radiochemical assays of 
enzyme activity, the radioactivity of the sample was esti­
mated by counting in 10 ml of 0.6% (w/v) Butyl PBD in a
toluene:methoxyethanol mixture (2:1 v/v) using a Beckman 
LS-350 liquid scintillation system.
Uridine kinase
The activity of uridine kinase (E.C. 2.7.1.48.)
14was measured by assay of the conversion of C-uridine to 
14C-UMP(+ UDP + UTP). The incubation was carried out by 
adding 0.2 mis of tissue extract to 0.8 mis of the incubation
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mixture; the final concentrations being 0.1M Tris-HCl,
pH 7.5; 2.5 mM MgCl^/ 5 mM ATP; and 100 yM uridine
14(5 Ci/ml of C-uridine). All reagents, except uridine, 
were preincubated with the supernatant solution at 37°C 
for 2-3 minutes. The reaction was started by the addition 
of uridine and 50 yl sample volumes were taken at 2 minute 
intervals over a 20 minute period. The reaction was termin­
ated by pipetting the 50 yl sample volume onto a circle of 
DE81 paper. The paper was washed once in ice-cold 0.1 mM 
ammonium formate (10 minutes), twice at room temperature 
(5 minutes each) and finally in 95% ethanol. The paper 
was then dried and the radioactivity determined.
Thymidine kinase
The activity of thymidine kinase (E.C. 2.7.1.21.)
14was measured by assay of the conversion of C-thymidine to 
14C-TMP(+ TDP + TTP). The incubation was carried out by 
adding 0.2 mis of tissue extract to 0.8 mis of the incuba­
tion mixture, (the final concentrations being 0.1 M Tris-HCl,
pH 7.5; 2.5 mM MgC^r 5 mM ATP; and 10 0 yM thymidine,
145 yCi/ml of C-thymidine). All reagents, except thymidine, 
were pre-incubated with the supernatant at 37° for 2-3 
minutes. The reaction was started by the addition of 
thymidine and 100 yl sample volumes were taken at 1 minute 
intervals. The reaction was terminated by boiling the 100 yl 
samples for 2 minutes. The protein was removed by centrifu­
gation and 40 yl samples of the supernatant solution,
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together with thymidine and TMP standards were spotted on 
3MM Whatman paper (45 cm x 52 cm) and chromatographed 
using GW3 solvent, Wood (1968), (Butanol:Propanol:Acetone:
80% Formic Acid:30% TCA, 6.4:3.2:4:4:2.4, v/v) overnight. 
Thymidine and thymidine nucleotide spots were removed and 
the radioactivity determined by counting in 10 mis of 
Butyl PBD scintillant.
Uridylate kinase (E.C. 2.7.4.4.)
The activity of uridylate kinase in the tissue
extract was measured by the addition of 200 yl of extract
to 0.8 mis of medium; the final concentrations being 0.1 M
Tris-HCl, pH 7.8, 2.5 mM MgCl2, 0.5 mM EGTA, 5mM ATP and
35 mM UMP (25 yCi/ml H-UMP). Pre-incubation, sampling, 
termination and chromatography were as described for the 
assay of thymidine kinase (except that 50 yl samples were 
taken at 1 minute intervals). UMP, UDP and UTP spots were 
removed from the developed chromatograms and the radio­
activity determined by counting in butyl PBD scintillant.
Uridine phosphorylase (E.C. 2.4.2.3.)
Activity was measured by the conversion of 
3 3H-uridine to H-uracil. The incubation was carried out by 
the addition of 40 yl of tissue extract to 960 yl of a medium 
(the final concentrations were 10 mM Sodium arsenate-acetate 
buffer, pH 7.5, 0.1 M Tris-HCl, pH 7.5, 100 yM uridine 
(50 yCi/ml). Pre-incubation, sampling and termination of 
the reaction were as described for the assay of thymidine
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kinase. The protein was removed by centrifugation and 
40 pi samples of the supernatant fluid, together with 
uridine and uracil standard samples, were spotted on 3MM 
Whatman paper and chromatographed overnight in an 86% 
butan-l-ol:Ammonium bicarbonate solvent (94.5:4.5 v/v)
(Hamel, 1972). Uridine and Uracil spots were removed and 
the radioactivity determined as determined previously.
Carbamyl-Phosphate Synthetase II
The activity of this enzyme was determined using
a modification of the radiochemical assay of Levine and
Kretchmer (1971). The incubation solution (1 ml) contained
50 mM potassium-Hepes buffer, pH 7.4, 25 mM ATP, 25 mM
MgCl^f 5 mM glutamine, 7.5% (v/v) dimethylsulfoxide and
2.5% (w/v) glycerol, 200 pi of the tissue extract and 4 mM 
14[ C] bicarbonate (1.25 mCi/mmole). Tubes were incubated
at 37°C for 30 minutes. At the end of the incubation, 50 pi
of 2.0 M hydroxylamine hydrochloride (pH 7) was added and
the mixture heated in a boiling water bath for 10 minutes.
After cooling, 100 pi of 50% (w/v) TCA was added, the protein
14precipate removed by centrifugation and excess CC^ removed 
by bubbling with carbon dioxide for 15 minutes. The radio­
activity was then determined.
Aspartate transcarbamylase
The activity of aspartate transcarbamylase 
(E.C. 2.1.3.2.) was determined by the method of Hoogenraad 
and Lee (1974). The incubation was carried out using 100 pi
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of the tissue extract in a final volume of 500 pi. The 
incubation was for 10 minutes at 37°C and the reaction was 
stopped by the addition of 0.5 ml of 0.5N HCIO^.
Dihydro orotase
The activity of dihydroorotase (E.C. 3.5.2.3.) 
was measured by converting dihydroorotate to carbamyl-L- 
aspartate which was then determined colorimetrically by 
the procedure described by Hoogenraad and Lee (1974).
900 yl of the tissue extract, in a total volume of 1.6 ml, 
were incubated for 30 minutes at 37°C. 250 yl samples were
taken at 5 minute intervals for the estimation of carbamyl- 
L-aspartate.
Dihydro orotate dehydrogenase
The activity of dihydroorotate dehydrogenase 
(E.C. 1.3.3.1.) was assayed by measuring the reduction of 
2,6-dichlorophenolindophenol (Miller et al., 1968). Hearts 
were homogenised in ten volumes of 0.25 M Sucrose, 5 mM 
Hepes, pH 7.2 and 0.4 ml of this tissue homogenate were 
used per assay (final volume of assay mixture 2.0 mis).
Activity was expressed as nanomoles of dichlorophenolindo- 
phenol reduced per minute per g wet weight.
Protidylate phosphoribosyltransferase (OPRT ase, E.C. 2.4.2.10.)
200 yl of the tissue extract were added to 800 yl of 
a reaction mixture; the final concentrations of components 
were 2.5 mM PP-ribose-P, 8 mM EDTA (to stabilise the stock
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PP-ribose-P solution), 100 mM Tris-HCl, pH 7.4; 12.5 mM
14MgCl^ and 1 mM [Carboxyl- C]-orotic acid (1 yCi/y mole).
Reactions were carried out in scintillation vials sealed
14with rubber caps. Liberated CC^ was trapped in 1 ml of
hyamine hydroxide present in an Eppendorf centrifuge tube.
After incubation for 45 minutes, with shaking, OPRT ase
activity was stopped by injection of 0.2 mis of 0.25 M
EDTA, pH 7.4. Because ODC ase activity does not require 
2 +Mg ions, decarboxylation was allowed to proceed for a
further 60 minutes. Injection of 0.2 mis of 5M perchloric
14acid stopped ODC ase activity and removed all CO2  from
the reaction mixture in 1 hour. The small tube, which
14contained the trapped CO2  in hyamine hydroxide, was trans­
ferred to a scintillation vial and the radioactivity 
determined.
Orotidine-5'-monophosphate decarboxylase (ODC ase)
ODC ase (E.C. 4.1.1.23.) was assayed using the
same assay method as for OPRT ase, except that orotic acid
14was replaced with [carboxyl- C] orotidine-5'-monophosphate 
(1 m Ci/m mole) in a final volume of 1.0 mis. The reaction 
was terminated after 45 minutes by the injection, into the 
reaction vial, of 0.2 ml of 5M perchloric acid and the 
radioactivity determined as above.
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145.2.5 Incorporation of C-Labelled 
Precursors into Orotic Acid
Cardiac tissue was minced in 3 volumes of Minimum 
Essential Medium (Eagle) Modified (MEM) for suspension 
cultures and homogenised, by hand, in an ice cold, loosely 
fitting glass tissue homogeniser (7 ml). The tissue homo­
genate was strained through a double layer of plain absorbent 
gauze ("Rydal" grade, Government stores, Australia) and, 
with modified MEM, made up to a suspension which was about 
20% tissue by weight. A sample of the tissue mince (2.5 ml) 
was then shaken for three hours at 37°C in 20 ml of MEM 
made 20 mM NaHCO^, 5.8 mM aspartic acid, 5.8 mM ATP, 10 mM 
6-azauridine (to inhibit the conversion of orotic acid to 
UMP, 3.8 mM glutamine and 4.8 mM MgSO^.
2 -The incorporation of either HCO^ or carbamyl-P 
substrate into orotic acid was measured by adding either 
1 mCi [^C] NaHCO^ or 8 yCi of [^C] carbamyl-P (final con­
centration 5.8 mM) to the incubation mixture and assaying 
the degree of incorporation of the substrate into orotic 
acid.
After 3 hours, the reaction was terminated by 
heating the reaction mixture in boiling water for 5 minutes. 
The reaction mixture was then cooled to room temperature 
and the insoluble material removed by centrifugation 
(10,000 g for 10 minutes). The supernatant fluid was kept 
and the sedimented material was washed with 10 ml of water,
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recentrifuged (10,000 g for 10 minutes) and the supernatant 
fraction pooled with that previously obtained. The com­
bined supernatant fraction was then diluted to 40 ml with 
water, mixed, heated to 100°C and the solution was saturated 
with an accurately known amount of orotic acid (350 mg).
The solution was allowed to cool slowly to 4°C to allow the
14 14recovery of the [ C] orotate. The crystals of [ C] orotate
and carrier orotate so obtained were recrystallised twice
from water and the radioactivity in a sample of the orotate
crystals determined.
5.3 Results and Discussion
5.3.1 Cardiac Pyrimidine Biosynthesis
Tables 5.1, 5.2 and 5.3 show the relative incor­
poration of 3 pyrimidine nucleotide precursors into various 
tissues of normal rats, and the proportion of these pre­
cursors found in the acid soluble and RNA fractions of these 
tissues. Table 5.1 shows that most of an administered dose 
of orotic acid (56%) was taken up by the liver and kidney, 
though this may be related to the high blood flow through 
these tissues. The high rate of uptake of orotic acid by 
liver (43%) and kidney (13%), however, does not appear to 
be a general feature of metabolite uptake - only 1.4% of 
uridine and 2.9% of uracil were taken up by the liver and 
0.4% of uridine and 0.5% of uracil were taken up by the kidney.
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The total uptake of orotic acid by the other tissues studied 
(heart, skeletal muscle, lung, brain and spleen) accounted 
for less than 6% of the administered dose. A further 2-3% 
of the radioactive label was found in the fluid of the 
peritoneal cavity and, from earlier studies (Chapter 3), it 
is apparent that a further 5-10% of the orotic acid was in 
the urine. Presumably, the remaining 25-30% of the adminis­
tered dose was either taken up, from the blood, by tissues 
other than those tissues investigated above, or was distri­
buted and diluted throughout the body by the lymph vessels 
of the peritoneal cavity.
In contrast to orotic acid, very little of the 
administered doses of uridine or uracil were found in the 
tissues of normal rats (5% of uridine and 12.5% of uracil). 
Although only 5% of the uridine was found in the tissues, 
the tissue/blood ratios were 33 (liver), 57 (kidney), 10 
(heart) and 15 (brain) suggesting that either the uridine 
was actively transported into the cells of these organs 
or that the uridine was rapidly phosphorylated to UMP and 
"trapped" in these cells. Conversely, uracil uptake by 
these tissues was very low, the tissue/blood ratios were 
1.4 (heart and brain) and 2.7 (liver and kidney). This 
may be due to a low level of uptake, or a high level of 
catabolic activity in these tissues.
In Table 5.2 the proportions of the pyrimidine 
label found in the acid soluble fractions of these tissues
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are shown; the results were very similar to those derived 
from whole tissue analysis (Table 5.1). The results for 
each label were averaged over the range of tissues examined: 
86% of the orotic acid (range 79-89%), 85% of the uridine 
(77-96%) and 85% of the uracil (77-94%) radioactivity in the 
whole tissue digestion (Table 5.1) was found in the acid 
soluble fraction (Table 5.2). Although all the samples in 
which the radioactivity was counted were corrected for 
quenching, the higher degree of quenching, due to the use 
of Soluene 100 in the whole tissue analysis makes the 
results obtained in Table 5.2 more representative of the 
minimum rate of uptake of pyrimidines.
In contrast to the data of Tables 5.1 and 5.2, 
which can only show the minimum values for the uptake of 
pyrimidine nucleotide precursors, the data of Table 5.3 
show the degree of incorporation of the various precursors 
into RNA. This table may be redrawn to show the percentage 
of the acid soluble fraction which is incorporated into RNA:
TABLE 5.3a
THE PERCENTAGE OF THE LABEL IN THE ACID SOLUBLE 
FRACTION WHICH WAS INCORPORATED INTO RNA
Orotic Acid Uridine Uracil
Heart 1.46 17.63 1.08
Brain 0.93 15.36 0.73
Liver 10.82 2.75 0.96
Kidney 21.73 24.31 —
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The results show that little of the uracil taken up by the 
tissues was incorporated into RNA, presumably due to the 
low anabolic activity and/or the high catabolic activity of 
the enzymes concerned with uracil metabolism. Possible 
anabolic pathways of uracil metabolism concern its direct 
conversion to UMP (uracil phosphoribosyltransferase) or 
its indirect conversion to UMP via uridine (uridine 
phosphorylase and uridine kinase). There are conflicting 
reports concerning the existence of a uracil phosphoribosyl- 
transferase in animal cells, but some tumor tissue cells 
and erythrocytes contain enzymes which may form nucleotides 
from PP-ribose-P and pyrimidines (Roux, 1973). Using the 
method of Kasbekar et al., 1964, no uracil phosphoribosyl- 
transferase activity could be demonstrated in cardiac 
tissue. The indirect conversion of uracil to UMP (uracil + 
ribose-l-P -* uridine) would seem to be a more feasible 
pathway for the following reasons: (1) uridine is readily
incorporated into cardiac RNA; (2) the activity of uridine 
phosphorylase is approximately 12 times that of uridine 
kinase (which catalyses the conversion of uridine to UMP); 
and, (3) the activity of phosphopentomutase (E.C. 2.7.5.6.) 
responsible for the formation of ribose-l-P does not appear 
to be rate limiting (the activity of phosphopentomutase in 
rabbit muscle is approximately 1.8 ymoles/min/g wet weight, 
Kämmen and Koo, 1969). Thus, anabolic pathways of uracil 
metabolism are apparently functional and should give rise 
to the same percentage incorporation of uracil and uridine
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into RNA. Nevertheless, the utilization of uracil in vivo 
appears to be much lower than that of orotic acid or uridine, 
presumably because of the greater activity of the pathways 
of catabolism; the uracil being degraded to carbon dioxide, 
ammonia and 3-alanine. Rats were given an intraperitoneal 
injection of 15 pCi of [2-^C] uracil (Section 5.2.2) to 
determine the extent of uracil degradation:
14 14[2- C]-uracil -* C02 + ammonia + 3-alanine (1)
After two hours, 70 ± 16% (mean ± S.D.) of the label was 
found in the expired carbon dioxide. Thus, uracil was not 
effectively used for nucleotide synthesis owing to the rapid 
degradation of this base. Canellakis (1957) has shown that, 
if large amounts of uracil were supplied to rat liver to 
saturate the degradation system, the conversion of uracil 
to UMP may occur, but only at a very low rate. Since the 
catabolic pathways of uracil are so active, one would expect 
that some of the uridine administered to the animals was 
also degraded and this was indeed shown to be the case.
In chromatographed perchloric acid extracts of blood plasma 
(Section 5.2.2), 43% of the radioactivity in the extract 
was found in the spot which corresponded to standard uridine 
and 39% of the label was found in the spot which corres­
ponded to standard uracil. Also, when rats were injected
14 14with [2- C]-uridine and the C02 recovered over a 2 hour 
period (Section 5.2.2), 56 ± 10% of the label was recovered
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as CO2 • Thus, a considerable proportion of the adminis­
tered dose of uridine and uracil was degraded and the 
"uptake" of uridine and uracil into the various tissues 
(Tables 5.1 and 5.2) represents only the minimum values of 
pyrimidine nucleotide precursor uptake. However, the uptake 
of label into the heart, spleen and lung probably repre­
sents the actual uptake of precursor as dihydrouracil 
dehydrogenase activity (E.C. 1.3.1.1.), the first enzyme 
in the degradative pathway of uracil metabolism, has not 
been detected in these tissues (Knox, 1972).
Table 5.3 also shows the relative incorporations 
of radioactive orotic acid and uridine into the RNA of the 
tissues. Relative to the liver, there was little orotic 
acid incorporation into the RNA of the heart. On the other 
hand, the labelling of heart RNA with uridine was high 
relative to that of liver RNA. The ability of a tissue to 
incorporate uridine into RNA may be considered evidence for 
the operation of the salvage pathway for the biosynthesis 
of RNA pyrimidines in that tissue, though the utilization 
of orotic acid only indicated the presence of the latter 
enzymes of the pathway de novo in these tissues. Both the 
brain and the heart possess a limited capacity to utilize 
orotic acid in the synthesis of pyrimidines, relative to 
their ability to utilise uridine. These findings strongly 
suggest that the heart and brain rely heavily on preformed 
precursors from the "salvage" pathway and, at best, use the
14
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pathway de novo to a much smaller extent. The kidney may 
apparently utilize either uridine or orotic acid in RNA 
biosynthesis. This is partly due to the different cell 
types in the kidney: Ross et al. (1975), have reported
that 97% of an orotic acid label was found in the tubular 
cells, mostly in the proximal tubule, while about 80% of 
uridine label was in the tubules, only 66% of which was in 
the proximal tubules. Consequently orotic acid was a 
better precursor of RNA for studies of compensatory renal 
hypertrophy since it was concentrated in the segments of 
greatest biological activity. The liver shows a prefer­
ential incorporation of orotic acid into RNA but has only 
a small capacity to utilize uridine.
Though these uptake studies indicated that the 
brain and the heart rely heavily on the salvage pathway of 
pyrimidine nucleotide biosynthesis, the incorporation of 
uridine into RNA may, in general, not be used as a measure 
of the rate of RNA biosynthesis by the cells. Uridine and 
uracil are not direct precursors of RNA and it is possible 
that changes in the capacity of cells to take up or 
phosphorylate uridine to the nucleoside triphosphate may 
cause changes in the rate of incorporation of uridine into 
RNA, unrelated to the rate of RNA synthesis.
Enzymes with regulatory capacity might be 
expected to have significantly lower catalytic capacity 
than the non-regulatory enzymes in the same metabolic
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sequence. The low-activity enzymes are potential bottle­
necks in the pathway where substrates may accumulate and 
are more likely to catalyze "non-equilibrium" reactions.
One of the most direct methods of investigating metabolic 
control is to measure the maximum catalytic capacity of 
each enzyme unique to the pathway. Most non-regulatory 
enzymes, which normally operate at rates well below their 
maximal catalytic capacity, are usually 10 to 100 fold more 
active than their regulatory counterparts (Krebs, 1963).
When the maximal activities of the enzymes of 
the pathway of pyrimidine biosynthesis de novo were 
measured in the normal heart (Table 5.4), the least active 
enzyme in the 105,000 g supernatant fraction was carbamyl 
phosphate synthetase II, its activity was 7% of the next 
most active enzyme, OPRT ase, and thus catalysed the rate 
limiting step of the pathway. The significance of the 
least active enzyme as a regulatory step comes from knowing 
that the most effective point at which control might be 
applied in a pathway is the point of minimum activity. 
However two points deserve consideration:
(a) Equilibrium reactions may control flux 
(Newsholme and Start, 1974). PP-ribose-P availability is 
thought to control flux through the pathway of purine 
synthesis de novo (Henderson and Paterson, 1973). The 
higher affinity of the purine pathway for PP-ribose-P, 
compared with the pyrimidine pathway, [K for PP-ribose-P
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-3for cardiac OPRT ase was 10 M (Matsushita and Fanburg,
1970) and the Km of PP-ribose-P amido-transferase 
(E.C. 2.4.2.14.) for PP-ribose-P was 2-10x10 
(Henderson and Paterson, 1973)] suggests that PP-ribose-P 
may also control flux through the pyrimidine pathway de 
novo. The low incorporation rate of bicarbonate, compared 
with carbamyl-P (25.5 ± 7.9 pmol bicarbonate/min/g wet 
weight and 795 ± 163 pmol carbamyl-P/min/g wet weight), 
however, suggests that carbamyl-P synthetase II catalysed 
activity was also an important regulatory reaction.
(b) The amount of enzyme activity available in 
the cell may be much less than that commonly deduced from 
studies in vitro, however, the regulation of the mammalian 
pyrimidine pathway de novo is so poorly understood, it is 
not possible to comment further on this possibility.
It is apparent from Table 5.4 that the activities 
of the two enzymes, OPRT ase and ODC ase (3.3 and 6.1 nmol/ 
min/g wet weight, respectively), considerably restricted 
the utilization of administered orotic acid, compared with 
the activity of the nucleoside monophosphate kinase 
(NMK ase), whose activity was 1,000 fold greater than the 
activity of OPRT ase and ODC ase. The activities of the 
enzymes ATC ase, DHO ase and DHO dehase (17, 52 and 85 
nmol/min/g wet weight, respectively) were of two orders of 
magnitude greater than CPS ase and were clearly not enzymes 
to which a regulatory role could be attributed. However,
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DHO dehase is a mitochondrial enzyme in hepatic tissue 
(Miller et al., 1968) and the transport of dihydro orotic 
acid out of the mitochondria (i.e. access control) may 
restrict the flux of the pathway de novo .
Table 5.5 shows the activity of the "salvage" 
pathway enzymes of pyrimidine synthesis. It is apparent 
that the activities of the enzymes of the salvage pathway 
were at least 60 fold greater than the activity of the 
apparent flux generating step of the pathway de novo 
(CPS ase II). The conversion of uridine or uracil to 
pyrimidine nucleotides, in normal cardiac tissue, was 
controlled by the activity of uridine kinase (uridine 
phosphorylase activity was 12 fold greater than uridine 
kinase activity). Although the equilibrium of the uridine 
phosphorylase reaction favors nucleoside synthesis, even 
if ribose 1-P is present in much smaller concentrations 
than phosphate (Reichard and Sköld, 1958), it has been 
suggested that the enzyme acts as a degradative enzyme in 
the brain (Guroff and Rhoads, 1969). This, however, does 
not appear to be the case in cardiac tissue since dihydro­
uracil dehydrogenase activity, the first step in the 
catabolism of uracil, was absent from cardiac tissue 
(Knox, 1972).
Thus, in normal cardiac tissue, the activity of 
the rate limiting enzyme of the salvage pathway (uridine 
kinase, 15 nmol/min/g wet weight) was far greater than the
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activity of the rate limiting step of the pathway de n o vo  
(CPS ase II, 0.23 noml/min/g wet weight). When these data 
are linked with the results of the studies of the incorpora­
tion of uridine and orotic acid into RNA, they suggest that 
the major source of pyrimidines in the heart was via the 
pyrimidine salvage pathway. The activity of thymidine 
kinase (Table 5.5) was very low (0.50 nmol/min/g wet weight 
in normal tissue) and this was consistent with the low 
levels of DNA synthesis found in a mitotically static tissue 
such as the heart (Morkin, 1971). The ability of the pathway
to synthesise orotic acid de novo was studied by measuring
14 14the incorporation of [ C]-bicarbonate or [ C]-carbamyl-P
into orotic acid. The method permitted the isolation of 
14[ C] orotate, synthesised in tissue minces, by co-
crystalization with carrier orotate. (The absence of
PP-ribose-P and the presence of 6-azauridine to inhibit
further anabolism, enabled the rate of incorporation of
precursors into orotic acid to be accurately measured.)
14When [ C]-bicarbonate was used as a substrate, 25.5 ± 7.9
pmol bicarbonate/min/g wet weight (mean ± S.D.) were incor-
14porated into orotic acid; when [ C] carbamyl phosphate 
was used as the precursor,795 ± 163 pmol carbamyl phosphate/ 
min/g wet weight (mean ± S.D.) were incorporated into 
orotic acid. Thus,the flux generating step in the synthesis 
of orotic acid was CPS ase II.
During cardiac hypertrophy, the enzymes of cardiac 
pyrimidine biosynthesis, both those of the pathway de  n ovo
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and the salvage pathways, increased in activity 
(Tables 5.4 and 5.5). Those enzymes which were not 
rate limiting - ATC ase, DHO ase, NMK ase, UP ase - 
did not increase in activity significantly (though there 
may have been a slight increase in ATC ase activity, 4 days 
after the induction of hypertrophy, p < 0.05). The enzymes 
catalysing the rate limiting step of both pathways - CPS 
ase II and UK ase - increased in activity (48% and 53%, 
respectively, in the 4 day hypertrophied hearts), and the 
two orotate enzymes, OPRT ase and ODC ase, also showed 
enhanced maximum catalytic activities (45% and 43%, 
respectively in the 4 day hypertrophied hearts). Thus, 
the regulatory enzymes of pyrimidine synthesis all appear 
to increase by approximately the same extent during hyper­
trophy. It was not possible to conclude with certainty 
from the data whether or not the cardiac enzymes CPS ase, 
ATC ase and DHO ase increased in activity in a coordinated 
manner as would be expected if they were to form a constant 
proportion complex (Klingenberg and Pette, 1962) in cardiac 
tissue (as has been shown in some mammalian cells, Yip and 
Knox, 1970). There was, however, a strong correlation 
among the changes in the activities of these three cardiac 
enzymes. The multiple correlation coefficients, R, (the 
multiple correlation coefficient is a measure of the 
"goodness of fit" of various parameters and tells, on a 
0 to 1 scale, what part of the variation in a parameter y 
was "explained" by a set of parameters x) of CPS ase,
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R 0 99ATC ase and DHO ase were ATC ase.CPS ase DHO ase ’ ,
R 0 9 9 RCPS ase.ATC ase DHO ase and DHO ase.ATC ase CPS
ase^'^. Similarly, ODC ase and OPRT ase are thought
to exist as a constant proportion complex in vivo and the
correlation coefficient of changes in the activities of
these two enzymes was 0.97. Thus, the data are certainly
consistent with a number of reports (for example Appel,
1968; Shoaf and Jones, 1973) which suggest that these
enzymes may exist as two constant proportion complexes
in vivo.
5.3.2 The Effects of Cardiac Hypertrophy on 
Cardiac Pyrimidine Biosynthesis
Orotic acid has been administered to patients in 
a number of clinical situations (Section 1.4) based on the 
rationale that the administration of orotic acid would lead 
to a greater production of nucleic acid precursors, pre­
sumably through enhanced pyrimidine biosynthesis. If this 
proposal was true, the activity of the enzymes of pyrimidine 
biosyntehsis may be expected to change during the development 
of cardiac hypertrophy, in rats treated with orotic acid.
One day after the induction of cardiac hypertrophy, the 
activities of the enzymes CPS ase II, ATC ase, OPRT ase,
ODC ase and NMK ase had increased in the orotic acid treated 
animals, though the changes in activity were not signifi­
cantly greater than the changes in these enzyme activities 
in the untreated 1 day hypertrophied hearts. Four days
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after the induction of hypertrophy, OPRT ase (p < 0.005),
ODC ase (p < 0.025), CPS ase (p < 0.005) and uridine kinase 
(0.025 < p < 0.05) activities had significantly increased 
in the orotic acid treated hypertrophied hearts, relative 
to the untreated four day hypertrophied hearts. Though 
CPS ase II activity had increased by 83% (0.23 ± 0.03 to 
0.42 ± 0.02 nmol/min/g wet weight in the normal and orotic 
acid treated, four day hypertrophied hearts respectively), 
the flux through the pathway de  n o v o was still controlled 
by CPS ase II (CPS ase activity was only 8% of OPRT ase 
activity, the next lowest activity of the pathway, and 2% 
of uridine kinase activity, the flux generating step of the 
salvage pathway). Thus, the major source of pyrimidines 
in the orotic acid treated, hypertrophied hearts was still 
the "salvage" pathway. The qualitative relationship which 
suggested that growing tissues contained more CPS ase II 
(Yip and Knox, 1970) and ATC ase (Herzfeld and Knox, 1972) 
than slowly or non-growing tissues was maintained. In the 
experiments reported here, this relationship held, even in 
a "slowly" growing tissue such as the heart, during normal 
growth, compensatory hypertrophy and "orotic acid enhanced" 
compensatory hypertrophy. Although the pathway of 
pyrimidine synthesis de  n o v o plays an apparently limited 
role in the synthesis of cardiac pyrimidines, the activities 
of both the pathway d e  n o v o and the salvage pathway enzymes 
increased during hypertrophy. This appears to be a common 
feature of enhanced growth situations, for a similar
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increase in the activities of the enzymes of both pathways 
has been reported during tumor growth (Herzfeld and Knox, 
1972) and in regenerating rat liver (Sköld, 1960a).
Bresnick et al. (1968) have shown that the 
administration of a purified diet supplemented with 1% 
orotic acid was attended by alterations in the size of 
the acid soluble nucleotide pool: the hepatic pyrimidine
concentrations were augmented by a factor of 3 and the 
hepatic purines were depressed by 50%, 2-3 days after the 
administration of orotic acid. If this was the case in 
the hypertrophing rat heart, it would have pathological 
results (Kübler and Spieckermann, 1970). By repeating 
the experiments of Bresnick et al. (1968), it was shown that 
the composition of the hepatic acid soluble fraction was 
grossly effected by the administration of orotic acid 
(Fig. 5.2). The concentration of hepatic pyrimidines, 
in terms of & 2 6 0^  wet weight, was enhanced (+56% after 
4 days) and that of hepatic purines was decreased (-23% 
after 4 days). Orotic acid administration also slightly 
depressed kidney purines (-17% after 4 days); elevated 
kidney pyrimidines (+66% after 4 days); enhanced cardiac 
pyrimidines (+71% after 4 days); and had no significant 
effect on cardiac purine concentrations. Thus, although 
only 10 mg/kg body wt/day of orotic acid was administered 
to rats (Bresnick et al., 1968, administered an artificial 
diet containing 1% orotic acid), gross changes in the acid
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soluble fraction of tissues still occured. These changes, 
at comparatively low dose levels of orotic acid, may be 
attributed to the saturation of the tissue transport pro­
cesses by orotic acid (Ord and Stocken, 1973, have shown 
that orotate entry into the liver was saturated at a level 
of 5 mg/kg body wt). The depletion of hepatic purines by 
orotic acid was attributed to an extensive depletion of 
PP-ribose-P by orotic acid (PP-ribose-P is used in the con­
version of orotic acid to OMP) (Rajalakshmi and 
Handschumacher, 1968). That orotic acid did not cause a 
decrease in the concentrations of cardiac purines in the 
experiments reported here was consistent with the proposal 
that pyrimidine synthesis was not diverting PP-ribose-P 
from purine synthesis. This may be due to the low concen­
tration of cardiac pyrimidines in relation to cardiac 
purines (after 6 days of orotic acid administration, the 
pyrimidine nucleotide concentration was less than 25% of 
the purine nucleotide concentration) and/or that pyrimidine 
synthesis in cardiac tissue did not involve PP-ribose-P, 
that is, was via the "salvage" pathways.
The proposition that the pathway of pyrimidine 
synthesis de novo was not very active in cardiac tissue was 
indirectly suggested by the results of a series of experi­
ments carried out in this laboratory by G. Kolos 
(unpublished results). The experiments were designed to 
determine whether or not allopurinol had an effect on the 
concentration of adenine nucleotides in the ischemic
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myocardium. Allopurinol, through its metabolites 
oxipurinol and oxipurinol-ribose phosphate, will inhibit 
ODC ase activity (Hitchings, 1974) and may be expected 
to stimulate adenine nucleotide synthesis because 
PP-ribose-P would not be used for pyrimidine synthesis 
de  n o v o . There were, however no significant differences 
in the cardiac adenine nucleotide concentrations of normal 
and allopurinol treated hearts: presumably the inhibition
of the pyrimidine pathway de  n o v o released minimal.amounts 
of PP-ribose-P for purine synthesis and the flux through 
the pathway de  n ovo was very low in normal rats.
If the heart does utilise preformed pyrimidines, 
then the most likely source of pyrimidines is the liver.
The liver is uniquely suited for this process because of 
the presence of CPS ase I in the mammalian liver. Although 
CPS ase II activity was localised in the cytosol of the 
liver and CPS ase I activity was localised in the mito­
chondria (and was thought to be used exclusively in the 
urea cycle), Tremblay et al. (1977) have reported that CPS 
ase I was the major source of carbamyl phosphate used in 
the synthesis of hepatic pyrimidines under normal physio­
logical conditions. Thus, ureotelic animals may be endowed 
with an exceptionally high capacity for the synthesis de  
novo of pyrimidines and the liver may, therefore, serve 
as an essential source of pyrimidines and their precursors 
for extra-hepatic tissues. That the liver supplies nucleotide
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precursors has been shown to occur in a number of other 
tissues: bone marrow cells are dependent upon hepatic
tissue for their purine supply (Lajtha and Vane, 1958); 
in fast growing, poorly differentiated tumors, with a 
doubling time of approximately 24 hours, Lawson et al.
(1975) have reported that CPS ase I activity was either 
nearly or completely absent and CPS ase II activity was 
only about l/3rd of the minimal rate required to provide 
sufficient carbamyl phosphate for pyrimidine synthesis in 
these cells. Hence, these tissues must use preformed bases. 
Hogans et al. (1971) have suggested that the brain also
utilizes preformed bases rather than synthesise pyrimidines 
by the pathway de novo. It was, therefore, of interest to 
investigate the effect of orotic acid on hepatic pyrimidine 
synthesis. Only ATC ase and ODC ase activities were 
measured, as changes in these activities are representative 
of changes in the pathway de novo (CPS ase, ATC ase and 
DHO ase exist as a constant proportion complex (Klingenberg 
and Pette, 1962) with a coordinate relationship between the 
activities in the liver (Mori et al., 1975) and ODC ase and 
OPRT ase activities also show a coordinate relationship 
between their activities in a number of conditions (Pinsky 
and Krooth, 1967a,b; Pausch et al., 1972)). The results 
of these experiments are shown in Table 5.7. The adminis­
tration of orotic acid (10 mg/kg body wt/day) caused a 
marked elevation of hepatic ATC ase and ODC ase activities. 
One day after the commencement of orotic acid feeding, ATC
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ase activity had increased 48% compared with normal 
activity (p < 0.025) and ODC ase activity increased 50% 
compared with normal activity (p < 0.005). On the other 
hand, the administration of uridine (10 mg/kg body wt/day) 
had no significant effect on either ATC ase or ODC ase 
activity (when compared to normal hepatic activities, 
p value for ATC ase activities was 0.1 < p < 0.15 and for 
ODC ase activities 0.30 < p < 0.35). Thus, orotic acid, 
unlike uridine, has a major effect on hepatic pyrimidine 
synthesis. Kolos et al. (1974) (Section 1.5) have shown 
that the administration of orotic acid to rats during com­
pensatory cardiac hypertrophy had a positive inotropic 
effect on the papillary muscles and that the administration 
of uridine had no effect under the same conditions. These 
results may be interpreted, in the light of these experi­
ments, as showing that excess hepatic pyrimidine synthesis 
was required so as to provide preformed pyrimidine bases 
for the cardiac "salvage" pathway and hence nucleotides 
for the enhanced nucleic acid synthesis induced by com­
pensatory cardiac hypertrophy (Chapter 3). If the positive 
inotropic effect of orotic acid was wholly or partly due to 
its effect on the availability of preformed bases, from 
extra-cardiac tissues, to act as substrates for the uridine 
"salvage" pathway, it would be expected that, in the isolated 
perfused heart, orotic acid would exert, at best, only a 
marginal effect on cardiac contractility and that uridine 
would exert a positive inotropic effect. Such results
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were reported by Buckley et al. (1971); they have reported
that uridine was positively inotropic for the ventricles of 
electrically-paced dog heart-lung preparations while orotic 
acid was not inotropic for the ventricles of such preparations.
Differences in the incorporation of uridine and 
orotic acid into the RNA of tissues may be attributed to 
differences in (a) cellular transport across membranes;
(b) intracellular pool sizes; and (c) enzyme activities.
(a) The mechanism by which nucleosides enter the 
cell is poorly understood. It is thought that as the nucleo­
sides enter the cell they are phosphorylated and effectively 
trapped within the cell. Stambrook et al. (1973), using 
Chinese hamster V79 cells, have reported that uridine up­
take was saturated at an extra-cellular concentration of 
200 yM; in these experiments and those of Kolos et al.
(1974), uridine was administered at a dose level of not 
greater than 5 mg/kg body weight. If this dose was adminis­
tered intravenously, it would correspond to a blood concen­
tration of 320 yM, however, the dose was administered by 
oral intubation and it is unlikely that the blood concen­
tration of uridine ever reached 200 yM. Ord and Stocken 
(1973) have reported that orotic acid does not compete with 
uridine for transport into regenerating liver and that the 
uptake of orotic acid into the liver does not become 
saturating until the dose exceeds 5 mg/kg body weight, when 
administered intramuscularly; in these experiments and
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those of Kolos et al. (1974), orotic acid was administered
at a dose level of not greater than 5 mg/kg body weight 
every 12 hours. Thus, although no data are available on 
the transport of pyrimidines into cardiac tissue, it seems 
unlikely that differences in the transport of precursors 
into the tissues were responsible for differences in the 
incorporation of pyrimidines into the RNA of tissues.
(b) Although differences in the size of the 
uridine and orotic acid intracellular pools will contribute 
to variations in the incorporation of these precursors into 
cardiac RNA, such differences would not qualitatively change 
the conclusion that uridine was more readily incorporated 
into cardiac RNA. Both orotic acid and uridine concentra­
tions in cardiac tissue were below the limit of resolution 
of present assay techniques [orotic acid was not able to
be detected in cardiac tissue using the enzymatic assay 
of Möllering (Bergmeyer, 1974) (limit of resolution 0.5 
nmol/g wet weight) and uridine is thought to be phosphoryl- 
ated to UMP as it enters into the eucaryotic cell (Stambrook 
et al., 1973)]. Thus, both orotic acid and uridine intra­
cellular pools were too small to effect the results pre­
sented here.
(c) The results presented in this chapter suggest 
that the differences in the incorporation of uridine and 
orotic acid into cardiac RNA were due to differences in the 
activities of the enzymes of the pathway de novo and
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"salvage" pathway. The activity of the flux generating step 
of the pyrimidine salvage pathway was 60 fold greater than 
the activity of the flux generating step of the cardiac 
pathway de novo in normal, hypertrophied and orotic acid 
treated, hypertrophied hearts. Thus, uridine, rather than 
orotic acid, was more readily incorporated into cardiac RNA.
The results suggest that orotic acid may stimulate 
hepatic pyrimidine synthesis and provide preformed bases 
for extra-hepatic tissues. This extra-cardiac role of 
orotic acid was supported by the following results:
(a) In Chapter 3 it was shown that orotic acid 
administration enhanced protein synthesis in the hyper­
trophied heart, yet Nievel and Bray (1976) have shown that 
when nucleotide precursors were added to a whole cell homo­
genate, a 600 g post-nuclear supernatant fraction or a
1500 g post-mitochondrial supernatant fraction, and incubated 
at 37°C for 10 minutes before the precipitation of the micro­
somal fractions, orotic acid decreased the capacity of the 
microsomal fractions to incorporate labelled amino acids. 
Uridine significantly stimulated both endogenous and poly U 
directed protein synthesis by microsomal fractions or ribo- 
nucleoprotein particles, suggesting that it is uridine 
rather than orotic acid which enhances cardiac hypertrophy.
(b) Previous results (Kolos et al., 1974;
Donohoe et al., 1974) have shown that orotic acid, but not 
uridine, had a positive inotropic effect on papillary
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muscle (which is continuous with the ventricular wall) 
contractility in vivo: Buckley et al. (1971) have
reported that uridine, but not orotic acid, had a positive 
inotropic effect on ventricular contractility in vitro.
This apparent contradiction may only be resolved if orotic 
acid was used, in vivo, to stimulate pyrimidine base 
synthesis in extra-cardiac tissues for use in the pyrimidine 
salvage pathway of the heart.
(c) In Fig. 5.2, the administration of orotic 
acid was shown to decrease hepatic purines and increase 
hepatic pyrimidines, yet in cardiac tissue both purines and 
pyrimidines decreased in concentration. Presumably, this 
was because PP-ribose-P synthetase activity may be rate 
limiting for RNA synthesis in the liver of the rat (Fausto, 
1969) and both the purine and pyrimidine pathways were com­
peting for PP-ribose-P. On the other hand, cardiac tissue/ 
by using preformed bases for pyrimidine synthesis, allows 
PP-ribose-P to be used exclusively by the purine synthetic 
pathway. This would be expected to confer an advantage on 
the orotic acid treated, hypertrophied hearts in that, not 
only did orotic acid enhance cardiac pyrimidine concentra­
tions (Table 5.6) by stimulating hepatic pyrimidine synthesis 
but it may indirectly "stimulate" cardiac purine synthesis 
by not competing with that pathway for PP-ribose-P. The 
degree of "enhanced" purine metabolism is difficult to 
estimate for there are two opposing forces: firstly, the
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purine pathway has a higher affinity for PP-ribose-P
-3(Km of OPRT ase for PP-ribose-P was 10 M, Matsushita 
and Fanburg, 1970, and the Km of PP-ribose-P amidotrans- 
ferase (E.C. 2.4.2.14.) for PP-ribose-P was 2-10x10 ~*M, 
Henderson and Paterson, 1973); secondly, PP-ribose-P 
synthesis can be accelerated if cells were provided with 
base substrates for nucleotide synthesis (Bagnara et al., 
1974) .
(d) It is of interest that isoprenaline, a 
cardiac stimulant, enhanced uridine kinase activity and 
the incorporation of uridine into RNA in phytohemagglutinin- 
stimulated lymphocytes and mouse salivary glands (Roux et 
al., 1973) .
Thus, the heart possesses a very limited capacity 
to utilize orotic acid for the biosynthesis of RNA and 
pyrimidines in comparison with its ability to utilize 
uridine. This strongly suggests that both the normal heart 
and the heart undergoing compensatory hypertrophy, unlike 
the liver and the kidney, rely heavily on preformed bases 
and the salvage pathway to provide pyrimidines and at best 
only used the pathway de novo to a much smaller extent.
The effect of orotic acid was to enhance pyrimidine bio- 
syntehsis in extra-cardiac tissues - probably the liver - 
rather than act solely as a precursor for pyrimidine 
synthesis de novo, Other sources of pyrimidine bases are 
apparently available, for when hepatic pyrimidine synthesis
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de novo was inhibited by 6-azauridine (Keppler et al., 
1970), there was no decrease in hepatic UTP concentration. 
The blockage was completely compensated for, probably by 
salvage pathway synthesis.
A depletion of nucleotide pools may serve to 
inhibit cellular growth and induce cell death under some 
circumstances. The consequences of nucleotide deficiency 
depend not only on the nucleotides involved but also on 
the extent and the period of depletion. During compensa­
tory hypertrophy and after an ischemic episode, the heart 
will be particularly prone to pathological consequences as 
a result of nucleotide deficiency and a major beneficial 
effect of orotic acid, in such circumstances, will be to 
facilitate the supply of pyrimidines to the effected 
region.
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Figure 5.2 Alterations in the Purine and Pyrimidine Composition 
of the Acid Soluble Fraction of Tissues due to the 
Feeding of Orotic Acid.
Male rats were maintained on a diet supplemented with orotic 
acid (10 mg/kg body wt/day). The concentrations of the acid soluble 
pyrimidines (open symbols) and purines (closed symbols) in the heart 
( ▼ ), liver ( • ) and kidney ( ■ ) were ascertained as described in the 
text. Each point represents the mean ± S.D. values for 5 animals.
TABLE 5.1
INCORPORATION OF RADIOACTIVELY LABELLED (TRITIUM) 
PYRIMIDINES INTO THE TISSUES OF NORMAL RATS
Orotic Acid Incorporation
Tissue % total 
radioactivity
nnmol/g wet wt (xlO ) nmol/tissue (xlO2)
Heart 1.63± 0.13 1.15+ 0.13 0.06
Skeletal muscle 2.00± 0. 07 106.821 17.42 5.55
Lung 1.95± 0.41 1.87± 0.36 0.10
Liver 70.421 0.73 821.791 17.74 42.61
Kidney 130.891 3.69 248.581 3.11 12.89Brain 1.461 0.02 2.681 0.11 0.14
Spleen 1.141 0.21 0.641 0.11 0.04
Blood 0.041 0.02 0.541 0.13 0.03
Total = 61.41
Uridine Incorporation
Tissue
nmol/g wet wt (xlO^) pnmol/tissue (xlO ) % total radioactivity
Heart 2.341 0.12 1.691 0.11 0.03
Skeletal muscle 3.091 0.04 194.971 4.19 3 .01
Lung 3.331 0.02 2.891 0.77 0.05
Liver 7.621 0.10 89.201 5.84 1.38
Kidney 13.281 0.12 26.701 0.29 0.41
Brain 3.551 0.32 6.891 0.46 0.10
Spleen 2.161 0.09 1.251 0.01 0.02
Blood 0.231 0.02 3.001 0.08 0.05
Total = 5.04
Uracil Incorporation
Tissue
nmol/g wet wt (xlO^) nmol/tissue (xlO^) % total radioactivity
Heart 1.98 1 0.10 1.46 1 0.11 0.09
Skeletal muscle 1.93 1 0.05 123.79 1 3.52 7.50
Lung 1.681 0.22 1.82 10.19 0.11
Liver 3.891 0.17 47.14 1 0.14 2.86
Kidney 3.94 1 0.26 7.81 1 0.47 0.48
Brain 2.07 1 0.08 3.62 1 0.38 0.22
Spleen 1.801 0.03 0.98 1 0.10 0.06
Blood 1.44 1 0.11 19.72 1 0.85 1.20
Total = 12.51
The treatment of the animals and assay of the incorporation of pyrimidines 
were as described in the experimental section. Rats were killed 2 hours 
after receiving i.p. injections of pyrimidines (2 yCi/g body weight).
TABLE 5.2
THE INCORPORATION OF TRITIUM LABELLED PYRIMIDINES 
INTO THE ACID SOLUBLE TISSUE FRACTIONS OF NORMAL RATS
Incorporation into the acid soluble fraction
Orotic Acid Uridine Uracil
nmol/g wet wt nmol/g wet wt nmol/g wet wt 
(xlO2) (xlO2) (xlO2)
Heart 1.43 ± 0.03 1.88 ± 0.07 1.72 ± 0.06
Brain 1.27 ± 0.03 3.16 ± 0.20 1.82 ± 0.13
Spleen 0.99 ± 0.16 1.67 ± 0.05 1.70 + 0.02 -
Liver 55.01 ± 0.95 7.32 ± 0.04 3.05 ± 0.03
Kidney 115.68 ± 0.20 10.99 ± 0.11 3.05 ± 0.04
The treatment of the animals and assay of the incorporation 
of pyrimidines were as described in the experimental section. 
Rats were killed 2 hours after receiving i.p. injections of 
the pyrimidines (2 pCi/g body wt).
TABLE 5.3
THE INCORPORATION OF TRITIUM LABELLED PYRIMIDINES 
INTO THE RNA FRACTION OF TISSUES OF NORMAL RATS
Tissue
Incorporation into the tissue RNA fraction
Orotic Acid
nmol/g wet wt 
4(xlO )
Uridine
nmol/g wet wt 
4(xlO )
Uracil
nmol/g wet wt 
4(xlO )
Heart 2.09 33.16 1.86
Brain 1.19 48.54 1.33
Spleen 8.23 - -
Liver 595.21 20.13 2.93
Kidney 2513.73 267.17 -
The treatment of the animals and assay of the incorporation 
of pyrimidines were as described in the experimental section. 
Rats were killed 2 hours after receiving i.p. injections of 
the pyrimidines (2 yci/g body wt).
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TABLE 5.7
INFLUENCE OF OROTIC ACID AND URIDINE 
ON ENZYMES OF THE HEPATIC DE NOVO PYRIMIDINE PATHWAY
Normal
Diet
Normal 
Diet Plus 
Uridine
Normal 
Diet Plus 
Orotic Acid
ADC ase 455 ± 131 549 ± 49 675 ± 96
0.10 < p < 0.15 0.01 < p < 0.025
ODC ase 66.9 ± 20.1 70.3 ± 12.3 100.4 ± 9.1
0.30 < p < 0.35 p < 0.005
Assay of the maximum catalytic activity of the hepatic 
enzymes of the pyrimidine pathway de novo was carried out 
as described in experimental section. Enzyme activities 
are expressed as nmol of substrate converted/min/g wet wt. 
Each value is expressed as the mean ± S.D. of determina­
tions from 5 animals. The significance of the results, 
expressed as p values, is given in the table.
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CHAPTER 6
OROTIC ACID AND THE PROBLEM OF VASCULARITY 
IN MYOCARDIAL HYPERTROPHY
6.1 Introduction
Over and above any chemical and pharmacological 
considerations of the safety of any given supply of orotic 
acid for use in clinical medicine, there remains the 
problem of whether the stimulation of hypertrophy, induced 
by orotic acid (see Chapter 3), may allow the overgrowth 
of the heart to outstrip the microvasculature of the organ 
and thus predispose the tissue to an episode of myocardial 
ischemia.
The present chapter reports the result of investi­
gations into whether hypertrophy, stimulated by orotic acid, 
takes place at the relative expense of the existing cardiac 
microcirculation, i.e. are the demands of hypertrophy likely 
to expose a deficiency of diseased microcirculation to open 
anastomotic channels or increase its overall perfusion rate 
to maintain the processes of hypertrophy? The vascular bed 
density is one of the most important factors determining 
the tissue oxygen tension. Rakusan et al. (1967) quotes an
estimate that an increase of 70% in the intercapillary dis­
tance results in a decrease of tissue oxygen tension below 
a critical level, if it is not compensated for by an increase
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in the efficiency of oxygen extraction by the tissues. 
Myocardial oxygen extraction ranges from 70-75% (greater 
than that of any other organ), is constant over a wide 
range of arterial oxygen saturations and does not change 
with exercise, anaemia or hypoxia (Messer et al., 1962). 
Case et al. (1955) have demonstrated that, when the reserve
coronary blood flow was limited by experimental coronary 
artery constriction, increased myocardial oxygen extraction 
was a limited but significant factor. The ability of the 
heart to compensate for increases in the intercapillary 
distance by a decrease in oxygen consumption or an increase 
in the efficiency of oxygen extraction by the tissues 
appears to be functionally limited.
During normal growth of the rabbit heart (Shipley 
et al., 1937) or of the human heart (Linzback, 1960;
Roberts and Wearn, 1941) capillary growth has been found 
to occur in proportion to the increase in muscle size, 
resulting in a constant density of capillaries per square 
millimetre of muscle tissue. In cardiac enlargement pro­
duced in the new born rat by anaemia (Poupa et al., 1964; 
Rakusan et al., 1967) or aortic constriction (Shipley et 
al., 1937; Rakusan et al., 1967), both capillaries and 
muscle cells have been found to proliferate in proportion, 
with no change in capillary density per unit weight of 
tissue. By contrast, a diminished capillary density was 
observed in cardiac hypertrophy in older animals (Rakusan
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et al. , 1967). In the hypertrophied human heart, a decrease 
in the capillary density was observed (Roberts and Wearn,
1941; Hort, 1955; Linzback, 1960).
An answer to the problem of vascularity was 
sought from an analysis of, (a) the incidence of coronary 
artery disease and microcirculatory derangement, and (b) 
a comparative quantitation of the incidence of microcircu- 
latory anastomoses, in groups of animals with hypertrophied 
hearts which were treated with orotic acid.
The previous chapters in this thesis have been 
concerned with the effects, and the mechanism of action, 
of orotic acid as a support for the hypertrophying myocardium. 
However, before orotic acid could be considered "safe" for 
use in states were there was a stress placed upon the heart 
for a greater output (for example, hypertension) or where 
there was a need for surviving muscle to carry a greater 
work load (for example, post myocardial infarction), it was 
necessary to investigate whether the rate of stimulated 
hypertrophy, due to orotic acid, takes place at the relative 
expense of the existing cardiac microcirculation. In order 
to gather information on this question the capacity of the 
cardiac vascular bed was determined in a number of disease 
states. In the experiments described in this chapter, the 
functional capacity of the hearts was placed in jeopardy by 
rendering the hearts susceptible to coronary artery disease 
(due to an atherogenic diet), by inducing cardiac hypertrophy
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and by inducing the heart to hypertrophy (due to aortic 
stenosis) under conditions of coronary artery disease.
It was hoped that by examining the functional capacity of 
the vascular bed under the array of disease states des­
cribed above, a definitive answer on the effect of orotic 
acid enhanced growth on the cardiac vasculature could be 
obtained.
In view of the many reports in the literature of 
the effects of orotic acid feeding on the metabolism of 
lipids and the effects of orotic acid on the serum and 
tissue lipid concentrations of rabbits fed a high choles­
terol diet (that is, an atherogenic diet), we were drawn 
into an investigation of the effects of orotic acid on the 
overall lipid metabolism of the rabbit. Windmueller and 
Levy (1967) showed that the administration of orotic acid 
to rats was followed by a marked reduction in hepatic 
ß-lipoprotein synthesis (or release), a marked decrease 
in plasma ß-lipoprotein concentration and a decreased 
release of triglycerides from the liver. The administration 
of orotic acid has been shown to cause liver steatosis in 
the rat (Standerfer and Handler, 1955 and Creasey et al., 
1961). Kelley et al., 1970 have shown that orotic acid 
administration to patients resulted in only a slight 
decrease in plasma concentration of cholesterol, triglycer­
ides, ß-lipoproteins and pre ß-lipoproteins. In addition, 
there was no evidence in this study of hepatic dysfunction 
in any of the patients following orotic acid administration.
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Simon (1968) has emphasised the effectiveness of the orotates 
as electrolyte carriers and the importance of magnesium ions 
to activate the cholesterol-esterases and mobilize the 
vessel wall deposits. Thus, the present chapter also deals 
with the changes in the lipid and electrolyte concentrations 
as a result of feeding orotic acid to animals which had been 
rendered susceptible to coronary artery disease.
The administration of orotic acid to the mouse, 
chick and monkey (Valli et al., 1968) has not been accompanied 
by the development of steatosis of the liver, suggesting 
that the differences noted may be related to species variation. 
A schematic representation of the normal uptake, transport, 
secretion and storage of lipids by hepatocytes and of the 
changes induced by orotic acid, are shown in Fig. 6.1. There 
is general agreement on the following sequence of events in 
the normal rat hepatocyte (Glaumann et al., 1975; Hamilton, 
1967; Jones et al., 1967; Mahley et al., 1969; Redman and 
Cherian, 1972; Stein and Stein, 1967). Lipid enters the 
cell at the Space of Disse in the form of free fatty acids 
and glycerol which traverse the plasma membrane of the endo­
plasmic reticulum, and are converted to form triglycerides 
and other lipids. Lipid is transformed into very low density 
lipoproteins by the addition of proteins and carbohydrate 
moieties, probably in the smooth endoplasmic reticulum as 
well as in the Golgi apparatus. VLDL particles are then 
packaged into vacuoles, which then detach and, by exocytosis, 
are secreted into the Space of Disse.
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Morphologically, orotic acid induced liver 
steatosis is unique (Novikoff et al., 1966). Lipid drop­
lets are found throughout the cytoplasm of hepatocytes in 
the entire lobule. The endoplasmic reticulum forms 
vesicles within which one or more droplets are present 
and lipid transport to the Golgi apparatus is interrupted. 
The Golgi elements are flat and lack VLDL (Novikoff et al. , 
1974) .
6.2 Experimental
6.2.1 Animals
The action of orotic acid on hyperlipaemia and 
lipid metabolism in the rabbit was studied in several series 
of rabbit experiments. Because of limited animal holding 
space the series were performed on separate occasions 
throughout the year, but at all times control rabbits, being 
fed either cholesterol or cholesterol and orotic acid, were 
maintained in the colony.
The rabbits were obtained from the Animal Breeding 
Establishment of the Australian National University. The 
rabbits were of a semi-lop strain which had been developed 
by random outbreeding from a nucleus of New Zealand white 
rabbits with the induction of full-lop, wild and Californian 
strains. In all cases male rabbits were used. The initial 
weight and age of the animals was 2-2.5 kg and 3 months
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respectively. Before starting the series, the animals 
were kept for at least two weeks to accommodate themselves 
to the experimental conditions.
Plasma cholesterol was determined before the 
start of the experiments and the rabbits were divided into 
groups with similar initial mean levels of plasma choles­
terol (Section 6.2.7). It is well known that there is a 
variation in the sensitivity to cholesterol feeding between 
different animals (Kritchevsky, 1964) and this variation is 
greatest on a medium concentration of dietary cholesterol.
A minimum number of 10 rabbits in each of the 
following groups were to be studied:
(1) normal rabbits (control)
(2) normal rabbits fed orotic acid
(3) rabbits with aortic stenosis (hypertension)
(4) rabbits with aortic stenosis and fed orotic acid
(5) rabbits fed cholesterol
(6) rabbits fed cholesterol and orotic acid
(7) rabbits with aortic stenosis and fed cholesterol
(8) rabbits with aortic stenosis and fed cholesterol
and orotic acid
The appropriate groups of rabbits were placed on a 
cholesterol diet (rabbits were fed exactly 100 g of rabbit 
pellets per day which were 0.9% with respect to cholesterol) 
for 6-8 weeks prior to further treatment and the appropriate
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diets were maintained therafter until the end of the 
experiments (14 weeks).
The animals were observed carefully with regard 
to their general condition and daily food consumption, 
their body weights were checked regularly and their food 
consumption was calculated by weighing the food left 
before the next feeding.
The serum and tissue lipid concentrations of 
those rabbits fed both cholesterol and orotic acid were 
found to be markedly elevated compared with those animals 
fed a diet supplemented with cholesterol only (Section 6.3.1). 
Following a period of 8 weeks on this orotic acid and 
cholesterol supplemented diet, the animals were found to be 
in a poor state of health and were unable to survive the 
surgical procedure required to constrict the abdominal aorta. 
The experimental protocol was therefore amended and the 
experimental groups, (8) (rabbits with aortic stenosis fed 
both cholesterol and orotic acid), together with its control 
group (7) (rabbits with aortic stenosis fed cholesterol), 
were deleted from the protocol.
6.2.2 Preparation of the Test Foods
The test foods were prepared by thoroughly mixing 
the additives (cholesterol and orotic acid) into the diets. 
The feed was compounded and supplied in mash form by Bunge
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Australia, Pty Ltd, Murrumburrah, N.S.W.. Cholesterol 
and other additives were uniformly mixed with the diets 
using a cement mixer, and pellets (1/2" long) were pre­
pared with a Templewood Jr pelleting machine fitted with 
a 5/32" die (Provender Lister Blackstone Pty Ltd, Revesby, 
N.S.W.). Commercial grade cholesterol was supplied by 
Ajax Chemicals Ltd, Sydney, and was used in the diets at 
a concentration of 0.9% w/w, corrected for impurities 
(Section 6.2.9) .
The test diets were prepared in lots sufficient 
to last for 3 months and were kept at 4°C until shortly 
before use.
6.2.3 Induction of Aortic Stenosis in Rabbits
After the animals had been fed an appropriate 
ration for 2 months, the hearts of the rabbits in groups 
(3) and (4) (see Section 5.2.1) were induced to hypertrophy 
by producing aortic stenosis.
Forty minutes prior to anaesthesia, the rabbits 
were given a pre-operative medication containing an analgesic 
(0.6 mg/kg omnopon (papaveretum)) and an antemetic agent 
(13 yg/kg scopolamine hydrobromide (hyoscine)) (Roche 
Products Pty Ltd, England), made to 0.2 ml in saline (0.9% 
w/v) and this volume injected intramuscularly into the 
biceps femoris. Anaesthesia was induced with Pentothal
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(2.5% w/v, sodium thiopental, Abbott Laboratories Pty Ltd, 
Australia). The pentothal was administered by way of the 
distal end of the ear vein, in doses of 5.0 mg and at 
intervals of 30-60 seconds in order to achieve the desired 
level of anaesthesia (Stage 3, plane 2 as defined by Lumb 
and Jones, 1973) with a minimum of respiratory depression. 
Inter-rabbit variability was so great that the dose 
required for surgical anaesthesia had to be individualized. 
Anaesthesia was then maintained using Fluothane (Halothane, 
ICI Pty Ltd, Australia) in conjunction with a Stephens 
Drawover Anaesthetic Machine (Australian Anaesthetic 
Equipment Co. Pty Ltd, Australia). To avoid an excessively 
high inspired halothane tension, oxygen was used as. a 
vehicle for the halothane, and the rabbits were allowed 
to breathe spontaneously. The halothane/oxygen mixture 
was administered at a flow rate of 30 mis oxygen/min/kg 
body weight, through a rubber anaesthetic mask. During 
the operation, the supine animals were warmed on a tempera­
ture-controlled (37°C) stainless steel table.
Aseptic precautions were observed throughout the 
operations described. The aorta was exposed via a midline 
abdominal incision, 6-7 cm long. The parietal peritoneum 
was reflected from the aorta, caudal to the diaphragm.
A 3 metric (2/0 B.P.C.) black silk suture (Ethicon) was 
placed about the aorta cephalad to the origin of the aorta 
suprarenal artery. A rod of rounded metal (2.0 mm in 
external diameter and 3.0 cm in length) was placed adjacent
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to the aorta, and both the aorta and piece of metal were 
encircled by the suture (see Fig. 3.1). This was then 
firmly tied and the metal withdrawn. The abdominal wall 
was closed with interrupted catgut sutures (3 metric, 2/0 
B.P.C.). The subcutis and skin were then individually 
closed with interrupted 3 metric black silk sutures. The 
wound was liberally dusted with cicatrin antibiotic powder 
(Calmic Pharmaceuticals Pty Ltd, Australia) and the animal 
was kept warm for the following 24 hours.
6.2.4 Surgical Procedure and Perfusion Technique
Rabbits were heparinised (2,500 units) 30 minutes 
prior to the killing of the animal. After 30 minutes, the 
rabbits were given an intravenous anaesthetic dose of 
Nembutal (40 mg/kg body weight). They were killed by 
cutting across the neck, both carotid arteries and jugular 
veins being opened to allow exsanguination.
As soon as the animal was dead, the chest cavity 
was exposed by cutting the diaphram away from the body wall 
and removing the rib cage. The pericardium was removed 
and the ascending aorta exposed. A cannula (a blunted 13 
gauge needle) was inserted into the aorta, tied securely 
in place, and the heart continuously perfused with Krebs- 
Henseleit bicarbonate buffer, pH 7.4 (Krebs and Henseleit, 
1932) at the rate of 3.75 ml per minute. The heart was 
then removed by cutting across the pulmonary
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veins as they insert into the atria, cutting the superior 
and inferior vena cava where they insert and finally 
cutting the pulmonary trunk as it branches into the left 
and right pulmonary arteries. The heart was now held 
only by the aorta and this was cut distal to the insertion 
of the cannula. The heart was then lifted out via the 
cannula and placed in a bowl of Krebs-Henseleit buffer, 
pH 7.4 at 45°C while still being perfused. The heart was 
perfused with a minimum of 50 ml of buffer, until the 
heart became very pale in color and bloodless. The heart 
was then perfused, at an exact rate of 2.0 ml/min, with 
about 40 ml of a Prussian blue preparation (see below), 
using a Unita I syringe pump (B. Braun Melsungen AG, West 
Germany) fitted with a 50 ml glass syringe. Perfusion was 
continued until the vessels were well demarcated. The 
Prussian blue preparation was maintained at 60°C until 
immediately before use, in order that it would not become 
too viscous or gel during the vessel staining procedure.
The syringe pump was then stopped, the cannula 
removed and the aorta securely tied. The heart was then 
held by the cotton used to tie the aorta and it was suspended 
in at least 200 ml of cold buffered formalin (10%).
The Prussian blue perfusion medium consisted of 
equal portions of a suspension of Prussian blue (Ferric- 
ferrocyanide) stock solution and gelatin solution (10% solution 
w/v). This perfusion medium was mixed immediately before use 
and was maintained at 60°C to hold the gelatin as a solution.
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The Prussian blue suspension was prepared by 
mixing equal volumes of solutions of ferric chloride (2% 
w/v) and potassium ferrocyanide (2% w/v). The insoluble 
precipitate of dense blue Prussian blue was then washed 
three times in distilled water. A final suspension in 0.85% 
saline was carried out and the precipitate, after decantation 
of the supernatant, was used as a stock solution.
6.2.5 Measurement of Vascular Changes in the 
Rabbit Heart
After fixation in 10% buffered formaldehyde (ph 7.4), 
the hearts were immersed in glycerol for at least 10 days.
This rendered the tissues sufficiently translucent to allow 
the coronary arteries, outlined by the solidified Prussian 
blue/gelatin mixture, to be traced. Excess pericardial adipose 
tissue was dissected from the base of the heart and the atria 
and auricles were excised to ensure optimum visualisation of 
the origins of both left and right coronary arteries. The dis­
tributions of the vessels were then mapped by means of a Zeiss 
stereodissecting microscope. Measurements of the luminal 
diameters of selected vessels were made by means of a gradicle, 
incorporated in the optics of the microscope and calibrated to 
a preselected standard magnification against the graduations of 
a Neubauer red cell counting chamber (haemocytometer). In each 
selected vascular segment, internal diameters were measured in 
three planes to determine the mean diameter of the vessel. The
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mid-segment of the ultimate segment of the left anterior 
descending coronary artery, together with the mid-segment 
diameters of the first three divisions of the dominant 
terminal branch of this vessel were measured. In all but 
two hearts, the right terminal division had the greater 
dimensions and a more consistent distribution and was 
therefore selected for measurement (Fig. 6.2).
The number of patent branches arising from the 
left anterior descending coronary artery and supplying 
only the left ventricle was also determined. The final 
parameter of cardiac vascularity examined was the close­
ness of apposition of the left and right coronary terminal 
arteriolar circulations at the apex of the heart. This 
was determined on an arbitrary scale of 1-3 units (1 dis­
tant, 2 moderately close, and 3 close) and the mean value 
for each group of hearts examined was determined.
The mean septum thickness was also determined.
The heart was bisected by a transverse cut at right angles 
to the longitudinal plane of the septum (Fig. 6.2). The 
mean septum thickness was then determined by measuring the 
minimum width of the septum at three positions in the mid­
segment of the septum (Fig. 6.3).
6.2.6 Determination of the Plasma Free Fatty 
Acid Concentration
The Ni method of Ho (1970) was used for the 
determination of the plasma long chain free fatty acid (FFA)
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concentrations. The volumes of reagents used in the 
original method were increased four fold to make sample 
handling more manageable. Plasma samples of 40 PI were 
used. Samples of authentic palmitic acid (10-250 nmol) 
were used as standards, and were passed through the entire 
extraction procedure. The final extracts from standards 
and plasma samples were dissolved in 10 mis of 0.4% (w/v)
2,5-diphenyl-oxazole (PPO), 0.04% (w/v) p-bis [2-(5-phenyl- 
oxazolyl)] benzene (POPOP) in toluene: Triton x 100
(2:1 v/v), and the radioactivity determined by liquid 
scintillation counting (Beckman LS-350).
6.2.7 Determination of Some Important Serum 
and Plasma Constituents
+ + 2 +The serum concentrations of Na , K , Ca and
2+Mg were determined with a Varian Techtron Atomic Absorption 
Spectrophotometer model 1200, using the methods described by 
Varian Techtron in their book "Analytical Methods for Flame 
Spectroscopy".
The method of Sommers et al. (1975) was employed
for the routine determination of the cholesterol content of 
serum. Serum triglyceride levels were determined by the 
method of Biggs et al. (1975). The serum uric acid level
was determined by the method of Carroll et al. (1971) and
the serum urea levels by the diacetylmonoxime-antipyrine 
method of Ceriotti (1971).
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The protein concentrations of serum samples were 
determined by the method of Lowry et al. (1951) . The
method of Doumas et al. (1971) was used for the determina­
tion of albumin. In both cases, bovine serum albumin 
(fraction V (corrected for moisture content) was used as 
a standard. The moisture content of the bovine serum albu­
min was determined by the method of Hunter (1966) . The 
serum concentrations of chloride, iron, inorganic phosphorus, 
total CC>2' glue030/ creatinine, bilirubin and serum lactate 
dehydrogenase (E.C. 1.1.1.27.), aspartate aminotransferase 
(E.C. 2.6.1.1.) alkaline phosphatase (E.C. 3.1.3.1.) and 
alanine aminotransferase (E.C. 2.6.1.2.) activities were 
measured using the Technicon SMAC System of the Biochemistry 
Department, Canberra Hospital.
6.2.8 Determination of Tissue Total Lipid, 
Cholesterol and Triglyceride Contents
Samples of liver (approx. 2 g wet weight) and of 
the intima of the aortic arch (approx. 30 mg dry, defatted 
weight), which had been removed from the nembutal anaesthe­
tised rabbits, were, individually, homogenised in 17 volumes 
of chloroform/methanol (2:1 v/v), using an all-glass Potter- 
Elvehjem homogeniser. The homogenate of the aorta was 
allowed to stand overnight before centrifugation, and the 
liver homogenate was centrifuged immediately (2,750 g,
5 minutes). The supernatant fluid obtained after centri­
fugation of each homogenate was treated by the method of
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Folch et al. (1957) to yield the total lipid extract.
Nonlipids were removed from the filtrate obtained by the 
Folch extraction, by passing the filtrate through a 
Sephadex G-25 column (1 x 10 cm for the lipid extract 
from liver and 0.6 x 6 cm for the lipid extract from the 
aorta), as described by Wuthier (1966). The lipid extract 
was evaporated to dryness using a rotary evaporator and 
weighed. The total lipid extract was dissolved in isopro­
panol and the triglycride and total cholesterol contents 
of the lipid extract determined (Section 6.2.7).
6.2.9 Determination of Total Cholesterol in Feed
A sample of rabbit feed (5 g) was heated under 
reflux, with 130 ml of 0.77 N KOH in 77% (v/v) aqueous
ethanol for 2 hours. After cooling, the mixture was shaken, 
first with 50 ml of petroleum ether (60-80°C) and then with 
40 ml water. After a suitable dilution, the cholesterol 
concentration of the petroleum ether phase was measured 
(Section 6.2.7) .
6.2.10 Determination of Ascorbic Acid in Blood 
and Tissues
The dinitrophenylhydrazine method of Roe (1954) 
was used for the determination of the ascorbic acid levels 
in whole blood and tissue samples, the samples having been 
deproteinised with a 5% (w/v) trichloroacetic acid solution.
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6.2.11 Distribution of Serum Lipoproteins
The distribution of lipoproteins in the serum 
of groups (1), (2), (5) and (6) (see Section 6.2.1) was
studied using gel electrophoresis.
The pre-staining solution was prepared as follows: 
ethylene glycol (25 ml) was heated to 100°C and Sudan black 
(100 mg) was added. The solution was kept at 60°C for one 
hour and filtered through a Whatman number one filter paper.
Fifty yl of fresh serum was added to 50 yl of the 
pre-staining solution in an Eppendorf centrifuge tube. The 
mixture was shaken, incubated at 37°C for 30 minutes and 
centrifuged for 2 minutes in an Eppendorf model 3200 
Centrifuge to remove excess dye.
The distribution of lipoproteins in the serum was 
studied after separation of 15 yl of pre-stained serum on 
polyacrylamide gel (Wollenweber and Kahlke, 1970). The 
gels were run at 5 mA/tube for 50 minutes and the intensity 
of the gel bands immediately measured by densitometry (at 
623 nm), using a Varian Techtron spectrophotometer model 635, 
fitted with a gel scanner accessory. The nomenclature 
"a-", "3-" and "pre-3-" bands was used for the main rabbit 
lipoprotein bands, as the electrophoretic mobilities of 
these bands corresponded to the mobilities of the human a-,
3- and pre-3- bands on the medium used.
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6.3 Results
6.3.1 The Effect of Orotic Acid on Some
Important Serum Components and Tissue 
Lipids in Rabbits
Various publications have described the liver 
steatosis and serum lipid alterations produced in rats by 
feeding orotic acid (Creasey et al., 1961; Novikoff et 
al., 1966). Other publications (Andrus et al., 1964;
Kruski and Narayan, 1976) indicated that the administration 
of orotic acid to animals receiving a high cholesterol diet 
had no consistent effect on serum cholesterol concentrations. 
In this section, the effects of the administration of a high 
cholesterol diet, supplemented with orotic acid, on some 
important serum components are reported.
As shown in Table 6.2, the addition of cholesterol 
(0.9% w/w of diet) to the basal diet of the rabbit resulted 
in a moderate increase in the serum cholesterol and tri­
glyceride levels. When the diet was augmented with both 
cholesterol (0.9% w/w of diet) and orotic acid (0.02% w/w 
of diet) , there was a 7.14 fold increase in the serum 
cholesterol concentrations and a 2.96 fold increase in the 
serum triglyceride levels when compared with the serum 
levels of those rabbits whose diet was supplemented with 
cholesterol alone (Table 6.2, Figs 6.5 and 6.6). In con­
trast, normal serum concentrations of free fatty acids were
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found in those animals fed orotic acid, cholesterol or 
cholesterol and orotic acid supplemented diets. There 
were no significant changes in the levels of urea, uric 
acid, total protein, albumin, bilirubin and carbon dioxide 
in the serum of the various groups of rabbits studied 
(Table 6.4). [Although there was a statistically signi­
ficant increase in the serum urea of animals treated with 
orotic acid compared with normal animals (p < 0.05), the 
urea concentrations were still within the normal range 
of values observed for rabbit serum.] Nor were there any 
alterations in the levels of serum electrolytes (calcium, 
magnesium, iron, sodium, potassium, chloride and inorganic 
phosphorus) (Table 6.1).
Consistent with changes in the serum, the 
addition of cholesterol to the basal diet resulted in a 
moderate increase in the total cholesterol concentration 
in the liver and the intima of the aortic arch (Table 6.5). 
Levels were further elevated by the addition of both 
orotic acid and cholesterol to the basal diet (Table 6.5). 
(The total cholesterol concentrations were 23.1 ± 4.6 g/kg 
wet wt and 3.2 ± 1.6 g/kg wet wt in the livers of choles­
terol and orotic acid treated and cholesterol treated 
animals respectively. The total cholesterol concentrations 
in the intima of the aortic arch were 16.9 ± 4.8 and 
105.0 ± 14.3 mg cholesterol/g defatted wt in the cholesterol 
treated and cholesterol and orotic acid treated animals 
respectively.)
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Diet also altered the distribution of the serum 
lipoproteins (Table 6.6). The concentrations of low 
density lipoproteins (LDL) and very low density lipoprotein 
(VLDL) were measured together (LDL has 3 mobility in both 
normal and hypercholesterolemic rabbits but VLDL has pre~3 
mobility in normal rabbits and 3 mobility in the hyper- 
cholesterolemic rabbit, Eisenberg and Levy, 1975). The 
predominant lipoprotein in normal rabbit serum was high 
density lipoprotein (HDL) with a mobility (Table 6.6). In 
the cholesterol fed rabbits, there was an 8.3 fold increase 
in the serum concentration of VLDL and LDL compared with 
the serum of normal rabbits. In the cholesterol and orotic 
acid treated animals there was only a 4.0 fold increase in 
the serum concentration of VLDL and LDL, compared with 
normal animals, despite a 47 fold increase (Table 6.2) in 
the serum cholesterol (compared with normal animals).
Although supplementing the basal diet of normal 
rabbits with orotic acid caused a decrease in the serum 
triglyceride level, the administration of orotic acid to 
rabbits with hypertrophied hearts (due to either a high 
cholesterol diet or constriction of the abdominal aorta) 
resulted in hypertriglyceridaemia (Table 6.2). Orotic acid 
also reduced the blood glucose level in the latter groups, 
though no change was observed when the diet of normal 
animals was supplemented with orotic acid (Table 6.4). 
Therefore, the changes in the serum glucose concentration 
in rabbits with hypertrophied hearts would not appear to be
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due to increased tissue glycogen synthesis associated 
with orotic acid feeding (Table 4.3). The changes in 
serum triglyceride and glucose concentrations may be 
associated with an increased serum insulin concentration, 
though this was not observed in orotic acid treated rats 
with hypertrophied hearts (Section 4.3). Elevated insulin 
levels have been reported in association with hypertri- 
glyceridaemia and a correlation between insulin levels and 
triglyceride levels has been reported (Bierman et al.,
1970). The roles of insulin in triglyceride metabolism 
are complex and somewhat contradictory. Insulin may 
directly stimulate triglyceride production in the liver 
(Tzagournis et al., 1968), however, by blocking the release 
of triglycerides from the liver (Windmueller and Levy, 1967), 
orotic acid would oppose this effect. Presumably, the 
triglycerides in the serum of orotic acid fed animals was 
derived from the intestinal cells. Mahler and Parkes (1970) 
reported that insulin stimulated lipogenesis in pig aortic 
intimal cells (the pig is a good model of atherosclerosis, 
the condition closely approximates that of the human,
Clarkson 1972) and thus increased serum insulin concentra­
tions may contribute to the increased lipid infiltration 
of the aorta in orotic acid treated rabbits fed a high 
cholesterol diet (Table 6.5 and Fig. 6.4).
Summarised in Table 6.3, are the effects of 
feeding rabbits cholesterol and/or orotic acid on the
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activities of the serum enzymes lactate dehydrogenase 
(LDH), alanine aminotransferase (ALT), aspartate aminotrans­
ferase (AST) and alkaline phosphatase (AP). AP activity 
was found to remain within the normal range in all the 
groups of rabbits studied. ALT, AST and LDH activities 
increased pari passu with the development of hepatic 
steatosis. The serum enzyme changes are typical of the 
patterns seen in all forms of fatty liver in the absence 
of hepatitus (Schmidt and Schmidt, 1974) (the total concen­
trations of liver lipids were 39.4 ± 2.7 and 81.1 ± 3.5 
g/kg wet wt in the cholesterol and cholesterol and orotic 
acid treated animals respectively).
6.3.2 The Effect of Orotic Acid on the Cardiac 
Vascular System of the Rabbit
The use of hearts of different sizes, as a result 
of hypertrophy, created difficulties when a size criterion 
was used for a comparison of the various branches of the 
coronary artery. Hort (1977) has reported that there was 
a close correlation between the diameter of the coronary 
arteries and the diameter of the heart. Assuming that the 
heart was approximately a sphere and that the cardiac weight 
was proportional to the volume, then the diameter of the 
heart should be proportional to the cube root of the heart 
weight. All measurements of the mean diameters of the 
various segments of the left anterior descending coronary
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artery were therefore expressed as the diameter (mm)/cube 
root of the heart weight (g).
Both the mean septum thickness and the heart 
weights were used as a measure of the hypertrophic response. 
As shown in Table 6.9, there was a significant increase in 
the mean septum thickness/cube root of the heart weight in 
those rabbits fed a cholesterol supplemented diet and in 
those rabbits with experimental aortic stenosis. An increase 
in the mean septum thickness was also observed in the hyper­
trophied hearts of rabbits treated with orotic acid, though 
this was not significantly different from either the mean 
septum thickness of either normal or untreated, hypertrophied 
hearts.
In order to investigate the vascularity of the 
heart, under the various conditions described in the 
experimental section, the diameters of segments of the left 
anterior descending coronary artery at the apex of the heart 
were measured. The apex of the heart was chosen, as indi­
cated above, because it is the left ventricular segment 
which is most susceptible to a deficiency of perfusion in 
states of coronary insufficiency and this could be expected 
to be the most likely area in which stress induced vascular 
anastomoses might necessarily develop. The mean diameter 
of the mid-portion of the terminal segment (as defined in 
the experimental section) of the left anterior descending
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coronary artery/cube root of the heart weight was not 
significantly different from normal hearts in the hearts 
of those animals fed cholesterol or cholesterol and orotic 
acid. Nor was this parameter significantly different in 
the hypertrophied hearts, both treated and untreated 
with orotic acid, compared with normal hearts. This 
parameter was, however, significantly greater in the 
orotic acid treated hypertrophied hearts compared with 
the untreated hypertrophied hearts (p < 0.05, Table 6.9).
This latter result suggests that the local coronary 
arteries have acquired a greater perfusion capacity when 
hypertrophy occurred in the presence of orotic acid 
administration. This pattern of increased coronary 
diameter in the orotic acid treated hearts was more pro­
nounced when the mean diameters of the first, second and 
third divisions of the dominant terminal branch of the 
left anterior descending coronary artery (as defined in 
the experimental section) were measured and expressed 
as a fraction of the cube root of the heart weight.
Table 6.9 shows that there was a significant decrease 
in the mean diameters of the first and third segments 
of the dominant terminal branch in those hypertrophied 
hearts not treated with orotic acid, compared with normal 
animals. The mean diameters of the first, second and third 
segments of the dominant terminal branch of the left anterior
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descending coronary artery of those hypertrophied hearts 
treated with orotic acid were all greater than the corres­
ponding values in the normal heart, though not signifi­
cantly greater than in the normal heart. Thus, in the 
orotic acid treated, hypertrophied hearts, unlike the un­
treated hypertrophied hearts, there was a close correlation 
between the diameter of the coronary arteries and the growth 
of the myocardium. In those hypertrophied hearts not 
treated with orotic acid, the growth of the coronary 
arteries was slower than the growth of the myocardium.
Two other parameters of vascularity which were 
also examined were the number of patent branches of the 
left anterior descending coronary artery and the closeness 
of apposition of the left and right coronary arteries at 
the apex of the heart. Table 6.9 shows the number of 
patent branches of the left anterior descending coronary 
artery and indicates that there was no significant increase 
in the number of perfused branches of the artery in the 
cholesterol, orotic acid, and orotic acid and cholesterol 
treated hearts and in the untreated hypertrophied hearts. 
There was, however, a significant increase in the number 
of branches, and hence the vascularity, in the orotic acid 
treated, hypertrophied hearts compared with normal hearts. 
The closeness of apposition of the left and right coronary 
arteries at the apex of the heart was measured on an 
arbitrary scale (1 distant, 2 moderately close, and 
3 close). Because the minimum particulate size of the
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Prussian blue suspension was 10 ym, the smallest vessel 
delineated was the metarteriole and perhaps the precapillary. 
Thus the measurements recorded as "closeness of apposition" 
were an index of the capacity of the metarteriolar bed or 
alternatively an index of the potential perfusion of the 
capillary bed. On this scale orotic acid had no significant 
effect on the vascularity of hypertrophied hearts.
Thus, irrespective of whether vascularity was 
measured by the diameter of the coronary arteries or by 
the number of branches of the coronary artery, those hyper­
trophied hearts treated with orotic acid possessed a vascu­
lar system commensurate with the size of the heart. Those 
hypertrophied hearts not treated with orotic acid possessed 
a decreased vascularity indicating that the rate of growth of 
the coronary vascular capacity lagged behind the rate of growth 
of the heart. In the cholesterol treated and the cholesterol 
and orotic acid treated hearts, the cardiac vascularity was 
not significantly different from that of normal animals.
Finally, a problem associated with these experi­
ments that should be mentioned is that the size and shape 
of the heart is altered by rigor mortis, the degree of which 
will be influenced by the post perfusion interval and the 
environment. Thus, although it is impossible to determine 
the exact diameters of the vessels examined, the hearts 
were perfused at a constant rate and under conditions of 
constant temperature. Immediately the perfusion was com­
pleted, the hearts were immersed in formalin solution (4°C).
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The diameter of the vessels measured was therefore the 
"minimum cold capacity" of the vessels and as such enabled 
comparisons among the various groups of hearts to be 
carried out. Although the techniques used in these experi­
ments yield an accurate estimate of the development of the 
coronary arterial circulation, the techniques are suitable 
only for the measurement of the larger coronary vessels 
and are limited by the variability of the coronary circu­
lation. Recent advances involving the quantitation of 
microscopic features in histopathology, using automated 
image analysis systems (for example, the Quantimet system) 
would be ideally suited to a full investigation of the 
coronary circulation and it is to be hoped that experiments 
such as these reported here would be performed with such 
equipment.
6.4 Discussion
6.4.1 Possible Explanations of the Effects of
Orotic Acid on the Serum and Tissue Levels 
of Cholesterol in the Rabbit
Animal models have been used in the study of 
atherosclerosis as atherosclerosis may be produced in a com­
paratively short time, dietary and environmental factors may 
be controlled and the preclinical testing of various drugs 
for the prevention, reduction or reversal of atherosclerosis 
may be carried out. The main advantage of the rabbit in such
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studies has been the rapidity with which the animal becomes 
hypercholesterolemic, and its vasculature atherosclerotic 
when fed a cholesterol-supplemented diet. Support for the 
use of the rabbit as a model of atherosclerosis has appeared 
recently when it was reported that the animal employs the 
same mechanism for lipid transport into atherosclerotic 
plaques as man (Walton, 1973) .
The experiments described in this chapter were 
designed to investigate the effects of orotic acid on the 
vasculature of normal and diseased rabbit hearts. Cardiac 
competence was stressed by inducing hypertrophy (by con­
striction of the abdominal aorta) and by making the animal 
hypercholesterolemic and hence atherosclerotic.
Though Windmueller and Levy (1967) showed that the 
administration of orotic acid to rats produced hepatic steato­
sis, no such effect could be demonstrated in the mouse, 
chick or monkey (Valli et al., 1968). Kelley et al. (1970)
reported finding no evidence of hepatic dysfunction when 
orotic acid was administered to man. Because hepatic 
steatosis, subsequent to the feeding of orotic acid, appeared 
to occur only in the rat, and since many reports on the 
effects of a moderate cholesterol diet on the rabbit were 
available, it was decided to use the rabbit as the experi­
mental model in these studies.
Though the effects of orotic acid on the serum 
cholesterol levels of the rabbit were quite unexpected, in
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retrospect, several explanations are possible. The serum 
level of cholesterol is determined by, and in order of 
probable importance (Oliver, 1976) :
(a) the amount of cholesterol being synthesised
by the body;
(b) the rate of its catabolism and excretion
in the bile;
(c) the cholesterol equilibrium between plasma
and the tissues;
(d) the amount absorbed by the gut, in
accordance with dietary intake.
The absorption of cholesterol takes place in the 
small intestine, probably in the jejunum, being facilitated 
by bile acids, esterifying enzymes and the high fat content 
of the intestine. The absorbed fats are transferred from 
the enterocytes to the lymphatics in the form of chylomicrons 
(fat globules containing triglycerides, cholesterol, phospho­
lipids and protein). Chyle percolates through the major 
lymphatic channels into the thoracic duct and thence into 
the venous system. The triglyceride component is removed 
from the chylomicron in the peripheral tissues (muscle and 
adipose tissue) by the action of lipoprotein lipase and the 
"remnants" of the chylomicron, including the cholesterol, 
are cleared mainly by the liver (Redgrave, 197 3) . Although 
exogenous cholesterol is first associated with chylomicrons, 
it may exchange with other lipoproteins [including VLDL 
and LDL of intestinal origin (Windmueller and Levy, I960)] .
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Cholesterol absorbed by the liver may enter the biosynthetic 
pathways or be converted to bile acids and excreted (the 
choice between the anabolic and catabolic pathways is influ­
enced by hormonal and species specific factors, van Lancker 
1976) .
Most tissues are capable of some cholesterogenesis 
(Dietschy and Wilson, 1968), however, only the liver can 
catabolise or excrete cholesterol in significant amounts.
The elimination of cholesterol from extrahepatic tissues is 
probably achieved through the high density lipoproteins (HDL) 
which show a high affinity for cell unesterified cholesterol 
(Bailey, 1973; Stein and Stein, 1973) and promote the efflux 
of cholesterol from erythrocytes in vitro (Glomset, 1970).
Cholesterol uptake may decrease the level of 
cholesterol biosynthesis in the liver and bone marrow but 
not in other tissues. Although large amounts of cholesterol 
are derived from extrahepatic tissues, the relationship 
between hepatic cholesterol biosynthesis and blood levels 
remains to be established.
There is evidence that both the uptake (Brown and 
Goldstein, 1976) and synthesis (Goldstein and Brown, 1974) of 
cholesterol by fibroblasts and other extrahepatic cells are 
regulated by the interaction of LDL with membrane receptors. 
The LDL receptor binds both LDL and VLDL and, therefore, 
although the serum concentration of LDL plus VLDL was lower 
in the cholesterol and orotic acid fed animals than in the
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rabbits receiving a diet supplemented only with cholesterol, 
it was higher than that in the serum of normal rabbits 
(Table 6.6) and will function to restrict cholesterol 
synthesis in extrahepatic tissues. Thus, the increased 
serum concentration of cholesterol in the orotic acid and 
cholesterol treated rabbits does not appear to be due to 
altered cholesterol biosynthesis in extrahepatic tissues.
The dietary cholesterol intake is sufficient to restrict 
hepatic cholesterol biosynthesis and the circulating con­
centrations of VLDL and LDL in the cholesterol and orotic 
acid treated animals are sufficient to restrict cholesterol 
biosynthesis in extrahepatic tissues.
If cholesterol biosynthesis was not a cause of 
the enhanced serum and tissue concentrations of cholesterol 
in orotic acid and cholesterol fed rabbits, changes in the 
metabolism of steroids may be involved. It has been reported 
that rabbits are unable to increase their production of bile 
acids during cholesterol feeding (Hellstrom, 1965) and may 
therefore be prone to a large increase in total body choles­
terol under such conditions. In addition, the activity of 
the hydroxylases involved in the conversion of cholesterol 
into bile seems to be dependent on the activity of the 
cytochrome P-450 fraction (Bjorkhem and Danielsson, 1974). 
Since orotic acid treatment of male rats decreases the cyto­
chrome P-450 fraction (Holtzman and Gillette, 1969), it is 
possible that the increased body cholesterol concentrations 
in the orotic acid and cholesterol fed rabbits was due in
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part to a diminished concentration of the cytochrome.
Carrella et al. (1976) have reported that orotic acid
feeding influenced steroid metabolism in male rat livers.
The rate of 12 ot-hydroxylation of 7a-hydroxy-4-cholesten- 
3-one was decreased by about 50%, whereas the 7a-hydroxyla- 
tion of cholesterol (the rate limiting step in the con­
version of cholesterol into bile acids) and the 26 hydroxyla- 
tion of 53-cholestane-3ot, 7a-diol were not significantly 
decreased. These changes in enzyme activity were ascribed 
by Carrella et al. (1976), not to a diminished amount of
cytochrome P-450, but to a "more general effect on the liver 
system". Thus, the feeding of orotic acid may reduce the 
rate of catabolism of cholesterol in the liver both through 
a decrease in the cytochrome P-450 fraction and a diminished 
activity of some of the enzymes of steroid catabolism.
There is disagreement over the effects of ascorbate 
on cholesterol metabolism. Some investigators have described 
hypocholesterolemia and other atheroma reducing effects as 
a result of ascorbate supplemented diets in rabbits and rats 
(Sokoloff et al., 1967) but others have denied such effects 
(Rolek and Dale, 1972). Investigators have described dis­
turbances of cholesterol metabolism in guinea pigs and monkeys 
secondary to ascorbate deficiency, including increased choles­
terol biosynthesis (Becker et al., 1953), increased choles­
terol levels in blood and tissues (Phillips, 1967), decreased 
cholesterol catabolism (Guchhait et al., 1963) and atheromatous 
changes in blood vessels (Fujinami et al., 1971). There
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appeared to be a significant negative correlation between 
the concentration of ascrobate in the liver and the concen­
tration of cholesterol in the serum and liver (Ginter, 1973). 
Thus, the results of feeding cholesterol and orotic acid to 
rabbits (Section 6.3.1) would appear to be similar to changes 
in the lipid metabolism observed in animals deficient in 
ascorbate. Feeding orotic acid to rats has been reported 
to cause an increase in the excretion of ascorbate (Skrbic 
et al., 1976). It could therefore be inferred that some 
of the effects of orotic acid on rabbits, fed a high choles­
terol diet, may be mediated through changes in the liver 
ascorbate concentration. Table 6.7 shows the concentrations 
of ascorbate in the heart, liver, spleen and serum of rabbits 
fed normal and orotic acid supplemented diets. This table 
shows that although the serum ascorbate concentration was 
lower in rabbits fed orotic acid and/or cholesterol, the 
ascorbate concentrations in the heart, liver and spleen of 
these rabbits did not deviate significantly from normal 
(though there was a slight decrease in the cardiac ascorbate 
concentration in those animals fed a cholesterol supple­
mented diet). Thus, the accumulation of cholesterol in the 
blood serum and the liver of rabbits fed a diet supplemented 
with cholesterol and orotic acid, cannot be attributed to an 
ascorbate deficiency.
Many reports have implicated altered calcium and 
magnesium concentrations in the development of high serum 
concentrations of cholesterol. Bersohn and Oelofse (1957),
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Yacowitz et al., (1965) and Rademeyer and Booyens (1965)
have reported an inverse relationship between the concentra­
tion of serum cholesterol and the levels of serum calcium 
and magnesium in man and rats. In rabbits fed a calcium 
deficient diet, the blood cholesterol concentration was 
reported to be increased (Iacono, 1964).
Lacson et al. (1966) have reported that, following
the parenteral injection of Mg EDTA (109 pmol/kg body wt/day), 
there was plaque reversal in the atherosclerotic arteries 
of rabbits. Nieper (1974) reported an increase in vessel 
elasticity in patients diagnosed as having atherosclerosis, 
after treatment with magnesium orotate (22 ymol/kg body 
wt/day). The interpretation of the above is difficult.
Lacson et al. (1966) believed that Mg EDTA acted by chelating
calcium ions, though he offered no supporting evidence for 
this conclusion. The high formation constants of metal com­
plexes with orotic acid (Chapter 3) suggest that orotic 
acid may have a similar effect. Nieper's explanation of 
his results was that orotic acid acts as an electrolyte 
carrier and that magnesium ions may activate the cholesterol- 
esterases and mobilise the vessel wall deposits. This 
explanation may equally be applied to Lacson's work.
Kaiden (1973) reported that, when added to an 
atherogenic ration, orotic acid did not produce hypocholes- 
terolaemia in rabbits. He also found that when the animals 
were fed a mixture of alkaline (group I elements) and alka­
line earth (group II elements) together with atherogenic
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fodder and orotic acid, atherosclerotic changes were accentu­
ated in the aorta and coronary arteries, and fatty degenera­
tion was produced in the liver.
Thus, alterations in the dietary intake, the blood 
and tissue concentrations of group one and group two elements 
may cause gross changes in the body lipid metabolism.
Tables 6.1 and 6.8 show the serum concentrations of various 
group one (sodium and potassium) and group two (calcium and 
magnesium) elements. There were no significant changes in 
the serum concentrations of sodium and potassium in either 
the cholesterol or the cholesterol and orotic acid fed 
animals, compared with normal animals. Serum magnesium 
concentrations decreased in animals fed a cholesterol supple­
mented diet, compared with normal animals, and was further 
decreased in animals whose diet was supplemented with both 
orotic acid and cholesterol. Although the serum magnesium 
concentration in the orotic acid and cholesterol treated 
animals was significantly lower than in normal animals, it 
was still within the normal range of values (the serum 
magnesium concentrations were 1.31 ± 0.24, 1.02 ± 0.05, and 
0.85 ± 0.03 mM in the normal, cholesterol and cholesterol 
and orotic acid treated animals; the normal range of plasma 
magnesium is 0.84 - 1.22 mM, Table 6.1). Thus there was an 
inverse correlation between the serum magnesium concentration 
and the serum cholesterol concentration (Table 6.2). These 
changes in the serum magnesium concentration were a function 
of the blood cholesterol concentrations and not of a magnesium
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deficient diet for the recommended dietary intake of 
magnesium is 0.03 - 0.04% of the diet (Kunkel and Pearson, 
1948) and the fodder contained 0.15% magnesium. Although 
serum calcium was slightly increased in those animals fed 
a cholesterol supplemented diet, compared with normal 
animals, it remained normal in animals fed both cholesterol 
and orotic acid. The rabbit is remarkable in that serum 
calcium levels reflect dietary calcium levels and therefore 
changes in the serum calcium levels do not reflect changes 
in total body calcium concentrations. [Serum calcium levels 
in the rabbit are not strictly controlled by the parathyroid- 
calcitonin-vitamin D interrelationships (Hunt and Harrington, 
1974) . ]
The calcium and magnesium concentrations in the 
kidney and liver showed some changes as a result of feeding 
rabbits diets supplemented with cholesterol or cholesterol 
and orotic acid. The total magnesium concentration in the 
rabbit kidney increased slightly in the cholesterol and the 
cholesterol and orotic acid fed animals, as did the total 
calcium content of the kidneys in the cholesterol and orotic 
acid fed animals. There were no significant changes in the 
calcium and magnesium contents of the livers of rabbits in 
the various groups of animals studied (Table 6.8).
Thus, although there are many reports in the 
literature of calcium and magnesium ions effecting changes 
in lipid metabolism, there was no evidence that this was the
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cause of the increased serum concentration of cholesterol 
observed in rabbits whose diets had been supplemented with 
orotic acid.
In summary, the most probable cause of the 
increased serum cholesterol concentrations observed as a 
result of feeding both cholesterol and orotic acid to 
rabbits were changes in the rate of cholesterol catabolism 
and excretion in the bile brought about by orotic acid.
6.4.2 Orotic Acid and Myocardial Vascularity
In the heart of the infant there is a capillary 
for every five or six myocardial fibres (Roberts and Wearn, 
1941). This means that there are four or five fibres 
enclosed in each space of the capillary network. In the 
heart of the adult there is a capillary adjacent to each 
muscle fibre, and there is only one fibre in each space of 
the capillary network. Since the number of fibres is the 
same in the adult as in the infant, there must be a four 
fold increase in the number of capillaries in the left 
ventricle of the adult. In spite of the growth of the 
capillary network, the width of the spaces of the network 
is essentially the same in the heart of the adult and the 
infant. During hypertrophy the fibres simply become thicker 
and longer, as an extension of normal growth, and the spaces 
become only slightly wider (Linzback, 1960) .
250
In hypertrophy, due to pressure overload, there 
is an increase in the number of muscle fibres, nuclei and 
capillaries. The increase in the number of muscle fibres 
appears to be due to longitudinal cleavage between points 
of anastomosis of the myocardial syncytium and as a result 
the number of fibre layers may be greatly increased 
(Linzback, 1960). The total number of capillaries increases 
to the same extent as the number of muscle fibres and the 
ratio of one capillary per muscle fibre remains the same. 
During pathological hypertrophy, the mesh of the capillary 
network becomes a little wider in accordance with a thicken­
ing of the heart muscle (Hort, 1977) but the ratio of one 
capillary per muscle fibre remains the same.
Now consider the coronary arteries. From several 
investigations it has been reported that the growth of the 
coronary arteries, under pathological conditions, was not 
as great as that of the myocardium (for example,
Schoenmackers, 1949; Vogelberg, 1957). Hort (1977) reported 
that during physiological growth, there was a rather close 
correlation between the growth of the human coronary arteries 
and the growth of the myocardium, but that under pathological 
conditions the growth of the coronary arteries was slower 
than that of the myocardium. The question is whether this 
slower rate of growth of the coronary arteries, during 
myocardial hypertrophy, could have a detrimental effect on
the heart.
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The data in Table 6.9 indicates that in both the 
cholesterol treated animals and in the groups of animals 
with hypertrophied hearts, the coronary circulation of 
those animals treated with orotic acid was not significantly 
different from that of normal animals. Compared with those 
animals with hypertrophied hearts not treated with orotic 
acid, the coronary circulation of hypertrophied hearts 
treated with orotic acid was significantly greater, on the 
basis of both number of perfused vessels and the' size of 
these vessels. The results showed that under conditions of 
developing compensatory hypertrophy, the growth of the 
coronary arteries was slower than that of the myocardium, 
but that with orotic acid treatment there was a close corre­
lation between the dilatation of the coronary artery system and 
the growth of the myocardium.
These results, together with a report of Hort 
(1977) that the capillary/fibre ratio of 1 was maintained 
in both physiological and pathological hypertrophy, shows 
that the vascular system of hypertrophied hearts treated 
with orotic acid was normal, when expressed as a function 
of cardiac size. The results would also suggest that the 
enhanced cardiac vascularity of orotic acid treated hearts, 
compared with untreated hearts, should be effective in pre­
venting cardiac hypoxia that might otherwise be associated 
with the enhanced energy demands, for protein and nucleic 
acid syntheses, of the orotic acid treated hearts. Nor was
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the use of orotic acid likely to precipitate myocardial 
ischemia in states of coronary artery disease, as judged 
from the coronary circulation of those rabbits fed a 
cholesterol and orotic acid supplemented diet.
Figure 6.1 Some aspects of lipid distribution in rat 
hepatocytes.
Lipids enter the cell at the end of the space 
of Disse and transverse the plasma membrane and the membrane 
of the endoplasmic reticulum (ER) (1). Within the ER 
cisternae (2) fatty acids and glycerol are combined to form 
triglycerides and other lipids. The lipids may take the 
form of storage spheres (presumably the smooth endoplasmic 
reticulum, 3, buds off "transitional vesicles" within which 
are small lipid droplets) or may enter the secretory path­
way. Lipids are transformed into very low density lipopro­
teins (VLDL) in the smooth endoplasmic reticulum and the 
Golgi apparatus (G). VLDL particles are packaged into 
vacuoles by the Golgi apparatus and these vacuoles (GV) 
detach and are secreted into the space of Disse.
In orotic acid induced steatosis, lipid droplets 
(LD) are found throughout the cytoplasm of hepatocytes.
The endoplasmic reticulum forms vesicles within which one 
or more droplets are present. Lipid transport to the Golgi 
apparatus is interrupted and the Golgi elements are flat
and lack VLDL.
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Figure 6.2 Left Anterior Descending Coronary Artery.
In each selected vascular segment, internal 
diameters were measured in three plans to 
determine the mean diameter of the vessel.
The sections measured were the mid-segment of 
the ultimate segment of the left anterior 
descending coronary artery (X) and the mid­
segment diameters of the first three divisions 
of the dominant terminal branch of this vessel 
(A , B and C). The mean septum thickness was 
determined by measuring the average minimum 
width of the septum when the heart was bisected 
by a transverse cut at right angles to the plane 
of the septum.
Figure 6.3 Determination of the Mean Septum Thickness
The heart was bisected by a transverse cut 
at right angles to the plane of the septum 
(Fig. 6.2). The mean septum thickness was 
then determined by measuring the minimum 
width of the ventricular septum at three 
positions in the mid-segment of the septum 
(indicated by the arrows in the above 
figure). The septum was selected for the 
measurement of left ventricular thickness 
because the taeniae cavnea are less prominent 
here as compared with the anterior, lateral 
and posterior parts of the internal surface 
of the ventricle.
Figure 6.4 Gross appearance of the rabbit liver.
The liver of a rabbit fed a normal diet.Top left: 
Top right: The liver of a rabbit fed a diet supplemented 
with orotic acid (10 mg/kg/day).
Bottom left: The liver of a rabbit fed a diet supplemented
with cholesterol (0.9% w/w).
Bottom right: The liver of a rabbit fed a diet supplemented
with orotic acid (10 mg/kg/day) and 
cholesterol (0.9% w/w).
Figure 6.5 The effects of the administration of Orotic
Acid and/or Cholesterol-supplemented diet3 on 
the serum cholesterol level of rabbits.
The graph shows the mean ± S.E.M. of the serum 
cholesterol levels of three groups of raboits.
The first group (six rabbits) was fed a diet 
supplemented with cholesterol; the second 
group (six rabbits) was fed a diet supplemented 
with both cholesterol and orotic acid; the 
third group (six rabbits) was fed a diet supple­
mented with cholesterol for 8 weeks followed by 
a diet supplemented with both cholesterol and 
orotic acid. The preparation of the diets, the 
treatment of the animals and the assay of 
cholesterol were as described in the experimental 
section.
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Figure 6.6 The effect of the administration of Orotic Acid 
and/or Cholesterol-supplemented diets on the serum triglyceride 
levels of rabbits. The treatment of the animals and the assay 
of triglycerides were as described in the experimental section. 
Results were plotted as the mean ± S.E.M. of 6 determinations.
TABLES 6.1, 6.2, 6.3 and 6.4
Effect of orotic acid feeding of some important 
constitutents in the serum of normal rabbits, rabbits with 
aortic stenosis and rabbits which had been fed a high 
cholesterol diet (see Section 6.2.1). The results are 
shown as mean ± S.E.M.. The normal ranges of values of the 
serum components for male New Zealand white rabbits (unless 
otherwise indicated) is shown at the left of the Table. 
These values have been taken from the following literature 
references:
A. Kozma, C. et al. (1974) in The Biology of the
Laboratory Rabbit (Weisbroth, S.H., et al. 
eds), pp. 62-64, Academic Press, New York.
B. Plasma value. Cole, W.H. et al. (1944), Am. J.
Physiol. 141, 165-171.
C. Plasma value. Kunkel, et al. (1948), J. Lab.
Clin. Med. 3_2, 1027.
D. Normal range of values for human serum.
Eastham, R.D. (1971), Biochemical Values 
in Clinical Medicine, J. Wright and Sons Ltd, 
Bristol.
E. Byers, S.O. and Friedman, M. (1970), Atherosclerosis
11, 373-382.
F. Mean values only. Lutton, C.E. and Tsaltas, T.T.
(1965), Proc. Soc. Exp. Biol. Med. 118, 
1048-1051.
G. Altman, P.L. and Dittmer, D.S. (1973), Biological
Data Book, Vol. 2, 2nd edn, Federation of Am. 
Soc. for Exp. Biol., Maryland.
H. Based on data from Mackay, M.E. (1955), Biochem. J.
60, 475-481 and Suensson, H. (1946), Ark.
Kemi Min. Geol. 22, 1.
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TABLE 6.5
THE EFFECT OF CHOLESTEROL AND OROTIC ACID SUPPLEMENTED 
DIETS ON THE CONCENTRATION OF HEPATIC AND AORTIC LIPIDS
LIVER Cholesterol
Cholesterol 
Orotic Acid Control
Total Lipids 39.4± 2.7 81.1 ± 3.5 -
Total
Cholesterol 3.2 ± 1.6 23.1 ± 4.6 -
AORTA
Total
Cholesterol 16.96±4.80 105.00±14.30 4.7110.30
Total
Triglycerides 17.90±3.20 28.10± 4.42 1.3810.24
The effect of normal, cholesterol and cholesterol and 
orotic acid supplemented diets on the concentration of 
hepatic and aortic lipids. The lipid concentrations are 
expressed as the mean ± S.D. and are the results of five 
determinations. The lipid concentrations are given as 
g/kg wet weight of liver and g/kg dry defatted weight 
of aorta. These lipids were extracted and assayed as 
described in Section 6.2. The gross appearance of the 
livers of orotic acid, cholesterol, and orotic acid and 
cholesterol fed animals is shown in Fig. 6.4.
TABLE 6.6
THE EFFECT OF OROTIC ACID AND CHOLESTEROL SUPPLEMENTED 
DIETS ON THE SERUM LIPOPROTEIN CONCENTRATION
High Density 
Lipoproteins
Very Low Density 
Lipoproteins plus 
Low Density 
Lipoproteins
Normal Diet 1 0.31
Cholesterol n oo O C QSupplemented Diet 0 . o z z . D y
Orotic Acid n n .
Supplemented Diet x . xz U.
Orotic Acid and
Cholesterol 0.63 1.25
Supplemented Diet
The effect of orotic acid and/or cholesterol supplemented 
diets on the concentration of serum lipoprotiens. The 
lipoproteins were analysed by disc gel electrophoresis 
as described in the experimental section. The results 
are expressed in terms of the high density lipoprotein 
concentration of the serum of normal rabbits, the latter 
being taken as 1.
TABLE 6.7
THE EFFECT OF CHOLESTEROL AND OROTIC ACID ON THE SERUM 
AND TISSUE ASCORBATE CONCENTRATIONS
Normal
Diet
Cholesterol
Diet
Cholesterol and 
Orotic Acid Diet
Heart 49.3 ± 3.3 39.3 ± 3.5
(p < 0.01)
47.8 ± 1.4
(N.S.)
Liver 165.4 ± 11.8 163.8 ± 12.6 
(N.S.)
145.2 ± 9.4
(N.S. )
Spleen 364.5 + 8.0 349.5 ± 9.9
(N.S.)
355.0 ± 18.9 
(N.S.)
Serum 27.6 ± 4.3 15.6 ± 1.5
(p < 0.005)
15.9 ± 1.2
(p < 0.005)
Results are expressed as the mean ± S.D.. The figures 
in brackets represent the p values (Student's t test) 
of a comparison of the data with that of normal animals. 
Experimental details are given in the text.
TABLE 6.8
THE EFFECT OF CHOLESTEROL AND OROTIC ACID SUPPLEMENTED 
DIETS ON THE CALCIUM AND MAGNESIUM CONCENTRATIONS IN 
THE LIVER, KIDNEY AND SERUM
MAGNESIUM
Normal Cholesterol Cholesterol and Orotic Acid
Kidney 6.11 ± 0.11 6.24 ± 0.05* 6.32 ± 0.15*
Liver 6.71 ± 0.30 6.88 ± 0.27 6.99 ± 0.07
Serum 1.31 ± 0.24 1.02 ± 0.05 0.85 ± 0.03*
CALCIUM
Kidney 1.23 ± 0.04 1.24 ± 0.02 1.29 ± 0.03*
Liver 1.30 ± 0.04 1.34 ± 0.03 1.39 ± 0.02
Serum 3.82 ± 0.04 4.07 ± 0.08* 3.78 ± 0.10
Effect of feeding either orotic acid and cholesterol or 
cholesterol on the kidney, liver and serum concentrations 
of calcium and magnesium. The results are expressed as 
mmol/litre or mmol/kg wet wt and are shown as the 
mean ± S.D.. Those results which were significantly 
different from normal values are indicated by *. Tissue 
samples were digested as described in Section 4.2 and 
the calcium and magnesium concentrations were determined 
as described in Section 6.2.8.
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CHAPTER 7
GENERAL DISCUSSION
7.1 Orotic Acid as a Positive Inotropic Agent
The evaluation of the ventricular muscle-pump 
function of the heart still constitutes a major problem in 
cardiology. In recent years, the various contractile 
properties of the isolated mammalian myocardium have been 
well characterised, permitting a coherent and unifying 
description of cardiac muscle performance to be developed. 
The mechanical activity of the cardiac muscle may now be 
defined in terms of the interrelationship between force 
development, the instantaneous length during shortening 
and the velocity of shortening, independent of the time 
course of activation (Brutsaert, 1974).
A major goal in the studies of cardiac contractile 
properties was to distinguish alterations in ventricular 
performance due to changes in loading conditions (the 
Frank-Starling adaptation or homeometric autoregulation) 
from either positive or negative inotropic effects (changes 
in contractility or heterometric autoregulation). More 
pragmatically, the aim was to accurately distinguish an 
intrinsically "good" heart from a "bad" one.
This leads to the concept of the contractility 
(or contractile behaviour) of the heart muscle. As Brady
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(1968) has pointed out, the term, "myocardial contractility", 
does not have a unique operational definition. Leonard and 
Hajdu (1962) defined "a change in contractility" as a change 
in the contractile force, independent of changes in the 
initial muscle length. Blinks and Koch-Weser (1963) included 
changes in the force-velocity relationship and the active 
state duration in this definition. Brady (1968) proposed 
two definitions of contractility. The first, "static con­
tractility", referred to the time course of tension developed 
in a muscle in which the contractile element was held at a 
constant length; the second, "dynamic contractility", 
referred to the rate at which tension developed in a muscle 
allowed to contract in such a manner that the contractile 
elements shortened at a constant velocity. In both of these 
definitions, the derivative of the tension developed would 
provide a measure of the contractility.
Bearing in mind Brady's definitions of contractility,
the results of Kolos et al. (1974) would suggest, on a priori
grounds, that orotic acid may cause a change in myocardial
contractility (Kolos et al., 1974, reported that the maximum
rates of rise of tension were 27.0 ± 4.8 and 43.7 ± 6.8 
2g/mm /sec in the untreated and orotic acid treated hearts, 
four days after the induction of hypertrophy, respectively). 
However, the ability of a muscle to develop tension appears 
to be related to the number of strong physicochemical inter­
actions between the proteins of the thick and thin filaments
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(Katz, 1970) and is not a direct measure of contractility.
The definitions of static and dynamic contractility, pro­
posed by Brady (1958), appear to be merely model-dependent 
abstractions (Brutsaert and Paulus, 1977).
In view of the present knowledge of cardiac muscle 
performance, contractility may now be defined in a more 
general and model-independent manner (Fig. 7.1). "Contract­
ility" can be defined as "the time independent interrelation­
ship between force, velocity and length". In this sense, 
changes in initial muscle length do not influence contractility. 
The term, "change in contractility", reflects any shift of 
this time-independent interrelationship, i.e. when, for any 
given constant load and for any instantaneous length, the 
velocity of shortening has been altered. This moves the 
entire force-length-velocity surface (Fig. 7.1) into a new 
position, either upwards (calcium, catecholamines) or down­
wards (myocardial failure, anoxia). This new level is again 
unique for the changed contractile state and is independent 
of the initial muscle length (preload) and of the time after 
activation (Brutsaert and Paulus, 1977).
Three possible areas of study that may have some 
bearing on the effect of orotic acid on myocardial contract­
ility were:
(1) The rate of myosin cross-bridge movement as 
a result of an altered myosin ATP ase activity. By measuring
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the ATP ase activities of myosins extracted from muscles 
whose speeds of shortening had previously been measured, 
Barany (1967) reported that, over a wide range of speeds, 
the ATP ase activity of myosin was proportional to the 
speed of shortening (vmax) and hence related to the con­
tractility of the muscle.
In high salt concentrations, the myosin ATP ase
activity was found to be stimulated by both (K+) EDTA and 
2+Ca . The significance of this is difficult to assess 
2+ +since the Ca - and (K ) EDTA- ATP ase activities were
2+inhibited by Mg (Luchi and Kritcher, 1966). Further, at
low ionic strength, myosin ATP ase exhibited a low level
2of activity in the absence of Mg and the activity was
-4 2+fully inhibited at 10 M Mg (Thomas and Alpert, 1977).
Since the free intracellular magnesium concentrations of
normal, hypertrophied, and hypertrophied and orotic acid
-4 -3treated hearts were in the range 10 - 10 M (Table 4.11)
2+the physiological significance of the activities of Ca 
and (K+) EDTA activated ATP ase still has to be resolved.
Clark and Spudich (1977) have suggested that the
physiologically significant enzymatic activity of myosin
is the actin activated ATP ase activity, measured at low
ionic strength and in the presence of magnesium. This does
2+ +not preclude the use of Ca - and (K ) EDTA- ATP ase activi 
ties as measures of the maximum catalytic capacity of the 
ATP ase. When considered with reports which show a strong
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correlation between ATP ase activity and V (Barany,
1967; Alpert and Mulieri, 1977), the reports suggest that 
2+ +Ca - and (K ) EDTA - ATP ase activities may still be used 
as measures of the "change in contractility".
There is no general agreement as to the effect
of hypertrophy on the ATP ase activity of myosin. Katagiri
2+and Morkin (1974) reported that the Ca stimulated ATP ase
activity was reduced and Wikman-Coffelt et al. (1975) have
2+reported the Ca -ATP ase activity to be increased. In
Chapter 3 it was shown that (K+) EDTA-stimulated ATP ase
activity was not significantly different from normal in
hypertrophied hearts, either treated with orotic acid or
2+untreated. It was also shown that the Ca -stimulated 
myosin ATP ase activities were depressed in untreated, 
hypertrophied hearts and elevated in orotic acid treated, 
hypertrophied hearts. The reason for the differences 
between reports is unknown though some of the variability 
may be due to differences in the severity and duration of 
the imposed stress.
(2) The ability of a muscle to develop tension 
appears to be determined by the number of strong physico­
chemical interactions between the proteins of the thick 
and thin filaments. Studies of the physiological properties 
of papillary muscles, isolated from normal and hypertrophied 
hearts (Section 1.5), indicated that there were no signifi­
cant differences in the tension developed and the maximum
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rate of rise of tension in hypertrophied hearts. In those 
hypertrophied hearts which were treated with orotic acid, 
both the developed tension and the maximum rate of rise 
of tension were elevated.
As Huxley and Niedergerke (1954) have noted, the 
maximal tension that can be developed should be greater in 
a muscle with longer sarcomeres than in one with shorter 
sarcomeres, for there would be more sites for interaction 
between the actin and myosin of the former. This does not 
explain the elevated tension developed in those hyper­
trophied hearts treated with orotic acid, for the sarcomere 
length has been found to be normal in both the hypertrophied 
and the failing heart (Grimm et al., 1963; Hatt and 
Swynghedauw, 1968; Linzbach, 1960). Nor were the changes 
in tension due to changes in the proportion of connective 
tissue in hypertrophied and orotic acid treated, hyper­
trophied hearts, for it was shown in Section 3.3.2 that 
there were no differences in the collagen content of orotic 
acid treated and untreated hypertrophied and normal hearts, 
1-5 days after the induction of hypertrophy.
(3) The calcium flux within the muscle may change 
as a result of the altered performance of the sarcoplasmic 
reticulum and/or the plasma membrane. Limited data are 
available concerning the effect of hypertrophy on the trans­
membrane electrical activity and the results are somewhat 
controversial. Uhley (1961) found no differences in the
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amplitude of the left ventricular action potential during 
left ventricular hypertrophy; Kaufman et al. (1971) found
no differences in the amplitude of the right ventricular 
resting potential and the duration of the action potential 
during right ventricular hypertrophy; and Tritthart et 
al. (1975) found an increase in the resting potential and
a reduction in the rate of rise of the action potential 
during hypertrophy. Although no experiments were under­
taken to investigate the effect of hypertrophy and orotic 
acid on the cellular components directly involved in 
excitation-contraction coupling, it is of interest to note 
that Krug et al. (1977) have reported that feeding orotic
acid caused an increase in the amplitude of the first 
surface-positive wave of the primary cortical potential 
and a drop in the stimulus threshold for elicitation of 
cortical evoked potentials. Possible direct influences of 
nucleotides on neuronal excitation processes were also 
indicated: for example, the anticonvulsive effects of
uridine reported by Roberts (1973) .
From the results presented here (Section 1.5 and 
Section 3.3.3), it is apparent that, in the short term, 
cardiac hypertrophy caused significant changes neither in 
the turnover rate of the individual actin-myosin cross­
bridges (as reflected in the cardiac myosin ATP ase activity) 
nor in the number of cross-bridge interactions (as reflected 
in the maximum rate of rise of tension and the active 
tension in the papillary muscles). On the other hand, four
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days after the induction of hypertrophy, those animals 
which were treated with orotic acid showed a positive 
"change in contractility" as determined by either the rate 
at which tension developed (Brady, 1968) or, more 
accurately, by an increase in myosin ATP ase activity.
That changes occurred in both the maximum developed tension 
and the myosin ATP ase activity does suggest that both the 
turnover rate of the individual cross-bridges between the 
actin and myosin myofilaments and the number of cross­
bridge interactions may be altered.
The direct measurement of the actinomyosin content 
of the hypertrophied or failing heart reflects to a large 
degree the variability of changes in the tissue composition 
that follow hemodynamic overloading. Grimm et al. (1966)
and Sobel and Cohen (1958) failed to show any significant 
decrease in the amount of extractable contractile proteins 
but Benson (1955) and Meerson et al. (1964) found extractable
actomyosin to be decreased in the failing heart. Davis et 
al. (1959) found a normal proportion of actomyosin to total
protein, though the increased water content of the hyper­
trophied and failing hearts reduced the actinomyosin content 
per gram of tissue weight. However, any changes in the 
myofibrilar content per unit of cross sectional area alone
would be expected to elevate the developed tension but not
2 +V or the Ca -ATP ase. On the other hand, a prolonga-max  ^ 3
tion of the action potential per se would increase both the
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developed tension and the shortening velocity (Jacob et 
al., 1977) . This would be consistent with the results 
observed in the case of the orotic acid treated hyper­
trophied hearts and warrants further investigation.
In terms of the present concepts of contractility 
and the application of muscle mechanics to ventricular 
function evaluation, the results would seem to suggest that 
supplementing the diet of rats, in which compensatory cardiac 
hypertrophy had been induced with orotic acid, caused a true 
alteration in myocardial contractility. However, both in 
the isolated cardiac muscle and in the intact heart, the 
conceptual basis of "changing contractility" still represents 
an unresolved area which warrants careful consideration.
This uncertainty was raised by Brutsaert and Paulus (1977) 
when they asked: "Does a shift in the force-velocity sur­
face (Fig. 7.1), with a concomitant shift in V , reflect 
a true alteration in the actinomyosin ATP ase turnover rate 
of each individual cross-bridge between the actin and myosin 
filaments or does it merely reflect a change in the number 
and rate of cross-bridge interactions?" The effect of orotic 
acid on the hypertrophied heart may represent the latter.
7.2 Orotic Acid and the Mechanism of Cardiac Adaptation 
to Heightened Physiological Demands
To study the mechanism of hearts long-term adapta­
tion and deadaptation and to elucidate ways of controlling the 
process are some of the major tasks of modern medical science.
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Meerson and Breger (1977) have proposed that the short 
term adaptation of the heart cells to changing demands, 
is controlled by the energy status of the heart and that 
by influencing protein synthesis, the energy status of the 
heart may also determine long term adaptation.
In Chapter 4 it was shown that it was not the
absolute energy status of the heart (as measured by the
total ATP concentration) that decreased at the onset of
hypertrophy, but the relative proportion of ATP to other
adenylates that decreased. Thus, the energy status of the
heart may be measured by three parameters: the Atkinson
energy charge; the phosphorylation state of the adenine
nucleotides (PSAN); and the adenine nucleotide ratio (ANR)
(Section 4.3.4). The concept of the Atkinson energy charge
assumes that the adenylate kinase catalysed reaction is at
equilibrium (which was not the case in all of the groups of
hearts examined, Section 4.3.2); assumes that there is an 
2 +excess of Mg in the cell and that the total magnesium 
concentration does not change (in Section 4.3.1 it was 
shown that the free magnesium concentration does change 
during hypertrophy); assumes that ADP and ATP are competi­
tive ligands (which is not always the case, for example, 
muscle hexokinase); and, finally, the energy charge hypo­
thesis does not take into consideration changes in the intra­
cellular pH. Thus, the Atkinson energy charge, as presently 
defined, is not an appropriate measure of the energy status
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of the hypertrophying heart. Indeed, the only reason the 
energy charge hypothesis was introduced into Chapter 4 was 
that it provided a convenient formulation for expressing a 
relationship amongst the adenine nucleotides.
The second parameter, the ANR, is a more rigorously
defined thermodynamic quantity but, like the Atkinson energy
charge does not take into consideration changes in the free 
2+Mg concentration. Since the ANR is calculated from the 
total cardiac ATP, ADP and inorganic phosphate concentra­
tions, cellular compartmentalisation is not taken into 
consideration. The ADP which is bound to actin becomes 
accessible to creatine kinase at a very slow rate (Szent- 
Gyorgyi and Prior, 1966) and may account for 65% of tissue 
ADP (Seraydarian, 1962) and clearly should not be included 
without qualification in a determination of the energy status 
of the heart. Coty and Pederson (1975) found that the 
internal pH of their liver mitochondria was pH 8.63; 
assuming this to be the same in cardiac mitochondria, the 
cytoplasmic pH to be 7.1, the pK^ for phosphoric acid to 
be 6.8, a total cardiac inorganic phosphate concentration 
of 4 ymol/g (Table 4.1) and assuming that cardiac mitochondria 
occupy 1/3 of the total cell volume (Page and McCallister, 
1973), then the phosphate concentration in the mitochondria 
would be 11.3 mM and 1.3 mM in the cytoplasm. Although 
such calculations are necessarily crude and speculative, 
they do indicate that small changes in the cytoplasmic
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phosphate concentration would be masked in a determination 
of the total cell phosphate content.
The PSAN has none of the above disadvantages.
By virtue of the methods used in the determination of this
24-parameter (Section 4.3.4), changes in Mg , pH and phosphate 
are included in the calculations. If Meerson and Berger 
(1977) are correct and it is the energy status of the cell 
which controls the development of hypertrophy, then the 
correct measure of the energy status is the PSAN, not the 
ANR (as used by Meerson and Berger, 1977) or the Atkinson 
energy charge. Table 4.10 shows that the PSAN fell in both 
the orotic acid treated and the untreated, hypertrophied 
hearts, the fall being greater in the untreated hearts.
It is not clear whether this indicates that there is a 
critical level of the PSAN, below which an activation of 
the hypertrophic response occurs or whether other, undefined 
factors are also involved. The results in Fig. 4.2 show a 
very strong correlation between the total cardiac adenine 
nucleotide concentration and changes in the rates of pro­
tein synthesis, especially in the orotic acid treated hearts, 
suggesting an increased rate of adenine nucleotide synthesis 
occurs very early in the development of hypertrophy. Since 
the total adenine nucleotide concentration changes pari 
passu with the rates of protein synthesis, the results 
suggest an enhanced rate of adenine nucleotide synthesis.
It, therefore, seems likely that an accelerated rate of
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synthesis of the adenine nucleotides is an important 
factor among those metabolic processes involved in the 
activation of cardiac protein synthesis.
Current evidence suggests that the rate of purine 
biosynthesis is limited by the availability of PP-ribose-P. 
For example, in lymphoblasts derived from the peripheral 
blood of a patient with gout and with an increased activity 
of PP-ribose-P synthetase, there was an accelerated rate of 
purine biosynthesis de novo (Nuki et al., 1977). Studies 
using lymphocytes and hepatic tissue have shown that an 
increase in PP-ribose-P generation always precedes an 
increase in the rate of purine synthesis de novo (Boer et 
al. , 1976 ; Brosh et al., 1976 ; Chambers et al., 1974). 
Finally, the availability of PP-ribose-P has been proposed 
as a limiting factor in cardiac purine biosynthesis (Zimmer 
and Gerlach, 1977). How then is the rate of PP-ribose-P 
synthesis controlled? Reports in the literature suggest 
that either the activity of the pentose phosphate pathway 
or the intracellular phosphate concentration may limit the 
availability of PP-ribose-P. By accelerating the oxidative 
pentose phosphate pathway with methylene blue or with 
ascorbic acid, at physiological concentrations of inorganic 
phosphate, Sperling (1977) was unable to accelerate either 
the rate of purine biosynthesis or the rate of PP-ribose-P 
generation in cultured human fibroblasts and lymphoblasts 
and human peripheral leucocytes. Sperling (1977) also
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reported a marked acceleration of the synthesis of 
PP-ribose-P at high inorganic phosphate concentrations in 
leucocytes and lymphoblasts. These results suggest that 
it is the synthesis of PP-ribose-P, rather than the availa­
bility of ribose 5-P that is the rate limiting step and 
that an increase in the inorganic phosphate concentration 
may be a regulatory factor in purine biosynthesis. Further 
evidence that the pentose phosphate pathway was not crucial 
for PP-ribose-P availability comes from work on patients 
and on cell lines deficient in glucose 6-P dehydrogenase 
activity (Raivio, 1977). Even with low residual enzyme 
activity, defects in purine synthesis or metabolism have 
not been reported (Raivio, 1977). The latter, however, 
ignores other sources of pentose sugars such as the 
Bonsignore reaction pathway and the reverse of the new 
pentose phosphate pathway of Williams (Bonsignore, et al., 
1962; Williams et al., 1977).
Thus, the results in this thesis are compatible 
with the series of events outlined in Fig. 7.2 and based 
on the proposal of Meerson and Breger (1977).
The concept of coordinate regulation of the purine 
and pyrimidine pathways of synthesis de novo by the availa­
bility of PP-ribose-P is an attractive one, however, there 
is no conclusive evidence to support such an idea. For 
example, in lymphoblasts derived from the peripheral blood 
of a patient with gout and with increased activity of
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PP-ribose-P synthetase, there was no increase in the intra­
cellular pyrimidine concentration, despite a two fold 
increase in the intracellular PP-ribose-P concentration 
and an accelerated rate of purine synthesis de  n o v o (Nuki 
et al., 1977). Thus pyrimidine synthesis de novo in the 
heart, if indeed it does occur (Chapter 5), is unlikely to 
respond to an increased synthesis of PP-ribose-P. The 
differences in the 's of the enzymes of the pyrimidine 
and purine pathways of synthesis de novo would also suggest 
a higher affinity of the purine pathway for PP-ribose-P
(K of OPRT ase for PP-ribose-P was 1 mM, Matsushita and m
Fanburg, 1970, and the of PP-ribose-P amidotransferase 
for PP-ribose-P was 20-100 yM, Henderson and Paterson, 1973). 
Thus, in terms of the model presented in Fig. 7.2, the 
hypertrophic response would be expected to cause an increase 
in purine biosynthesis, but not in pyrimidine biosynthesis 
and the latter may become rate limiting for RNA synthesis 
(and hence protein synthesis). The administration of orotic 
acid would provide the necessary pyrimidine nucleotide pre­
cursors (Chapter 5 and Section 7.3) to overcome any such 
deficiencies in the availability of pyrimidine nucleotides, 
and thus allow for an increased concentration of cardiac 
RNA (Fig. 3.4a) and an increased rate of protein synthesis 
(Fig. 3.5a). Alterations in protein synthesis are not only 
of significance for heart weight, but result in altered 
structural and enzymatic properties of the cardiac cells 
which are decisive for mechanical performance. By promoting
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protein synthesis, orotic acid treatment would be expected 
to exert a positive influence on the potential of the 
hypertrophying heart to adapt to an altered environment.
Although the chain of events shown in Fig. 7.2 
are consistent with the results presented in this thesis 
and the proposed effects of orotic acid on the development 
of cardiac hypertrophy, they do not represent a single, 
uniform model of control during hypertrophy. Indeed, hyper­
trophy appears to be the result of many subtle changes and 
includes metabolic contributions of other organs of the 
body. In Chapter 5, the influence of hepatic pyrimidine 
biosynthesis on the development of cardiac hypertrophy was 
discussed. Another organ potentially involved in cardiac 
hypertrophy is the thyroid. For example, thyroxine has a 
powerful regulatory effect on the expression of myosin 
genes in the rat ventricular myocardium (Hoh, 1975) as well 
as stimulating RNA and protein synthesis (Tata, 1963) .
The following pertinent point is made in a recent 
book on control theory (Zorkoczy, 1972):
". . . for control there must exist a
clearly specified chain of events from the 
present state of affairs to the desired state, 
a chain which is under the influence of the 
control system. Such chains can be made to 
exist in man-made systems, but are rarely 
found in ecological, economic, social and 
other complex systems. The more usual situation
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in complex systems is that the causal chain 
is not identified, or that it varies with 
time in an unknown manner, or that a 'link' 
in the chain is affected by several causes, 
not all of which can be influenced by the 
control system, or any combination of these 
circumstances.
" . . .  The present state of development 
of control theory and practice is such that, 
even if a satisfactory model of a truely 
complex system suddenly became available, we 
still would not know how to set about controlling 
such a system . . . but owing to the unique
position of the subject, a student and practi­
tioner of control can expect to contribute in 
no small measure to the solution of the urgent 
problems facing mankind."
It may be that the series of events described in 
this section are only parallel consequences of a primary 
initiating event. The sequence does, however, provide an 
overall biochemical view of hypertrophy upon which further 
investigations may be carried out.
7.3 Mechanism of Orotic Acid Enhanced Myocardial Performance
The administration of orotic acid was proposed by 
Meerson (1969) to lead to a greater production of nucleic 
acid precursors and, by implication, prime the processes of 
protein synthesis. Pyrimidine nucleotide precursors were 
also believed to lead to a greater production of pyrimidine
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nucleotide coenzymes, which are essential for energy 
metabolism and the catabolism of lipids and carbohydrates. 
Theoretically, the administration of precursors, together 
with folic acid (a cofactor in both pyrimidine and purine 
biosyntheses) and vitamin B,^ (which stimulates the syn­
thesis of thymidine, thymine and deoxyribose, all of which 
are precursors for DNA synthesis) should facilitate the 
synthesis of nucleic acids and proteins. Clinical and 
experimental evidence gathered during the past decade 
(Section 1.5) has suggested beneficial results following 
orotic acid therapy and has thus supported this claim by 
Meerson (1969) .
In order to evaluate this claim by Meerson in a 
rigorous manner, several questions need to be answered:
(1) What is the mechanism of action of orotic
acid?
(2) Could the enhanced protein and nucleic acid 
synthesis observed as a result of orotic acid administration 
be achieved using other pyrimidine or purine compounds?
(3) Is orotic acid enhanced growth a general 
phenomenon, applicable to any growth situation or does orotic 
acid have a particular effect on the hypertrophying heart?
Studies of the uptake of orotic acid (Tables 5.1 
and 5.2) revealed that only a small proportion of an adminis­
tered dose of labelled orotic acid could be found in the
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heart (0.06%) and that the highest proportion of the 
administered dose of orotic acid (4.3%) was found in the 
liver. An insignificant fraction of a therapeutic dose 
of orotic acid (1.5 yg of a 10 mg/kg/day dose in 250 g rats) 
was found in cardiac tissue. These studies also showed that 
only 1.46% of the 14.3 pmol of orotic acid in the acid 
soluble fraction per gram of cardiac tissue was incorporated 
into RNA, compared with 17.63% of the 18.8 pmol of uridine/g 
(Tables 5.2 and 5.3). The results clearly show that the 
salvage pathways of pyrimidine synthesis were more active 
than the pathway de novo in vivo.
Further evidence for the dependence of cardiac 
metabolism on the salvage pathways of pyrimidine synthesis 
came from a study of the maximum catalytic capacities of 
the enzymes of pyrimidine synthesis (Tables 5.4 and 5.5).
The rate limiting step in the conversion of orotic acid to 
UMP was that catalysed by OPRT ase, the activity of which, 
in cardiac muscle, was only 22% of the maximum catalytic 
activity of uridine kinase. In addition, the rate limiting 
step of the pathway of pyrimidine synthesis de novo was the 
reaction catalysed by CPS ase II (max. catalytic activity 
in the normal rat 0.23 nmol/min/g), with an activity of 
only 1.6% of the activity of uridine kinase. That CPS ase 
II catalysed the rate limiting step of the pathway de novo 
was confirmed by studies of the incorporation of the sub­
strate and product of CPS ase II into orotic acid (25 ± 8 
14pmol of [ C] bicarbonate were incorporated into orotate/min/g,
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compared with 795 ± 163 pmol of carbamyl phosphate).
Thus, the evidence presented in Chapter 5 indicated that 
most, if not all, of the cardiac pyrimidines were synthesised 
by the "salvage" pathways of pyrimidine synthesis. The 
activities of the enzymes Of the pathway de novo were much 
lower than the activities of the enzymes of the "salvage" 
pathways and the rates of incorporation of "salvage" path­
way metabolites into RNA were higher than the rates of 
incorporation of pathway de novo intermediates.
Tables 5.5 and 5.4 also showed that the activities 
of both the salvage pathway enzymes and the enzymes of the 
pathway de novo increased during the hypertrophying process, 
maintaining the relative importance of the salvage pathways 
in pyrimidine metabolism (CPS ase II activity increased by 
83%, 4 days after the induction of hypertrophy and uridine 
kinase activity by 53%, 4 days after the induction of hyper­
trophy) . The results indicated that orotic acid had no 
significant effect on the activity of these enzymes during 
hypertrophy. Thus, orotic acid would seem to play only a 
minor metabolic role in cardiac pyrimidine metabolism.
Table 5.7 shows that the administration of orotic 
acid does enhance the activity of the enzymes of hepatic 
pyrimidine synthesis de  n o v o . The results presented in 
Chapter 5 are entirely consistent with the theory that 
orotic acid acts primarily to stimulate hepatic pyrimidine 
biosynthesis, and the liver in turn supplied preformed bases
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to the heart for RNA synthesis. In view of the reported 
impermeability of the cell membrane to phosphorylated 
nucleotides, the pyrimidine bases were presumably trans­
ported to the heart as the nucleoside uridine.
Transport studies by other groups have provided 
evidence that rapidly proliferating cells within several 
different tissues (bone marrow and spleen) use preformed 
purine bases as nutrients. These bases are provided by the 
liver and carried to the tissues by erythrocytes (Lerner 
and Lowry, 1974; Lowry and Lerner, 1974; Pritchard et al., 
1970). In addition, other organs, such as the brain, need 
pyrimidine compounds to maintain function (Geiger, 1958). 
Presumably, these pyrimidines originate in the liver and 
are carried in the blood in low concentrations (Levine et 
al., 1974). Thus, there are many examples in the literature 
of the supply of nucleotide precursors, by the liver, to 
distant organs and to these, the heart should now be added.
It is also apparent that this is just another example of 
the association between liver and muscle metabolism, others
f
being the Cori cycle and the glutamine-alanine cycle.
Thus, in answer to the first question, orotic 
acid appears to act primarily in the liver by stimulating 
the synthesis of pyrimidines, which are subsequently exported 
to the heart.
With regard to the use of other nucleic acid pre­
cursors as therapeutic agents, consider firstly purine
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compounds. Zöllner and Gröbner (1977) have reported that 
there is always a linear relationship between dietary 
purine content and uric acid excretion, independent of the 
source of the purine compound. These findings would 
suggest that dietary purines would play a minor role (if 
any) in the regulation of purine synthesis, contrary to 
the conclusions of other workers. Regarding the use of 
pyrimidine compounds, the results of Kolos (Section 1.5) 
and the results shown in Table 5.7 (which show that the 
activities of hepatic ODC ase and ATC ase increased by 43% 
and 48%, respectively with orotic acid treatment and in­
creased by only 5% and 20% respectively with uridine therapy) 
suggest that uridine may not be as effective as orotic acid 
in stimulating pyrimidine synthesis. There are no reports 
in the literature that other pyrimidine compounds stimulate 
mammalian pyrimidine synthesis, though Lacroute (1968) has 
reported that dihydro-orotate may play a regulatory role 
in pyrimidine synthesis in Saccharomyces cerevisiae. Thus, 
orotic acid may play a unique role in the enhancement of 
pyrimidine synthesis in various tissues.
As to the universality of orotic acid enhanced 
growth, the data are consistent with orotic acid causing 
an enhanced rate of growth in rapidly growing tissues, pro­
vided that the increased rate of growth was partly due to 
an increased rate of RNA synthesis. In the hypertrophied 
kidney (Fig. 3.7), orotic acid was shown to have no effect
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on the development of hypertrophy, presumably because the 
increased RNA concentration observed in the hypertrophied 
kidney (Fig. 3.7) was due, not to an enhanced rate of RNA 
synthesis but rather, as proposed by Hill et al. (1974),
to a decreased rate of RNA breakdown.
Thus, the results presented in this thesis add 
considerable support to the claim by Meerson (1969) that 
the administration of orotic acid leads to a greater pro­
duction of nucleic acid precursors for RNA synthesis, 
though the compound acts indirectly through the liver 
rather than as a direct precursor of cardiac nucleic acids 
as proposed by Meerson.
The results are totally at variance with the pro­
posal of Nieper (1969, 1970, 1973a, 1973b and 1974) that 
the orotates act primarily as electrolyte carriers which 
show a strong affinity for tissues with an active pentose 
phosphate pathway (see Section 3.3.4).
Finally, the results do not preclude other
effects of orotic acid: for example, in Section 7.1, it
was proposed that one explanation of the increased max.
24-rate of rise of tension and the increased myosin Ca
stimulated myosin ATP ase activity (V ) was an alteration-1 max
of the excitation-coupling. Indeed, both orotic acid 
(Krug et al., 1977) and uridine (Roberts, 1973) have been 
reported to influence the neuronal excitation process.
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7.4 The Possible Use of Orotic Acid as a Therapeutic 
Substance
Most of the enzymes which participate in pyrimidine 
biosynthesis have been studied extensively in vitro but the 
characteristics of control in vivo remain sketchy. Much 
emphasis has been placed on pyrimidine biosynthesis in 
systems which exhibit rapid cellular proliferation. More 
recently, the intimate involvement of pyrimidine compounds 
in other areas of cellular systems, including carbohydrate, 
lipid, bilirubin and membrane metabolism, has been recognised. 
Orotic acid may have a variety of chemical effects. The pur­
ported pharmacological uses of orotic acid are numerous 
(Section 1.4.1). Orotic acid has been claimed to increase 
the rate of regeneration after myocardial infarction; to 
counteract galactose-induced cataracts and to aid in the 
management of galactosaemia; to nullify the diabetogenic 
action of alloxan; and to have an anti-inflammatory action 
in gouty arthritis, similar to colchicine. The usefulness 
of allopurinol in the treatment of gout could depend in part 
upon this last action of orotic acid. Pyrimidine nucleotides 
are required as carriers of sugars and lipids and this may 
account for other pharmacological effects of orotic acid.
The era of interventions to save the jeopardised, 
acutely ischemic myocardium started in 1949, when studies 
by Corday et al. (1949) demonstrated that, in the beating
heart, myocardial perfusion was primarily dependent upon
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the level of systemic blood pressure. This soon led to 
the adaptation of vasopressors in the treatment of cardio­
genic shock. Although these agents might increase cardiac 
output and dilate the coronary circulation, it was feared 
that, by increasing peripheral vascular resistence or 
myocardial contractility, they might raise the nutritional 
demands of the ischemic myocardium to a level which could 
not be satisfied by the compromised blood supply (Maroko 
et al., 1973) .
In recent years, the view that the fate of the 
acutely ischemic myocardium was irrevocably sealed at the 
time of a coronary occlusion, has been challenged (Epstein 
et al., 1975; Maroko et al., 1975). New techniques for 
interventions that might reduce infarct size have emerged. 
The control of infarct size is meaningful, for if it can 
be minimized, the crippling effects of an "irreversibly" 
damaged heart and the subsequent hazard of cardiac arrest 
might be prevented.
Conceptually, it might not be possible to signi­
ficantly effect the nutrition of an acutely jeopardized 
myocardium through an obstructed coronary artery, but it 
still may be possible to reduce the ischemic process at 
the periphery of the ischemic zone by augmenting the 
collateral circulation and by supplementing conventional 
therapy with preparations related to protein and nucleic 
acid synthesis. The coronary collateral circulation
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comprises interarterial anastomoses and overlapping 
arteries, capable of maintaining the viability of the 
peripheral hypoxic tissue. Because all collateral circu- 
lations are dependent upon adequate perfusion pressure, 
interventions aimed at maintaining viability must avoid 
excessive reductions in diastolic pressure (Corday et al., 
1949). Excessive systolic pressure should be avoided as 
it increases the muscle tension which will constrict intra- 
myocardial vessels.
Chance (quoted by Morgan, 1976) has reported 
that the degree of oxygenation of myoglobin in the infarcted 
heart changed from completely oxygenated to completely de- 
oxygenated over a very narrow area of the myocardium around 
the infarcted region and has suggested that there is no 
such thing as a border zone of oxygenation around the in­
farcted area. However, one should consider a border zone 
of viability, rather than of oxygenation, and the critical 
question may be how long one of these zones can survive.
If an intervention is protective and prolongs the interval 
of survival, then it may also modify the physical space in 
which the zone of viability persists. Further, since the 
coronary flow reduction is less marked at the periphery 
than at the center of an infarct in the zone of "absent 
function" (as described by Bruyneel and Opie, 1976), the 
border zone, if any, would lie inside this region of "absent 
function". Evidence of such a border zone of viability
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comes from many reports. Gudbjarnason et al. (1964) have
described the presence of hypertrophied myocardial cells 
in the area around an experimentally induced infarct and 
an increase in the concentration of RNA and DNA in the 
infarcted region of the heart. Wilcken et al. (1970) have
reported ultrastructural evidence of cell regeneration and 
active protein synthesis in damaged myocardial cells at 
the edge of experimentally induced infarcts in dogs.
Thus, to limit the size of an infarct, therapy 
should provide:
(1) a reduction of myocardial oxygen demands 
through a reduction of heart rate and an optimization of 
ventricular volume loading or a reduction of aortic 
resistence;
(2) an augmentation of oxygen supply by 
improving collateral circulation with adequate diastolic 
pressure;
(3) an enhancement of anaerobic metabolism 
through the delivery of optimal substrates for glycolysis;
(4) an enhancement of substrate movement across 
the cell membrane;
(5) an enhanced rate of synthesis of cellular 
components, especially nucleic acids and proteins;
(6) protection against autolytic processes; and
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(7) an improvement of the re-entry of blood 
flow into the ischemic zone by reducing regional tissue 
swelling.
In both the ischemic heart and the heart under­
going hypertrophy, the cells display evidence of electrical 
and biochemical instability. In both cases, cellular 
viability depends upon the ability of the heart to provide 
sufficient "high energy phosphate" and cellular "structural 
components" to maintain cellular homeostasis. To the extent 
that both cardiac hypertrophy and cardiac ischemia involve 
these aspects of cellular homeostasis, orotic acid "therapy" 
may be discussed in terms of these seven properties.
The usefulness of orotic acid as a therapeutic 
agent may be examined in terms of the above criteria for 
limiting the damage caused by an infarct. The internal 
diameter of the left anterior descending coronary artery 
and the number of perfused branches of the coronary artery 
were significantly increased in the orotic acid treated, 
hypertrophied hearts, compared with the untreated, hyper­
trophied hearts (Chapter 6). The improved coronary circu­
lation should improve the supply of oxygen and substrates 
to the hypertrophied heart. The increased tension developed 
(Section 1.5) and the mass action effect of the increased 
uridine nucleotide concentration on cardiac glycogen 
synthesis, in the orotic acid treated, hypertrophied hearts 
caused an increase in the intracellular stores of glycogen.
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The increased glycogen stores would provide sufficient sub­
strates for anaerobic glycolysis to overcome any short­
term localised hypoxia associated with the hypertrophic 
growth response. Thus, compared with those hearts not 
treated with orotic acid, the hearts so treated exhibited 
an augmented coronary circulation (and hence an augmented 
oxygen and substrate supply), an increased capacity and 
potential for anaerobic metabolism (as measured by the 
cardiac glycogen concentration) and an enhanced uptake of 
substrates (glucose for glycogen synthesis). Although the 
orotic acid treated hearts possessed the capacity for en­
hanced anaerobic metabolism, there was no evidence of a 
change from aerobic to anaerobic metabolism. The control 
of glycolysis was typical of the control expected under 
aerobic conditions, the cardiac lactate concentration was 
normal and the cytoplasmic [NAD+][NADH]^ ratio was the 
same as in normal aerobic hearts.
The results presented in Chapter 3 clearly indi­
cated an enhanced rate of the synthesis of cellular com­
ponents, especially RNA and protein, in those hearts treated 
with orotic acid.
The normal serum enzyme activities in the orotic 
acid treated, hypertrophied hearts (Kolos et al., 1974) 
indicated that there was no increased cellular damage asso­
ciated with the orotic acid treatment and suggested that 
there was an absence of increased autolytic processes
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(compared with normal hearts) in the orotic acid treated 
hypertrophied hearts.
With respect to the two remaining points (a 
reduction of cardiac energy demands through a reduction 
of the heart rate and an optimization of ventricular 
volume loading; the improvement of the re-entry of blood 
flow into the ischemic zone), no experiments were undertaken.
It is postulated that orotic acid treatment may 
promote cell viability in the region of the infarct and/or 
the hypertrophic response of cells in the region around the 
infarct. The data in this thesis are consistent with the 
postulated overall effect of the promotion of growth and 
an enhancement of the rates of various pathways where pyri­
midine cofactors are involved. The implications of the 
impairment of myocardial function, as a result of an infarct, 
have been discussed by Sobel et al. (1972). By promoting 
cell viability (and therefore myocardial function) and 
lessening the loss of myocardial mass as a result of an 
infarct, orotic acid would be expected to lessen the 
tendency of the heart to become akinetic or dyskinetic.
In the absence of orotic acid treatment, the larger infarcted 
area of damage would cause the non-infarcted myocardial 
tissue to expend considerable contractile force to generate 
tension with a corresponding reduction in the force available 
to pump blood. That orotic acid treatment does enhance the 
prognosis of patients suffering from myocardial infarction
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has been amply reported by the various clinical trials 
in which it has been used (Section 1.5) in the USSR.
7.5 General Conclusions
Chronic pressure overload leads to myocardial 
hypertrophy, whereby the increase in muscle mass is pri­
marily due to an increase in the ventricular wall thickness. 
When the afterload is not excessive, hypertrophy is effective 
in maintaining cardiac pump function, although the individual 
myocardial units operate at a reduced level of contractility. 
Hypertrophy clearly has both a beneficial and a detrimental 
aspect, since on the one hand it enables the heart to pump 
against an increased load, but on the other hand it leads 
to a decrease in intrinsic contractility. Despite this 
diminution of contractility, hypertrophy may be effective 
in preserving the strength and the extent of overall left 
ventricular contraction as long as the afterload does not 
become excessive. Throughout this thesis, the results that 
have been presented were consistent with an increased intrin­
sic contractility of the orotic acid treated, hypertrophied
hearts (as measured by either the maximum developed tension 
2 +or the Ca -stimulated myosin ATP ase activity) and a diminu­
tion of the detrimental effects of the hypertrophic response 
(a decreased coronary vascular system and an apparent lack 
of pyrimidines for RNA synthesis).
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If the increase in cardiac mass signifies an 
adaptation to greater physiological demands, the constitu­
ents of the myocardial tissue must increase correspondingly 
so as to support the myocardium contractile capacity. The 
results presented in Chapter 3 indicated that the total RNA 
concentration and the rate of protein synthesis were in­
creased in the orotic acid treated hypertrophied hearts 
(compared with the untreated hypertrophied hearts), yet 
the myocardial mass was the same in the treated and the un­
treated hypertrophied hearts. The differences in the rates 
of protein and nucleic acid syntheses would appear to indi­
cate less than optimal rates of protein and nucleic acid 
syntheses in the untreated hypertrophied hearts. Similarly, 
in Chapter 6 it was shown that in the untreated hypertrophied 
hearts, the growth of the coronary arteries was less than 
that of the myocardium, yet in the orotic acid treated 
hypertrophied hearts, the growth of the coronary arteries 
was normal. Thus, the results presented in this thesis 
suggest that the synthetic functions, the contractile 
function and the coronary circulation were all signifi­
cantly improved as a result of the orotic acid treatment.
The studies reported here have lent considerable support 
to Meerson's claim that orotic acid administration enhanced 
the processes of adaptation in the myocardium to an increased 
work load. The mechanism of this adaptation is discussed in 
detail in Chapter 5 and in Section 7.3.
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The period immediately following the induction 
of hypertrophy appears to be a critical phase in the 
development of hypertrophy. From the results presented 
in this thesis and those of other workers, it would appear 
that detailed investigations of the control of myocardial 
protein synthesis and degradation should provide a further 
insight into the biochemical changes that occur during 
hypertrophy. Recent advances in the study of eucaryotic 
mRNA, and cardiac myosin mRNA in particular, have enabled 
the study of both the transcriptional and the translational 
properties of mRNA to be undertaken. The application of 
these techniques to the study of cardiac myosin synthesis 
during the development of hypertrophy, together with studies 
of the synthesis and degradation of myosin, should provide 
information on the control of protein synthesis during 
hypertrophy and the effects of orotic acid on protein 
synthesis. Detailed studies of these biochemical parameters 
would also give some insight into whether the changes 
observed during hypertrophy were due directly to a primary 
initiating event or merely parallel changes associated with
that event.
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R e s t in g  l e n g t h - t e n s i o n  (LT) c u rv e  i s  i n d i c a t e d  on t h e  b a s a l  p la n e .
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from  B r u t s a e r t  an d  P a u lu s  (1977)
FACTORS IN THE ENVIRONMENT
CELL FUNCTION LEVEL
ENERGY-SUPPLYING SYSTEM -> PS AN
PP-RIBOSE-P AVAILABILITY 
PURINE SYNTHESIS DE NOVO
SHORT-TERM ADAPTATION -t~
PROTEIN SYNTHESIS
CELL STRUCTURES
LONG-TERM ADAPTATION
Figure 7.2 Diagram of the possible events in cardiac 
hypertrophy.
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